Action,ActionId,AuthorityGroup,Company,CompanyId,Country,CountryId,Drug,DrugId,EntityType,HighestDevStatus,HighestDevStatusForInd,HighestDevStatusForIndId,HighestDevStatusId,Indication,IndicationId,IsActiveCompany,LatestChange,ParentCompany,ParentCompanyId,Status,StatusDate,StatusId,StatusSortCode,TherapyArea,TherapyAreaId
Adjuvant,524,OTHER,Silence Therapeutics plc,22356,Tanzania,TZ,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,2003-05-06 00:00:00,DX,3,Respiratory disease,711
Antiviral,991,OTHER,Silence Therapeutics plc,22356,Zambia,ZM,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Antimicrobial,1593,OTHER,Silence Therapeutics plc,22356,Zambia,ZM,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Adjuvant,524,OTHER,Silence Therapeutics plc,22356,South Africa,ZA,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Antibacterial,1594,OTHER,Silence Therapeutics plc,22356,South Africa,ZA,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Albert Einstein College of Medicine,24282,US,US,KOA-18,10999,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,1995-09-26 14:53:02,Yeshiva University,20704,No Development Reported,1995-09-26 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,CytRx Corporation,15585,US,US,CRL-1018,11007,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,1995-09-27 00:00:00,CytRx Corporation,15585,Discontinued,1995-09-27 00:00:00,DX,3,Respiratory disease,711
Surfactant,1610,LOCAL_AND_MAJOR,CytRx Corporation,15585,US,US,CRL-1018,11007,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,1995-09-27 00:00:00,CytRx Corporation,15585,Discovery,1995-09-27 00:00:00,DR,6,Respiratory disease,711
Systemic antipsoriatic product,15184,OTHER,Silence Therapeutics plc,22356,South Africa,ZA,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Adjuvant,524,OTHER,Silence Therapeutics plc,22356,Romania,RO,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Antimicrobial,1593,OTHER,Silence Therapeutics plc,22356,Romania,RO,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Therapeutic vaccine,12379,OTHER,Silence Therapeutics plc,22356,Romania,RO,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Adjuvant,524,OTHER,Silence Therapeutics plc,22356,Nigeria,NG,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Anticancer,1545,OTHER,Silence Therapeutics plc,22356,Kuwait,KW,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Adjuvant,524,OTHER,Silence Therapeutics plc,22356,Gambia,GM,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Systemic antipsoriatic product,15184,OTHER,Silence Therapeutics plc,22356,South Africa,ZA,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 3 Clinical,1995-10-12 00:00:00,C3,10,Respiratory disease,711
Adjuvant,524,LOCAL_AND_MAJOR,Silence Therapeutics plc,22356,UK,GB,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,1995-10-12 00:00:00,C2,9,Respiratory disease,711
Systemic antipsoriatic product,15184,OTHER,Silence Therapeutics plc,22356,Nigeria,NG,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,1995-10-12 00:00:00,C2,9,Respiratory disease,711
Antiviral,991,OTHER,Silence Therapeutics plc,22356,Gambia,GM,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,1995-10-12 00:00:00,C2,9,Respiratory disease,711
Adjuvant,524,OTHER,Silence Therapeutics plc,22356,Gambia,GM,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,1995-10-12 00:00:00,C2,9,Respiratory disease,711
Subunit vaccine,12371,LOCAL_AND_MAJOR,MaxPharma,26965,US,US,"M tuberculosis vaccine (LEAPS), CEL-SCI (MaxPharma)",11526,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2011-12-28 00:00:00,CEL-SCI Corp,15339,No Development Reported,2011-12-28 00:00:00,NDR,2,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,MaxPharma,26965,US,US,"M tuberculosis vaccine (LEAPS), CEL-SCI (MaxPharma)",11526,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2011-12-28 00:00:00,CEL-SCI Corp,15339,Discovery,1999-09-29 00:00:00,DR,6,Respiratory disease,711
DNA gyrase inhibitor,431,OTHER,The Global Alliance for TB Drug Development,29411,Haiti,HT,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2014-10-14 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,The Global Alliance for TB Drug Development,29411,Malaysia,MY,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,The Global Alliance for TB Drug Development,29411,Phase 3 Clinical,2014-08-04 00:00:00,C3,10,Respiratory disease,711
DNA gyrase inhibitor,431,OTHER,The Global Alliance for TB Drug Development,29411,World,WO,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,The Global Alliance for TB Drug Development,29411,Phase 2 Clinical,2005-10-17 00:00:00,C2,9,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Pasteur Merieux Connaught Canada,19267,US,US,"vaccine (BCG), Connaught/Whitehead",12124,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2001-08-24 00:00:00,Sanofi,1009547,No Development Reported,2001-08-24 00:00:00,NDR,2,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Trustees of Health & Hospitals of The City of Boston,21398,US,US,"vaccine (BCG), Connaught/Whitehead",12124,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2001-08-24 00:00:00,Trustees of Health & Hospitals of The City of Boston,21398,Discovery,1996-04-18 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Massachusetts Institute of Technology,18225,US,US,"vaccine (BCG), Connaught/Whitehead",12124,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2001-08-24 00:00:00,Massachusetts Institute of Technology,18225,Discovery,1996-04-18 00:00:00,DR,6,Respiratory disease,711
Bacterial nucleic acid synthesis inhibitor,3984,OTHER,Bayer AG,14455,Spain,ES,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,Bayer AG,14455,Phase 2 Clinical,2005-10-17 00:00:00,C2,9,Respiratory disease,711
Topoisomerase IV inhibitor,9320,OTHER,Bayer AG,14455,Tanzania,TZ,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,Bayer AG,14455,Phase 2 Clinical,2005-10-17 00:00:00,C2,9,Respiratory disease,711
Systemic dermatological antibacterial product,15187,OTHER,Bayer AG,14455,Tanzania,TZ,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,Bayer AG,14455,Phase 2 Clinical,2005-10-17 00:00:00,C2,9,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,University of Illinois,20592,US,US,B-4157,12634,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2000-05-15 00:00:00,University of Illinois,20592,No Development Reported,2000-05-15 00:00:00,NDR,2,Respiratory disease,711
Anticancer,1545,LOCAL_AND_MAJOR,Indiana University,20593,US,US,"dihydrofolate reductase inhibitors, Duquesne/Indiana",12146,Chemical,Discovery,No Development Reported,NDR,DR,Mycobacterium tuberculosis infection,221,true,2011-01-04 00:00:00,Indiana University,20593,No Development Reported,2011-01-04 00:00:00,NDR,2,Respiratory disease,711
Anticancer,1545,LOCAL_AND_MAJOR,Indiana University,20593,US,US,"dihydrofolate reductase inhibitors, Duquesne/Indiana",12146,Chemical,Discovery,No Development Reported,NDR,DR,Mycobacterium tuberculosis infection,221,true,2011-01-04 00:00:00,Indiana University,20593,Discovery,2003-03-30 00:00:00,DR,6,Respiratory disease,711
Antiparasitic,2638,LOCAL_AND_MAJOR,Duquesne University,20569,US,US,"dihydrofolate reductase inhibitors, Duquesne/Indiana",12146,Chemical,Discovery,No Development Reported,NDR,DR,Mycobacterium tuberculosis infection,221,true,2011-01-04 00:00:00,Duquesne University,20569,No Development Reported,2011-01-04 00:00:00,NDR,2,Respiratory disease,711
Lipid subunit vaccine,12374,LOCAL_AND_MAJOR,Paligent Inc,19142,US,US,"vaccine (tuberculosis), Procept",15602,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2005-12-31 00:00:00,Paligent Inc,19142,Discovery,1997-07-30 00:00:00,DR,6,Respiratory disease,711
DNA synthesis inhibitor,140,LOCAL_AND_MAJOR,Harbor Therapeutics Inc,24345,US,US,PP-29,15867,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2003-07-02 00:00:00,Harbor Therapeutics Inc,24345,Discovery,1997-03-01 00:00:00,DR,6,Respiratory disease,711
Nuclease inhibitor,9166,LOCAL_AND_MAJOR,University of Illinois,20592,US,US,pafuramidine,16755,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2008-02-22 00:00:00,University of Illinois,20592,Discontinued,2000-01-28 00:00:00,DX,3,Respiratory disease,711
Antiparasitic,2638,LOCAL_AND_MAJOR,University of Illinois,20592,US,US,pafuramidine,16755,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2008-02-22 00:00:00,University of Illinois,20592,Discontinued,2000-01-28 00:00:00,DX,3,Respiratory disease,711
Fungicide,1748,LOCAL_AND_MAJOR,University of Illinois,20592,US,US,pafuramidine,16755,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2008-02-22 00:00:00,University of Illinois,20592,Discontinued,2000-01-28 00:00:00,DX,3,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,University of North Carolina,20634,US,US,pafuramidine,16755,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2008-02-22 00:00:00,University of North Carolina,20634,Discontinued,2000-01-28 00:00:00,DX,3,Respiratory disease,711
Antiparasitic,2638,LOCAL_AND_MAJOR,Immtech Pharmaceuticals Inc,17195,US,US,pafuramidine,16755,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2008-02-22 00:00:00,Immtech Pharmaceuticals Inc,17195,Discovery,2000-10-23 00:00:00,DR,6,Respiratory disease,711
Fungicide,1748,LOCAL_AND_MAJOR,Immtech Pharmaceuticals Inc,17195,US,US,pafuramidine,16755,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2008-02-22 00:00:00,Immtech Pharmaceuticals Inc,17195,Discovery,2000-10-23 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Panacea Biotec Ltd,25333,India,IN,Panacea-0394,29616,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-02-20 00:00:00,Panacea Biotec Ltd,25333,No Development Reported,2008-02-20 00:00:00,NDR,2,Respiratory disease,711
DNA RNA polymerase inhibitor,139,LOCAL_AND_MAJOR,Bristol-Myers Squibb Pharma Co,26864,US,US,DuP-105,2973,Chemical,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2004-03-02 00:00:00,Bristol-Myers Squibb Co,15065,No Development Reported,2001-06-27 00:00:00,NDR,2,Respiratory disease,711
Gastrointestinal diagnostic agent,7213,LOCAL_AND_MAJOR,Navidea Biopharmaceuticals Inc,18471,US,US,technetium Tc 99m tilmanocept,34061,Chemical,Launched,Discovery,DR,L,Mycobacterium tuberculosis infection,221,true,2014-12-12 00:00:00,Navidea Biopharmaceuticals Inc,18471,Discovery,2013-09-19 00:00:00,DR,6,Respiratory disease,711
Protease inhibitor,331,LOCAL_AND_MAJOR,Medivir AB,18015,Sweden,SE,"antibacterial protease inhibitors, Medivir/University of London",35747,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2003-08-19 00:00:00,Medivir AB,18015,No Development Reported,2003-08-19 00:00:00,NDR,2,Respiratory disease,711
Protease inhibitor,331,LOCAL_AND_MAJOR,University of London,20607,UK,GB,"antibacterial protease inhibitors, Medivir/University of London",35747,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2003-08-19 00:00:00,University of London,20607,Discovery,2001-08-28 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,University of London,20607,UK,GB,"antibacterial protease inhibitors, Medivir/University of London",35747,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2003-08-19 00:00:00,University of London,20607,Discovery,2001-08-28 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,ANI Pharmaceuticals Inc,27120,US,US,"tuberculosis vaccine (BioVant), BioSante",39902,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-12-23 00:00:00,ANI Pharmaceuticals Inc,27120,No Development Reported,2008-12-23 00:00:00,NDR,2,Respiratory disease,711
DNA gyrase inhibitor,431,LOCAL_AND_MAJOR,NicOx SA,23741,France,FR,NCX-976,47140,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2005-01-31 00:00:00,NicOx SA,23741,No Development Reported,2005-01-31 00:00:00,NDR,2,Respiratory disease,711
Phospho MurNAc pentapeptide transferase inhibitor,64334,LOCAL_AND_MAJOR,Sankyo Co Ltd,19658,Japan,JP,"capuramycin derivative translocase inhibitors (tuberculosis, Clostridium difficile infection, Chrons disease), Sequella",48440,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2012-05-03 00:00:00,Daiichi Sankyo Co Ltd,1017506,Discontinued,2004-11-01 00:00:00,DX,3,Respiratory disease,711
Bacterial cell wall synthesis inhibitor,104,LOCAL_AND_MAJOR,Sankyo Co Ltd,19658,Japan,JP,"capuramycin derivative translocase inhibitors (tuberculosis, Clostridium difficile infection, Chrons disease), Sequella",48440,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2012-05-03 00:00:00,Daiichi Sankyo Co Ltd,1017506,Discontinued,2004-11-01 00:00:00,DX,3,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Sankyo Co Ltd,19658,Japan,JP,"capuramycin derivative translocase inhibitors (tuberculosis, Clostridium difficile infection, Chrons disease), Sequella",48440,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2012-05-03 00:00:00,Daiichi Sankyo Co Ltd,1017506,Discovery,2003-09-01 00:00:00,DR,6,Respiratory disease,711
Mycobacterial antigen complex 85B modulator,33970,OTHER,Aeras Global TB Vaccine Foundation,1007376,Sweden,SE,"HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell",48499,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-07-29 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 1 Clinical,2007-12-04 00:00:00,C1,8,Respiratory disease,711
Mycobacterial antigen complex 85B modulator,33970,OTHER,Aeras Global TB Vaccine Foundation,1007376,South Africa,ZA,"HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell",48499,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-07-29 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 2 Clinical,2013-07-29 00:00:00,C2,9,Respiratory disease,711
Protein subunit vaccine,12372,OTHER,Sanofi Pasteur,22127,South Africa,ZA,"HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell",48499,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-07-29 00:00:00,Sanofi,1009547,Phase 2 Clinical,2013-07-29 00:00:00,C2,9,Respiratory disease,711
Mycobacterial antigen complex 85B modulator,33970,OTHER,Statens Serum Institut,21502,Finland,FI,"HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell",48499,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-07-29 00:00:00,Statens Serum Institut,21502,Phase 1 Clinical,2009-01-26 00:00:00,C1,8,Respiratory disease,711
Protein subunit vaccine,12372,OTHER,Statens Serum Institut,21502,Finland,FI,"HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell",48499,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-07-29 00:00:00,Statens Serum Institut,21502,Phase 1 Clinical,2009-01-26 00:00:00,C1,8,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Statens Serum Institut,21502,South Africa,ZA,"HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell",48499,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-07-29 00:00:00,Statens Serum Institut,21502,Phase 2 Clinical,2013-07-29 00:00:00,C2,9,Respiratory disease,711
Fungicide,1748,LOCAL_AND_MAJOR,Central Drug Research Institute,15350,India,IN,"galactopyranose derivatives (antifungal/antitubercular), Central Drug Research Institute",50637,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2005-01-24 00:00:00,Council of Scientific and Industrial Research (India),15561,No Development Reported,2005-01-24 00:00:00,NDR,2,Respiratory disease,711
Glycosyltransferase inhibitor,1025,LOCAL_AND_MAJOR,Central Drug Research Institute,15350,India,IN,"galactopyranose derivatives (antifungal/antitubercular), Central Drug Research Institute",50637,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2005-01-24 00:00:00,Council of Scientific and Industrial Research (India),15561,No Development Reported,2005-01-24 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Lupin Ltd,21932,India,IN,LL-4858,51319,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2010-03-26 00:00:00,Lupin Ltd,21932,Discovery,2004-04-01 00:00:00,DR,6,Respiratory disease,711
Protein subunit vaccine,12372,OTHER,Intercell AG,28463,Tanzania,TZ,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2013-05-28 00:00:00,Valneva SE,1084202,Discontinued,2013-05-28 00:00:00,DX,3,Respiratory disease,711
Recombinant bacterial vector vaccine,12369,OTHER,Intercell AG,28463,South Africa,ZA,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2013-05-28 00:00:00,Valneva SE,1084202,Phase 2 Clinical,2012-08-17 00:00:00,C2,9,Respiratory disease,711
Recombinant bacterial vector vaccine,12369,OTHER,Intercell AG,28463,Tanzania,TZ,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2013-05-28 00:00:00,Valneva SE,1084202,Phase 2 Clinical,2012-08-17 00:00:00,C2,9,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Intercell AG,28463,Netherlands,NL,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2013-05-28 00:00:00,Valneva SE,1084202,Phase 1 Clinical,2005-11-18 00:00:00,C1,8,Respiratory disease,711
Recombinant bacterial vector vaccine,12369,OTHER,Intercell AG,28463,Austria,AT,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2013-05-28 00:00:00,Valneva SE,1084202,Discovery,2004-03-17 00:00:00,DR,6,Respiratory disease,711
Protein subunit vaccine,12372,OTHER,Aeras Global TB Vaccine Foundation,1007376,Netherlands,NL,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-05-28 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 2 Clinical,2009-03-02 00:00:00,C2,9,Respiratory disease,711
Recombinant bacterial vector vaccine,12369,OTHER,Sanofi Pasteur,22127,Switzerland,CH,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-05-28 00:00:00,Sanofi,1009547,Phase 1 Clinical,2010-12-31 00:00:00,C1,8,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Statens Serum Institut,21502,Denmark,DK,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-05-28 00:00:00,Statens Serum Institut,21502,Discovery,2004-03-17 00:00:00,DR,6,Respiratory disease,711
Protein subunit vaccine,12372,LOCAL_AND_MAJOR,Statens Serum Institut,21502,Denmark,DK,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-05-28 00:00:00,Statens Serum Institut,21502,Discovery,2004-03-17 00:00:00,DR,6,Respiratory disease,711
Recombinant bacterial vector vaccine,12369,LOCAL_AND_MAJOR,Statens Serum Institut,21502,Denmark,DK,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-05-28 00:00:00,Statens Serum Institut,21502,Discovery,2004-03-17 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Statens Serum Institut,21502,Netherlands,NL,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-05-28 00:00:00,Statens Serum Institut,21502,Phase 1 Clinical,2005-11-18 00:00:00,C1,8,Respiratory disease,711
Protein subunit vaccine,12372,OTHER,Statens Serum Institut,21502,Netherlands,NL,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-05-28 00:00:00,Statens Serum Institut,21502,Phase 1 Clinical,2005-11-18 00:00:00,C1,8,Respiratory disease,711
Recombinant viral vector vaccine,12370,OTHER,Oxford-Emergent Tuberculosis Consortium Ltd,1040955,South Africa,ZA,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-07 00:00:00,Emergent BioSolutions Inc,1011990,Phase 1 Clinical,2008-07-23 00:00:00,C1,8,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Oxford-Emergent Tuberculosis Consortium Ltd,1040955,South Africa,ZA,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-07 00:00:00,Emergent BioSolutions Inc,1011990,Phase 2 Clinical,2008-07-23 00:00:00,C2,9,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,University of Oxford,22182,UK,GB,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-07 00:00:00,University of Oxford,22182,Discovery,2000-12-31 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,University of Oxford,22182,Africa,X0,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-07 00:00:00,University of Oxford,22182,Phase 1 Clinical,2002-09-30 00:00:00,C1,8,Respiratory disease,711
Recombinant viral vector vaccine,12370,OTHER,University of Oxford,22182,South Africa,ZA,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-07 00:00:00,University of Oxford,22182,Phase 2 Clinical,2007-12-31 00:00:00,C2,9,Respiratory disease,711
Recombinant viral vector vaccine,12370,OTHER,TB-VAC,1020621,Senegal,SN,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-03-07 00:00:00,TB-VAC,1020621,Phase 2 Clinical,2011-08-08 00:00:00,C2,9,Respiratory disease,711
Recombinant viral vector vaccine,12370,OTHER,TB-VAC,1020621,UK,GB,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-03-07 00:00:00,TB-VAC,1020621,Phase 1 Clinical,2008-07-23 00:00:00,C1,8,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Emergent BioSolutions Inc,1011990,South Africa,ZA,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-03-07 00:00:00,Emergent BioSolutions Inc,1011990,Phase 2 Clinical,2014-03-07 00:00:00,C2,9,Respiratory disease,711
Recombinant viral vector vaccine,12370,OTHER,Emergent BioSolutions Inc,1011990,South Africa,ZA,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-03-07 00:00:00,Emergent BioSolutions Inc,1011990,Phase 2 Clinical,2014-03-07 00:00:00,C2,9,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Emergent BioSolutions Inc,1011990,Senegal,SN,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-03-07 00:00:00,Emergent BioSolutions Inc,1011990,Phase 2 Clinical,2014-03-07 00:00:00,C2,9,Respiratory disease,711
TLR-4 antagonist,7813,LOCAL_AND_MAJOR,Cadila Pharmaceuticals Ltd,30025,India,IN,cadi-05,55173,Biological,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2014-12-03 00:00:00,Cadila Pharmaceuticals Ltd,30025,No Development Reported,2014-12-03 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Cadila Pharmaceuticals Ltd,30025,India,IN,cadi-05,55173,Biological,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2014-12-03 00:00:00,Cadila Pharmaceuticals Ltd,30025,No Development Reported,2014-12-03 00:00:00,NDR,2,Respiratory disease,711
Subunit vaccine,12371,OTHER,Archivel Farma SL,1014222,South Africa,ZA,RUTI,57308,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2012-05-24 00:00:00,Archivel Farma SL,1014222,Phase 2 Clinical,2010-06-30 00:00:00,C2,9,Respiratory disease,711
DNA gyrase inhibitor,431,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"gyrase inhibitors (Mycobacterium tuberculosis infection), GlaxoSmithKline/The Global Alliance for TB Drug Development",57733,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2006-12-31 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2006-12-31 00:00:00,DR,6,Respiratory disease,711
Thymidylate synthase inhibitor,372,LOCAL_AND_MAJOR,Tydockpharma Srl,1036974,Italy,IT,"ThyX inhibitors (Helicobacter pylori/Mycobacterium tuberculosis infections), Tydockpharma",59276,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2008-01-14 00:00:00,Tydockpharma Srl,1036974,Discovery,2008-01-14 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,The Lilly TB Drug Discovery Initiative,1042702,US,US,CPZEN-45,59885,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2008-10-07 00:00:00,The Lilly TB Drug Discovery Initiative,1042702,Discovery,2008-10-07 00:00:00,DR,6,Respiratory disease,711
Transcriptional regulator protein EthR inhibitor,74415,LOCAL_AND_MAJOR,Institut Pasteur,17237,Western Europe,XW,"EthR inhibitors (mycobacterium tuberculosis), BioVersys",61115,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2012-07-10 00:00:00,Institut Pasteur,17237,Discontinued,2012-07-10 00:00:00,DX,3,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Genexine Co Ltd,29830,South Korea,KR,GX-140,61171,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2010-06-19 00:00:00,Genexine Co Ltd,29830,Discovery,2008-06-30 00:00:00,DR,6,Respiratory disease,711
Therapeutic vaccine,12379,OTHER,SinoBiomed Inc,1032007,China,CN,"recombinant multivalent tuberculosis vaccine, SinoBiomed",61931,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2011-01-06 00:00:00,SinoBiomed Inc,1032007,Discovery,2008-08-21 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,Upstream Biosciences Inc,1035256,Canada,CA,"antibacterial therapies (tuberculosis), Upstream Biosciences",62917,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-01-10 00:00:00,Upstream Biosciences Inc,1035256,No Development Reported,2012-01-10 00:00:00,NDR,2,Respiratory disease,711
Isocitrate lyase inhibitor,68490,OTHER,Emory University,20573,South Africa,ZA,"isocitrate lyase prodrug inhibitors (tuberculosis), iThemba Pharmaceuticals",65567,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2008-03-31 00:00:00,Emory University,20573,Discovery,2007-08-31 00:00:00,DR,6,Respiratory disease,711
Mycolic acid synthase inhibitor,6542,LOCAL_AND_MAJOR,Shaheed Beheshti Medical University,1034641,Iran,IR,KBF-611,65935,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-06-19 00:00:00,Shaheed Beheshti Medical University,1034641,No Development Reported,2012-06-19 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Snowdon Inc,1033991,US,US,SND-159,64976,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2009-02-05 00:00:00,Snowdon Inc,1033991,Discovery,2009-02-05 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Statens Serum Institut,21502,UK,GB,"protein subunit vaccine (Mycobacterium tuberculosis, intranasal), Novartis Vaccines & Diagnostics/Statens Serum Institut",66563,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2011-11-30 00:00:00,Statens Serum Institut,21502,No Development Reported,2011-11-30 00:00:00,NDR,2,Respiratory disease,711
Unspecified vaccine,12380,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,"BCG Vaccine (oral lipid matrix, Liporale), Immune Solutions/Aeras Global TB foundation",66314,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2010-05-04 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Discovery,2010-05-04 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Transgene SA,23924,France,FR,"Mycobacterium tuberculosis vaccine, Transgene",67820,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2010-07-29 00:00:00,ACCRA,1020515,Discovery,2010-07-29 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Imaxio,1007058,France,FR,IMX-461,66409,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-08-01 00:00:00,Imaxio,1007058,Discovery,2012-03-02 00:00:00,DR,6,Respiratory disease,711
Recombinant viral vector vaccine,12370,LOCAL_AND_MAJOR,Imaxio,1007058,France,FR,IMX-461,66409,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-08-01 00:00:00,Imaxio,1007058,Discovery,2012-03-02 00:00:00,DR,6,Respiratory disease,711
Protein kinase G inhibitor,3958,LOCAL_AND_MAJOR,Vichem Chemie Ltd,1031147,Hungary,HU,"PknG inhibitors (Mycobacterium tuberculosis infection), Vichem Chemie",68370,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2015-04-24 00:00:00,Vichem Chemie Ltd,1031147,Discovery,2008-03-15 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Colorado State University,20562,US,US,H-56,69824,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-08-22 00:00:00,Colorado State University,20562,Clinical,2011-01-23 00:00:00,CU,7,Respiratory disease,711
Antibacterial,1594,OTHER,Infectious Disease Research Institute,27376,South Africa,ZA,ID-93,68617,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-09-20 00:00:00,Infectious Disease Research Institute,27376,Phase 1 Clinical,2013-09-20 00:00:00,C1,8,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,Infectious Disease Research Institute,27376,US,US,ID-93,68617,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-09-20 00:00:00,Infectious Disease Research Institute,27376,Phase 1 Clinical,2012-08-15 00:00:00,C1,8,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Infectious Disease Research Institute,27376,US,US,ID-93,68617,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-09-20 00:00:00,Infectious Disease Research Institute,27376,Discovery,2009-12-31 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,The Global Alliance for TB Drug Development,29411,India,IN,"gyrase B inhibitors (tuberculosis infection), AZ/TB Alliance",71700,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-11-30 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2010-05-03 00:00:00,DR,6,Respiratory disease,711
Nitric oxide donor,698,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,TBA-354,71742,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-01-30 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2009-10-02 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,University of Illinois,20592,US,US,TBA-354,71742,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-01-30 00:00:00,University of Illinois,20592,Discovery,2009-10-02 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,University of Ghent,24987,Belgium,BE,"tuberculosis vaccine, VIB/Ghent University",70144,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-10-07 00:00:00,University of Ghent,24987,No Development Reported,2014-10-07 00:00:00,NDR,2,Respiratory disease,711
Live attenuated bacterial vaccine,12363,LOCAL_AND_MAJOR,University of Ghent,24987,Belgium,BE,"tuberculosis vaccine, VIB/Ghent University",70144,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-10-07 00:00:00,University of Ghent,24987,Discovery,2011-01-26 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Nagoya City University,1022846,Japan,JP,"glucopyranoside derivatives (Mycobacterium tuberculosis infection), Nagoya City University",70208,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-02-18 00:00:00,Nagoya City University,1022846,No Development Reported,2013-02-18 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Nagoya City University,1022846,Japan,JP,"glucopyranoside derivatives (Mycobacterium tuberculosis infection), Nagoya City University",70208,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-02-18 00:00:00,Nagoya City University,1022846,No Development Reported,2013-02-18 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,OTHER,Pharmarare SA,1062315,World,WO,DasKloster 0249-01,71313,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2010-09-30 00:00:00,Pharmarare SA,1062315,Discovery,2010-09-30 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,McMaster University,21238,Canada,CA,Ad5Ag85A,71323,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,false,2012-05-07 00:00:00,McMaster University,21238,Phase 1 Clinical,2009-07-31 00:00:00,C1,8,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Tianjin CanSino Biotechnology Inc,1069870,Canada,CA,Ad5Ag85A,71323,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2012-05-07 00:00:00,Tianjin CanSino Biotechnology Inc,1069870,Phase 1 Clinical,2011-08-31 00:00:00,C1,8,Respiratory disease,711
Thioredoxin reductase inhibitor,6506,LOCAL_AND_MAJOR,Intervet Innovation GmbH,1061424,Germany,DE,"thioredoxin reductase inhibitors (tuberculosis), Intervet Innovation",70840,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-02-26 00:00:00,Intervet Innovation GmbH,1061424,Discovery,2010-05-04 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Hans Knoell Institute of Natural Products Research,24984,Germany,DE,"benzothiazinones (tuberculosis), Hans Knoell Institute",70901,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-09-25 00:00:00,Hans Knoell Institute of Natural Products Research,24984,No Development Reported,2013-09-25 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Qurient Therapeutics,1062405,South Korea,KR,"Q-201, Qurient",71430,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-04-17 00:00:00,Qurient Therapeutics,1062405,No Development Reported,2012-04-17 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Qurient Therapeutics,1062405,South Korea,KR,"Q-201, Qurient",71430,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-04-17 00:00:00,Qurient Therapeutics,1062405,No Development Reported,2012-04-17 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Hans Knoell Institute of Natural Products Research,24984,Germany,DE,"benzothiazinones (tuberculosis), Hans Knoell Institute",70901,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-09-25 00:00:00,Hans Knoell Institute of Natural Products Research,24984,Discovery,2009-02-26 00:00:00,DR,6,Respiratory disease,711
Epimerase inhibitor,520,LOCAL_AND_MAJOR,New Medicines for Tuberculosis,1062637,Switzerland,CH,"benzothiazinones (tuberculosis), Hans Knoell Institute",70901,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-09-25 00:00:00,New Medicines for Tuberculosis,1062637,No Development Reported,2013-09-25 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,AstraZeneca plc,14190,UK,GB,"folate biosynthesis inhibitors (tuberculosis), AZ/TB Alliance",71614,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-11-30 00:00:00,AstraZeneca plc,14190,No Development Reported,2012-11-30 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,NeED Pharmaceuticals Srl,1013076,Italy,IT,ND-601,71115,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-03-21 00:00:00,NeED Pharmaceuticals Srl,1013076,Discovery,2011-04-20 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Texas A&M University System,23290,US,US,"malate synthase (tuberculosis infection), GSK/TB Alliance/Texas A&M University",71667,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2007-12-31 00:00:00,Texas A&M University System,23290,Discovery,2007-12-31 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,The Global Alliance for TB Drug Development,29411,India,IN,"gyrase B inhibitors (tuberculosis infection), AZ/TB Alliance",71700,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-11-30 00:00:00,The Global Alliance for TB Drug Development,29411,No Development Reported,2012-11-30 00:00:00,NDR,2,Respiratory disease,711
Eukaryotic initiation 2 alpha kinase 2 inhibitor,51121,LOCAL_AND_MAJOR,Numerate Inc,1037610,US,US,"tuberculosis therapeutics, Numerate",73050,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-12-21 00:00:00,Numerate Inc,1037610,Discovery,2009-12-31 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Numerate Inc,1037610,US,US,"tuberculosis therapeutics, Numerate",73050,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-12-21 00:00:00,Numerate Inc,1037610,Discovery,2009-12-31 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,"tuberculosis vaccine, TapImmune",74286,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-09-23 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Discovery,2011-10-27 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Quantum Pharmaceuticals LLC,1072312,Russian Federation,RU,QP-42,76732,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-07-24 00:00:00,Quantum Pharmaceuticals LLC,1072312,No Development Reported,2013-07-24 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Orient Pharma Co Ltd,1042436,Taiwan,TW,"tuberculosis therapeutics (capsule), Orient",75681,Chemical,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2012-01-19 00:00:00,Orient Europharma,DOL1000087,Phase 1 Clinical,2012-01-19 00:00:00,C1,8,Respiratory disease,711
Bifunctional aminoacyl tRNA synthetase inhibitor,33999,LOCAL_AND_MAJOR,Omnia Molecular,1065893,Spain,ES,"leucyl-tRNA synthetase inhibitors (Mycobacterium tuberculosis infection), Omnia Molecular",75760,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-10-14 00:00:00,Omnia Molecular,1065893,No Development Reported,2014-10-14 00:00:00,NDR,2,Respiratory disease,711
DNA vaccine,1879,LOCAL_AND_MAJOR,Shanghai H&G Biotechnology Co,1066720,China,CN,"Ag85A/B DNA vaccine (tuberculosis), Shanghai H&G Biotechnology",75084,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-17 00:00:00,Shanghai H&G Biotechnology Co,1066720,Discovery,2006-12-31 00:00:00,DR,6,Respiratory disease,711
miRNA agent,38419,LOCAL_AND_MAJOR,National University of Singapore,20633,Singapore,SG,"miRNA-like molecules (tuberculosis), NUS",77116,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-06-20 00:00:00,National University of Singapore,20633,Discovery,2012-02-28 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Microbion Corp,1055897,US,US,"MB-11, Microbion",77124,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-01-17 00:00:00,Microbion Corp,1055897,Discovery,2012-02-28 00:00:00,DR,6,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,Shanghai H&G Biotechnology Co,1066720,China,CN,"ESAT-6/Ag85A-expressing recombinant BCG vaccine (Mycobacterium tuberculosis), Shanghai H&G",75152,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-17 00:00:00,Shanghai H&G Biotechnology Co,1066720,No Development Reported,2013-01-17 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,VELES Pharma CJSC,1069315,US,US,"recombinant protein vaccine (nanoparticle, tuberculosis infection prevention/treatment), VELES Pharma",77247,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-04-12 00:00:00,VELES Pharma CJSC,1069315,Discovery,2012-04-12 00:00:00,DR,6,Respiratory disease,711
Beta lactamase inhibitor,86,LOCAL_AND_MAJOR,Albert Einstein College of Medicine,24282,US,US,"carbapenem + beta lactamase inhibitor (Mycobacterium tuberculosis infection), Albert Einstein College of Medicine",79321,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-05-28 00:00:00,Yeshiva University,20704,Discovery,2007-10-04 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,International Center for Genetic Engineering and Biotechnology (ICGEB),24669,Italy,IT,"repurposed mepenzolate bromide (tuberculosis), Sphaera/ICGEB",78319,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-05-07 00:00:00,International Center for Genetic Engineering and Biotechnology (ICGEB),24669,Discovery,2012-05-07 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,International Center for Genetic Engineering and Biotechnology (ICGEB),24669,Italy,IT,"repurposed mepenzolate bromide (tuberculosis), Sphaera/ICGEB",78319,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-05-07 00:00:00,International Center for Genetic Engineering and Biotechnology (ICGEB),24669,Discovery,2012-05-07 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,iThemba Pharmaceuticals Pty Ltd,1049788,South Africa,ZA,"NBTIs (Mycobacterium tuberculosis infection), iThemba",79395,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-03-13 00:00:00,iThemba Pharmaceuticals Pty Ltd,1049788,Discovery,2010-01-20 00:00:00,DR,6,Respiratory disease,711
Anti-inflammatory,2953,LOCAL_AND_MAJOR,Center for Genetic Engineering and Biotechnology,15353,Cuba,CU,"interferon gamma follow-on biologic, CIGB/Heber Biotec",79519,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2009-12-31 00:00:00,Center for Genetic Engineering and Biotechnology,15353,Launched,2009-12-31 00:00:00,L,13,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Qurient Therapeutics,1062405,South Korea,KR,"TB I series (tuberculosis infection), Qurient Therapeutics",78036,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2013-06-28 00:00:00,Qurient Therapeutics,1062405,No Development Reported,2013-06-28 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,OTHER,Institut Pasteur,17237,South Korea,KR,"TB I series (tuberculosis infection), Qurient Therapeutics",78036,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2013-06-28 00:00:00,Institut Pasteur,17237,Discontinued,2010-03-31 00:00:00,DX,3,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Universidade Federal de Minas Gerais,25676,Brazil,BR,"sMTL-13 vaccine (Mycobacterium tuberculosis infection), Universidade Federal de Minas Gerais",79289,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-08-25 00:00:00,Universidade Federal de Minas Gerais,25676,No Development Reported,2014-08-25 00:00:00,NDR,2,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,Universidade Federal de Minas Gerais,25676,Brazil,BR,"sMTL-13 vaccine (Mycobacterium tuberculosis infection), Universidade Federal de Minas Gerais",79289,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-08-25 00:00:00,Universidade Federal de Minas Gerais,25676,No Development Reported,2014-08-25 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Chengdu Institute of Biological Products,1016340,China,CN,Ka Shu Ning,80062,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,1998-12-31 00:00:00,Sinopharm,1055632,Launched,1998-12-31 00:00:00,L,13,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Shanghai Institute of Biological Products Co Ltd,1071897,China,CN,"BCG vaccine (intradermal), Shanghai Institute of Biological Products",80067,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2001-12-31 00:00:00,Sinopharm,1055632,Launched,2001-12-31 00:00:00,L,13,Respiratory disease,711
ATP-dependent Clp protease 2 inhibitor,26620,LOCAL_AND_MAJOR,NovoBiotic Pharmaceuticals LLC,1031362,US,US,lassomycin,81058,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-09-10 00:00:00,NovoBiotic Pharmaceuticals LLC,1031362,Discovery,2012-09-10 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Lanzhou Institute of Biological Products,1061250,China,CN,"BCG vaccine (intradermal), Lanzhou Institute of Biological Products",80322,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2001-12-31 00:00:00,Sinopharm,1055632,Launched,2001-12-31 00:00:00,L,13,Respiratory disease,711
Live attenuated bacterial vaccine,12363,LOCAL_AND_MAJOR,Lanzhou Institute of Biological Products,1061250,China,CN,"BCG vaccine (intradermal), Lanzhou Institute of Biological Products",80322,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2001-12-31 00:00:00,Sinopharm,1055632,Launched,2001-12-31 00:00:00,L,13,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Lanzhou Institute of Biological Products,1061250,China,CN,"BCG vaccine (intradermal), Lanzhou Institute of Biological Products",80322,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2001-12-31 00:00:00,Sinopharm,1055632,Registered,2001-12-31 00:00:00,R,12,Respiratory disease,711
Live attenuated bacterial vaccine,12363,LOCAL_AND_MAJOR,Lanzhou Institute of Biological Products,1061250,China,CN,"BCG vaccine (intradermal), Lanzhou Institute of Biological Products",80322,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2001-12-31 00:00:00,Sinopharm,1055632,Registered,2001-12-31 00:00:00,R,12,Respiratory disease,711
ATP synthase inhibitor,49687,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"ATP synthase inhibitors (tuberculosis), TB Alliance/California Institute for Biomedical Research",82643,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-06-30 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2012-11-30 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Albert Einstein College of Medicine,24282,US,US,"TCA1 analogs (Mycobacterium tuberculosis infection), SRI/HHMI/AECM",85774,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-06-17 00:00:00,Yeshiva University,20704,Discovery,2013-06-17 00:00:00,DR,6,Respiratory disease,711
Unspecified enzyme modulator,1051,LOCAL_AND_MAJOR,Scripps Research Institute,21102,US,US,"TCA1 analogs (Mycobacterium tuberculosis infection), SRI/HHMI/AECM",85774,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-06-17 00:00:00,Scripps Research Institute,21102,Discovery,2013-06-17 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,GlobalAcorn,1086420,UK,GB,GA3 MEP-TB,86658,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2015-04-17 00:00:00,GlobalAcorn,1086420,No Development Reported,2015-04-17 00:00:00,NDR,2,Respiratory disease,711
Bacterial protein synthesis inhibitor,1538,LOCAL_AND_MAJOR,Chiron PathoGenesis,18741,US,US,rifalazil,8658,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2014-10-30 00:00:00,Novartis AG,23137,Suspended,2000-02-14 00:00:00,S,5,Respiratory disease,711
Bacterial protein synthesis inhibitor,1538,OTHER,Chiron PathoGenesis,18741,Brazil,BR,rifalazil,8658,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2014-10-30 00:00:00,Novartis AG,23137,Suspended,2000-02-14 00:00:00,S,5,Respiratory disease,711
Recombinant viral vector vaccine,12370,OTHER,Okairos,1035490,Italy,IT,"tuberculosis vaccine, Okairos",85469,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-05-30 00:00:00,GlaxoSmithKline plc,28355,Discovery,2013-05-30 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,University of Illinois at Urbana-Champaign,1073122,US,US,"anti-tuberculosis agents, University of Illinois/University of Illinois at URBANA-CHAMPAIGN",87132,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-08-27 00:00:00,University of Illinois,20592,Discovery,2013-08-27 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,State University of New York at Stony Brook,26884,US,US,"MTB fatty acid bio synthesis enzyme inhibitors (multi-drug resistant tuberculosis), State University of New York at Stony Brook",88952,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2006-02-17 00:00:00,State University of New York,26880,Discovery,2006-02-17 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,University of Tennessee,26292,US,US,"menA inhibitors (Mycobacterium tuberculosis), University of Tennessee/University of Tennessee Research Foundation Office of Technology Transfer",88391,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-11-04 00:00:00,University of Tennessee,26292,Discovery,2013-11-04 00:00:00,DR,6,Respiratory disease,711
Live attenuated bacterial vaccine,12363,LOCAL_AND_MAJOR,University of California Los Angeles,25623,US,US,"rBCG30 vaccine (improved version, tuberculosis), UCLA",89141,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-11-29 00:00:00,University of California,20547,Discovery,2013-11-29 00:00:00,DR,6,Respiratory disease,711
Bacterial cell wall synthesis inhibitor,104,LOCAL_AND_MAJOR,Shenyang Hongqi Pharmaceutical Co Ltd,1075626,China,CN,"ethambutol hydrochloride (150 mg) + pyrazinamide (300 mg) + rifampicin (90 mg) + isoniazid (60 mg) (oral tablet, tuberculosis), Shenyang Hongqi Pharmaceutical/Liaoning Hongwuxing Pharmaceutical",88505,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-11-15 00:00:00,Shanghai Fosun Pharmaceutical (Group) Co Ltd,1015871,Discovery,2009-02-01 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Johns Hopkins University Office of Technology Transfer,1083716,US,US,"recombinant PknD subunit protein vaccine (Mycobacterium tuberculosis infection), Johns Hopkins University",89337,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-12-19 00:00:00,Johns Hopkins University,20596,Discovery,2013-12-19 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,GlaxoSmithKline plc,28355,UK,GB,"anti-tuberculosis drugs (Mycobacterium tuberculosis infection), GlaxoSmithKline",90381,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-03-16 00:00:00,GlaxoSmithKline plc,28355,Discovery,2014-03-16 00:00:00,DR,6,Respiratory disease,711
Putative membrane protein mmpL3 inhibitor,85843,LOCAL_AND_MAJOR,GlaxoSmithKline plc,28355,UK,GB,BM-212,89603,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-07-20 00:00:00,GlaxoSmithKline plc,28355,Discovery,2012-07-20 00:00:00,DR,6,Respiratory disease,711
Unspecified vaccine,12380,LOCAL_AND_MAJOR,BioNet-Asia Co Ltd,1049946,Thailand,TH,"anti-tuberculosis vaccine, BioNet-Asia",91450,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-05-26 00:00:00,BioNet-Asia Co Ltd,1049946,Launched,2014-05-26 00:00:00,L,13,Respiratory disease,711
Antibacterial,1594,OTHER,Pfizer Inc,18767,Portugal,PT,rifabutin,4229,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2008-10-07 00:00:00,Pfizer Inc,18767,Launched,2007-03-21 00:00:00,L,13,Respiratory disease,711
RNA polymerase inhibitor,347,OTHER,Pfizer Inc,18767,Portugal,PT,rifabutin,4229,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2008-10-07 00:00:00,Pfizer Inc,18767,Launched,2007-03-21 00:00:00,L,13,Respiratory disease,711
Antibacterial multidrug resistance inhibitor,4855,LOCAL_AND_MAJOR,Pharmstandard OJSC,1047078,Russian Federation,RU,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Pharmstandard OJSC,1047078,Registered,2013-12-19 00:00:00,R,12,Respiratory disease,711
Antibacterial multidrug resistance inhibitor,4855,OTHER,Janssen Research & Development LLC,1067538,South Korea,KR,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Phase 2 Clinical,2009-12-17 00:00:00,C2,9,Respiratory disease,711
Antibacterial multidrug resistance inhibitor,4855,LOCAL_AND_MAJOR,Janssen Research & Development LLC,1067538,US,US,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Registered,2012-12-31 00:00:00,R,12,Respiratory disease,711
ATP synthase inhibitor,49687,OTHER,Janssen Research & Development LLC,1067538,Russian Federation,RU,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Discovery,2009-10-30 00:00:00,DR,6,Respiratory disease,711
Antibacterial multidrug resistance inhibitor,4855,OTHER,Janssen Research & Development LLC,1067538,Ukraine,UA,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Discovery,2009-07-30 00:00:00,DR,6,Respiratory disease,711
Antibacterial multidrug resistance inhibitor,4855,OTHER,Janssen Research & Development LLC,1067538,Philippines,PH,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Registered,2014-11-06 00:00:00,R,12,Respiratory disease,711
ATP synthase inhibitor,49687,OTHER,Janssen Research & Development LLC,1067538,Vietnam,VN,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Pre-registration,2014-11-06 00:00:00,PR,11,Respiratory disease,711
Alpha 1 antitrypsin modulator,1624,LOCAL_AND_MAJOR,Omni Bio Pharmaceutical Inc,1047826,US,US,"p-ATT (type 1/2 diabetes/influenza/tuberculosis/anthrax/HIV infection/transplant rejection/GVHD), Omni Bio",66767,Chemical,Phase 2 Clinical,Discovery,DR,C2,Mycobacterium tuberculosis infection,221,true,2013-01-31 00:00:00,Omni Bio Pharmaceutical Inc,1047826,Discovery,2010-08-06 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,EpiVax Inc,1009858,US,US,"T-cell epitope-based DNA vaccine (tuberculosis), EpiVax",68339,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,1997-12-31 00:00:00,EpiVax Inc,1009858,Discovery,1997-12-31 00:00:00,DR,6,Respiratory disease,711
Recombinant viral vector vaccine,12370,OTHER,ID Pharma Co Ltd,27318,Japan,JP,"SeV gene vaccine (tuberculosis), DNAVEC",70034,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-02-08 00:00:00,Lupin Ltd,21932,Discovery,2011-02-08 00:00:00,DR,6,Respiratory disease,711
Caspase recruitment domain protein-15 stimulator,10236,LOCAL_AND_MAJOR,Innate Immunotherapeutics Ltd,29958,US,US,"MIS-416/immunogen (anthrax/malaria/tuberculosis/neutropenia), Innate",60213,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-01-12 00:00:00,Innate Immunotherapeutics Ltd,29958,Discovery,2010-12-21 00:00:00,DR,6,Respiratory disease,711
Immunostimulant,393,LOCAL_AND_MAJOR,Innate Immunotherapeutics Ltd,29958,US,US,"MIS-416/immunogen (anthrax/malaria/tuberculosis/neutropenia), Innate",60213,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-01-12 00:00:00,Innate Immunotherapeutics Ltd,29958,Discovery,2010-12-21 00:00:00,DR,6,Respiratory disease,711
Antiparasitic,2638,LOCAL_AND_MAJOR,GlaxoSmithKline plc,28355,US,US,"thiolactomycin analog, GlaxoSmithKline",33073,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-08-08 00:00:00,GlaxoSmithKline plc,28355,Discovery,2001-02-28 00:00:00,DR,6,Respiratory disease,711
Inactivated bacterial vaccine,12366,LOCAL_AND_MAJOR,Dartmouth-Hitchcock Medical Center,30837,US,US,DAR-901,90231,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2014-02-28 00:00:00,Dartmouth-Hitchcock Medical Center,30837,Phase 1 Clinical,2014-02-28 00:00:00,C1,8,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,AstraZeneca plc,14190,US,US,CWGNC-4_1,90432,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-07-02 00:00:00,AstraZeneca plc,14190,Discovery,2012-07-02 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,AstraZeneca plc,14190,US,US,CWGNC-4_1,90432,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-07-02 00:00:00,AstraZeneca plc,14190,Discovery,2012-07-02 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Statens Serum Institut,21502,South Africa,ZA,SSI H56-IC31,74849,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-11-08 00:00:00,Statens Serum Institut,21502,Phase 2 Clinical,2013-11-08 00:00:00,C2,9,Respiratory disease,711
Protein synthesis inhibitor,339,LOCAL_AND_MAJOR,Microbiotix Inc,28907,US,US,MBX-600,76748,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-03-20 00:00:00,Microbiotix Inc,28907,Discovery,2012-03-20 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,iDialog,1054637,Russian Federation,RU,"heterocyclic compounds (Mycobacterium tuberculosis), iDialog",76783,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-03-21 00:00:00,ChemRar,1050615,Discovery,2012-03-21 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,iDialog,1054637,Russian Federation,RU,"heterocyclic compounds (Mycobacterium tuberculosis), iDialog",76783,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-03-21 00:00:00,ChemRar,1050615,Discovery,2012-03-21 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"tuberculosis therapy, TB Alliance/Johns Hopkins University",82716,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-06-30 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2012-11-30 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,OTHER,Chemical Diversity Research Institute Ltd,1009877,Russian Federation,RU,"small molecule therapeutics (Mycobacterium tuberculosis infection), ChemDiv Research Institute/Novartis Institute for Tropical Diseases/Silvius Pharma",76796,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2014-08-14 00:00:00,ChemDiv Inc,1012947,Discovery,2010-09-30 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,OTHER,Chemical Diversity Research Institute Ltd,1009877,Russian Federation,RU,"small molecule therapeutics (Mycobacterium tuberculosis infection), ChemDiv Research Institute/Novartis Institute for Tropical Diseases/Silvius Pharma",76796,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2014-08-14 00:00:00,ChemDiv Inc,1012947,Discontinued,2014-08-14 00:00:00,DX,3,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,National Institutes of Health,20518,US,US,"thiolactomycin analog, GlaxoSmithKline",33073,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-08-08 00:00:00,US Government,20516,No Development Reported,2008-08-08 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Johns Hopkins University,20596,US,US,"L-homoserine, Johns Hopkins",18364,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2001-01-30 00:00:00,Johns Hopkins University,20596,Discovery,1998-07-24 13:56:01,DR,6,Respiratory disease,711
DNA vaccine,1879,LOCAL_AND_MAJOR,Shanghai H&G Biotechnology Co,1066720,China,CN,"ESAT-6/Ag85A DNA vaccine (Mycobacterium tuberculosis), Shanghai H&G",75153,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-17 00:00:00,Shanghai H&G Biotechnology Co,1066720,Discovery,2011-12-20 00:00:00,DR,6,Respiratory disease,711
Mycobacterial antigen complex 85A modulator,33967,LOCAL_AND_MAJOR,Shanghai H&G Biotechnology Co,1066720,China,CN,"ESAT-6/Ag85A DNA vaccine (Mycobacterium tuberculosis), Shanghai H&G",75153,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-17 00:00:00,Shanghai H&G Biotechnology Co,1066720,No Development Reported,2013-01-17 00:00:00,NDR,2,Respiratory disease,711
Proteasome inhibitor,4917,LOCAL_AND_MAJOR,Harvard University,20584,US,US,"proteasome inhibitors (tuberculosis), Harvard University/Harvard University Office of Technology Development",86021,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-08-21 00:00:00,Harvard University,20584,Discovery,2012-02-01 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Fudan University,DOL1000375,China,CN,I-2906,67739,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-02-01 00:00:00,Fudan University,DOL1000375,Discovery,2009-10-16 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Fudan University,DOL1000375,China,CN,I-2906,67739,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-02-01 00:00:00,Fudan University,DOL1000375,Discovery,2009-10-16 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Fudan University,DOL1000375,China,CN,I-2906,67739,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-02-01 00:00:00,Fudan University,DOL1000375,No Development Reported,2013-02-01 00:00:00,NDR,2,Respiratory disease,711
Nitric oxide donor,698,LOCAL_AND_MAJOR,Chiron PathoGenesis,18741,US,US,pretomanid,13323,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-09-05 00:00:00,Novartis AG,23137,Suspended,2000-02-14 00:00:00,S,5,Respiratory disease,711
Aminoglycoside antibiotic,1541,OTHER,UMeWorld Ltd,28431,Canada,CA,"streptomycin (nanoparticle encapsulated, tuberculosis), AlphaRx",56894,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2011-08-02 00:00:00,UMeWorld Ltd,28431,Discovery,2007-02-20 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,UK National Institute of Medical Research,20466,UK,GB,"DNA vaccine (tuberculosis), NIMR/Sequella",22154,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-10-13 00:00:00,Medical Research Council (MRC),18438,Discovery,1999-02-19 00:00:00,DR,6,Respiratory disease,711
RNA polymerase inhibitor,347,LOCAL_AND_MAJOR,Nanosystem Ltd,1071336,Russian Federation,RU,"rifampicin nanoparticles (tuberculosis), NPK Nanosistema",81330,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-06-27 00:00:00,Nanosystem Ltd,1071336,Discovery,2010-07-01 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Intercell AG,28463,South Africa,ZA,SSI H56-IC31,74849,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2013-11-08 00:00:00,Valneva SE,1084202,Discontinued,2013-05-28 00:00:00,DX,3,Respiratory disease,711
Therapeutic vaccine,12379,OTHER,Intercell AG,28463,South Africa,ZA,SSI H56-IC31,74849,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2013-11-08 00:00:00,Valneva SE,1084202,Discontinued,2013-05-28 00:00:00,DX,3,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Chimerix Inc,30079,US,US,"Mycobacterium tuberculosis infection targeting compounds, Chimerix",69571,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-09-16 00:00:00,Chimerix Inc,30079,No Development Reported,2014-09-16 00:00:00,NDR,2,Respiratory disease,711
DNA vaccine,1879,LOCAL_AND_MAJOR,Shanghai H&G Biotechnology Co,1066720,China,CN,"Ag85A DNA vaccine (Mycobacterium tuberculosis), Shanghai H&G",75158,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-17 00:00:00,Shanghai H&G Biotechnology Co,1066720,No Development Reported,2013-01-17 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Microbion Corp,1055897,US,US,MBS-103,68316,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-09-25 00:00:00,Microbion Corp,1055897,Discovery,2010-09-27 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,Novartis Institute for Tropical Diseases Pvt Ltd,1017949,Singapore,SG,"small molecule therapeutics (Mycobacterium tuberculosis infection), ChemDiv Research Institute/Novartis Institute for Tropical Diseases/Silvius Pharma",76796,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2014-08-14 00:00:00,Novartis AG,23137,Discontinued,2014-08-14 00:00:00,DX,3,Respiratory disease,711
Immunomodulator,1596,LOCAL_AND_MAJOR,LeukoMed Inc,30043,US,US,LMP-420,41819,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2009-03-16 00:00:00,LeukoMed Inc,30043,Discovery,2002-09-26 00:00:00,DR,6,Respiratory disease,711
TNF alpha synthesis inhibitor,382,LOCAL_AND_MAJOR,LeukoMed Inc,30043,US,US,LMP-420,41819,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2009-03-16 00:00:00,LeukoMed Inc,30043,Discovery,2002-09-26 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Procrysta Biologix Inc,1080144,US,US,PCB-101,83811,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-04-18 00:00:00,Procrysta Biologix Inc,1080144,Discovery,2011-03-14 00:00:00,DR,6,Respiratory disease,711
DNA gyrase inhibitor,431,OTHER,Dainippon Pharmaceutical Co Ltd,15606,China,CN,sparfloxacin,4439,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,1999-12-31 00:00:00,Sumitomo Chemical Co Ltd,20268,Launched,1999-12-31 00:00:00,L,13,Respiratory disease,711
Antibacterial,1594,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Philippines,PH,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 2 Clinical,2008-04-30 00:00:00,C2,9,Respiratory disease,711
Anti-inflammatory,2953,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Philippines,PH,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 2 Clinical,2008-04-30 00:00:00,C2,9,Respiratory disease,711
Antibacterial,1594,OTHER,Otsuka Pharmaceutical Co Ltd,18717,South Korea,KR,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 2 Clinical,2008-04-30 00:00:00,C2,9,Respiratory disease,711
Mycolic acid synthase inhibitor,6542,OTHER,Otsuka Pharmaceutical Co Ltd,18717,South Korea,KR,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 2 Clinical,2008-04-30 00:00:00,C2,9,Respiratory disease,711
Anticancer,1545,LOCAL_AND_MAJOR,Otsuka Pharmaceutical Co Ltd,18717,Japan,JP,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 3 Clinical,2011-12-31 00:00:00,C3,10,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Otsuka Pharmaceutical Co Ltd,18717,Japan,JP,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 3 Clinical,2011-12-31 00:00:00,C3,10,Respiratory disease,711
Angiogenesis inhibitor,61,LOCAL_AND_MAJOR,Otsuka Pharmaceutical Co Ltd,18717,Japan,JP,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 3 Clinical,2011-12-31 00:00:00,C3,10,Respiratory disease,711
Anticancer,1545,OTHER,Otsuka Pharmaceutical Co Ltd,18717,South Africa,ZA,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 2 Clinical,2006-11-30 00:00:00,C2,9,Respiratory disease,711
Angiogenesis inhibitor,61,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Latvia,LV,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 2 Clinical,2008-04-30 00:00:00,C2,9,Respiratory disease,711
Anticancer,1545,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Latvia,LV,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 3 Clinical,2011-09-19 00:00:00,C3,10,Respiratory disease,711
Antibacterial,1594,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Lithuania,LT,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 3 Clinical,2011-09-19 00:00:00,C3,10,Respiratory disease,711
Mycolic acid synthase inhibitor,6542,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Lithuania,LT,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 3 Clinical,2011-09-19 00:00:00,C3,10,Respiratory disease,711
Anticancer,1545,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Philippines,PH,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 3 Clinical,2013-07-26 00:00:00,C3,10,Respiratory disease,711
Mycolic acid synthase inhibitor,6542,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Philippines,PH,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 3 Clinical,2013-07-26 00:00:00,C3,10,Respiratory disease,711
Angiogenesis inhibitor,61,OTHER,Otsuka Pharmaceutical Co Ltd,18717,South Korea,KR,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Registered,2014-10-29 00:00:00,R,12,Respiratory disease,711
Anticancer,1545,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Peru,PE,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 3 Clinical,2013-07-26 00:00:00,C3,10,Respiratory disease,711
Anti-inflammatory,2953,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Germany,DE,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Launched,2014-11-13 00:00:00,L,13,Respiratory disease,711
Mycolic acid synthase inhibitor,6542,LOCAL_AND_MAJOR,Otsuka Pharmaceutical Co Ltd,18717,Japan,JP,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Launched,2014-09-30 00:00:00,L,13,Respiratory disease,711
Bacterial protein synthesis inhibitor,1538,LOCAL_AND_MAJOR,AstraZeneca plc,14190,US,US,posizolid,26493,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2012-12-27 00:00:00,AstraZeneca plc,14190,Phase 1 Clinical,2009-12-22 00:00:00,C1,8,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,GenomIdea Inc,1008113,Japan,JP,"DNA vaccines (HJV vector, tuberculosis), GenomIdea",60030,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2007-04-20 00:00:00,AnGes MG Inc,28514,Discovery,2007-04-20 00:00:00,DR,6,Respiratory disease,711
Anticancer,1545,LOCAL_AND_MAJOR,Vakzine Projekt Management GmbH,1020740,Germany,DE,VPM-1002,55569,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-03-27 00:00:00,Vakzine Projekt Management GmbH,1020740,Phase 1 Clinical,2008-09-05 00:00:00,C1,8,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Vakzine Projekt Management GmbH,1020740,Germany,DE,VPM-1002,55569,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-03-27 00:00:00,Vakzine Projekt Management GmbH,1020740,Phase 2 Clinical,2011-09-26 00:00:00,C2,9,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Immunobiology Ltd,27371,UK,GB,T-Biovax,67683,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-10-17 00:00:00,Immunobiology Ltd,27371,Discovery,2010-08-11 00:00:00,DR,6,Respiratory disease,711
Heat shock protein modulator,7992,LOCAL_AND_MAJOR,Immunobiology Ltd,27371,UK,GB,T-Biovax,67683,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-10-17 00:00:00,Immunobiology Ltd,27371,Discovery,2010-08-11 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,GlaxoSmithKline plc,28355,US,US,"leucyl tRNA synthetase modulators (tuberculosis), GlaxoSmithKline",70581,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-10-17 00:00:00,GlaxoSmithKline plc,28355,Discovery,2013-10-17 00:00:00,DR,6,Respiratory disease,711
Bacterial cell wall synthesis inhibitor,104,LOCAL_AND_MAJOR,L2 Diagnostics Llc,1007281,US,US,"alanine racemase inhibitors (Mycobacterium tuberculosis infection), L2 Diagnostics",72479,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2015-01-02 00:00:00,L2 Diagnostics Llc,1007281,No Development Reported,2015-01-02 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Yonsei University,25184,South Korea,KR,"therapeutic DNA vaccine (tuberculosis), Pohang/Yonsei Universities",53019,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2009-12-24 00:00:00,Yonsei University,25184,Discovery,2003-09-30 00:00:00,DR,6,Respiratory disease,711
DNA vaccine,1879,LOCAL_AND_MAJOR,Genvax Ltd,1015643,UK,GB,"DNA vaccine (Mycobacterium tuberculosis infection), Genvax",57745,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2009-09-07 00:00:00,Medical Marketing International Group plc,1003702,No Development Reported,2009-09-07 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,OTHER,Pfizer Inc,18767,Singapore,SG,"rifampicin + isoniazid (fixed dose combination, tuberculosis), Pfizer",89460,Chemical,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-12-17 00:00:00,Pfizer Inc,18767,Phase 1 Clinical,2013-12-17 00:00:00,C1,8,Respiratory disease,711
Live attenuated bacterial vaccine,12363,OTHER,Universidad de Zaragoza,25210,South Africa,ZA,MTBVAC,89744,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-11-15 00:00:00,Universidad de Zaragoza,25210,Discovery,2013-11-15 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Universidad de Zaragoza,25210,Switzerland,CH,MTBVAC,89744,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-11-15 00:00:00,Universidad de Zaragoza,25210,Phase 1 Clinical,2013-01-31 00:00:00,C1,8,Respiratory disease,711
Protein kinase inhibitor,336,LOCAL_AND_MAJOR,The Vavilov Institute of General Genetics,1073514,Russian Federation,RU,"microbacterial protein kinase inhibitors (tuberculosis infection), The Vavilov Institute of General Genetics",81211,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-09-24 00:00:00,The Vavilov Institute of General Genetics,1073514,No Development Reported,2014-09-24 00:00:00,NDR,2,Respiratory disease,711
TGF beta antagonist,377,LOCAL_AND_MAJOR,InterMune Inc,26430,US,US,Actimmune,3365,Biological,Launched,No Development Reported,NDR,L,Mycobacterium tuberculosis infection,221,false,2014-09-19 00:00:00,Roche Holding AG,19446,No Development Reported,2007-03-31 00:00:00,NDR,2,Respiratory disease,711
Anticancer hormone,62253,LOCAL_AND_MAJOR,InterMune Inc,26430,US,US,Actimmune,3365,Biological,Launched,No Development Reported,NDR,L,Mycobacterium tuberculosis infection,221,false,2014-09-19 00:00:00,Roche Holding AG,19446,No Development Reported,2007-03-31 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,PolyMedix Inc,1011746,US,US,PMX-10072,63306,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2013-09-09 00:00:00,PolyMedix Inc,1011746,Discontinued,2013-09-09 00:00:00,DX,3,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Chiron PathoGenesis,18741,US,US,PA-342,10997,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,1996-11-01 00:00:00,Novartis AG,23137,Discovery,1995-09-26 13:55:49,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Southern Research Institute,20226,US,US,"tuberculosis therapy, iThemba Pharmaceuticals/Southern Research Institute",67092,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-06-22 00:00:00,Southern Research Institute,20226,No Development Reported,2012-06-22 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Phage Therapeutics Inc,27485,US,US,"bacteriophage (Mycobacterium tuberculosis infection), Phage Therapeutics",34469,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-12-31 00:00:00,Phage Therapeutics Inc,27485,Discontinued,2003-12-31 00:00:00,DX,3,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Sequella Inc,28087,US,US,"antibacterial diamines (tuberculosis), Sequella",56356,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-10-13 00:00:00,Sequella Inc,28087,No Development Reported,2008-10-13 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Sequella Inc,28087,US,US,"antibacterial diamines (tuberculosis), Sequella",56356,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-10-13 00:00:00,Sequella Inc,28087,No Development Reported,2008-10-13 00:00:00,NDR,2,Respiratory disease,711
Cell wall synthesis inhibitor,7052,LOCAL_AND_MAJOR,Sequella Inc,28087,US,US,"antibacterial diamines (tuberculosis), Sequella",56356,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-10-13 00:00:00,Sequella Inc,28087,No Development Reported,2008-10-13 00:00:00,NDR,2,Respiratory disease,711
CD4 agonist,5027,LOCAL_AND_MAJOR,ApoVax Inc,29552,US,US,ApoVax104-TB,68211,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2015-01-05 00:00:00,ApoVax Inc,29552,Discovery,2008-08-31 00:00:00,DR,6,Respiratory disease,711
Natural killer cell stimulator,7757,LOCAL_AND_MAJOR,ApoVax Inc,29552,US,US,ApoVax104-TB,68211,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2015-01-05 00:00:00,ApoVax Inc,29552,Discovery,2008-08-31 00:00:00,DR,6,Respiratory disease,711
CD4 agonist,5027,LOCAL_AND_MAJOR,ApoVax Inc,29552,US,US,ApoVax104-TB,68211,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2015-01-05 00:00:00,ApoVax Inc,29552,No Development Reported,2015-01-05 00:00:00,NDR,2,Respiratory disease,711
Natural killer cell stimulator,7757,LOCAL_AND_MAJOR,ApoVax Inc,29552,US,US,ApoVax104-TB,68211,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2015-01-05 00:00:00,ApoVax Inc,29552,No Development Reported,2015-01-05 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,GlaxoSmithKline plc,28355,UK,GB,"pleuromutilin derivatives (tuberculosis), GlaxoSmithKline/The Global Alliance for TB Drug Development",56410,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-06-18 00:00:00,GlaxoSmithKline plc,28355,Discovery,2005-03-21 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,GlaxoSmithKline plc,28355,UK,GB,"pleuromutilin derivatives (tuberculosis), GlaxoSmithKline/The Global Alliance for TB Drug Development",56410,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-06-18 00:00:00,GlaxoSmithKline plc,28355,No Development Reported,2012-06-18 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Medical Research Council Technology,1054893,UK,GB,"GlgE inhibitors (tuberculosis), MCRT",78428,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-06-25 00:00:00,Medical Research Council (MRC),18438,No Development Reported,2013-06-25 00:00:00,NDR,2,Respiratory disease,711
Antidepressant,2941,LOCAL_AND_MAJOR,National University of Singapore,20633,Singapore,SG,pascolizumab,17132,Biological,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2014-06-23 00:00:00,National University of Singapore,20633,Phase 2 Clinical,2012-10-11 00:00:00,C2,9,Respiratory disease,711
Anxiolytic,2942,LOCAL_AND_MAJOR,National University of Singapore,20633,Singapore,SG,pascolizumab,17132,Biological,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2014-06-23 00:00:00,National University of Singapore,20633,No Development Reported,2014-06-23 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Aquila Biopharmaceuticals Inc,24317,US,US,"tuberculosis vaccine (CD1), Antigenics",22778,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2002-10-15 00:00:00,Agenus Inc,23221,Discovery,1999-03-30 00:00:00,DR,6,Respiratory disease,711
Bacterial protein synthesis inhibitor,1538,LOCAL_AND_MAJOR,Sequella Inc,28087,US,US,sutezolid,11088,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-07-17 00:00:00,Sequella Inc,28087,Phase 1 Clinical,2013-07-17 00:00:00,C1,8,Respiratory disease,711
Bacterial protein synthesis inhibitor,1538,OTHER,Sequella Inc,28087,Europe,X5,sutezolid,11088,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-07-17 00:00:00,Sequella Inc,28087,Discovery,2013-07-17 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,OTHER,Sequella Inc,28087,Africa,X0,SQ-109,31010,Chemical,Phase 3 Clinical,Phase 3 Clinical,C3,C3,Mycobacterium tuberculosis infection,221,true,2012-12-19 00:00:00,Sequella Inc,28087,Phase 2 Clinical,2010-12-06 00:00:00,C2,9,Respiratory disease,711
Cell wall synthesis inhibitor,7052,OTHER,Sequella Inc,28087,Africa,X0,SQ-109,31010,Chemical,Phase 3 Clinical,Phase 3 Clinical,C3,C3,Mycobacterium tuberculosis infection,221,true,2012-12-19 00:00:00,Sequella Inc,28087,Phase 2 Clinical,2010-12-06 00:00:00,C2,9,Respiratory disease,711
Cell wall synthesis inhibitor,7052,LOCAL_AND_MAJOR,Infectex,1068619,Russian Federation,RU,SQ-109,31010,Chemical,Phase 3 Clinical,Phase 3 Clinical,C3,C3,Mycobacterium tuberculosis infection,221,true,2012-12-19 00:00:00,Maxwell Biotech Group,1061894,Phase 3 Clinical,2012-12-19 00:00:00,C3,10,Respiratory disease,711
Antiviral,991,LOCAL_AND_MAJOR,Verta Ltd,1004196,Russian Federation,RU,golotimod,25023,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2013-11-12 00:00:00,Verta Ltd,1004196,Launched,2008-08-15 00:00:00,L,13,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Crucell NV,17254,US,US,AERAS-402,53975,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2010-09-22 00:00:00,Johnson & Johnson,17332,Phase 1 Clinical,2006-10-25 00:00:00,C1,8,Respiratory disease,711
Recombinant viral vector vaccine,12370,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,AERAS-402,53975,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2010-09-22 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 1 Clinical,2006-10-25 00:00:00,C1,8,Respiratory disease,711
Recombinant viral vector vaccine,12370,LOCAL_AND_MAJOR,Polymun Scientific Immunobiologische Forschung GmbH,21851,Austria,AT,"tuberculosis vaccine (nasal, influenza virus carrier), Polymun",54201,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-06-10 00:00:00,Polymun Scientific Immunobiologische Forschung GmbH,21851,Phase 1 Clinical,2013-06-10 00:00:00,C1,8,Respiratory disease,711
Anticancer,1545,LOCAL_AND_MAJOR,Shenzhen Neptunus Interlong Bio-Technique Co Ltd,1015704,China,CN,"recombinant human interleukin-2 (cancer/AIDS/autoimmune disorders/infections), Shenzhen Neptunus",80864,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2012-09-10 00:00:00,Shenzhen Neptunus Bioengineering Co Ltd,1031729,Launched,2012-09-10 00:00:00,L,13,Respiratory disease,711
Immunomodulator,1596,LOCAL_AND_MAJOR,Shenzhen Neptunus Interlong Bio-Technique Co Ltd,1015704,China,CN,"recombinant human interleukin-2 (cancer/AIDS/autoimmune disorders/infections), Shenzhen Neptunus",80864,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2012-09-10 00:00:00,Shenzhen Neptunus Bioengineering Co Ltd,1031729,Launched,2012-09-10 00:00:00,L,13,Respiratory disease,711
Antiviral,991,LOCAL_AND_MAJOR,Shenzhen Neptunus Interlong Bio-Technique Co Ltd,1015704,China,CN,"recombinant human interleukin-2 (cancer/AIDS/autoimmune disorders/infections), Shenzhen Neptunus",80864,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2012-09-10 00:00:00,Shenzhen Neptunus Bioengineering Co Ltd,1031729,Launched,2012-09-10 00:00:00,L,13,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Cadila Pharmaceuticals Ltd,30025,India,IN,"rifampicin + isoniazid + piperine (fixed dose combination, tuberculosis), Cadila Pharmaceuticals",69440,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2009-10-31 00:00:00,Cadila Pharmaceuticals Ltd,30025,Launched,2009-10-31 00:00:00,L,13,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Mycosynthetix Inc,1060481,US,US,"anti-TB antibiotics (Mycobacterium tuberculosis), Mycosynthetix/Institute for Tuberculosis Research",70759,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2009-02-12 00:00:00,Mycosynthetix Inc,1060481,Discovery,2009-02-12 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"cyclopeptides (oral, tuberculosis), TB Alliance/Sanofi",82710,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-11-30 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2012-11-30 00:00:00,DR,6,Respiratory disease,711
Carbapenem,73547,LOCAL_AND_MAJOR,INSERM Transfert,1035636,France,FR,"L,D-transpeptidase inhibitors (Mycobacterium tuberculosis infection), INSERM",78290,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-05-24 00:00:00,INSERM,17229,Discovery,2012-05-24 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Institute of Medicinal Biotechnology Chinese Academy of Medical Sciences,1012170,China,CN,"small molecule antibiotic (Mycobacterium tuberculosis infection/Pseudomonas aeruginosa infection), Institute of Medicinal Biotechnology",83764,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-11-19 00:00:00,Chinese Academy of Medical Sciences & Peking Union Medical College,1066199,Discovery,2012-11-19 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Institute of Medicinal Biotechnology Chinese Academy of Medical Sciences,1012170,China,CN,"small molecule antibiotic (Mycobacterium tuberculosis infection/Pseudomonas aeruginosa infection), Institute of Medicinal Biotechnology",83764,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-11-19 00:00:00,Chinese Academy of Medical Sciences & Peking Union Medical College,1066199,Discovery,2012-11-19 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Sequella Inc,28087,US,US,"Mycobacterium tuberculosis MtrAB system inhibitors, Sequella",78689,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-03-01 00:00:00,Sequella Inc,28087,Discovery,2011-03-01 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Sequella Inc,28087,US,US,"Mycobacterium tuberculosis MtrAB system inhibitors, Sequella",78689,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-03-01 00:00:00,Sequella Inc,28087,Discovery,2011-03-01 00:00:00,DR,6,Respiratory disease,711
Recombinant bacterial vector vaccine,12369,LOCAL_AND_MAJOR,Finlay Institute,15912,Cuba,CU,"BCG/M smegmatis vector based live recombinant vaccine (tuberculosis infection), Finlay",73188,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2009-12-31 00:00:00,Finlay Institute,15912,Discovery,2009-12-31 00:00:00,DR,6,Respiratory disease,711
Protein subunit vaccine,12372,LOCAL_AND_MAJOR,Finlay Institute,15912,Cuba,CU,"BCG/M smegmatis vector based live recombinant vaccine (tuberculosis infection), Finlay",73188,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2009-12-31 00:00:00,Finlay Institute,15912,Discovery,2009-12-31 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Finlay Institute,15912,Cuba,CU,"BCG/M smegmatis vector based live recombinant vaccine (tuberculosis infection), Finlay",73188,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2009-12-31 00:00:00,Finlay Institute,15912,Discovery,2009-12-31 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Alberta Glycomics Centre,1071408,Canada,CA,"carbohydrate-based therapeutic agents (tuberculosis/mycobacterial infection), Alberta Glycomics Centre",79199,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-07-06 00:00:00,Alberta Glycomics Centre,1071408,Discovery,2012-07-06 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Alberta Glycomics Centre,1071408,Canada,CA,"carbohydrate-based therapeutic agents (tuberculosis/mycobacterial infection), Alberta Glycomics Centre",79199,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-07-06 00:00:00,Alberta Glycomics Centre,1071408,Discovery,2012-07-06 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,Vivonyx Inc,1071865,World,WO,"V-001, Vivonyx",79997,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2012-06-21 00:00:00,Vivonyx Inc,1071865,Launched,2012-06-21 00:00:00,L,13,Respiratory disease,711
Unspecified drug target,59620,OTHER,Vivonyx Inc,1071865,World,WO,"V-001, Vivonyx",79997,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2012-06-21 00:00:00,Vivonyx Inc,1071865,Launched,2012-06-21 00:00:00,L,13,Respiratory disease,711
Antiviral,991,OTHER,Harbor Therapeutics Inc,24345,Mexico,MX,HE-2000,19980,Chemical,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2013-01-28 00:00:00,Harbor Therapeutics Inc,24345,Discovery,2002-11-22 00:00:00,DR,6,Respiratory disease,711
Energy metabolism modulator,1732,OTHER,Harbor Therapeutics Inc,24345,Mexico,MX,HE-2000,19980,Chemical,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2013-01-28 00:00:00,Harbor Therapeutics Inc,24345,No Development Reported,2013-01-28 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Abera Bioscience AB,1091260,Sweden,SE,"multivalent vaccine (Bera-V, Mycobacterium tuberculosis infection), Abera Bioscience/Statens Serum/Institut Pasteur",89342,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-12-20 00:00:00,Abera Bioscience AB,1091260,Discovery,2013-12-20 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Anacor Pharmaceuticals Inc,30118,US,US,"anti-tuberculosis therapeutics, Anacor/Infectious Disease Research Institute",89753,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-12-31 00:00:00,Anacor Pharmaceuticals Inc,30118,Discovery,2009-05-27 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Vertex Pharmaceuticals Inc,20739,US,US,"anti-tuberculosis therapeutics, Vertex Pharmaceuticals",89966,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-06-12 00:00:00,Vertex Pharmaceuticals Inc,20739,Discovery,2013-06-12 00:00:00,DR,6,Respiratory disease,711
DXP reductoisomerase inhibitor,6324,LOCAL_AND_MAJOR,Colorado State University,20562,US,US,"inhibitors of isoprenoid biosynthesis enzymes (tuberculosis infection), The Lilly TB Drug Discovery Initiative/Colorado State University",89970,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-08-30 00:00:00,Colorado State University,20562,Discovery,2005-12-31 00:00:00,DR,6,Respiratory disease,711
Mycolic acid synthase inhibitor,6542,LOCAL_AND_MAJOR,BioVersys AG,1052531,Switzerland,CH,"EthR inhibitors (mycobacterium tuberculosis), BioVersys/ University of Lille/ GSK",92193,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-05-27 00:00:00,BioVersys AG,1052531,Discovery,2014-05-27 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Qurient Therapeutics,1062405,South Korea,KR,"TB A series (tuberculosis infection), Qurient",77998,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-06-28 00:00:00,Qurient Therapeutics,1062405,Discovery,2012-04-17 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Qurient Therapeutics,1062405,South Korea,KR,"TB A series (tuberculosis infection), Qurient",77998,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-06-28 00:00:00,Qurient Therapeutics,1062405,No Development Reported,2013-06-28 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Beijing Tuberculosis & Thoracic Tumor Research Institute,1060211,China,CN,TBI-166,57790,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2014-12-22 00:00:00,Beijing Tuberculosis & Thoracic Tumor Research Institute,1060211,Discovery,2011-03-28 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Beijing Tuberculosis & Thoracic Tumor Research Institute,1060211,China,CN,TBI-166,57790,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2014-12-22 00:00:00,Beijing Tuberculosis & Thoracic Tumor Research Institute,1060211,Discontinued,2013-06-30 00:00:00,DX,3,Respiratory disease,711
Protein kinase C modulator,1457,LOCAL_AND_MAJOR,"Indian Institute of Integrative Medicine, Jammu",1058778,India,IN,"rifampicin + isoniazid + piperine (fixed dose combination, tuberculosis), Cadila Pharmaceuticals",69440,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,false,2009-10-31 00:00:00,Council of Scientific and Industrial Research (India),15561,Discontinued,2009-10-31 00:00:00,DX,3,Respiratory disease,711
RNA polymerase inhibitor,347,LOCAL_AND_MAJOR,"Indian Institute of Integrative Medicine, Jammu",1058778,India,IN,"rifampicin + isoniazid + piperine (fixed dose combination, tuberculosis), Cadila Pharmaceuticals",69440,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,false,2009-10-31 00:00:00,Council of Scientific and Industrial Research (India),15561,Discontinued,2009-10-31 00:00:00,DX,3,Respiratory disease,711
Bacterial protein synthesis inhibitor,1538,OTHER,Pfizer Inc,18767,South Africa,ZA,sutezolid,11088,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2013-07-17 00:00:00,Pfizer Inc,18767,Phase 2 Clinical,2011-08-11 00:00:00,C2,9,Respiratory disease,711
Antibacterial,1594,OTHER,Pfizer Inc,18767,South Africa,ZA,sutezolid,11088,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2013-07-17 00:00:00,Pfizer Inc,18767,Discontinued,2013-07-17 00:00:00,DX,3,Respiratory disease,711
Ribosome binding agent,463,LOCAL_AND_MAJOR,Pfizer Inc,18767,US,US,sutezolid,11088,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2013-07-17 00:00:00,Pfizer Inc,18767,Discontinued,2013-07-17 00:00:00,DX,3,Respiratory disease,711
DNA gyrase inhibitor,431,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"quinolone analogs (Mycobacterium tuberculosis), KRICT/TB Alliance",57730,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-11-30 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2003-04-25 00:00:00,DR,6,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,Genesis Research and Development Corp Ltd,25513,New Zealand,NZ,"MED-1 vaccine (tuberculosis), Genesis",40637,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2009-04-30 00:00:00,Genesis Research and Development Corp Ltd,25513,Discovery,2002-01-29 00:00:00,DR,6,Respiratory disease,711
DNA gyrase inhibitor,431,LOCAL_AND_MAJOR,Korea Research Institute of Chemical Technology,17684,South Korea,KR,"quinolone analogs (Mycobacterium tuberculosis), KRICT/TB Alliance",57730,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-11-30 00:00:00,Korea Research Institute of Chemical Technology,17684,Discovery,2003-04-25 00:00:00,DR,6,Respiratory disease,711
DNA gyrase inhibitor,431,LOCAL_AND_MAJOR,Dong Wha Pharmaceutical Co Ltd,15745,South Korea,KR,DW-286,35974,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-04-27 00:00:00,Dong Wha Pharmaceutical Co Ltd,15745,No Development Reported,2006-08-13 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,University of Illinois,20592,US,US,"replicating and nonreplicating Mycobacterium tuberculosis inhibitors (tuberculosis), SRI International/University of Illinois",82340,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-07-25 00:00:00,University of Illinois,20592,No Development Reported,2013-07-25 00:00:00,NDR,2,Respiratory disease,711
Arabinosyltransferase inhibitor,6676,LOCAL_AND_MAJOR,Ohio State University,20649,US,US,"tuberculosis therapy, Ohio State University",17342,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2009-12-24 00:00:00,Ohio State University,20649,No Development Reported,2009-12-24 00:00:00,NDR,2,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Corixa Corp,15542,US,US,"MTB72F vaccine (tuberculosis), GSK/Aeras",9490,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-08-26 00:00:00,GlaxoSmithKline plc,28355,Discovery,1995-10-01 00:00:00,DR,6,Respiratory disease,711
Subunit vaccine,12371,LOCAL_AND_MAJOR,Corixa Corp,15542,US,US,"MTB72F vaccine (tuberculosis), GSK/Aeras",9490,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-08-26 00:00:00,GlaxoSmithKline plc,28355,Phase 1 Clinical,2004-03-08 00:00:00,C1,8,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,TBI-166,57790,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2014-12-22 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2007-01-11 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Institute of Materia Medica Chinese Academy of Medical Sciences & Peking Union Medical College,19595,China,CN,TBI-166,57790,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2014-12-22 00:00:00,Chinese Academy of Medical Sciences & Peking Union Medical College,1066199,No Development Reported,2014-12-22 00:00:00,NDR,2,Respiratory disease,711
DPR oxidase inhibitor,78977,LOCAL_AND_MAJOR,Scripps Research Institute,21102,US,US,"DprE inhibitors (tuberculosis), TB Alliance/California Institute for Biomedical Research",82660,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2013-06-30 00:00:00,Scripps Research Institute,21102,Discontinued,2013-06-30 00:00:00,DX,3,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Myongji University (MJU),1004393,South Korea,KR,"actinomycetes metabolites (multi-drug resistant tuberculosis infection), Univeristy of Illinois/Institute for Tuberculosis Research/Univeristy of Illinois at Urbana-Champaign",71899,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2014-01-24 00:00:00,Myongji University (MJU),1004393,No Development Reported,2013-09-26 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Myongji University (MJU),1004393,South Korea,KR,"actinomycetes metabolites (multi-drug resistant tuberculosis infection), Univeristy of Illinois/Institute for Tuberculosis Research/Univeristy of Illinois at Urbana-Champaign",71899,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2014-01-24 00:00:00,Myongji University (MJU),1004393,No Development Reported,2013-09-26 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,SRI International,20234,US,US,"replicating and nonreplicating Mycobacterium tuberculosis inhibitors (tuberculosis), SRI International/University of Illinois",82340,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-07-25 00:00:00,SRI International,20234,No Development Reported,2013-07-25 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Epimmune Inc,15573,US,US,Theradigm-tuberculosis,10406,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2001-12-09 00:00:00,Takeda Pharmaceutical Co Ltd,20300,No Development Reported,2001-12-09 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Epimmune Inc,15573,US,US,Theradigm-tuberculosis,10406,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2001-12-09 00:00:00,Takeda Pharmaceutical Co Ltd,20300,Discovery,1995-06-22 14:36:07,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Antibiotic Co,24897,Bulgaria,BG,T9,10994,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2002-01-02 00:00:00,Antibiotic Co,24897,No Development Reported,2002-01-02 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Antibiotic Co,24897,Bulgaria,BG,T9,10994,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2002-01-02 00:00:00,Antibiotic Co,24897,No Development Reported,2002-01-02 00:00:00,NDR,2,Respiratory disease,711
Anticancer,1545,OTHER,Silence Therapeutics plc,22356,Tanzania,TZ,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,2003-05-06 00:00:00,DX,3,Respiratory disease,711
Systemic antipsoriatic product,15184,OTHER,Silence Therapeutics plc,22356,Tanzania,TZ,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,2003-05-06 00:00:00,DX,3,Respiratory disease,711
Inactivated bacterial vaccine,12366,OTHER,Silence Therapeutics plc,22356,Zambia,ZM,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Antimicrobial,1593,OTHER,Silence Therapeutics plc,22356,Nigeria,NG,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Cytokine release modulator,1291,OTHER,Silence Therapeutics plc,22356,Gambia,GM,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Inactivated bacterial vaccine,12366,OTHER,Silence Therapeutics plc,22356,Gambia,GM,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Antiviral,991,OTHER,Silence Therapeutics plc,22356,Zambia,ZM,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 3 Clinical,1997-10-13 00:00:00,C3,10,Respiratory disease,711
Anticancer,1545,OTHER,Silence Therapeutics plc,22356,Zambia,ZM,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 3 Clinical,1997-10-13 00:00:00,C3,10,Respiratory disease,711
Antibacterial,1594,OTHER,Silence Therapeutics plc,22356,Gambia,GM,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 3 Clinical,1997-10-13 00:00:00,C3,10,Respiratory disease,711
Cytokine release modulator,1291,OTHER,Silence Therapeutics plc,22356,Nigeria,NG,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,1995-10-12 00:00:00,C2,9,Respiratory disease,711
Therapeutic vaccine,12379,OTHER,Silence Therapeutics plc,22356,Nigeria,NG,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,1995-10-12 00:00:00,C2,9,Respiratory disease,711
Cytokine release modulator,1291,OTHER,Silence Therapeutics plc,22356,Gambia,GM,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,1995-10-12 00:00:00,C2,9,Respiratory disease,711
Therapeutic vaccine,12379,OTHER,Silence Therapeutics plc,22356,Gambia,GM,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,1995-10-12 00:00:00,C2,9,Respiratory disease,711
Therapeutic vaccine,12379,OTHER,Silence Therapeutics plc,22356,Kuwait,KW,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,1995-10-12 00:00:00,C2,9,Respiratory disease,711
Inactivated bacterial vaccine,12366,OTHER,Silence Therapeutics plc,22356,Kuwait,KW,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,1995-10-12 00:00:00,C2,9,Respiratory disease,711
Antiparasitic,2638,LOCAL_AND_MAJOR,Indiana University,20593,US,US,"dihydrofolate reductase inhibitors, Duquesne/Indiana",12146,Chemical,Discovery,No Development Reported,NDR,DR,Mycobacterium tuberculosis infection,221,true,2011-01-04 00:00:00,Indiana University,20593,No Development Reported,2011-01-04 00:00:00,NDR,2,Respiratory disease,711
Fungicide,1748,LOCAL_AND_MAJOR,Indiana University,20593,US,US,"dihydrofolate reductase inhibitors, Duquesne/Indiana",12146,Chemical,Discovery,No Development Reported,NDR,DR,Mycobacterium tuberculosis infection,221,true,2011-01-04 00:00:00,Indiana University,20593,No Development Reported,2011-01-04 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Indiana University,20593,US,US,"dihydrofolate reductase inhibitors, Duquesne/Indiana",12146,Chemical,Discovery,No Development Reported,NDR,DR,Mycobacterium tuberculosis infection,221,true,2011-01-04 00:00:00,Indiana University,20593,No Development Reported,2011-01-04 00:00:00,NDR,2,Respiratory disease,711
Antiparasitic,2638,LOCAL_AND_MAJOR,Indiana University,20593,US,US,"dihydrofolate reductase inhibitors, Duquesne/Indiana",12146,Chemical,Discovery,No Development Reported,NDR,DR,Mycobacterium tuberculosis infection,221,true,2011-01-04 00:00:00,Indiana University,20593,Discovery,2003-03-30 00:00:00,DR,6,Respiratory disease,711
Ribosome binding agent,463,LOCAL_AND_MAJOR,PathoGenesis Ltd,24982,US,US,"tobramycin (nebulized), Novartis",11232,Chemical,Launched,No Development Reported,NDR,L,Mycobacterium tuberculosis infection,221,true,2013-01-09 00:00:00,Novartis AG,23137,Discovery,1996-05-01 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,PathoGenesis Ltd,24982,US,US,"tobramycin (nebulized), Novartis",11232,Chemical,Launched,No Development Reported,NDR,L,Mycobacterium tuberculosis infection,221,true,2013-01-09 00:00:00,Novartis AG,23137,Discovery,1996-05-01 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Whitehead Institute for Biomedical Research,20939,US,US,"vaccine (BCG), Connaught/Whitehead",12124,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2001-08-24 00:00:00,Whitehead Institute for Biomedical Research,20939,Discovery,1996-04-18 00:00:00,DR,6,Respiratory disease,711
Live attenuated bacterial vaccine,12363,LOCAL_AND_MAJOR,Whitehead Institute for Biomedical Research,20939,US,US,"vaccine (BCG), Connaught/Whitehead",12124,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2001-08-24 00:00:00,Whitehead Institute for Biomedical Research,20939,Discovery,1996-04-18 00:00:00,DR,6,Respiratory disease,711
Live attenuated bacterial vaccine,12363,LOCAL_AND_MAJOR,Trustees of Health & Hospitals of The City of Boston,21398,US,US,"vaccine (BCG), Connaught/Whitehead",12124,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2001-08-24 00:00:00,Trustees of Health & Hospitals of The City of Boston,21398,No Development Reported,2001-08-24 00:00:00,NDR,2,Respiratory disease,711
Live attenuated bacterial vaccine,12363,LOCAL_AND_MAJOR,Trustees of Health & Hospitals of The City of Boston,21398,US,US,"vaccine (BCG), Connaught/Whitehead",12124,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2001-08-24 00:00:00,Trustees of Health & Hospitals of The City of Boston,21398,Discovery,1996-04-18 00:00:00,DR,6,Respiratory disease,711
Antiparasitic,2638,LOCAL_AND_MAJOR,Duquesne University,20569,US,US,"dihydrofolate reductase inhibitors, Duquesne/Indiana",12146,Chemical,Discovery,No Development Reported,NDR,DR,Mycobacterium tuberculosis infection,221,true,2011-01-04 00:00:00,Duquesne University,20569,Discovery,2003-03-30 00:00:00,DR,6,Respiratory disease,711
Topoisomerase IV inhibitor,9320,OTHER,The Global Alliance for TB Drug Development,29411,Haiti,HT,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2014-10-14 00:00:00,DR,6,Respiratory disease,711
Bacterial nucleic acid synthesis inhibitor,3984,OTHER,The Global Alliance for TB Drug Development,29411,Peru,PE,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2014-10-14 00:00:00,DR,6,Respiratory disease,711
Bacterial nucleic acid synthesis inhibitor,3984,OTHER,The Global Alliance for TB Drug Development,29411,Malaysia,MY,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,The Global Alliance for TB Drug Development,29411,Phase 3 Clinical,2014-08-04 00:00:00,C3,10,Respiratory disease,711
DNA gyrase inhibitor,431,OTHER,The Global Alliance for TB Drug Development,29411,Africa,X0,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,The Global Alliance for TB Drug Development,29411,Phase 3 Clinical,2007-11-08 00:00:00,C3,10,Respiratory disease,711
Bacterial nucleic acid synthesis inhibitor,3984,OTHER,The Global Alliance for TB Drug Development,29411,Africa,X0,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,The Global Alliance for TB Drug Development,29411,Phase 3 Clinical,2007-11-08 00:00:00,C3,10,Respiratory disease,711
Bacterial nucleic acid synthesis inhibitor,3984,OTHER,The Global Alliance for TB Drug Development,29411,World,WO,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,The Global Alliance for TB Drug Development,29411,Phase 2 Clinical,2005-10-17 00:00:00,C2,9,Respiratory disease,711
Topoisomerase IV inhibitor,9320,OTHER,Bayer AG,14455,China,CN,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,Bayer AG,14455,Phase 3 Clinical,2011-10-19 00:00:00,C3,10,Respiratory disease,711
DNA gyrase inhibitor,431,OTHER,Bayer AG,14455,China,CN,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,Bayer AG,14455,Phase 3 Clinical,2011-10-19 00:00:00,C3,10,Respiratory disease,711
Topoisomerase IV inhibitor,9320,OTHER,Bayer AG,14455,Spain,ES,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,Bayer AG,14455,Phase 2 Clinical,2005-10-17 00:00:00,C2,9,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Hoechst Marion Roussel Inc,25224,US,US,rifapentine,15102,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-12-02 00:00:00,Sanofi,1009547,Launched,1998-10-31 00:00:00,L,13,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Hoechst Marion Roussel Inc,25224,US,US,rifapentine,15102,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-12-02 00:00:00,Sanofi,1009547,Phase 3 Clinical,1997-05-08 17:17:42,C3,10,Respiratory disease,711
DNA synthesis inhibitor,140,LOCAL_AND_MAJOR,Harbor Therapeutics Inc,24345,US,US,PP-29,15867,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2003-07-02 00:00:00,Harbor Therapeutics Inc,24345,No Development Reported,2003-07-02 00:00:00,NDR,2,Respiratory disease,711
Antiparasitic,2638,LOCAL_AND_MAJOR,Harbor Therapeutics Inc,24345,US,US,PP-29,15867,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2003-07-02 00:00:00,Harbor Therapeutics Inc,24345,Discovery,1997-03-01 00:00:00,DR,6,Respiratory disease,711
TLR-2 agonist,7806,LOCAL_AND_MAJOR,Universidade Estadual de Campinas,24983,Brazil,BR,P-MAPA,15596,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-06-18 00:00:00,Universidade Estadual de Campinas,24983,Discovery,2009-03-21 00:00:00,DR,6,Respiratory disease,711
Nuclease inhibitor,9166,LOCAL_AND_MAJOR,Georgia State University,21235,US,US,pafuramidine,16755,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2008-02-22 00:00:00,Georgia State University,21235,Discontinued,2000-01-28 00:00:00,DX,3,Respiratory disease,711
Antiparasitic,2638,LOCAL_AND_MAJOR,Georgia State University,21235,US,US,pafuramidine,16755,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2008-02-22 00:00:00,Georgia State University,21235,Discovery,2000-10-23 00:00:00,DR,6,Respiratory disease,711
Topoisomerase II inhibitor,142,LOCAL_AND_MAJOR,Georgia State University,21235,US,US,pafuramidine,16755,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2008-02-22 00:00:00,Georgia State University,21235,Discovery,2000-10-23 00:00:00,DR,6,Respiratory disease,711
Antiparasitic,2638,LOCAL_AND_MAJOR,University of Illinois,20592,US,US,pafuramidine,16755,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2008-02-22 00:00:00,University of Illinois,20592,Discovery,2000-10-23 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,University of Illinois,20592,US,US,pafuramidine,16755,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2008-02-22 00:00:00,University of Illinois,20592,Discovery,2000-10-23 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Wellesley College,25687,US,US,"antimycobacterials, Wellesley College",18382,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2001-11-28 00:00:00,Wellesley College,25687,No Development Reported,2001-11-28 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Wellesley College,25687,US,US,"antimycobacterials, Wellesley College",18382,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2001-11-28 00:00:00,Wellesley College,25687,Discovery,1998-07-24 15:57:33,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Panacea Biotec Ltd,25333,India,IN,Panacea-0394,29616,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-02-20 00:00:00,Panacea Biotec Ltd,25333,No Development Reported,2008-02-20 00:00:00,NDR,2,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Sequella Inc,28087,US,US,"peptide vaccine (tuberculosis), Intercell/Sequella",32516,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2004-04-30 00:00:00,Sequella Inc,28087,No Development Reported,2004-04-30 00:00:00,NDR,2,Respiratory disease,711
Radiodiagnostic,5720,LOCAL_AND_MAJOR,Navidea Biopharmaceuticals Inc,18471,US,US,technetium Tc 99m tilmanocept,34061,Chemical,Launched,Discovery,DR,L,Mycobacterium tuberculosis infection,221,true,2014-12-12 00:00:00,Navidea Biopharmaceuticals Inc,18471,Discovery,2013-09-19 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Medivir AB,18015,Sweden,SE,"antibacterial protease inhibitors, Medivir/University of London",35747,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2003-08-19 00:00:00,Medivir AB,18015,Discovery,2001-08-28 12:25:25,DR,6,Respiratory disease,711
DNA vaccine,1879,LOCAL_AND_MAJOR,Oxxon Therapeutics Ltd,27753,UK,GB,"TB vaccine (prophylactic, Prime-Boost), Oxxon Therapeutics",42764,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2009-01-02 00:00:00,Oxford BioMedica plc,23434,No Development Reported,2009-01-02 00:00:00,NDR,2,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Oxxon Therapeutics Ltd,27753,UK,GB,"TB vaccine (prophylactic, Prime-Boost), Oxxon Therapeutics",42764,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2009-01-02 00:00:00,Oxford BioMedica plc,23434,Phase 1 Clinical,2002-11-28 00:00:00,C1,8,Respiratory disease,711
Anti-inflammatory,2953,LOCAL_AND_MAJOR,Sankyo Co Ltd,19658,Japan,JP,"capuramycin derivative translocase inhibitors (tuberculosis, Clostridium difficile infection, Chrons disease), Sequella",48440,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2012-05-03 00:00:00,Daiichi Sankyo Co Ltd,1017506,Discontinued,2004-11-01 00:00:00,DX,3,Respiratory disease,711
Phospho MurNAc pentapeptide transferase inhibitor,64334,LOCAL_AND_MAJOR,Sankyo Co Ltd,19658,Japan,JP,"capuramycin derivative translocase inhibitors (tuberculosis, Clostridium difficile infection, Chrons disease), Sequella",48440,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2012-05-03 00:00:00,Daiichi Sankyo Co Ltd,1017506,Discovery,2003-09-01 00:00:00,DR,6,Respiratory disease,711
Protein subunit vaccine,12372,OTHER,Aeras Global TB Vaccine Foundation,1007376,Finland,FI,"HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell",48499,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-07-29 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 1 Clinical,2009-01-26 00:00:00,C1,8,Respiratory disease,711
Protein subunit vaccine,12372,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,"HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell",48499,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-07-29 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Discovery,2005-03-30 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Statens Serum Institut,21502,Finland,FI,"HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell",48499,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-07-29 00:00:00,Statens Serum Institut,21502,Phase 1 Clinical,2009-01-26 00:00:00,C1,8,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,NicOx SA,23741,France,FR,NCX-976,47140,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2005-01-31 00:00:00,NicOx SA,23741,Discovery,2003-07-31 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Intercell AG,28463,Austria,AT,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2013-05-28 00:00:00,Valneva SE,1084202,Discovery,2004-03-17 00:00:00,DR,6,Respiratory disease,711
Protein subunit vaccine,12372,OTHER,Valneva SE,1084202,South Africa,ZA,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-05-28 00:00:00,Valneva SE,1084202,Phase 2 Clinical,2013-05-28 00:00:00,C2,9,Respiratory disease,711
Protein subunit vaccine,12372,LOCAL_AND_MAJOR,Sanofi Pasteur,22127,France,FR,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-05-28 00:00:00,Sanofi,1009547,Phase 1 Clinical,2008-02-12 00:00:00,C1,8,Respiratory disease,711
Recombinant bacterial vector vaccine,12369,OTHER,Statens Serum Institut,21502,Netherlands,NL,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-05-28 00:00:00,Statens Serum Institut,21502,Phase 2 Clinical,2009-03-02 00:00:00,C2,9,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Statens Serum Institut,21502,South Africa,ZA,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-05-28 00:00:00,Statens Serum Institut,21502,Phase 2 Clinical,2012-01-11 00:00:00,C2,9,Respiratory disease,711
Protein subunit vaccine,12372,OTHER,Statens Serum Institut,21502,Tanzania,TZ,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-05-28 00:00:00,Statens Serum Institut,21502,Phase 2 Clinical,2012-01-11 00:00:00,C2,9,Respiratory disease,711
Recombinant bacterial vector vaccine,12369,OTHER,Statens Serum Institut,21502,Netherlands,NL,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-05-28 00:00:00,Statens Serum Institut,21502,Phase 1 Clinical,2005-11-18 00:00:00,C1,8,Respiratory disease,711
RNA polymerase inhibitor,347,OTHER,UMeWorld Ltd,28431,Canada,CA,"rifampicin (nanoparticle encapsulated, tuberculosis), AlphaRx",53605,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2009-01-08 00:00:00,UMeWorld Ltd,28431,No Development Reported,2009-01-08 00:00:00,NDR,2,Respiratory disease,711
Adjuvant,524,LOCAL_AND_MAJOR,Cadila Pharmaceuticals Ltd,30025,India,IN,cadi-05,55173,Biological,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2014-12-03 00:00:00,Cadila Pharmaceuticals Ltd,30025,Phase 3 Clinical,2005-03-31 00:00:00,C3,10,Respiratory disease,711
Recombinant viral vector vaccine,12370,OTHER,Oxford-Emergent Tuberculosis Consortium Ltd,1040955,Senegal,SN,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-07 00:00:00,Emergent BioSolutions Inc,1011990,Discontinued,2014-03-07 00:00:00,DX,3,Respiratory disease,711
Recombinant viral vector vaccine,12370,OTHER,Oxford-Emergent Tuberculosis Consortium Ltd,1040955,UK,GB,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-07 00:00:00,Emergent BioSolutions Inc,1011990,Discontinued,2014-03-07 00:00:00,DX,3,Respiratory disease,711
Mycobacterial antigen complex 85A modulator,33967,OTHER,Oxford-Emergent Tuberculosis Consortium Ltd,1040955,South Africa,ZA,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-07 00:00:00,Emergent BioSolutions Inc,1011990,Phase 2 Clinical,2008-07-23 00:00:00,C2,9,Respiratory disease,711
Mycobacterial antigen complex 85A modulator,33967,OTHER,Oxford-Emergent Tuberculosis Consortium Ltd,1040955,Senegal,SN,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-07 00:00:00,Emergent BioSolutions Inc,1011990,Phase 2 Clinical,2011-08-08 00:00:00,C2,9,Respiratory disease,711
Mycobacterial antigen complex 85A modulator,33967,LOCAL_AND_MAJOR,University of Oxford,22182,UK,GB,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-07 00:00:00,University of Oxford,22182,Phase 1 Clinical,2002-09-30 00:00:00,C1,8,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,TB-VAC,1020621,Africa,X0,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-03-07 00:00:00,TB-VAC,1020621,Clinical,2007-03-25 00:00:00,CU,7,Respiratory disease,711
Recombinant viral vector vaccine,12370,OTHER,Emergent BioSolutions Inc,1011990,UK,GB,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-03-07 00:00:00,Emergent BioSolutions Inc,1011990,Phase 1 Clinical,2014-03-07 00:00:00,C1,8,Respiratory disease,711
Antibacterial,1594,OTHER,GlaxoSmithKline plc,28355,Spain,ES,"InhA inhibitors (oral/tuberculosis), GlaxoSmithKline/The Global Alliance for TB Drug Development",56371,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2005-03-21 00:00:00,GlaxoSmithKline plc,28355,Discovery,2005-03-21 00:00:00,DR,6,Respiratory disease,711
Topoisomerase inhibitor,143,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"gyrase inhibitors (Mycobacterium tuberculosis infection), GlaxoSmithKline/The Global Alliance for TB Drug Development",57733,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2006-12-31 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2006-12-31 00:00:00,DR,6,Respiratory disease,711
Topoisomerase inhibitor,143,LOCAL_AND_MAJOR,GlaxoSmithKline plc,28355,UK,GB,"gyrase inhibitors (Mycobacterium tuberculosis infection), GlaxoSmithKline/The Global Alliance for TB Drug Development",57733,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2006-12-31 00:00:00,GlaxoSmithKline plc,28355,Discovery,2006-12-31 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"antibacterial compounds (Mycobacterium tuberculosis), Cumbre/The Global Alliance for TB Drug Development",57737,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2009-12-22 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2006-09-27 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Summit Plc,1017551,UK,GB,"N-acetyltransferase inhibitors (tuberculosis), Summit/Lilly TB Drug Discovery Initiative",57219,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2008-10-07 00:00:00,Summit Plc,1017551,Discovery,2005-05-03 00:00:00,DR,6,Respiratory disease,711
Cytochrome P450 reductase inhibitor,416,LOCAL_AND_MAJOR,NeED Pharmaceuticals Srl,1013076,Italy,IT,ND-701,59777,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-03-21 00:00:00,NeED Pharmaceuticals Srl,1013076,Discovery,2007-04-25 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,NeED Pharmaceuticals Srl,1013076,Italy,IT,ND-701,59777,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-03-21 00:00:00,NeED Pharmaceuticals Srl,1013076,Discovery,2007-04-25 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,NeED Pharmaceuticals Srl,1013076,Italy,IT,ND-201,59784,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-03-21 00:00:00,NeED Pharmaceuticals Srl,1013076,Discovery,2008-04-01 00:00:00,DR,6,Respiratory disease,711
Therapeutic vaccine,12379,OTHER,Avanti Therapeutics,1045576,World,WO,"tuberculosis vaccine, Avanti Therapeutics",62573,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-09-25 00:00:00,Avanti Therapeutics,1045576,No Development Reported,2013-09-25 00:00:00,NDR,2,Respiratory disease,711
Immunostimulant,393,OTHER,SinoBiomed Inc,1032007,China,CN,"recombinant multivalent tuberculosis vaccine, SinoBiomed",61931,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2011-01-06 00:00:00,SinoBiomed Inc,1032007,No Development Reported,2011-01-06 00:00:00,NDR,2,Respiratory disease,711
Immunostimulant,393,OTHER,SinoBiomed Inc,1032007,China,CN,"recombinant multivalent tuberculosis vaccine, SinoBiomed",61931,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2011-01-06 00:00:00,SinoBiomed Inc,1032007,Discovery,2008-08-21 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,OTHER,Upstream Biosciences Inc,1035256,Canada,CA,"antibacterial therapies (tuberculosis), Upstream Biosciences",62917,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-01-10 00:00:00,Upstream Biosciences Inc,1035256,Discovery,2009-01-31 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,Emory University,20573,South Africa,ZA,"isocitrate lyase prodrug inhibitors (tuberculosis), iThemba Pharmaceuticals",65567,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2008-03-31 00:00:00,Emory University,20573,Discontinued,2008-03-31 00:00:00,DX,3,Respiratory disease,711
Protein subunit vaccine,12372,OTHER,Statens Serum Institut,21502,UK,GB,"protein subunit vaccine (Mycobacterium tuberculosis, intranasal), Novartis Vaccines & Diagnostics/Statens Serum Institut",66563,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2011-11-30 00:00:00,Statens Serum Institut,21502,No Development Reported,2011-11-30 00:00:00,NDR,2,Respiratory disease,711
Unspecified vaccine,12380,LOCAL_AND_MAJOR,Immune Solutions Ltd,1053537,New Zealand,NZ,"BCG Vaccine (oral lipid matrix, Liporale), Immune Solutions/Aeras Global TB foundation",66314,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2010-05-04 00:00:00,Immune Solutions Ltd,1053537,Discovery,2010-05-04 00:00:00,DR,6,Respiratory disease,711
Recombinant viral vector vaccine,12370,OTHER,Imaxio,1007058,UK,GB,IMX-461,66409,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-08-01 00:00:00,Imaxio,1007058,Phase 1 Clinical,2013-08-01 00:00:00,C1,8,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Imaxio,1007058,France,FR,IMX-461,66409,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-08-01 00:00:00,Imaxio,1007058,Phase 1 Clinical,2010-05-06 00:00:00,C1,8,Respiratory disease,711
Mycobacterial antigen complex 85A modulator,33967,LOCAL_AND_MAJOR,Imaxio,1007058,France,FR,IMX-461,66409,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-08-01 00:00:00,Imaxio,1007058,Discovery,2012-03-02 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,iThemba Pharmaceuticals Pty Ltd,1049788,South Africa,ZA,"nitroimidazole derivatives (tuberculosis), iThemba Pharmaceuticals",67090,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2010-05-06 00:00:00,iThemba Pharmaceuticals Pty Ltd,1049788,Discovery,2010-05-06 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,Aeras Global TB Vaccine Foundation,1007376,South Africa,ZA,ID-93,68617,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-09-20 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 1 Clinical,2013-09-20 00:00:00,C1,8,Respiratory disease,711
Therapeutic vaccine,12379,OTHER,Aeras Global TB Vaccine Foundation,1007376,South Africa,ZA,ID-93,68617,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-09-20 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 1 Clinical,2013-09-20 00:00:00,C1,8,Respiratory disease,711
Adjuvant,524,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,ID-93,68617,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-09-20 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Discovery,2012-05-09 00:00:00,DR,6,Respiratory disease,711
Protein subunit vaccine,12372,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,ID-93,68617,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-09-20 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Discovery,2012-05-09 00:00:00,DR,6,Respiratory disease,711
Adjuvant,524,OTHER,Infectious Disease Research Institute,27376,South Africa,ZA,ID-93,68617,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-09-20 00:00:00,Infectious Disease Research Institute,27376,Phase 1 Clinical,2013-09-20 00:00:00,C1,8,Respiratory disease,711
Adjuvant,524,LOCAL_AND_MAJOR,Infectious Disease Research Institute,27376,US,US,ID-93,68617,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-09-20 00:00:00,Infectious Disease Research Institute,27376,Phase 1 Clinical,2012-08-15 00:00:00,C1,8,Respiratory disease,711
Adjuvant,524,LOCAL_AND_MAJOR,Infectious Disease Research Institute,27376,US,US,ID-93,68617,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-09-20 00:00:00,Infectious Disease Research Institute,27376,Discovery,2009-12-31 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Bio Farma,19368,Indonesia,ID,Lipovax-Fg115-TB,68627,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2015-04-16 00:00:00,Bio Farma,19368,Discovery,2015-04-16 00:00:00,DR,6,Respiratory disease,711
Bacterial pathogenicity factor modulator,3983,LOCAL_AND_MAJOR,Vichem Chemie Ltd,1031147,Hungary,HU,"PknG inhibitors (Mycobacterium tuberculosis infection), Vichem Chemie",68370,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2015-04-24 00:00:00,Vichem Chemie Ltd,1031147,No Development Reported,2015-04-24 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Vichem Chemie Ltd,1031147,Hungary,HU,"PknG inhibitors (Mycobacterium tuberculosis infection), Vichem Chemie",68370,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2015-04-24 00:00:00,Vichem Chemie Ltd,1031147,No Development Reported,2015-04-24 00:00:00,NDR,2,Respiratory disease,711
A-G adenine DNA glycosylase inhibitor,10360,LOCAL_AND_MAJOR,Medical Research Council Technology,1054893,UK,GB,"Mut Y inhibitors (Mycobacterium tuberculosis infection), MRCT",66921,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-06-21 00:00:00,Medical Research Council (MRC),18438,Discovery,2010-06-17 00:00:00,DR,6,Respiratory disease,711
Recombinant bacterial vector vaccine,12369,LOCAL_AND_MAJOR,VIB,25058,Belgium,BE,"tuberculosis vaccine, VIB/Ghent University",70144,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-10-07 00:00:00,University of Antwerp,22741,No Development Reported,2014-10-07 00:00:00,NDR,2,Respiratory disease,711
Recombinant bacterial vector vaccine,12369,LOCAL_AND_MAJOR,University of Ghent,24987,Belgium,BE,"tuberculosis vaccine, VIB/Ghent University",70144,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-10-07 00:00:00,University of Ghent,24987,Discovery,2011-01-26 00:00:00,DR,6,Respiratory disease,711
Protein tyrosine phosphatase beta inhibitor,36900,LOCAL_AND_MAJOR,Aarden Pharmaceuticals Inc,1058608,US,US,"protein tyrosine phosphatase inhibitor (tuberculosis infection, cancer, autoimmune diseases), Aarden Pharmacueticals",69351,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2015-01-05 00:00:00,Aarden Pharmaceuticals Inc,1058608,Discovery,2009-11-10 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,University of California San Diego,25451,US,US,NTF-1836,72331,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-02-05 00:00:00,University of California,20547,Discovery,2011-07-01 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,McMaster University,21238,Canada,CA,Ad5Ag85A,71323,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,false,2012-05-07 00:00:00,McMaster University,21238,Discontinued,2011-08-31 00:00:00,DX,3,Respiratory disease,711
Recombinant bacterial vector vaccine,12369,LOCAL_AND_MAJOR,McMaster University,21238,Canada,CA,Ad5Ag85A,71323,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,false,2012-05-07 00:00:00,McMaster University,21238,Discontinued,2011-08-31 00:00:00,DX,3,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Tianjin CanSino Biotechnology Inc,1069870,China,CN,Ad5Ag85A,71323,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2012-05-07 00:00:00,Tianjin CanSino Biotechnology Inc,1069870,Discovery,2012-05-07 00:00:00,DR,6,Respiratory disease,711
Live attenuated viral vaccine,12364,LOCAL_AND_MAJOR,PaxVax Inc,1032157,US,US,"adenovirus 4-based vaccine (oral, tuberculosis), PaxVax",72040,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-11-27 00:00:00,PaxVax Inc,1032157,No Development Reported,2012-11-27 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Medicine in Need,1054651,US,US,"capreomycin (inhalant/powder, tuberculosis), Medicines in Need",70827,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-09-24 00:00:00,Medicine in Need,1054651,Discovery,2008-10-16 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Qurient Therapeutics,1062405,South Korea,KR,"Q-201, Qurient",71430,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-04-17 00:00:00,Qurient Therapeutics,1062405,Discovery,2010-10-31 00:00:00,DR,6,Respiratory disease,711
Live attenuated viral vaccine,12364,LOCAL_AND_MAJOR,PaxVax Inc,1032157,US,US,"adenovirus 4-based vaccine (oral, tuberculosis), PaxVax",72040,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-11-27 00:00:00,PaxVax Inc,1032157,Discovery,2011-06-21 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,ImCure Therapeutics,1014446,US,US,184045,70838,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-02-26 00:00:00,ImCure Therapeutics,1014446,Discovery,2011-03-28 00:00:00,DR,6,Respiratory disease,711
Epimerase inhibitor,520,LOCAL_AND_MAJOR,Hans Knoell Institute of Natural Products Research,24984,Germany,DE,"benzothiazinones (tuberculosis), Hans Knoell Institute",70901,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-09-25 00:00:00,Hans Knoell Institute of Natural Products Research,24984,Discovery,2009-02-26 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,New Medicines for Tuberculosis,1062637,Switzerland,CH,"benzothiazinones (tuberculosis), Hans Knoell Institute",70901,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-09-25 00:00:00,New Medicines for Tuberculosis,1062637,Discovery,2009-03-19 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,AstraZeneca plc,14190,UK,GB,"folate biosynthesis inhibitors (tuberculosis), AZ/TB Alliance",71614,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-11-30 00:00:00,AstraZeneca plc,14190,Discovery,2011-02-04 00:00:00,DR,6,Respiratory disease,711
DNA gyrase B inhibitor,71209,OTHER,AstraZeneca plc,14190,India,IN,"gyrase B inhibitors (tuberculosis infection), AZ/TB Alliance",71700,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-11-30 00:00:00,AstraZeneca plc,14190,Discovery,2010-05-03 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,The Institute of Microbiology Chinese Academy of Sciences,1015456,China,CN,"protease inhibitors (tuberculosis infection, TB Alliance/Institute of Microbiology Chinese Academy of Sciences",71743,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-18 00:00:00,Chinese Academy of Sciences,23863,Discovery,2009-05-27 00:00:00,DR,6,Respiratory disease,711
Protein subunit vaccine,12372,LOCAL_AND_MAJOR,Shanghai H&G Biotechnology Co,1066720,China,CN,"ESAT-6/Ag85A-expressing recombinant BCG vaccine (Mycobacterium tuberculosis), Shanghai H&G",75152,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-17 00:00:00,Shanghai H&G Biotechnology Co,1066720,No Development Reported,2013-01-17 00:00:00,NDR,2,Respiratory disease,711
Recombinant bacterial vector vaccine,12369,LOCAL_AND_MAJOR,Shanghai H&G Biotechnology Co,1066720,China,CN,"ESAT-6/Ag85A-expressing recombinant BCG vaccine (Mycobacterium tuberculosis), Shanghai H&G",75152,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-17 00:00:00,Shanghai H&G Biotechnology Co,1066720,Discovery,2007-08-28 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Finlay Institute,15912,Cuba,CU,"Streptomyces vector-based live recombinant vaccine (tuberculosis infection), Finlay Institute",73326,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-10-15 00:00:00,Finlay Institute,15912,Discovery,2009-12-31 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,"tuberculosis vaccine, TapImmune",74286,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-09-23 00:00:00,Aeras Global TB Vaccine Foundation,1007376,No Development Reported,2014-09-23 00:00:00,NDR,2,Respiratory disease,711
DNA vaccine,1879,LOCAL_AND_MAJOR,Shanghai H&G Biotechnology Co,1066720,China,CN,"Ag85A/B DNA vaccine (tuberculosis), Shanghai H&G Biotechnology",75084,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-17 00:00:00,Shanghai H&G Biotechnology Co,1066720,No Development Reported,2013-01-17 00:00:00,NDR,2,Respiratory disease,711
Mycobacterial antigen complex 85A modulator,33967,LOCAL_AND_MAJOR,Shanghai H&G Biotechnology Co,1066720,China,CN,"Ag85A/B DNA vaccine (tuberculosis), Shanghai H&G Biotechnology",75084,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-17 00:00:00,Shanghai H&G Biotechnology Co,1066720,Discovery,2006-12-31 00:00:00,DR,6,Respiratory disease,711
Mycobacterium early secretory antigen modulator,25527,LOCAL_AND_MAJOR,Statens Serum Institut,21502,Denmark,DK,"Ag85B-ESAT-6 fusion protein vaccine (CAF-01-adjuvanted, tuberculosis), Statens Serum Institut",75087,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2009-10-31 00:00:00,Statens Serum Institut,21502,Phase 1 Clinical,2009-10-31 00:00:00,C1,8,Respiratory disease,711
miRNA agent,38419,LOCAL_AND_MAJOR,National University of Singapore,20633,Singapore,SG,"miRNA-like molecules (tuberculosis), NUS",77116,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-06-20 00:00:00,National University of Singapore,20633,No Development Reported,2014-06-20 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Omnia Molecular,1065893,Spain,ES,"leucyl-tRNA synthetase inhibitors (Mycobacterium tuberculosis infection), Omnia Molecular",75760,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-10-14 00:00:00,Omnia Molecular,1065893,No Development Reported,2014-10-14 00:00:00,NDR,2,Respiratory disease,711
Anti-inflammatory,2953,LOCAL_AND_MAJOR,Heber Biotec SA,1062884,Cuba,CU,"interferon gamma follow-on biologic, CIGB/Heber Biotec",79519,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2009-12-31 00:00:00,Center for Genetic Engineering and Biotechnology,15353,Launched,2009-12-31 00:00:00,L,13,Respiratory disease,711
Interferon gamma ligand,51201,LOCAL_AND_MAJOR,Center for Genetic Engineering and Biotechnology,15353,Cuba,CU,"interferon gamma follow-on biologic, CIGB/Heber Biotec",79519,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2009-12-31 00:00:00,Center for Genetic Engineering and Biotechnology,15353,Launched,2009-12-31 00:00:00,L,13,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Center for Genetic Engineering and Biotechnology,15353,Cuba,CU,"interferon gamma follow-on biologic, CIGB/Heber Biotec",79519,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2009-12-31 00:00:00,Center for Genetic Engineering and Biotechnology,15353,Clinical,2008-02-11 00:00:00,CU,7,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Qurient Therapeutics,1062405,South Korea,KR,"TB I series (tuberculosis infection), Qurient Therapeutics",78036,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2013-06-28 00:00:00,Qurient Therapeutics,1062405,No Development Reported,2013-06-28 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Qurient Therapeutics,1062405,South Korea,KR,"TB I series (tuberculosis infection), Qurient Therapeutics",78036,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2013-06-28 00:00:00,Qurient Therapeutics,1062405,Discovery,2010-03-31 00:00:00,DR,6,Respiratory disease,711
DXP reductoisomerase inhibitor,6324,LOCAL_AND_MAJOR,George Washington University,26026,US,US,"Dxr inhibitors (Mycobacterium tuberculosis infection), George Washington University",79298,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-12-01 00:00:00,George Washington University,26026,Discovery,2011-12-01 00:00:00,DR,6,Respiratory disease,711
Leucyl tRNA synthetase inhibitor,36223,LOCAL_AND_MAJOR,Anacor Pharmaceuticals Inc,30118,US,US,"benzoxaborole Leucyl-tRNA synthase inhibitors (bacterial infection), Anacor",78175,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-05-14 00:00:00,Anacor Pharmaceuticals Inc,30118,Discovery,2012-05-14 00:00:00,DR,6,Respiratory disease,711
Topoisomerase II inhibitor,142,LOCAL_AND_MAJOR,iThemba Pharmaceuticals Pty Ltd,1049788,South Africa,ZA,"NBTIs (Mycobacterium tuberculosis infection), iThemba",79395,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-03-13 00:00:00,iThemba Pharmaceuticals Pty Ltd,1049788,No Development Reported,2014-03-13 00:00:00,NDR,2,Respiratory disease,711
Topoisomerase II inhibitor,142,LOCAL_AND_MAJOR,iThemba Pharmaceuticals Pty Ltd,1049788,South Africa,ZA,"NBTIs (Mycobacterium tuberculosis infection), iThemba",79395,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-03-13 00:00:00,iThemba Pharmaceuticals Pty Ltd,1049788,Discovery,2010-01-20 00:00:00,DR,6,Respiratory disease,711
Inactivated bacterial vaccine,12366,LOCAL_AND_MAJOR,Chongqing Zhifei Biological Products Co Ltd,1062383,China,CN,Wei Ka,81037,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2001-12-31 00:00:00,Chongqing Zhifei Biological Products Co Ltd,1062383,Registered,2001-12-31 00:00:00,R,12,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,NovoBiotic Pharmaceuticals LLC,1031362,US,US,lassomycin,81058,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-09-10 00:00:00,NovoBiotic Pharmaceuticals LLC,1031362,Discovery,2012-09-10 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,Shanghai Sun-Sail Pharmaceutical Science & Technology Co Ltd,1049303,China,CN,"ethylenediamine derivative (mycobacterium tuberculosis), Shanghai Sun-Sail Pharmaceutical Science & Technology",81181,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-07-31 00:00:00,Shionogi & Co Ltd,19898,Discovery,2012-07-31 00:00:00,DR,6,Respiratory disease,711
Anti-inflammatory,2953,LOCAL_AND_MAJOR,PHARMACLON LLC,1073552,Russian Federation,RU,"interferon gamma follow-on biologic, PHARMACLON LLC",81264,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2013-07-23 00:00:00,PHARMACLON LLC,1073552,Launched,2013-07-23 00:00:00,L,13,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,PHARMACLON LLC,1073552,Russian Federation,RU,"interferon gamma follow-on biologic, PHARMACLON LLC",81264,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2013-07-23 00:00:00,PHARMACLON LLC,1073552,Launched,2013-07-23 00:00:00,L,13,Respiratory disease,711
Vaccine,386,LOCAL_AND_MAJOR,Chongqing Zhifei Biological Products Co Ltd,1062383,China,CN,"primary immunization-booster TB vaccine, Chongqing Zhifei Biological Products",81359,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-05-04 00:00:00,Chongqing Zhifei Biological Products Co Ltd,1062383,Discovery,2012-05-04 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,AnHui Longcom Biologic Pharmacy Co Ltd,1073327,China,CN,AEC/BC02,81363,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-09-21 00:00:00,Chongqing Zhifei Biological Products Co Ltd,1062383,Discovery,2012-09-21 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,University of Oxford,22182,UK,GB,ChAdOx1-85A,84564,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-06-12 00:00:00,University of Oxford,22182,Phase 1 Clinical,2013-06-12 00:00:00,C1,8,Respiratory disease,711
Bacterial protein synthesis inhibitor,1538,LOCAL_AND_MAJOR,Nanosystem Ltd,1071336,Russian Federation,RU,"rifabutin nanoparticles (iv, Mycobacterium tuberculosis), Nanosystem",82299,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-12-07 00:00:00,Nanosystem Ltd,1071336,Discovery,2012-12-07 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"ATP synthase inhibitors (tuberculosis), TB Alliance/California Institute for Biomedical Research",82643,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-06-30 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2012-11-30 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Johnson & Johnson,17332,US,US,"diarylquinolines (tuberculosis), TB Alliance/J & J/University of Auckland/University of Illinois at Chicago",82662,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-06-30 00:00:00,Johnson & Johnson,17332,Discovery,2012-11-30 00:00:00,DR,6,Respiratory disease,711
Live attenuated bacterial vaccine,12363,LOCAL_AND_MAJOR,University of California Los Angeles,25623,US,US,"bacteria-based booster vaccine (tuberculosis), UCLA",85546,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-06-15 00:00:00,University of California,20547,Discovery,2011-06-15 00:00:00,DR,6,Respiratory disease,711
Bacterial protein synthesis inhibitor,1538,OTHER,Chiron PathoGenesis,18741,Brazil,BR,rifalazil,8658,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2014-10-30 00:00:00,Novartis AG,23137,Phase 2 Clinical,1997-10-21 00:00:00,C2,9,Respiratory disease,711
Bacterial protein synthesis inhibitor,1538,LOCAL_AND_MAJOR,Chiron PathoGenesis,18741,US,US,rifalazil,8658,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2014-10-30 00:00:00,Novartis AG,23137,Phase 2 Clinical,1998-12-31 00:00:00,C2,9,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,GlobalAcorn,1086420,UK,GB,GA3 MEP-TB,86658,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2015-04-17 00:00:00,GlobalAcorn,1086420,Discovery,2012-11-14 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,GlobalAcorn,1086420,UK,GB,GA4 NM-TB,86659,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2015-04-17 00:00:00,GlobalAcorn,1086420,No Development Reported,2015-04-17 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,GlobalAcorn,1086420,UK,GB,GA4 NM-TB,86659,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2015-04-17 00:00:00,GlobalAcorn,1086420,Discovery,2012-11-14 00:00:00,DR,6,Respiratory disease,711
Bacterial cell wall synthesis inhibitor,104,LOCAL_AND_MAJOR,Sichuan Long March Pharmaceutical Co Ltd,1088430,China,CN,SKLB-TB37,87680,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-06-16 00:00:00,Sichuan Long March Pharmaceutical Co Ltd,1088430,Discovery,2011-06-16 00:00:00,DR,6,Respiratory disease,711
Pantoate beta alanine ligase inhibitor,19060,LOCAL_AND_MAJOR,University of Illinois at Urbana-Champaign,1073122,US,US,"pantothenate synthetase inhibitors (tuberculosis/bacterial infections), University of Illinois/University of Illinois at URBANA-CHAMPAIGN",88214,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-10-30 00:00:00,University of Illinois,20592,Discovery,2013-10-30 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"urea compounds (tuberculosis), TB Alliance/Sanofi",89824,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-01-23 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2014-01-23 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Science & Technology Corporation @ UNM,28506,US,US,modified formulation of isoniazid (drug-resistant tuberculosis) University of New Mexico/Science & Technology Corporation @ UNM,88285,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-05-05 00:00:00,University of New Mexico,20639,Discovery,2013-05-05 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,University of New Mexico,20639,US,US,modified formulation of isoniazid (drug-resistant tuberculosis) University of New Mexico/Science & Technology Corporation @ UNM,88285,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-05-05 00:00:00,University of New Mexico,20639,Discovery,2004-08-31 00:00:00,DR,6,Respiratory disease,711
Unspecified vaccine,12380,LOCAL_AND_MAJOR,University of California Los Angeles,25623,US,US,"rBCG30 vaccine (improved version, tuberculosis), UCLA",89141,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-11-29 00:00:00,University of California,20547,Discovery,2013-11-29 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Liaoning Hongwuxing Pharmaceutical Co Ltd,1090092,China,CN,"ethambutol hydrochloride (150 mg) + pyrazinamide (300 mg) + rifampicin (90 mg) + isoniazid (60 mg) (oral tablet, tuberculosis), Shenyang Hongqi Pharmaceutical/Liaoning Hongwuxing Pharmaceutical",88505,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-11-15 00:00:00,Liaoning Hongwuxing Pharmaceutical Co Ltd,1090092,Discovery,2013-11-15 00:00:00,DR,6,Respiratory disease,711
RNA polymerase inhibitor,347,LOCAL_AND_MAJOR,Liaoning Hongwuxing Pharmaceutical Co Ltd,1090092,China,CN,"ethambutol hydrochloride (200 mg) + pyrazinamide (300 mg) + rifampicin (120 mg) + isoniazid (100 mg) (oral tablet, tuberculosis), Shenyang Hongqi Pharmaceutical/Liaoning Hongwuxing Pharmaceutical",88507,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-11-15 00:00:00,Liaoning Hongwuxing Pharmaceutical Co Ltd,1090092,Discovery,2013-11-15 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Johns Hopkins University,20596,US,US,"Methionine aminopeptidase inhibitors (Mycobacterium tuberculosis), Johns Hopkins University",89387,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-12-19 00:00:00,Johns Hopkins University,20596,Discovery,2010-01-31 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Sichuan University,1003379,China,CN,antituberculosis agents (tuberculosis) Sichuan University,95733,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-12-27 00:00:00,Sichuan University,1003379,Discovery,2013-12-27 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,University of Oslo,DOL1000150,Norway,NO,"prophylactic vaccine (tuberculosis), Vaccibody/University of Oslo",91534,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-06-10 00:00:00,University of Oslo,DOL1000150,Discovery,2014-06-10 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Vaccibody AS,1035099,Norway,NO,"prophylactic vaccine (tuberculosis), Vaccibody/University of Oslo",91534,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-06-10 00:00:00,Bio-Medisinsk Innovasjon AS,1015117,Discovery,2014-06-10 00:00:00,DR,6,Respiratory disease,711
FtsZ protein inhibitor,11742,LOCAL_AND_MAJOR,Sanofi,1009547,France,FR,"FtsZ inhibitors (Mycobacterium tuberculosis infection), Sanofi/Colorado State University/Stony Brook University",92356,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-04-15 00:00:00,Sanofi,1009547,Discovery,2014-04-15 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Novartis AG,23137,US,US,"clofazimine (active tuberculosis), Novartis",91861,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-06-25 00:00:00,Novartis AG,23137,Discovery,2014-06-25 00:00:00,DR,6,Respiratory disease,711
Bacterial cell wall synthesis inhibitor,104,LOCAL_AND_MAJOR,Sichuan Long March Pharmaceutical Co Ltd,1088430,China,CN,"ethambutol hydrochloride + pyrazinamide + rifampicin + isoniazid (oral tablet, tuberculosis), Sichuan Long March Pharmaceutical",96349,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-11-11 00:00:00,Sichuan Long March Pharmaceutical Co Ltd,1088430,No Development Reported,2008-11-11 00:00:00,NDR,2,Respiratory disease,711
Bacterial protein synthesis inhibitor,1538,OTHER,Pfizer Inc,18767,Netherlands,NL,rifabutin,4229,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2008-10-07 00:00:00,Pfizer Inc,18767,Registered,1995-07-17 00:00:00,R,12,Respiratory disease,711
Antibacterial,1594,OTHER,Pfizer Inc,18767,Netherlands,NL,rifabutin,4229,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2008-10-07 00:00:00,Pfizer Inc,18767,Registered,1995-07-17 00:00:00,R,12,Respiratory disease,711
Bacterial protein synthesis inhibitor,1538,LOCAL_AND_MAJOR,Pharmacia & Upjohn Co,18995,US,US,rifabutin,4229,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2008-10-07 00:00:00,Pfizer Inc,18767,No Development Reported,2002-09-02 00:00:00,NDR,2,Respiratory disease,711
ATP synthase inhibitor,49687,OTHER,Janssen Research & Development LLC,1067538,South Africa,ZA,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Pre-registration,2013-06-17 00:00:00,PR,11,Respiratory disease,711
Antibacterial multidrug resistance inhibitor,4855,OTHER,Janssen Research & Development LLC,1067538,Peru,PE,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Discovery,2009-07-30 00:00:00,DR,6,Respiratory disease,711
ATP synthase inhibitor,49687,LOCAL_AND_MAJOR,Janssen Research & Development LLC,1067538,US,US,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Registered,2012-12-31 00:00:00,R,12,Respiratory disease,711
Antibacterial multidrug resistance inhibitor,4855,LOCAL_AND_MAJOR,Janssen Research & Development LLC,1067538,US,US,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Pre-registration,2012-06-29 00:00:00,PR,11,Respiratory disease,711
ATP synthase inhibitor,49687,LOCAL_AND_MAJOR,Janssen Research & Development LLC,1067538,US,US,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Pre-registration,2012-06-29 00:00:00,PR,11,Respiratory disease,711
Antibacterial multidrug resistance inhibitor,4855,OTHER,Janssen Research & Development LLC,1067538,Thailand,TH,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Pre-registration,2013-06-17 00:00:00,PR,11,Respiratory disease,711
ATP synthase inhibitor,49687,OTHER,Janssen Research & Development LLC,1067538,India,IN,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Pre-registration,2013-06-17 00:00:00,PR,11,Respiratory disease,711
Anticancer,1545,OTHER,Immunitor Inc,1006860,Ukraine,UA,"heat-killed Mycobacterium vaccae (tablet formulation, tuberculosis), Immunitor",70934,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-03-26 00:00:00,Immune Network Ltd,21412,Phase 2 Clinical,2011-08-31 00:00:00,C2,9,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,Innate Immunotherapeutics Ltd,29958,US,US,"MIS-416/immunogen (anthrax/malaria/tuberculosis/neutropenia), Innate",60213,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-01-12 00:00:00,Innate Immunotherapeutics Ltd,29958,Discovery,2010-12-21 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Sarepta Therapeutics Inc,14240,US,US,"XDR-TB RNA-based therapeutics (tuberculosis), Sarepta therapeutics/Karolinska Institute",71453,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-01-05 00:00:00,Sarepta Therapeutics Inc,14240,Discovery,2011-01-05 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Sarepta Therapeutics Inc,14240,US,US,"XDR-TB RNA-based therapeutics (tuberculosis), Sarepta therapeutics/Karolinska Institute",71453,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-01-05 00:00:00,Sarepta Therapeutics Inc,14240,Discovery,2011-01-05 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Karolinska Institutet,21110,Sweden,SE,"XDR-TB RNA-based therapeutics (tuberculosis), Sarepta therapeutics/Karolinska Institute",71453,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-01-05 00:00:00,Karolinska Institutet,21110,Discovery,2011-01-05 00:00:00,DR,6,Respiratory disease,711
Adjuvant,524,LOCAL_AND_MAJOR,Innate Immunotherapeutics Ltd,29958,US,US,"MIS-416/immunogen (anthrax/malaria/tuberculosis/neutropenia), Innate",60213,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-01-12 00:00:00,Innate Immunotherapeutics Ltd,29958,Discovery,2010-12-21 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Omni Bio Pharmaceutical Inc,1047826,US,US,"p-ATT (type 1/2 diabetes/influenza/tuberculosis/anthrax/HIV infection/transplant rejection/GVHD), Omni Bio",66767,Chemical,Phase 2 Clinical,Discovery,DR,C2,Mycobacterium tuberculosis infection,221,true,2013-01-31 00:00:00,Omni Bio Pharmaceutical Inc,1047826,Discovery,2010-08-06 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Statens Serum Institut,21502,Denmark,DK,SSI H56-IC31,74849,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-11-08 00:00:00,Statens Serum Institut,21502,Discovery,2011-04-27 00:00:00,DR,6,Respiratory disease,711
Therapeutic vaccine,12379,OTHER,Statens Serum Institut,21502,South Africa,ZA,SSI H56-IC31,74849,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-11-08 00:00:00,Statens Serum Institut,21502,Phase 2 Clinical,2013-11-08 00:00:00,C2,9,Respiratory disease,711
Protein subunit vaccine,12372,OTHER,Aeras Global TB Vaccine Foundation,1007376,Denmark,DK,SSI H56-IC31,74849,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-11-08 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Discovery,2011-04-27 00:00:00,DR,6,Respiratory disease,711
Therapeutic vaccine,12379,OTHER,Aeras Global TB Vaccine Foundation,1007376,South Africa,ZA,SSI H56-IC31,74849,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-11-08 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 1 Clinical,2011-12-01 00:00:00,C1,8,Respiratory disease,711
Bacterial cell wall synthesis inhibitor,104,LOCAL_AND_MAJOR,Shenyang Hongqi Pharmaceutical Co Ltd,1075626,China,CN,"ethambutol hydrochloride (250 mg) + pyrazinamide (400 mg) + rifampicin (120 mg) + isoniazid (120 mg) (fixed dose combination, tuberculosis), Shenyang Hongqi Pharmaceutical",82062,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2009-12-31 00:00:00,Shanghai Fosun Pharmaceutical (Group) Co Ltd,1015871,Launched,2009-12-31 00:00:00,L,13,Respiratory disease,711
Enoyl ACP reductase inhibitor,6436,LOCAL_AND_MAJOR,Genzyme Corp,16299,US,US,"enoyl reductase inhibitors (antimicrobial), Genzyme",47123,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2004-05-25 00:00:00,Sanofi,1009547,Discovery,2002-11-25 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,GlaxoSmithKline plc,28355,US,US,"thiolactomycin analog, GlaxoSmithKline",33073,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-08-08 00:00:00,GlaxoSmithKline plc,28355,No Development Reported,2008-08-08 00:00:00,NDR,2,Respiratory disease,711
Bacterial cell wall synthesis inhibitor,104,OTHER,New Medicines for Tuberculosis,1062637,Albania,AL,PBTZ-169,90085,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-08-27 00:00:00,New Medicines for Tuberculosis,1062637,Discovery,2012-08-27 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,DAR-901,90231,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2014-02-28 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 1 Clinical,2014-02-28 00:00:00,C1,8,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Johns Hopkins University,20596,US,US,"L-homoserine, Johns Hopkins",18364,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2001-01-30 00:00:00,Johns Hopkins University,20596,No Development Reported,2001-01-30 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Only For Children Pharmaceuticals,1047869,France,FR,"isoniazid (oral/solution, tuberculosis), O4CP",91937,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-07-08 00:00:00,Only For Children Pharmaceuticals,1047869,Discovery,2014-07-08 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Cornell University,24136,US,US,"proteosome inhibitors (mycobacterium tuberculosis), Cornell University",86500,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2009-10-01 00:00:00,Cornell University,24136,Discovery,2009-10-01 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Harvard University,20584,US,US,"proteasome inhibitors (tuberculosis), Harvard University/Harvard University Office of Technology Development",86021,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-08-21 00:00:00,Harvard University,20584,Discovery,2012-02-01 00:00:00,DR,6,Respiratory disease,711
Antiparasitic,2638,LOCAL_AND_MAJOR,National Institutes of Health,20518,US,US,"thiolactomycin analog, GlaxoSmithKline",33073,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-08-08 00:00:00,US Government,20516,Discovery,2001-02-28 00:00:00,DR,6,Respiratory disease,711
DNA vaccine,1879,LOCAL_AND_MAJOR,Shanghai H&G Biotechnology Co,1066720,China,CN,"Ag85A DNA vaccine (Mycobacterium tuberculosis), Shanghai H&G",75158,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-17 00:00:00,Shanghai H&G Biotechnology Co,1066720,Discovery,2011-12-20 00:00:00,DR,6,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,Shanghai H&G Biotechnology Co,1066720,China,CN,"Ag85A DNA vaccine (Mycobacterium tuberculosis), Shanghai H&G",75158,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-17 00:00:00,Shanghai H&G Biotechnology Co,1066720,No Development Reported,2013-01-17 00:00:00,NDR,2,Respiratory disease,711
DNA vaccine,1879,LOCAL_AND_MAJOR,UK National Institute of Medical Research,20466,UK,GB,"DNA vaccine (tuberculosis), NIMR/Sequella",22154,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-10-13 00:00:00,Medical Research Council (MRC),18438,No Development Reported,2008-10-13 00:00:00,NDR,2,Respiratory disease,711
Protein subunit vaccine,12372,OTHER,Intercell AG,28463,South Africa,ZA,SSI H56-IC31,74849,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2013-11-08 00:00:00,Valneva SE,1084202,Phase 1 Clinical,2012-08-17 00:00:00,C1,8,Respiratory disease,711
Therapeutic vaccine,12379,OTHER,Intercell AG,28463,South Africa,ZA,SSI H56-IC31,74849,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2013-11-08 00:00:00,Valneva SE,1084202,Phase 1 Clinical,2012-08-17 00:00:00,C1,8,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Chimerix Inc,30079,US,US,"Mycobacterium tuberculosis infection targeting compounds, Chimerix",69571,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-09-16 00:00:00,Chimerix Inc,30079,No Development Reported,2014-09-16 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Microbion Corp,1055897,US,US,MBS-103,68316,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-09-25 00:00:00,Microbion Corp,1055897,No Development Reported,2013-09-25 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,OTHER,Novartis Institute for Tropical Diseases Pvt Ltd,1017949,Singapore,SG,"small molecule therapeutics (Mycobacterium tuberculosis infection), ChemDiv Research Institute/Novartis Institute for Tropical Diseases/Silvius Pharma",76796,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2014-08-14 00:00:00,Novartis AG,23137,Discovery,2010-09-30 00:00:00,DR,6,Respiratory disease,711
TNF alpha synthesis inhibitor,382,LOCAL_AND_MAJOR,LeukoMed Inc,30043,US,US,LMP-420,41819,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2009-03-16 00:00:00,LeukoMed Inc,30043,No Development Reported,2009-03-16 00:00:00,NDR,2,Respiratory disease,711
Bacterial nucleic acid synthesis inhibitor,3984,OTHER,Dainippon Pharmaceutical Co Ltd,15606,China,CN,sparfloxacin,4439,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,1999-12-31 00:00:00,Sumitomo Chemical Co Ltd,20268,Registered,1999-11-20 00:00:00,R,12,Respiratory disease,711
Bacterial nucleic acid synthesis inhibitor,3984,OTHER,Dainippon Pharmaceutical Co Ltd,15606,China,CN,sparfloxacin,4439,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,1999-12-31 00:00:00,Sumitomo Chemical Co Ltd,20268,Launched,1999-12-31 00:00:00,L,13,Respiratory disease,711
Angiogenesis inhibitor,61,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Philippines,PH,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 2 Clinical,2008-04-30 00:00:00,C2,9,Respiratory disease,711
Mycolic acid synthase inhibitor,6542,LOCAL_AND_MAJOR,Otsuka Pharmaceutical Co Ltd,18717,Japan,JP,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 1 Clinical,2005-12-19 00:00:00,C1,8,Respiratory disease,711
Anti-inflammatory,2953,LOCAL_AND_MAJOR,Otsuka Pharmaceutical Co Ltd,18717,Japan,JP,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 3 Clinical,2011-12-31 00:00:00,C3,10,Respiratory disease,711
Mycolic acid synthase inhibitor,6542,LOCAL_AND_MAJOR,Otsuka Pharmaceutical Co Ltd,18717,Japan,JP,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Pre-registration,2013-03-27 00:00:00,PR,11,Respiratory disease,711
Anti-inflammatory,2953,LOCAL_AND_MAJOR,Otsuka Pharmaceutical Co Ltd,18717,Japan,JP,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Registered,2014-07-04 00:00:00,R,12,Respiratory disease,711
Mycolic acid synthase inhibitor,6542,LOCAL_AND_MAJOR,Otsuka Pharmaceutical Co Ltd,18717,Japan,JP,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Registered,2014-07-04 00:00:00,R,12,Respiratory disease,711
Anticancer,1545,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Latvia,LV,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 2 Clinical,2008-04-30 00:00:00,C2,9,Respiratory disease,711
Anticancer,1545,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Lithuania,LT,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 3 Clinical,2011-09-19 00:00:00,C3,10,Respiratory disease,711
Antibacterial,1594,OTHER,Otsuka Pharmaceutical Co Ltd,18717,South Korea,KR,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Registered,2014-10-29 00:00:00,R,12,Respiratory disease,711
Antibacterial,1594,OTHER,Otsuka Pharmaceutical Co Ltd,18717,China,CN,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 2 Clinical,2008-04-30 00:00:00,C2,9,Respiratory disease,711
Angiogenesis inhibitor,61,OTHER,Otsuka Pharmaceutical Co Ltd,18717,China,CN,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 2 Clinical,2008-04-30 00:00:00,C2,9,Respiratory disease,711
Angiogenesis inhibitor,61,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Peru,PE,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 3 Clinical,2013-07-26 00:00:00,C3,10,Respiratory disease,711
Anticancer,1545,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Germany,DE,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Launched,2014-11-13 00:00:00,L,13,Respiratory disease,711
Mycolic acid synthase inhibitor,6542,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Germany,DE,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Launched,2014-11-13 00:00:00,L,13,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Otsuka Pharmaceutical Co Ltd,18717,Japan,JP,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Launched,2014-09-30 00:00:00,L,13,Respiratory disease,711
Anti-inflammatory,2953,LOCAL_AND_MAJOR,Otsuka Pharmaceutical Co Ltd,18717,Japan,JP,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Launched,2014-09-30 00:00:00,L,13,Respiratory disease,711
Angiogenesis inhibitor,61,LOCAL_AND_MAJOR,Otsuka Pharmaceutical Co Ltd,18717,Japan,JP,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Launched,2014-09-30 00:00:00,L,13,Respiratory disease,711
Anticancer,1545,LOCAL_AND_MAJOR,Otsuka Pharmaceutical Co Ltd,18717,US,US,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 3 Clinical,2011-12-31 00:00:00,C3,10,Respiratory disease,711
Ribosome binding agent,463,LOCAL_AND_MAJOR,AstraZeneca plc,14190,US,US,posizolid,26493,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2012-12-27 00:00:00,AstraZeneca plc,14190,Phase 2 Clinical,2012-12-27 00:00:00,C2,9,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Immunobiology Ltd,27371,UK,GB,T-Biovax,67683,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-10-17 00:00:00,Immunobiology Ltd,27371,Discovery,2010-08-11 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,T-Biovax,67683,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-10-17 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Discovery,2010-08-11 00:00:00,DR,6,Respiratory disease,711
Heat shock protein modulator,7992,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,T-Biovax,67683,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-10-17 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Discovery,2010-08-11 00:00:00,DR,6,Respiratory disease,711
Listeriolysin stimulator,14513,LOCAL_AND_MAJOR,Vakzine Projekt Management GmbH,1020740,Germany,DE,VPM-1002,55569,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-03-27 00:00:00,Vakzine Projekt Management GmbH,1020740,No Development Reported,2013-03-27 00:00:00,NDR,2,Respiratory disease,711
Listeriolysin stimulator,14513,LOCAL_AND_MAJOR,Vakzine Projekt Management GmbH,1020740,Germany,DE,VPM-1002,55569,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-03-27 00:00:00,Vakzine Projekt Management GmbH,1020740,Phase 1 Clinical,2008-09-05 00:00:00,C1,8,Respiratory disease,711
Electron transport inhibitor,518,LOCAL_AND_MAJOR,Helmholtz Zentrum fur Infektionsforschung GmbH,16277,Germany,DE,"thuggacines (tuberculosis), Helmholtz",82363,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-11-14 00:00:00,Helmholtz Zentrum fur Infektionsforschung GmbH,16277,Discovery,2007-05-15 00:00:00,DR,6,Respiratory disease,711
Electron transport inhibitor,518,LOCAL_AND_MAJOR,Ascenion GmbH,1050467,Germany,DE,"thuggacines (tuberculosis), Helmholtz",82363,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-11-14 00:00:00,Ascenion GmbH,1050467,Discovery,2012-11-14 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Create Vaccine Co,1089867,Japan,JP,"mucosal vaccines (rhPIV2 vector/nasal, tuberculosis), NIBIO/Aeras/Create Vaccine",89879,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-12-26 00:00:00,Create Vaccine Co,1089867,Discovery,2013-12-26 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Yonsei University,25184,South Korea,KR,"pyrazinamide analogs (tuberculosis infection), Yonsei University/TB Alliance",71894,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-03-28 00:00:00,Yonsei University,25184,Discovery,2011-03-28 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"pyrazinamide analogs (tuberculosis infection), Yonsei University/TB Alliance",71894,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-03-28 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2011-03-28 00:00:00,DR,6,Respiratory disease,711
Viral replication inhibitor,1532,LOCAL_AND_MAJOR,InterMune Inc,26430,US,US,Actimmune,3365,Biological,Launched,No Development Reported,NDR,L,Mycobacterium tuberculosis infection,221,false,2014-09-19 00:00:00,Roche Holding AG,19446,No Development Reported,2007-03-31 00:00:00,NDR,2,Respiratory disease,711
Interferon gamma ligand,51201,LOCAL_AND_MAJOR,InterMune Inc,26430,US,US,Actimmune,3365,Biological,Launched,No Development Reported,NDR,L,Mycobacterium tuberculosis infection,221,false,2014-09-19 00:00:00,Roche Holding AG,19446,No Development Reported,2007-03-31 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,The Vavilov Institute of General Genetics,1073514,Russian Federation,RU,"microbacterial protein kinase inhibitors (tuberculosis infection), The Vavilov Institute of General Genetics",81211,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-09-24 00:00:00,The Vavilov Institute of General Genetics,1073514,No Development Reported,2014-09-24 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Chiron PathoGenesis,18741,US,US,PA-342,10997,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,1996-11-01 00:00:00,Novartis AG,23137,Discontinued,1996-11-01 00:00:00,DX,3,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Verta Ltd,1004196,Russian Federation,RU,"golotimod (oral), SciClone/Verta",55521,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2011-10-10 00:00:00,Verta Ltd,1004196,No Development Reported,2011-10-10 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Agenus Inc,23221,US,US,"tuberculosis vaccine (CD1), Antigenics",22778,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2002-10-15 00:00:00,Agenus Inc,23221,Discovery,2001-11-21 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,TB-VAC,1020621,Netherlands,NL,"MTB72F vaccine (tuberculosis), GSK/Aeras",9490,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-08-26 00:00:00,TB-VAC,1020621,Discovery,2006-04-22 00:00:00,DR,6,Respiratory disease,711
Glycosyltransferase inhibitor,1025,LOCAL_AND_MAJOR,Medical Research Council (MRC),18438,UK,GB,"GlgE inhibitors (tuberculosis), MCRT",78428,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-06-25 00:00:00,Medical Research Council (MRC),18438,No Development Reported,2013-06-25 00:00:00,NDR,2,Respiratory disease,711
Unspecified vaccine,12380,LOCAL_AND_MAJOR,Medicine in Need,1054651,US,US,"auxotroph vaccine (tuberculosis), Medicine in Need",70953,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-09-24 00:00:00,Medicine in Need,1054651,No Development Reported,2014-09-24 00:00:00,NDR,2,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,ApoVax Inc,29552,US,US,ApoVax104-TB,68211,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2015-01-05 00:00:00,ApoVax Inc,29552,Discovery,2008-08-31 00:00:00,DR,6,Respiratory disease,711
CDw137 modulator,5449,LOCAL_AND_MAJOR,ApoVax Inc,29552,US,US,ApoVax104-TB,68211,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2015-01-05 00:00:00,ApoVax Inc,29552,No Development Reported,2015-01-05 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Sequella Inc,28087,US,US,"antibacterial diamines (tuberculosis), Sequella",56356,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-10-13 00:00:00,Sequella Inc,28087,Discovery,2005-09-23 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Sequella Inc,28087,US,US,"antibacterial diamines (tuberculosis), Sequella",56356,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-10-13 00:00:00,Sequella Inc,28087,Discovery,2005-09-23 00:00:00,DR,6,Respiratory disease,711
Cell wall synthesis inhibitor,7052,LOCAL_AND_MAJOR,Sequella Inc,28087,US,US,"antibacterial diamines (tuberculosis), Sequella",56356,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-10-13 00:00:00,Sequella Inc,28087,Discovery,2005-09-23 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Pohang University of Science & Technology,25083,South Korea,KR,"therapeutic DNA vaccine (tuberculosis), Pohang/Yonsei Universities",53019,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2009-12-24 00:00:00,Pohang University of Science & Technology,25083,Discovery,2003-09-30 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,National University of Singapore,20633,Singapore,SG,pascolizumab,17132,Biological,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2014-06-23 00:00:00,National University of Singapore,20633,No Development Reported,2014-06-23 00:00:00,NDR,2,Respiratory disease,711
IL-4 antagonist,225,LOCAL_AND_MAJOR,National University of Singapore,20633,Singapore,SG,pascolizumab,17132,Biological,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2014-06-23 00:00:00,National University of Singapore,20633,No Development Reported,2014-06-23 00:00:00,NDR,2,Respiratory disease,711
Antidepressant,2941,LOCAL_AND_MAJOR,National University of Singapore,20633,Singapore,SG,pascolizumab,17132,Biological,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2014-06-23 00:00:00,National University of Singapore,20633,No Development Reported,2014-06-23 00:00:00,NDR,2,Respiratory disease,711
Ribosome binding agent,463,OTHER,Sequella Inc,28087,Europe,X5,sutezolid,11088,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-07-17 00:00:00,Sequella Inc,28087,Discovery,2013-07-17 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,iThemba Pharmaceuticals Pty Ltd,1049788,South Africa,ZA,"tuberculosis therapy, iThemba Pharmaceuticals/Southern Research Institute",67092,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-06-22 00:00:00,iThemba Pharmaceuticals Pty Ltd,1049788,No Development Reported,2012-06-22 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,SciClone Pharmaceuticals Inc,19829,US,US,"golotimod (oral), SciClone/Verta",55521,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2011-10-10 00:00:00,SciClone Pharmaceuticals Inc,19829,Phase 1 Clinical,2006-05-25 00:00:00,C1,8,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,SciClone Pharmaceuticals Inc,19829,US,US,"golotimod (oral), SciClone/Verta",55521,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2011-10-10 00:00:00,SciClone Pharmaceuticals Inc,19829,No Development Reported,2011-10-10 00:00:00,NDR,2,Respiratory disease,711
STAT3 gene inhibitor,19075,LOCAL_AND_MAJOR,SciClone Pharmaceuticals Inc,19829,US,US,"golotimod (oral), SciClone/Verta",55521,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2011-10-10 00:00:00,SciClone Pharmaceuticals Inc,19829,No Development Reported,2011-10-10 00:00:00,NDR,2,Respiratory disease,711
Mycolic acid synthase inhibitor,6542,LOCAL_AND_MAJOR,GlaxoSmithKline plc,28355,UK,GB,"EthR inhibitors (mycobacterium tuberculosis), BioVersys/ University of Lille/ GSK",92193,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-05-27 00:00:00,GlaxoSmithKline plc,28355,Discovery,2014-05-27 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,New York Medical College,23270,US,US,"topoisomerase I inhibitors (tuberculosis infection), TB Alliance/NYMC/AZ",71897,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-06-27 00:00:00,New York University,20646,No Development Reported,2013-06-27 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,University of California Los Angeles,25623,US,US,"methionine sulfoximine (tuberculosis), UCLA",85542,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,1996-10-02 00:00:00,University of California,20547,Discovery,1996-10-02 00:00:00,DR,6,Respiratory disease,711
Cytokine synthesis stimulator,938,LOCAL_AND_MAJOR,SciClone Pharmaceuticals Inc,19829,US,US,golotimod,25023,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,false,2013-11-12 00:00:00,SciClone Pharmaceuticals Inc,19829,Phase 2 Clinical,2008-08-28 00:00:00,C2,9,Respiratory disease,711
Anticancer,1545,LOCAL_AND_MAJOR,Verta Ltd,1004196,Russian Federation,RU,golotimod,25023,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2013-11-12 00:00:00,Verta Ltd,1004196,Launched,2008-08-15 00:00:00,L,13,Respiratory disease,711
Fungicide,1748,LOCAL_AND_MAJOR,Sequella Inc,28087,US,US,SQ-109,31010,Chemical,Phase 3 Clinical,Phase 3 Clinical,C3,C3,Mycobacterium tuberculosis infection,221,true,2012-12-19 00:00:00,Sequella Inc,28087,Discovery,2000-10-09 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Sequella Inc,28087,US,US,SQ-109,31010,Chemical,Phase 3 Clinical,Phase 3 Clinical,C3,C3,Mycobacterium tuberculosis infection,221,true,2012-12-19 00:00:00,Sequella Inc,28087,Phase 1 Clinical,2006-09-30 00:00:00,C1,8,Respiratory disease,711
Cell wall synthesis inhibitor,7052,LOCAL_AND_MAJOR,Sequella Inc,28087,US,US,SQ-109,31010,Chemical,Phase 3 Clinical,Phase 3 Clinical,C3,C3,Mycobacterium tuberculosis infection,221,true,2012-12-19 00:00:00,Sequella Inc,28087,Phase 1 Clinical,2006-09-30 00:00:00,C1,8,Respiratory disease,711
Antibacterial,1594,OTHER,Sequella Inc,28087,Africa,X0,SQ-109,31010,Chemical,Phase 3 Clinical,Phase 3 Clinical,C3,C3,Mycobacterium tuberculosis infection,221,true,2012-12-19 00:00:00,Sequella Inc,28087,Phase 2 Clinical,2010-12-06 00:00:00,C2,9,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Infectex,1068619,Russian Federation,RU,SQ-109,31010,Chemical,Phase 3 Clinical,Phase 3 Clinical,C3,C3,Mycobacterium tuberculosis infection,221,true,2012-12-19 00:00:00,Maxwell Biotech Group,1061894,Phase 3 Clinical,2012-12-19 00:00:00,C3,10,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Crucell NV,17254,South Africa,ZA,AERAS-402,53975,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2010-09-22 00:00:00,Johnson & Johnson,17332,Phase 1 Clinical,2007-05-11 00:00:00,C1,8,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Crucell NV,17254,Kenya,KE,AERAS-402,53975,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2010-09-22 00:00:00,Johnson & Johnson,17332,Phase 2 Clinical,2010-09-22 00:00:00,C2,9,Respiratory disease,711
Fungicide,1748,LOCAL_AND_MAJOR,Shenzhen Neptunus Interlong Bio-Technique Co Ltd,1015704,China,CN,"recombinant human interleukin-2 (cancer/AIDS/autoimmune disorders/infections), Shenzhen Neptunus",80864,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2012-09-10 00:00:00,Shenzhen Neptunus Bioengineering Co Ltd,1031729,Launched,2012-09-10 00:00:00,L,13,Respiratory disease,711
Natural killer cell stimulator,7757,LOCAL_AND_MAJOR,Shenzhen Neptunus Interlong Bio-Technique Co Ltd,1015704,China,CN,"recombinant human interleukin-2 (cancer/AIDS/autoimmune disorders/infections), Shenzhen Neptunus",80864,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2012-09-10 00:00:00,Shenzhen Neptunus Bioengineering Co Ltd,1031729,Launched,2012-09-10 00:00:00,L,13,Respiratory disease,711
Anti-inflammatory,2953,OTHER,Harbor Therapeutics Inc,24345,Mexico,MX,HE-2000,19980,Chemical,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2013-01-28 00:00:00,Harbor Therapeutics Inc,24345,No Development Reported,2013-01-28 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,St Jude Children's Research Hospital,21814,US,US,"spectinamides (Mycobacterium tuberculosis infection), St Jude Children's Research Hospital/Microbiotix",78400,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-02-26 00:00:00,St Jude Children's Research Hospital,21814,Discovery,2012-03-27 00:00:00,DR,6,Respiratory disease,711
Ribosome binding agent,463,LOCAL_AND_MAJOR,St Jude Children's Research Hospital,21814,US,US,"spectinamides (Mycobacterium tuberculosis infection), St Jude Children's Research Hospital/Microbiotix",78400,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-02-26 00:00:00,St Jude Children's Research Hospital,21814,Discovery,2012-03-27 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Microbiotix Inc,28907,US,US,"spectinamides (Mycobacterium tuberculosis infection), St Jude Children's Research Hospital/Microbiotix",78400,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-02-26 00:00:00,Microbiotix Inc,28907,Discovery,2014-02-26 00:00:00,DR,6,Respiratory disease,711
RNA polymerase inhibitor,347,LOCAL_AND_MAJOR,Shenyang Hongqi Pharmaceutical Co Ltd,1075626,China,CN,"rifampicin + isoniazid (fixed dose combination, tuberculosis), Shenyang Hongqi Pharmaceutical",82095,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2009-12-31 00:00:00,Shanghai Fosun Pharmaceutical (Group) Co Ltd,1015871,Launched,2009-12-31 00:00:00,L,13,Respiratory disease,711
Antibacterial,1594,OTHER,GlaxoSmithKline plc,28355,Spain,ES,"isocitrate lyase inhibitors (tuberculosis), GlaxoSmithKline/The Global Alliance for TB Drug Developement",56373,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2007-05-31 00:00:00,GlaxoSmithKline plc,28355,Discovery,2005-03-21 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Mycosynthetix Inc,1060481,US,US,"anti-TB antibiotics (Mycobacterium tuberculosis), Mycosynthetix/Institute for Tuberculosis Research",70759,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2009-02-12 00:00:00,Mycosynthetix Inc,1060481,Discovery,2009-02-12 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Institute for Tuberculosis Research,1092461,US,US,"anti-TB antibiotics (Mycobacterium tuberculosis), Mycosynthetix/Institute for Tuberculosis Research",70759,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2009-02-12 00:00:00,Institute for Tuberculosis Research,1092461,Discovery,2009-02-12 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Institut Pasteur,17237,Sweden,SE,"multivalent vaccine (Bera-V, Mycobacterium tuberculosis infection), Abera Bioscience/Statens Serum/Institut Pasteur",89342,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-12-20 00:00:00,Institut Pasteur,17237,Discovery,2013-12-20 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,Statens Serum Institut,21502,Sweden,SE,"multivalent vaccine (Bera-V, Mycobacterium tuberculosis infection), Abera Bioscience/Statens Serum/Institut Pasteur",89342,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-12-20 00:00:00,Statens Serum Institut,21502,Discovery,2013-12-20 00:00:00,DR,6,Respiratory disease,711
Putative membrane protein mmpL3 inhibitor,85843,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"mycobacterial membrane protein large type 3 inhibitors (tuberculosis), TB Alliance",89552,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-08-20 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2014-08-20 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Infectious Disease Research Institute,27376,US,US,"anti-tuberculosis therapeutics, Anacor/Infectious Disease Research Institute",89753,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-12-31 00:00:00,Infectious Disease Research Institute,27376,Discovery,2013-12-31 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Infectious Disease Research Institute,27376,US,US,"anti-tuberculosis therapeutics, Anacor/Infectious Disease Research Institute",89753,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-12-31 00:00:00,Infectious Disease Research Institute,27376,Discovery,2013-12-31 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Institute for Tuberculosis Research,1092461,US,US,"actinomycetes metabolites (multi-drug resistant tuberculosis infection), Univeristy of Illinois/Institute for Tuberculosis Research/Univeristy of Illinois at Urbana-Champaign",71899,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-01-24 00:00:00,Institute for Tuberculosis Research,1092461,Discovery,2014-01-24 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,BioDelivery Sciences International Inc,21164,US,US,"clofazimine (oral cochleate formulation), BioDelivery",48519,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-08-19 00:00:00,BioDelivery Sciences International Inc,21164,Discovery,2002-12-31 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,"rBCG30, UCLA",9831,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,false,2014-07-07 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 1 Clinical,2004-02-17 00:00:00,C1,8,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"isocitrate lyase inhibitors (tuberculosis), GlaxoSmithKline/The Global Alliance for TB Drug Developement",56373,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2007-05-31 00:00:00,The Global Alliance for TB Drug Development,29411,No Development Reported,2007-05-31 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Beijing Tuberculosis & Thoracic Tumor Research Institute,1060211,China,CN,TBI-166,57790,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2014-12-22 00:00:00,Beijing Tuberculosis & Thoracic Tumor Research Institute,1060211,Discovery,2011-03-28 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,ID Vaccine Corp,23373,US,US,"rBCG30, UCLA",9831,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,false,2014-07-07 00:00:00,GlaxoSmithKline plc,28355,No Development Reported,2003-06-14 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Maxwell Biotech Group,1061894,Russian Federation,RU,SQ-109,31010,Chemical,Phase 3 Clinical,Phase 3 Clinical,C3,C3,Mycobacterium tuberculosis infection,221,false,2012-12-19 00:00:00,Maxwell Biotech Group,1061894,Discovery,2011-04-25 00:00:00,DR,6,Respiratory disease,711
Cell wall synthesis inhibitor,7052,LOCAL_AND_MAJOR,Maxwell Biotech Group,1061894,Russian Federation,RU,SQ-109,31010,Chemical,Phase 3 Clinical,Phase 3 Clinical,C3,C3,Mycobacterium tuberculosis infection,221,false,2012-12-19 00:00:00,Maxwell Biotech Group,1061894,Discovery,2011-04-25 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,University of Illinois,20592,US,US,"replicating and nonreplicating Mycobacterium tuberculosis inhibitors (tuberculosis), SRI International/University of Illinois",82340,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-07-25 00:00:00,University of Illinois,20592,Discovery,2012-01-27 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,Pfizer Inc,18767,Europe,X5,sutezolid,11088,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2013-07-17 00:00:00,Pfizer Inc,18767,Discovery,2011-04-11 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Pfizer Inc,18767,US,US,sutezolid,11088,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2013-07-17 00:00:00,Pfizer Inc,18767,Phase 1 Clinical,2009-05-19 00:00:00,C1,8,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,SPA Societa Prodotti Antibiotici SpA,20228,Italy,IT,rifametane,9630,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2009-03-26 00:00:00,SPA Societa Prodotti Antibiotici SpA,20228,No Development Reported,2009-03-26 00:00:00,NDR,2,Respiratory disease,711
DNA vaccine,1879,LOCAL_AND_MAJOR,Genesis Research and Development Corp Ltd,25513,New Zealand,NZ,"MED-1 vaccine (tuberculosis), Genesis",40637,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2009-04-30 00:00:00,Genesis Research and Development Corp Ltd,25513,Discovery,2002-01-29 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Genesis Research and Development Corp Ltd,25513,New Zealand,NZ,"MED-1 vaccine (tuberculosis), Genesis",40637,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2009-04-30 00:00:00,Genesis Research and Development Corp Ltd,25513,Discontinued,2009-04-30 00:00:00,DX,3,Respiratory disease,711
Immunostimulant,393,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,AERAS-407 rBCG,62397,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-11-27 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 1 Clinical,2008-03-31 00:00:00,C1,8,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,AERAS-407 rBCG,62397,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-11-27 00:00:00,Aeras Global TB Vaccine Foundation,1007376,No Development Reported,2014-11-27 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Institute of Materia Medica Chinese Academy of Medical Sciences & Peking Union Medical College,19595,China,CN,TBI-166,57790,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2014-12-22 00:00:00,Chinese Academy of Medical Sciences & Peking Union Medical College,1066199,Discovery,2007-01-11 00:00:00,DR,6,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,Epimmune Inc,15573,US,US,Theradigm-tuberculosis,10406,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2001-12-09 00:00:00,Takeda Pharmaceutical Co Ltd,20300,Discontinued,1997-09-23 00:00:00,DX,3,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,Epimmune Inc,15573,US,US,Theradigm-tuberculosis,10406,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2001-12-09 00:00:00,Takeda Pharmaceutical Co Ltd,20300,Discovery,1995-06-22 14:36:07,DR,6,Respiratory disease,711
Antimicrobial permeability enhancer,955,LOCAL_AND_MAJOR,CytRx Corporation,15585,US,US,CRL-1018,11007,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,1995-09-27 00:00:00,CytRx Corporation,15585,Discontinued,1995-09-27 00:00:00,DX,3,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,PathoGenesis Ltd,24982,US,US,"tobramycin (nebulized), Novartis",11232,Chemical,Launched,No Development Reported,NDR,L,Mycobacterium tuberculosis infection,221,true,2013-01-09 00:00:00,Novartis AG,23137,Phase 2 Clinical,1997-10-14 00:00:00,C2,9,Respiratory disease,711
Anticancer,1545,LOCAL_AND_MAJOR,Duquesne University,20569,US,US,"dihydrofolate reductase inhibitors, Duquesne/Indiana",12146,Chemical,Discovery,No Development Reported,NDR,DR,Mycobacterium tuberculosis infection,221,true,2011-01-04 00:00:00,Duquesne University,20569,Discovery,2003-03-30 00:00:00,DR,6,Respiratory disease,711
Subunit vaccine,12371,LOCAL_AND_MAJOR,CEL-SCI Corp,15339,US,US,"M tuberculosis vaccine (LEAPS), CEL-SCI (MaxPharma)",11526,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2011-12-28 00:00:00,CEL-SCI Corp,15339,Discovery,1996-01-08 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,University of Illinois,20592,US,US,B-4154,12633,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-08-08 00:00:00,University of Illinois,20592,No Development Reported,2008-08-08 00:00:00,NDR,2,Respiratory disease,711
Topoisomerase IV inhibitor,9320,OTHER,The Global Alliance for TB Drug Development,29411,Russian Federation,RU,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2014-10-14 00:00:00,DR,6,Respiratory disease,711
Bacterial nucleic acid synthesis inhibitor,3984,OTHER,The Global Alliance for TB Drug Development,29411,Russian Federation,RU,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2014-10-14 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,The Global Alliance for TB Drug Development,29411,Haiti,HT,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2014-10-14 00:00:00,DR,6,Respiratory disease,711
Systemic dermatological antibacterial product,15187,OTHER,The Global Alliance for TB Drug Development,29411,Peru,PE,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2014-10-14 00:00:00,DR,6,Respiratory disease,711
Topoisomerase IV inhibitor,9320,OTHER,The Global Alliance for TB Drug Development,29411,Georgia,GE,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2014-10-14 00:00:00,DR,6,Respiratory disease,711
Topoisomerase IV inhibitor,9320,OTHER,The Global Alliance for TB Drug Development,29411,Malaysia,MY,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,The Global Alliance for TB Drug Development,29411,Phase 3 Clinical,2014-08-04 00:00:00,C3,10,Respiratory disease,711
Topoisomerase IV inhibitor,9320,OTHER,The Global Alliance for TB Drug Development,29411,World,WO,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,The Global Alliance for TB Drug Development,29411,Phase 2 Clinical,2005-10-17 00:00:00,C2,9,Respiratory disease,711
Adjuvant,524,OTHER,Silence Therapeutics plc,22356,Zambia,ZM,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Therapeutic vaccine,12379,OTHER,Silence Therapeutics plc,22356,Zambia,ZM,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Antimicrobial,1593,OTHER,Silence Therapeutics plc,22356,South Africa,ZA,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Anticancer,1545,OTHER,Silence Therapeutics plc,22356,South Africa,ZA,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Inactivated bacterial vaccine,12366,OTHER,Silence Therapeutics plc,22356,South Africa,ZA,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Antibacterial,1594,OTHER,Silence Therapeutics plc,22356,Nigeria,NG,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Cytokine release modulator,1291,OTHER,Silence Therapeutics plc,22356,Nigeria,NG,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Antibacterial,1594,OTHER,Silence Therapeutics plc,22356,Kuwait,KW,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Systemic antipsoriatic product,15184,OTHER,Silence Therapeutics plc,22356,Kuwait,KW,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Antiviral,991,OTHER,Silence Therapeutics plc,22356,Gambia,GM,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Systemic antipsoriatic product,15184,OTHER,Silence Therapeutics plc,22356,Gambia,GM,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Antiviral,991,LOCAL_AND_MAJOR,Silence Therapeutics plc,22356,UK,GB,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Adjuvant,524,LOCAL_AND_MAJOR,Silence Therapeutics plc,22356,UK,GB,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Antimicrobial,1593,LOCAL_AND_MAJOR,Silence Therapeutics plc,22356,UK,GB,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Cytokine release modulator,1291,LOCAL_AND_MAJOR,Silence Therapeutics plc,22356,UK,GB,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Cytokine release modulator,1291,OTHER,Silence Therapeutics plc,22356,Tanzania,TZ,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,2001-09-30 00:00:00,C2,9,Respiratory disease,711
Therapeutic vaccine,12379,OTHER,Silence Therapeutics plc,22356,Tanzania,TZ,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,2001-09-30 00:00:00,C2,9,Respiratory disease,711
Cytokine release modulator,1291,OTHER,Silence Therapeutics plc,22356,Gambia,GM,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 3 Clinical,1997-10-13 00:00:00,C3,10,Respiratory disease,711
Systemic dermatological antibacterial product,15187,OTHER,Bayer AG,14455,China,CN,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,Bayer AG,14455,Phase 3 Clinical,2011-10-19 00:00:00,C3,10,Respiratory disease,711
Systemic dermatological antibacterial product,15187,OTHER,Bayer AG,14455,Spain,ES,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,Bayer AG,14455,Phase 2 Clinical,2005-10-17 00:00:00,C2,9,Respiratory disease,711
Topoisomerase IV inhibitor,9320,OTHER,Bayer AG,14455,Canada,CA,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,Bayer AG,14455,Phase 2 Clinical,2005-10-17 00:00:00,C2,9,Respiratory disease,711
DNA gyrase inhibitor,431,OTHER,Bayer AG,14455,Canada,CA,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,Bayer AG,14455,Phase 2 Clinical,2005-10-17 00:00:00,C2,9,Respiratory disease,711
Topoisomerase IV inhibitor,9320,OTHER,Bayer AG,14455,Brazil,BR,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,Bayer AG,14455,Phase 2 Clinical,2005-10-17 00:00:00,C2,9,Respiratory disease,711
Bacterial nucleic acid synthesis inhibitor,3984,OTHER,Bayer AG,14455,Tanzania,TZ,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,Bayer AG,14455,Phase 2 Clinical,2005-10-17 00:00:00,C2,9,Respiratory disease,711
Cytokine release modulator,1291,OTHER,Silence Therapeutics plc,22356,South Africa,ZA,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 3 Clinical,1995-10-12 00:00:00,C3,10,Respiratory disease,711
Antiviral,991,LOCAL_AND_MAJOR,Silence Therapeutics plc,22356,UK,GB,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,1995-10-12 00:00:00,C2,9,Respiratory disease,711
Anticancer,1545,OTHER,Silence Therapeutics plc,22356,Nigeria,NG,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,1995-10-12 00:00:00,C2,9,Respiratory disease,711
Systemic antipsoriatic product,15184,OTHER,Silence Therapeutics plc,22356,Gambia,GM,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,1995-10-12 00:00:00,C2,9,Respiratory disease,711
Inactivated bacterial vaccine,12366,OTHER,Silence Therapeutics plc,22356,Gambia,GM,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,1995-10-12 00:00:00,C2,9,Respiratory disease,711
Adjuvant,524,OTHER,Silence Therapeutics plc,22356,Kuwait,KW,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,1995-10-12 00:00:00,C2,9,Respiratory disease,711
Systemic antipsoriatic product,15184,OTHER,Silence Therapeutics plc,22356,Kuwait,KW,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,1995-10-12 00:00:00,C2,9,Respiratory disease,711
Antimicrobial,1593,OTHER,Silence Therapeutics plc,22356,Romania,RO,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,1995-10-12 00:00:00,C2,9,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Pasteur Merieux Connaught Canada,19267,US,US,"vaccine (BCG), Connaught/Whitehead",12124,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2001-08-24 00:00:00,Sanofi,1009547,Discovery,1996-04-18 00:00:00,DR,6,Respiratory disease,711
TLR-4 agonist,7812,LOCAL_AND_MAJOR,Farmabrasilis,1083670,Brazil,BR,P-MAPA,15596,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-06-18 00:00:00,Farmabrasilis,1083670,Discovery,2009-03-21 00:00:00,DR,6,Respiratory disease,711
Antiviral,991,LOCAL_AND_MAJOR,Universidade Estadual de Campinas,24983,Brazil,BR,P-MAPA,15596,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-06-18 00:00:00,Universidade Estadual de Campinas,24983,Discovery,2009-03-21 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Brigham & Women's Hospital,21048,US,US,"vaccine (tuberculosis), Procept",15602,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2005-12-31 00:00:00,Brigham & Women's Hospital,21048,Discovery,1997-07-30 00:00:00,DR,6,Respiratory disease,711
Lipid subunit vaccine,12374,LOCAL_AND_MAJOR,Paligent Inc,19142,US,US,"vaccine (tuberculosis), Procept",15602,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2005-12-31 00:00:00,Paligent Inc,19142,Discontinued,2005-12-31 00:00:00,DX,3,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Georgia State University,21235,US,US,pafuramidine,16755,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2008-02-22 00:00:00,Georgia State University,21235,Discontinued,2000-01-28 00:00:00,DX,3,Respiratory disease,711
Nuclease inhibitor,9166,LOCAL_AND_MAJOR,University of North Carolina,20634,US,US,pafuramidine,16755,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2008-02-22 00:00:00,University of North Carolina,20634,Discontinued,2000-01-28 00:00:00,DX,3,Respiratory disease,711
Antiparasitic,2638,LOCAL_AND_MAJOR,University of North Carolina,20634,US,US,pafuramidine,16755,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2008-02-22 00:00:00,University of North Carolina,20634,Discontinued,2000-01-28 00:00:00,DX,3,Respiratory disease,711
Topoisomerase II inhibitor,142,LOCAL_AND_MAJOR,Immtech Pharmaceuticals Inc,17195,US,US,pafuramidine,16755,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2008-02-22 00:00:00,Immtech Pharmaceuticals Inc,17195,Discovery,2000-10-23 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Wellesley College,25687,US,US,"antimycobacterials, Wellesley College",18382,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2001-11-28 00:00:00,Wellesley College,25687,No Development Reported,2001-11-28 00:00:00,NDR,2,Respiratory disease,711
Bacterial nucleic acid synthesis inhibitor,3984,LOCAL_AND_MAJOR,Harbor Therapeutics Inc,24345,US,US,PP-29,15867,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2003-07-02 00:00:00,Harbor Therapeutics Inc,24345,No Development Reported,2003-07-02 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Johns Hopkins University,20596,US,US,"antituberculosis agents, Johns Hopkins",30452,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-06-20 00:00:00,Johns Hopkins University,20596,Discovery,2000-09-05 00:00:00,DR,6,Respiratory disease,711
Autoimmune diagnostic agent,7217,LOCAL_AND_MAJOR,Navidea Biopharmaceuticals Inc,18471,US,US,technetium Tc 99m tilmanocept,34061,Chemical,Launched,Discovery,DR,L,Mycobacterium tuberculosis infection,221,true,2014-12-12 00:00:00,Navidea Biopharmaceuticals Inc,18471,Discovery,2013-09-19 00:00:00,DR,6,Respiratory disease,711
Protease inhibitor,331,LOCAL_AND_MAJOR,University of London,20607,UK,GB,"antibacterial protease inhibitors, Medivir/University of London",35747,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2003-08-19 00:00:00,University of London,20607,No Development Reported,2003-08-19 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Panacea Biotec Ltd,25333,India,IN,Panacea-0394,29616,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-02-20 00:00:00,Panacea Biotec Ltd,25333,Discovery,2000-07-13 00:00:00,DR,6,Respiratory disease,711
Subunit vaccine,12371,LOCAL_AND_MAJOR,ANI Pharmaceuticals Inc,27120,US,US,"tuberculosis vaccine (BioVant), BioSante",39902,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-12-23 00:00:00,ANI Pharmaceuticals Inc,27120,Discovery,2002-05-30 00:00:00,DR,6,Respiratory disease,711
Protein subunit vaccine,12372,OTHER,Aeras Global TB Vaccine Foundation,1007376,Sweden,SE,"HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell",48499,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-07-29 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 1 Clinical,2007-12-04 00:00:00,C1,8,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Aeras Global TB Vaccine Foundation,1007376,Finland,FI,"HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell",48499,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-07-29 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 1 Clinical,2009-01-26 00:00:00,C1,8,Respiratory disease,711
Protein subunit vaccine,12372,OTHER,Statens Serum Institut,21502,South Africa,ZA,"HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell",48499,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-07-29 00:00:00,Statens Serum Institut,21502,Phase 1 Clinical,2009-01-26 00:00:00,C1,8,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,FASgen Inc,1006466,US,US,FAS-20013,49581,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-08-25 00:00:00,FASgen Inc,1006466,Discovery,2003-09-24 00:00:00,DR,6,Respiratory disease,711
DNA gyrase inhibitor,431,LOCAL_AND_MAJOR,NicOx SA,23741,France,FR,NCX-976,47140,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2005-01-31 00:00:00,NicOx SA,23741,Discovery,2003-07-31 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Lupin Ltd,21932,India,IN,LL-3858,49162,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-07-24 00:00:00,Lupin Ltd,21932,Discovery,2004-03-12 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Lupin Ltd,21932,India,IN,LL-3858,49162,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-07-24 00:00:00,Lupin Ltd,21932,Phase 1 Clinical,2005-04-01 00:00:00,C1,8,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Lupin Ltd,21932,India,IN,LL-3858,49162,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-07-24 00:00:00,Lupin Ltd,21932,Phase 2 Clinical,2010-03-26 00:00:00,C2,9,Respiratory disease,711
Bacterial protein synthesis inhibitor,1538,OTHER,Ranbaxy Laboratories Ltd,21266,India,IN,RBx-8700,46560,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2004-04-05 00:00:00,Daiichi Sankyo Co Ltd,1017506,Discovery,2003-09-02 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Lupin Ltd,21932,India,IN,LL-4858,51319,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2010-03-26 00:00:00,Lupin Ltd,21932,Phase 1 Clinical,2006-05-17 00:00:00,C1,8,Respiratory disease,711
6-aminoglycoside N-acetyltransferase inhibitor,23008,LOCAL_AND_MAJOR,Summit Plc,1017551,UK,GB,"N-acetyltransferase inhibitors (tuberculosis), Summit/Lilly TB Drug Discovery Initiative",57219,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2008-10-07 00:00:00,Summit Plc,1017551,Discovery,2005-05-03 00:00:00,DR,6,Respiratory disease,711
Protein subunit vaccine,12372,OTHER,Intercell AG,28463,South Africa,ZA,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2013-05-28 00:00:00,Valneva SE,1084202,Discontinued,2013-05-28 00:00:00,DX,3,Respiratory disease,711
Protein subunit vaccine,12372,OTHER,Valneva SE,1084202,Tanzania,TZ,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-05-28 00:00:00,Valneva SE,1084202,Phase 2 Clinical,2013-05-28 00:00:00,C2,9,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Valneva SE,1084202,South Africa,ZA,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-05-28 00:00:00,Valneva SE,1084202,Phase 2 Clinical,2013-05-28 00:00:00,C2,9,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Cumbre Pharmaceuticals Inc,29103,US,US,"antibacterial compounds (Mycobacterium tuberculosis), Cumbre/The Global Alliance for TB Drug Development",57737,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2009-12-22 00:00:00,Cumbre Pharmaceuticals Inc,29103,Discontinued,2006-09-27 00:00:00,DX,3,Respiratory disease,711
Recombinant bacterial vector vaccine,12369,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-05-28 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Discovery,2005-06-27 00:00:00,DR,6,Respiratory disease,711
Recombinant bacterial vector vaccine,12369,OTHER,Sanofi Pasteur,22127,Netherlands,NL,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-05-28 00:00:00,Sanofi,1009547,Phase 2 Clinical,2009-03-02 00:00:00,C2,9,Respiratory disease,711
Protein subunit vaccine,12372,OTHER,Statens Serum Institut,21502,Netherlands,NL,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-05-28 00:00:00,Statens Serum Institut,21502,Phase 2 Clinical,2009-03-02 00:00:00,C2,9,Respiratory disease,711
Enoyl ACP reductase inhibitor,6436,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"InhA inhibitors (oral/tuberculosis), GlaxoSmithKline/The Global Alliance for TB Drug Development",56371,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2005-03-21 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2005-03-21 00:00:00,DR,6,Respiratory disease,711
Enoyl ACP reductase inhibitor,6436,OTHER,GlaxoSmithKline plc,28355,Spain,ES,"InhA inhibitors (oral/tuberculosis), GlaxoSmithKline/The Global Alliance for TB Drug Development",56371,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2005-03-21 00:00:00,GlaxoSmithKline plc,28355,Discovery,2005-03-21 00:00:00,DR,6,Respiratory disease,711
Subunit vaccine,12371,OTHER,Archivel Farma SL,1014222,Europe,X5,RUTI,57308,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2012-05-24 00:00:00,Archivel Farma SL,1014222,Phase 2 Clinical,2012-05-24 00:00:00,C2,9,Respiratory disease,711
Interferon gamma receptor agonist,215,LOCAL_AND_MAJOR,Cadila Pharmaceuticals Ltd,30025,India,IN,cadi-05,55173,Biological,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2014-12-03 00:00:00,Cadila Pharmaceuticals Ltd,30025,Phase 3 Clinical,2005-03-31 00:00:00,C3,10,Respiratory disease,711
Mycobacterial antigen complex 85A modulator,33967,OTHER,Oxford-Emergent Tuberculosis Consortium Ltd,1040955,UK,GB,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-07 00:00:00,Emergent BioSolutions Inc,1011990,Discontinued,2014-03-07 00:00:00,DX,3,Respiratory disease,711
Mycobacterial antigen complex 85A modulator,33967,OTHER,Oxford-Emergent Tuberculosis Consortium Ltd,1040955,UK,GB,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-07 00:00:00,Emergent BioSolutions Inc,1011990,Phase 1 Clinical,2008-07-23 00:00:00,C1,8,Respiratory disease,711
Recombinant viral vector vaccine,12370,OTHER,Oxford-Emergent Tuberculosis Consortium Ltd,1040955,UK,GB,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-07 00:00:00,Emergent BioSolutions Inc,1011990,Phase 1 Clinical,2008-07-23 00:00:00,C1,8,Respiratory disease,711
Recombinant viral vector vaccine,12370,OTHER,Oxford-Emergent Tuberculosis Consortium Ltd,1040955,Senegal,SN,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-07 00:00:00,Emergent BioSolutions Inc,1011990,Phase 2 Clinical,2011-08-08 00:00:00,C2,9,Respiratory disease,711
Recombinant viral vector vaccine,12370,LOCAL_AND_MAJOR,University of Oxford,22182,UK,GB,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-07 00:00:00,University of Oxford,22182,Discontinued,2008-07-23 00:00:00,DX,3,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,University of Oxford,22182,UK,GB,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-07 00:00:00,University of Oxford,22182,Phase 1 Clinical,2002-09-30 00:00:00,C1,8,Respiratory disease,711
Mycobacterial antigen complex 85A modulator,33967,OTHER,TB-VAC,1020621,UK,GB,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-03-07 00:00:00,TB-VAC,1020621,Phase 1 Clinical,2008-07-23 00:00:00,C1,8,Respiratory disease,711
Unspecified drug target,59620,OTHER,Upstream Biosciences Inc,1035256,Canada,CA,"antibacterial therapies (tuberculosis), Upstream Biosciences",62917,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-01-10 00:00:00,Upstream Biosciences Inc,1035256,No Development Reported,2012-01-10 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,NeED Pharmaceuticals Srl,1013076,Italy,IT,ND-201,59784,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-03-21 00:00:00,NeED Pharmaceuticals Srl,1013076,Discovery,2008-04-01 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,Avanti Therapeutics,1045576,World,WO,"tuberculosis vaccine, Avanti Therapeutics",62573,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-09-25 00:00:00,Avanti Therapeutics,1045576,Discovery,2009-02-13 00:00:00,DR,6,Respiratory disease,711
Therapeutic vaccine,12379,OTHER,Avanti Therapeutics,1045576,World,WO,"tuberculosis vaccine, Avanti Therapeutics",62573,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-09-25 00:00:00,Avanti Therapeutics,1045576,Discovery,2009-02-13 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Microbial Chemistry Research Foundation,14851,Japan,JP,CPZEN-45,59885,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2008-10-07 00:00:00,Microbial Chemistry Research Foundation,14851,Discovery,2008-04-09 00:00:00,DR,6,Respiratory disease,711
Transcriptional regulator protein EthR inhibitor,74415,LOCAL_AND_MAJOR,BioVersys AG,1052531,Switzerland,CH,"EthR inhibitors (mycobacterium tuberculosis), BioVersys",61115,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-07-10 00:00:00,BioVersys AG,1052531,Discovery,2012-07-10 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Melinta Therapeutics Inc,29298,US,US,"radezolid (oral, CAP/uSSSI), Melinta",59067,Chemical,Phase 2 Clinical,Discovery,DR,C2,Mycobacterium tuberculosis infection,221,true,2010-09-15 00:00:00,Melinta Therapeutics Inc,29298,Discovery,2010-09-15 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,University of Oxford,22182,UK,GB,FP-85A,63673,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2011-12-29 00:00:00,University of Oxford,22182,Phase 1 Clinical,2007-09-30 00:00:00,C1,8,Respiratory disease,711
Recombinant viral vector vaccine,12370,LOCAL_AND_MAJOR,University of Oxford,22182,UK,GB,FP-85A,63673,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2011-12-29 00:00:00,University of Oxford,22182,Phase 1 Clinical,2007-09-30 00:00:00,C1,8,Respiratory disease,711
Recombinant bacterial vector vaccine,12369,LOCAL_AND_MAJOR,McMaster University,21238,Canada,CA,Ad5Ag85A,71323,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,false,2012-05-07 00:00:00,McMaster University,21238,Phase 1 Clinical,2009-07-31 00:00:00,C1,8,Respiratory disease,711
Live attenuated bacterial vaccine,12363,OTHER,Tianjin CanSino Biotechnology Inc,1069870,Canada,CA,Ad5Ag85A,71323,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2012-05-07 00:00:00,Tianjin CanSino Biotechnology Inc,1069870,Phase 1 Clinical,2011-08-31 00:00:00,C1,8,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Aeras Global TB Vaccine Foundation,1007376,China,CN,Ad5Ag85A,71323,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2012-05-07 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Discovery,2012-05-07 00:00:00,DR,6,Respiratory disease,711
Live attenuated bacterial vaccine,12363,OTHER,Aeras Global TB Vaccine Foundation,1007376,China,CN,Ad5Ag85A,71323,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2012-05-07 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Discovery,2012-05-07 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Medisyn Technologies Inc,1005984,US,US,"Gram positive antibacterials (tuberculosis infection), Medisyn Technologies",65284,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2009-12-17 00:00:00,Medisyn Technologies Inc,1005984,Discovery,2009-12-17 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Dafra Pharma R&D,1040827,Belgium,BE,"DF-152 series (Mycobacterium tuberculosis infection), Dafra Pharma R&D",69801,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-01-25 00:00:00,Dafra Pharma International,1031290,Discovery,2011-01-25 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,LifePharms Inc,1060609,US,US,"antituberculosis agents, LifePharms Inc/Institute for Tuberculosis Research",70763,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-01-24 00:00:00,LifePharms Inc,1060609,Discovery,2010-03-26 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Immune Solutions Ltd,1053537,New Zealand,NZ,"BCG Vaccine (oral lipid matrix, Liporale), Immune Solutions/Aeras Global TB foundation",66314,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2010-05-04 00:00:00,Immune Solutions Ltd,1053537,Discovery,2010-05-04 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Statens Serum Institut,21502,Denmark,DK,H-56,69824,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-08-22 00:00:00,Statens Serum Institut,21502,No Development Reported,2013-08-22 00:00:00,NDR,2,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Colorado State University,20562,US,US,H-56,69824,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-08-22 00:00:00,Colorado State University,20562,No Development Reported,2013-08-22 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Reyon Pharmaceuticals Co Ltd,1022208,South Korea,KR,"tubercuslosis program, B&C Biopharm/Reyon Pharma/Wayne State University",67413,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2010-07-21 00:00:00,Reyon Pharmaceuticals Co Ltd,1022208,Discovery,2008-03-31 00:00:00,DR,6,Respiratory disease,711
Protein kinase inhibitor,336,LOCAL_AND_MAJOR,B&C Biopharm,1004322,South Korea,KR,"tubercuslosis program, B&C Biopharm/Reyon Pharma/Wayne State University",67413,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2010-07-21 00:00:00,B&C Biopharm,1004322,Discovery,2008-03-31 00:00:00,DR,6,Respiratory disease,711
Protein kinase inhibitor,336,LOCAL_AND_MAJOR,Wayne State University,20702,US,US,"tubercuslosis program, B&C Biopharm/Reyon Pharma/Wayne State University",67413,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2010-07-21 00:00:00,Wayne State University,20702,Discovery,2010-07-21 00:00:00,DR,6,Respiratory disease,711
Thioredoxin reductase inhibitor,6506,LOCAL_AND_MAJOR,Intervet Innovation GmbH,1061424,Germany,DE,"thioredoxin reductase inhibitors (tuberculosis), Intervet Innovation",70840,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-02-26 00:00:00,Intervet Innovation GmbH,1061424,No Development Reported,2013-02-26 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,University of California San Diego,25451,US,US,NTF-1836,72331,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-02-05 00:00:00,University of California,20547,Discovery,2011-07-01 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Medical Research Council Technology,1054893,UK,GB,"PknB inhibitors (Mycobacterium tuberculosis infection), MRCT",66920,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-09-23 00:00:00,Medical Research Council (MRC),18438,No Development Reported,2014-09-23 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Medical Research Council Technology,1054893,UK,GB,"Mut Y inhibitors (Mycobacterium tuberculosis infection), MRCT",66921,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-06-21 00:00:00,Medical Research Council (MRC),18438,No Development Reported,2012-06-21 00:00:00,NDR,2,Respiratory disease,711
A-G adenine DNA glycosylase inhibitor,10360,LOCAL_AND_MAJOR,Medical Research Council Technology,1054893,UK,GB,"Mut Y inhibitors (Mycobacterium tuberculosis infection), MRCT",66921,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-06-21 00:00:00,Medical Research Council (MRC),18438,No Development Reported,2012-06-21 00:00:00,NDR,2,Respiratory disease,711
Protein subunit vaccine,12372,OTHER,Aeras Global TB Vaccine Foundation,1007376,South Africa,ZA,ID-93,68617,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-09-20 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 1 Clinical,2013-09-20 00:00:00,C1,8,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,ID-93,68617,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-09-20 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Discovery,2012-05-09 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Infectious Disease Research Institute,27376,US,US,ID-93,68617,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-09-20 00:00:00,Infectious Disease Research Institute,27376,Phase 1 Clinical,2012-08-15 00:00:00,C1,8,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"folate biosynthesis inhibitors (tuberculosis), AZ/TB Alliance",71614,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-11-30 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2011-02-04 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"menaquinone synthase inhibitors (tuberculosis infection), Colorado State University/TB Alliance",71664,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2009-05-27 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2009-05-27 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,GlaxoSmithKline plc,28355,UK,GB,"malate synthase (tuberculosis infection), GSK/TB Alliance/Texas A&M University",71667,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2007-12-31 00:00:00,GlaxoSmithKline plc,28355,Discovery,2007-12-31 00:00:00,DR,6,Respiratory disease,711
RNA polymerase inhibitor,347,LOCAL_AND_MAJOR,Rutgers University,21239,US,US,"RNA polymerase inhibitors (tuberculosis infection), TB Alliance/Rutgers",71698,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-07-10 00:00:00,Rutgers University,21239,Discovery,2009-01-27 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,AstraZeneca plc,14190,India,IN,"gyrase B inhibitors (tuberculosis infection), AZ/TB Alliance",71700,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-11-30 00:00:00,AstraZeneca plc,14190,Discovery,2010-05-03 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,NeED Pharmaceuticals Srl,1013076,Italy,IT,ND-601,71115,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-03-21 00:00:00,NeED Pharmaceuticals Srl,1013076,No Development Reported,2014-03-21 00:00:00,NDR,2,Respiratory disease,711
Protease inhibitor,331,LOCAL_AND_MAJOR,The Institute of Microbiology Chinese Academy of Sciences,1015456,China,CN,"protease inhibitors (tuberculosis infection, TB Alliance/Institute of Microbiology Chinese Academy of Sciences",71743,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-18 00:00:00,Chinese Academy of Sciences,23863,Discovery,2009-05-27 00:00:00,DR,6,Respiratory disease,711
Protease inhibitor,331,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"protease inhibitors (tuberculosis infection, TB Alliance/Institute of Microbiology Chinese Academy of Sciences",71743,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-18 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2009-05-27 00:00:00,DR,6,Respiratory disease,711
Antibacterial multidrug resistance inhibitor,4855,LOCAL_AND_MAJOR,Snowdon Inc,1033991,US,US,SND-159,64976,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2009-02-05 00:00:00,Snowdon Inc,1033991,Discovery,2009-02-05 00:00:00,DR,6,Respiratory disease,711
Recombinant bacterial vector vaccine,12369,OTHER,RecipharmCobra Biologics,20370,UK,GB,"tuberculosis DNA vaccine (ORT), RecipharmCobra Biologics",69165,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-03-13 00:00:00,Recipharm AB,1058217,No Development Reported,2013-03-13 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,NeED Pharmaceuticals Srl,1013076,Italy,IT,ND-601,71115,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-03-21 00:00:00,NeED Pharmaceuticals Srl,1013076,Discovery,2011-04-20 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Ensoltek Co Ltd,1017455,South Korea,KR,Hesed-1000,71805,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-06-10 00:00:00,Ensoltek Co Ltd,1017455,Discovery,2011-06-10 00:00:00,DR,6,Respiratory disease,711
Protein subunit vaccine,12372,OTHER,Novartis Vaccines and Diagnostics Ltd,17976,UK,GB,"protein subunit vaccine (Mycobacterium tuberculosis, intranasal), Novartis Vaccines & Diagnostics/Statens Serum Institut",66563,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2011-11-30 00:00:00,Novartis AG,23137,Phase 1 Clinical,2007-02-26 00:00:00,C1,8,Respiratory disease,711
CD40 ligand modulator,5486,LOCAL_AND_MAJOR,Adjuvantix Ltd,1002784,UK,GB,ADX40-TB,64522,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-10-21 00:00:00,Adjuvantix Ltd,1002784,No Development Reported,2014-10-21 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Fundacao de Amparo a Pesquisa do Estado Sao Paulo,1003225,Brazil,BR,"ruthenium (II) based organic complexes (tuberculosis infection), FAPESP",71902,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2009-06-10 00:00:00,Fundacao de Amparo a Pesquisa do Estado Sao Paulo,1003225,Discovery,2009-06-10 00:00:00,DR,6,Respiratory disease,711
Bacterial pathogenicity factor modulator,3983,LOCAL_AND_MAJOR,Vichem Chemie Ltd,1031147,Hungary,HU,"PknG inhibitors (Mycobacterium tuberculosis infection), Vichem Chemie",68370,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2015-04-24 00:00:00,Vichem Chemie Ltd,1031147,Discovery,2008-03-15 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,TB Drug Boost,1054643,France,FR,"FurA inhibitors (Mycobacterium tuberculosis infection), TB Drug Boost",67299,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-06-20 00:00:00,TB Drug Boost,1054643,No Development Reported,2012-06-20 00:00:00,NDR,2,Respiratory disease,711
Antiparasitic,2638,LOCAL_AND_MAJOR,Wyeth BioPharma,20511,US,US,edodekin alfa,6934,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-06-27 00:00:00,Pfizer Inc,18767,Discontinued,2003-06-27 00:00:00,DX,3,Respiratory disease,711
Immunostimulant,393,LOCAL_AND_MAJOR,VIB,25058,Belgium,BE,"tuberculosis vaccine, VIB/Ghent University",70144,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-10-07 00:00:00,University of Antwerp,22741,Discovery,2011-01-26 00:00:00,DR,6,Respiratory disease,711
Immunostimulant,393,LOCAL_AND_MAJOR,University of Ghent,24987,Belgium,BE,"tuberculosis vaccine, VIB/Ghent University",70144,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-10-07 00:00:00,University of Ghent,24987,No Development Reported,2014-10-07 00:00:00,NDR,2,Respiratory disease,711
Recombinant bacterial vector vaccine,12369,LOCAL_AND_MAJOR,University of Ghent,24987,Belgium,BE,"tuberculosis vaccine, VIB/Ghent University",70144,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-10-07 00:00:00,University of Ghent,24987,No Development Reported,2014-10-07 00:00:00,NDR,2,Respiratory disease,711
Live attenuated bacterial vaccine,12363,LOCAL_AND_MAJOR,University of Ghent,24987,Belgium,BE,"tuberculosis vaccine, VIB/Ghent University",70144,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-10-07 00:00:00,University of Ghent,24987,No Development Reported,2014-10-07 00:00:00,NDR,2,Respiratory disease,711
Immunostimulant,393,LOCAL_AND_MAJOR,University of Ghent,24987,Belgium,BE,"tuberculosis vaccine, VIB/Ghent University",70144,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-10-07 00:00:00,University of Ghent,24987,Discovery,2011-01-26 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,Pharmarare SA,1062315,World,WO,DasKloster 0249-01,71313,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2010-09-30 00:00:00,Pharmarare SA,1062315,Discovery,2010-09-30 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Sphaera Pharma,1050976,India,IN,"repurposed mepenzolate bromide (tuberculosis), Sphaera/ICGEB",78319,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-05-07 00:00:00,Sphaera Pharma,1050976,Discovery,2012-05-07 00:00:00,DR,6,Respiratory disease,711
Antibacterial multidrug resistance inhibitor,4855,LOCAL_AND_MAJOR,Albert Einstein College of Medicine,24282,US,US,"carbapenem + beta lactamase inhibitor (Mycobacterium tuberculosis infection), Albert Einstein College of Medicine",79321,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-05-28 00:00:00,Yeshiva University,20704,No Development Reported,2014-05-28 00:00:00,NDR,2,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,TapImmune Inc,27762,US,US,"tuberculosis vaccine, TapImmune",74286,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-09-23 00:00:00,TapImmune Inc,27762,No Development Reported,2014-09-23 00:00:00,NDR,2,Respiratory disease,711
Recombinant fungal vector vaccine,33963,LOCAL_AND_MAJOR,Finlay Institute,15912,Cuba,CU,"Streptomyces vector-based live recombinant vaccine (tuberculosis infection), Finlay Institute",73326,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-10-15 00:00:00,Finlay Institute,15912,No Development Reported,2013-10-15 00:00:00,NDR,2,Respiratory disease,711
Protein subunit vaccine,12372,LOCAL_AND_MAJOR,Finlay Institute,15912,Cuba,CU,"Streptomyces vector-based live recombinant vaccine (tuberculosis infection), Finlay Institute",73326,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-10-15 00:00:00,Finlay Institute,15912,Discovery,2009-12-31 00:00:00,DR,6,Respiratory disease,711
Mycobacterial antigen complex 85B modulator,33970,LOCAL_AND_MAJOR,Shanghai H&G Biotechnology Co,1066720,China,CN,"Ag85A/B DNA vaccine (tuberculosis), Shanghai H&G Biotechnology",75084,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-17 00:00:00,Shanghai H&G Biotechnology Co,1066720,Discovery,2006-12-31 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Omnia Molecular,1065893,Spain,ES,"leucyl-tRNA synthetase inhibitors (Mycobacterium tuberculosis infection), Omnia Molecular",75760,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-10-14 00:00:00,Omnia Molecular,1065893,Discovery,2011-10-24 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,National University of Singapore,20633,Singapore,SG,"miRNA-like molecules (tuberculosis), NUS",77116,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-06-20 00:00:00,National University of Singapore,20633,Discovery,2012-02-28 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Chongqing Zhifei Biological Products Co Ltd,1062383,China,CN,Wei Ka,81037,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2001-12-31 00:00:00,Chongqing Zhifei Biological Products Co Ltd,1062383,Launched,2001-12-31 00:00:00,L,13,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Chongqing Zhifei Biological Products Co Ltd,1062383,China,CN,Wei Ka,81037,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2001-12-31 00:00:00,Chongqing Zhifei Biological Products Co Ltd,1062383,Registered,2001-12-31 00:00:00,R,12,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,Chongqing Zhifei Biological Products Co Ltd,1062383,China,CN,Wei Ka,81037,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2001-12-31 00:00:00,Chongqing Zhifei Biological Products Co Ltd,1062383,Registered,2001-12-31 00:00:00,R,12,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Shanghai H&G Biotechnology Co,1066720,China,CN,"ESAT-6/Ag85A-expressing recombinant BCG vaccine (Mycobacterium tuberculosis), Shanghai H&G",75152,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-17 00:00:00,Shanghai H&G Biotechnology Co,1066720,No Development Reported,2013-01-17 00:00:00,NDR,2,Respiratory disease,711
Protein subunit vaccine,12372,LOCAL_AND_MAJOR,Shanghai H&G Biotechnology Co,1066720,China,CN,"ESAT-6/Ag85A-expressing recombinant BCG vaccine (Mycobacterium tuberculosis), Shanghai H&G",75152,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-17 00:00:00,Shanghai H&G Biotechnology Co,1066720,Discovery,2007-08-28 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Shreya Life Sciences Pvt Ltd,1028690,India,IN,"anti-tuberculosis therapeutics, Shreya Life Sciences/NIO",76688,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2010-03-30 00:00:00,Shreya Life Sciences Pvt Ltd,1028690,Discovery,2010-03-30 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Qurient Therapeutics,1062405,South Korea,KR,"TB I series (tuberculosis infection), Qurient Therapeutics",78036,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2013-06-28 00:00:00,Qurient Therapeutics,1062405,Discovery,2010-03-31 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Center for Genetic Engineering and Biotechnology,15353,Cuba,CU,"interferon gamma follow-on biologic, CIGB/Heber Biotec",79519,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2009-12-31 00:00:00,Center for Genetic Engineering and Biotechnology,15353,Launched,2009-12-31 00:00:00,L,13,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Chengdu Institute of Biological Products,1016340,China,CN,Ka Shu Ning,80062,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,1998-12-31 00:00:00,Sinopharm,1055632,Registered,1998-12-31 00:00:00,R,12,Respiratory disease,711
Live attenuated bacterial vaccine,12363,LOCAL_AND_MAJOR,Shanghai Institute of Biological Products Co Ltd,1071897,China,CN,"BCG vaccine (intradermal), Shanghai Institute of Biological Products",80067,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2001-12-31 00:00:00,Sinopharm,1055632,Launched,2001-12-31 00:00:00,L,13,Respiratory disease,711
Unspecified drug target,59620,OTHER,Quantum Pharmaceuticals Ltd,1064010,Russian Federation,RU,QP-42,76732,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-07-24 00:00:00,Quantum Pharmaceuticals Ltd,1064010,Discovery,2010-06-05 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,Quantum Pharmaceuticals Ltd,1064010,Russian Federation,RU,QP-42,76732,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-07-24 00:00:00,Quantum Pharmaceuticals Ltd,1064010,Discovery,2010-06-05 00:00:00,DR,6,Respiratory disease,711
DNA vaccine,1879,LOCAL_AND_MAJOR,Savine Therapeutics Pty Ltd,1066884,Australia,AU,"TB SAVINE (cDNA vaccine, tuberculosis), Savine",77428,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-12-14 00:00:00,BioDiem Ltd,30212,Discovery,2011-12-14 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Universidade Federal de Minas Gerais,25676,Brazil,BR,"sMTL-13 vaccine (Mycobacterium tuberculosis infection), Universidade Federal de Minas Gerais",79289,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-08-25 00:00:00,Universidade Federal de Minas Gerais,25676,Discovery,2012-06-21 00:00:00,DR,6,Respiratory disease,711
Unspecified enzyme modulator,1051,LOCAL_AND_MAJOR,Howard Hughes Medical Institute,21084,US,US,"TCA1 analogs (Mycobacterium tuberculosis infection), SRI/HHMI/AECM",85774,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-06-17 00:00:00,Howard Hughes Medical Institute,21084,Discovery,2013-06-17 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,University of New Mexico,20639,US,US,modified formulation of isoniazid (drug-resistant tuberculosis) University of New Mexico/Science & Technology Corporation @ UNM,88285,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-05-05 00:00:00,University of New Mexico,20639,Discovery,2004-08-31 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,National Institute of Allergy and Infectious Diseases,20520,Tanzania,TZ,"vaccine (disseminated tuberculosis), NIAID",83281,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-02-11 00:00:00,US Government,20516,Phase 3 Clinical,2001-09-30 00:00:00,C3,10,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Eli Lilly & Co,17810,US,US,"Mycobacterium tuberculosis inhibitors (Mycobacterium tuberculosis infection), Eli Lilly",87565,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-09-12 00:00:00,Eli Lilly & Co,17810,Discovery,2013-09-12 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Montana State University,1002785,US,US,"antibacterial compounds (tuberculosis), Eli Lilly & Co/The University of Notre Dame du Lac/Montana State University/University of Illinois/Infectious Disease Research Institute",87600,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-09-11 00:00:00,Montana State University,1002785,Discovery,2013-09-11 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Infectious Disease Research Institute,27376,US,US,"antibacterial compounds (tuberculosis), Eli Lilly & Co/The University of Notre Dame du Lac/Montana State University/University of Illinois/Infectious Disease Research Institute",87600,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-09-11 00:00:00,Infectious Disease Research Institute,27376,Discovery,2013-09-11 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,University of Illinois,20592,US,US,"antibacterial compounds (tuberculosis), Eli Lilly & Co/The University of Notre Dame du Lac/Montana State University/University of Illinois/Infectious Disease Research Institute",87600,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-09-11 00:00:00,University of Illinois,20592,Discovery,2011-03-23 00:00:00,DR,6,Respiratory disease,711
DHNA octaprenyltransferase inhibitor,74361,LOCAL_AND_MAJOR,University of Tennessee Research Foundation Office of Technology Transfer,1089655,US,US,"menA inhibitors (Mycobacterium tuberculosis), University of Tennessee/University of Tennessee Research Foundation Office of Technology Transfer",88391,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-11-04 00:00:00,University of Tennessee,26292,Discovery,2013-11-04 00:00:00,DR,6,Respiratory disease,711
DPR oxidase inhibitor,78977,LOCAL_AND_MAJOR,Sichuan Long March Pharmaceutical Co Ltd,1088430,China,CN,SKLB-TB37,87680,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-06-16 00:00:00,Sichuan Long March Pharmaceutical Co Ltd,1088430,Discovery,2011-06-16 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"diarylquinolines (tuberculosis), TB Alliance/J & J/University of Auckland/University of Illinois at Chicago",82662,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-06-30 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2012-11-30 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Shenyang Hongqi Pharmaceutical Co Ltd,1075626,China,CN,"ethambutol hydrochloride + rifampicin + isoniazid (fixed dose combination, tuberculosis), Shenyang Hongqi Pharmaceutical",82091,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2008-12-31 00:00:00,Shanghai Fosun Pharmaceutical (Group) Co Ltd,1015871,Registered,2008-03-03 00:00:00,R,12,Respiratory disease,711
Recombinant viral vector vaccine,12370,LOCAL_AND_MAJOR,University of Oxford,22182,UK,GB,ChAdOx1-85A,84564,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-06-12 00:00:00,University of Oxford,22182,Phase 1 Clinical,2013-06-12 00:00:00,C1,8,Respiratory disease,711
Mycobacterial antigen complex 85A modulator,33967,LOCAL_AND_MAJOR,University of Oxford,22182,UK,GB,ChAdOx1-85A,84564,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-06-12 00:00:00,University of Oxford,22182,Discovery,2012-07-31 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,University of Illinois,20592,US,US,"anti-tuberculosis agents, University of Illinois/University of Illinois at URBANA-CHAMPAIGN",87132,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-08-27 00:00:00,University of Illinois,20592,Discovery,2013-08-27 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,University of California Los Angeles,25623,US,US,"bacteria-based booster vaccine (tuberculosis), UCLA",85546,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-06-15 00:00:00,University of California,20547,Discovery,2011-06-15 00:00:00,DR,6,Respiratory disease,711
Bacterial protein synthesis inhibitor,1538,LOCAL_AND_MAJOR,ActivBiotics Pharma LLC,1071434,US,US,rifalazil,8658,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2014-10-30 00:00:00,ActivBiotics Pharma LLC,1071434,Phase 2 Clinical,2010-12-21 00:00:00,C2,9,Respiratory disease,711
Ubiquitin like protein modulator,82052,LOCAL_AND_MAJOR,New York University,20646,US,US,"modified Pup modulators (Mycobacterium tuberculosis infection), New York University",88848,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-09-24 00:00:00,New York University,20646,Discovery,2013-09-24 00:00:00,DR,6,Respiratory disease,711
Nitric oxide donor,698,OTHER,The Global Alliance for TB Drug Development,29411,China,CN,pretomanid,13323,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-09-05 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2014-09-05 00:00:00,DR,6,Respiratory disease,711
Nitric oxide donor,698,OTHER,The Global Alliance for TB Drug Development,29411,South Africa,ZA,pretomanid,13323,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-09-05 00:00:00,The Global Alliance for TB Drug Development,29411,Phase 2 Clinical,2007-11-08 00:00:00,C2,9,Respiratory disease,711
Serine protease inhibitor,349,LOCAL_AND_MAJOR,Omni Bio Pharmaceutical Inc,1047826,US,US,"p-ATT (type 1/2 diabetes/influenza/tuberculosis/anthrax/HIV infection/transplant rejection/GVHD), Omni Bio",66767,Chemical,Phase 2 Clinical,Discovery,DR,C2,Mycobacterium tuberculosis infection,221,true,2013-01-31 00:00:00,Omni Bio Pharmaceutical Inc,1047826,Discovery,2010-08-06 00:00:00,DR,6,Respiratory disease,711
Caspase-3 inhibitor,7302,LOCAL_AND_MAJOR,Omni Bio Pharmaceutical Inc,1047826,US,US,"p-ATT (type 1/2 diabetes/influenza/tuberculosis/anthrax/HIV infection/transplant rejection/GVHD), Omni Bio",66767,Chemical,Phase 2 Clinical,Discovery,DR,C2,Mycobacterium tuberculosis infection,221,true,2013-01-31 00:00:00,Omni Bio Pharmaceutical Inc,1047826,Discovery,2010-08-06 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Sichuan Long March Pharmaceutical Co Ltd,1088430,China,CN,"ethambutol hydrochloride + pyrazinamide + rifampicin + isoniazid (oral tablet, tuberculosis), Sichuan Long March Pharmaceutical",96349,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-11-11 00:00:00,Sichuan Long March Pharmaceutical Co Ltd,1088430,Discovery,2006-04-02 00:00:00,DR,6,Respiratory disease,711
RNA polymerase inhibitor,347,OTHER,Pfizer Inc,18767,Netherlands,NL,rifabutin,4229,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2008-10-07 00:00:00,Pfizer Inc,18767,Registered,1995-07-17 00:00:00,R,12,Respiratory disease,711
RNA polymerase inhibitor,347,LOCAL_AND_MAJOR,Pharmacia & Upjohn Co,18995,US,US,rifabutin,4229,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2008-10-07 00:00:00,Pfizer Inc,18767,No Development Reported,2002-09-02 00:00:00,NDR,2,Respiratory disease,711
ATP synthase inhibitor,49687,OTHER,Janssen Research & Development LLC,1067538,Ukraine,UA,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Discovery,2009-07-30 00:00:00,DR,6,Respiratory disease,711
ATP synthase inhibitor,49687,OTHER,Janssen Research & Development LLC,1067538,Peru,PE,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Pre-registration,2014-11-06 00:00:00,PR,11,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Cumencor Pharmaceuticals,1053349,China,CN,"antibiotic (tuberculosis), MicuRx/Cumencor/Pfizer",68345,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2010-04-06 00:00:00,Cumencor Pharmaceuticals,1053349,Discovery,2010-04-06 00:00:00,DR,6,Respiratory disease,711
Proteasome inhibitor,4917,LOCAL_AND_MAJOR,Harvard University Office of Technology Development,1085770,US,US,"proteasome inhibitors (tuberculosis), Harvard University/Harvard University Office of Technology Development",86021,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-08-21 00:00:00,Harvard University,20584,No Development Reported,2014-08-21 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Shanghai H&G Biotechnology Co,1066720,China,CN,"Ag85A DNA vaccine (Mycobacterium tuberculosis), Shanghai H&G",75158,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-17 00:00:00,Shanghai H&G Biotechnology Co,1066720,Discovery,2011-12-20 00:00:00,DR,6,Respiratory disease,711
Mycobacterial antigen complex 85A modulator,33967,LOCAL_AND_MAJOR,Shanghai H&G Biotechnology Co,1066720,China,CN,"Ag85A DNA vaccine (Mycobacterium tuberculosis), Shanghai H&G",75158,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-17 00:00:00,Shanghai H&G Biotechnology Co,1066720,Discovery,2011-12-20 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Shanghai H&G Biotechnology Co,1066720,China,CN,"Ag85A DNA vaccine (Mycobacterium tuberculosis), Shanghai H&G",75158,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-17 00:00:00,Shanghai H&G Biotechnology Co,1066720,No Development Reported,2013-01-17 00:00:00,NDR,2,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Aeras Global TB Vaccine Foundation,1007376,South Africa,ZA,SSI H56-IC31,74849,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-11-08 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 1 Clinical,2011-12-01 00:00:00,C1,8,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Genzyme Corp,16299,US,US,"enoyl reductase inhibitors (antimicrobial), Genzyme",47123,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2004-05-25 00:00:00,Sanofi,1009547,Discovery,2002-11-25 00:00:00,DR,6,Respiratory disease,711
Antiparasitic,2638,LOCAL_AND_MAJOR,Genzyme Corp,16299,US,US,"enoyl reductase inhibitors (antimicrobial), Genzyme",47123,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2004-05-25 00:00:00,Sanofi,1009547,No Development Reported,2004-05-25 00:00:00,NDR,2,Respiratory disease,711
Enoyl ACP reductase inhibitor,6436,LOCAL_AND_MAJOR,Genzyme Corp,16299,US,US,"enoyl reductase inhibitors (antimicrobial), Genzyme",47123,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2004-05-25 00:00:00,Sanofi,1009547,No Development Reported,2004-05-25 00:00:00,NDR,2,Respiratory disease,711
Therapeutic vaccine,12379,OTHER,Sequella Inc,28087,UK,GB,"DNA vaccine (tuberculosis), NIMR/Sequella",22154,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-10-13 00:00:00,Sequella Inc,28087,Discovery,2001-11-29 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Shenyang Hongqi Pharmaceutical Co Ltd,1075626,China,CN,"ethambutol hydrochloride (250 mg) + pyrazinamide (400 mg) + rifampicin (120 mg) + isoniazid (120 mg) (fixed dose combination, tuberculosis), Shenyang Hongqi Pharmaceutical",82062,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2009-12-31 00:00:00,Shanghai Fosun Pharmaceutical (Group) Co Ltd,1015871,Registered,2009-05-22 00:00:00,R,12,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Shanghai H&G Biotechnology Co,1066720,China,CN,"ESAT-6/Ag85A DNA vaccine (Mycobacterium tuberculosis), Shanghai H&G",75153,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-17 00:00:00,Shanghai H&G Biotechnology Co,1066720,Discovery,2011-12-20 00:00:00,DR,6,Respiratory disease,711
Mycobacterium early secretory antigen modulator,25527,LOCAL_AND_MAJOR,Shanghai H&G Biotechnology Co,1066720,China,CN,"ESAT-6/Ag85A DNA vaccine (Mycobacterium tuberculosis), Shanghai H&G",75153,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-17 00:00:00,Shanghai H&G Biotechnology Co,1066720,Discovery,2011-12-20 00:00:00,DR,6,Respiratory disease,711
Protein subunit vaccine,12372,OTHER,Intercell AG,28463,South Africa,ZA,SSI H56-IC31,74849,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2013-11-08 00:00:00,Valneva SE,1084202,Discontinued,2013-05-28 00:00:00,DX,3,Respiratory disease,711
Inactivated bacterial vaccine,12366,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,DAR-901,90231,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2014-02-28 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 1 Clinical,2014-02-28 00:00:00,C1,8,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,SEEK,1031545,UK,GB,TB-v,90650,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-03-12 00:00:00,SEEK,1031545,Discovery,2014-03-12 00:00:00,DR,6,Respiratory disease,711
Glutamate receptor modulator,870,LOCAL_AND_MAJOR,Johns Hopkins University,20596,US,US,"L-homoserine, Johns Hopkins",18364,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2001-01-30 00:00:00,Johns Hopkins University,20596,Discovery,1998-07-24 13:56:01,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Chiron PathoGenesis,18741,US,US,pretomanid,13323,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-09-05 00:00:00,Novartis AG,23137,Discovery,2000-06-26 00:00:00,DR,6,Respiratory disease,711
Antiparasitic,2638,LOCAL_AND_MAJOR,St Jude Children's Research Hospital,21814,US,US,"thiolactomycin analog, GlaxoSmithKline",33073,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-08-08 00:00:00,St Jude Children's Research Hospital,21814,No Development Reported,2008-08-08 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Chimerix Inc,30079,US,US,"Mycobacterium tuberculosis infection targeting compounds, Chimerix",69571,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-09-16 00:00:00,Chimerix Inc,30079,Discovery,2011-01-04 00:00:00,DR,6,Respiratory disease,711
Anticancer,1545,LOCAL_AND_MAJOR,Otsuka Pharmaceutical Co Ltd,18717,Japan,JP,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Discovery,2005-03-16 00:00:00,DR,6,Respiratory disease,711
Mycolic acid synthase inhibitor,6542,LOCAL_AND_MAJOR,Otsuka Pharmaceutical Co Ltd,18717,Japan,JP,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Discovery,2005-03-16 00:00:00,DR,6,Respiratory disease,711
Anti-inflammatory,2953,LOCAL_AND_MAJOR,Otsuka Pharmaceutical Co Ltd,18717,Japan,JP,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 1 Clinical,2005-12-19 00:00:00,C1,8,Respiratory disease,711
Antibacterial,1594,OTHER,Otsuka Pharmaceutical Co Ltd,18717,EU,EU,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Pre-registration,2011-11-30 00:00:00,PR,11,Respiratory disease,711
Angiogenesis inhibitor,61,OTHER,Otsuka Pharmaceutical Co Ltd,18717,EU,EU,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Pre-registration,2011-11-30 00:00:00,PR,11,Respiratory disease,711
Mycolic acid synthase inhibitor,6542,OTHER,Otsuka Pharmaceutical Co Ltd,18717,EU,EU,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Pre-registration,2011-11-30 00:00:00,PR,11,Respiratory disease,711
Mycolic acid synthase inhibitor,6542,LOCAL_AND_MAJOR,Otsuka Pharmaceutical Co Ltd,18717,Japan,JP,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 2 Clinical,2008-04-30 00:00:00,C2,9,Respiratory disease,711
Antibacterial,1594,OTHER,Otsuka Pharmaceutical Co Ltd,18717,South Africa,ZA,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 2 Clinical,2006-11-30 00:00:00,C2,9,Respiratory disease,711
Mycolic acid synthase inhibitor,6542,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Estonia,EE,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 3 Clinical,2011-09-19 00:00:00,C3,10,Respiratory disease,711
Anticancer,1545,OTHER,Otsuka Pharmaceutical Co Ltd,18717,EU,EU,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Registered,2014-04-28 00:00:00,R,12,Respiratory disease,711
Mycolic acid synthase inhibitor,6542,OTHER,Otsuka Pharmaceutical Co Ltd,18717,EU,EU,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Registered,2014-04-28 00:00:00,R,12,Respiratory disease,711
Mycolic acid synthase inhibitor,6542,OTHER,Otsuka Pharmaceutical Co Ltd,18717,China,CN,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 2 Clinical,2008-04-30 00:00:00,C2,9,Respiratory disease,711
Antibacterial,1594,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Peru,PE,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 3 Clinical,2013-07-26 00:00:00,C3,10,Respiratory disease,711
Antibacterial,1594,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Germany,DE,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Launched,2014-11-13 00:00:00,L,13,Respiratory disease,711
Angiogenesis inhibitor,61,LOCAL_AND_MAJOR,Otsuka Pharmaceutical Co Ltd,18717,US,US,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 3 Clinical,2011-12-31 00:00:00,C3,10,Respiratory disease,711
Unspecified enzyme stimulator,1052,LOCAL_AND_MAJOR,Procrysta Biologix Inc,1080144,US,US,PCB-101,83811,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-04-18 00:00:00,Procrysta Biologix Inc,1080144,No Development Reported,2014-04-18 00:00:00,NDR,2,Respiratory disease,711
Live attenuated bacterial vaccine,12363,LOCAL_AND_MAJOR,Vakzine Projekt Management GmbH,1020740,Germany,DE,VPM-1002,55569,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-03-27 00:00:00,Vakzine Projekt Management GmbH,1020740,Discovery,2004-03-24 00:00:00,DR,6,Respiratory disease,711
Listeriolysin stimulator,14513,LOCAL_AND_MAJOR,Vakzine Projekt Management GmbH,1020740,Germany,DE,VPM-1002,55569,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-03-27 00:00:00,Vakzine Projekt Management GmbH,1020740,Phase 2 Clinical,2011-09-26 00:00:00,C2,9,Respiratory disease,711
Granulysin stimulator,48680,LOCAL_AND_MAJOR,GenomIdea Inc,1008113,Japan,JP,"DNA vaccines (HJV vector, tuberculosis), GenomIdea",60030,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2007-04-20 00:00:00,AnGes MG Inc,28514,Discovery,2007-04-20 00:00:00,DR,6,Respiratory disease,711
Anticancer,1545,OTHER,Immodulon Therapeutics Limited,1051823,Argentina,AR,"heat-killed Mycobacterium vaccae (tablet formulation, tuberculosis), Immunitor",70934,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-26 00:00:00,Immodulon Therapeutics Limited,1051823,Clinical,2010-03-31 00:00:00,CU,7,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Biowest Therapeutics Inc,18210,Canada,CA,Penetrin-A,9087,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2001-06-11 00:00:00,Biowest Therapeutics Inc,18210,Discovery,1994-07-01 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,Searchlight Minerals Corp,29482,UK,GB,"tuberculosis therapy, Phage Genomics",39313,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2005-04-29 00:00:00,Searchlight Minerals Corp,29482,Discovery,2002-04-18 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,OTHER,Searchlight Minerals Corp,29482,UK,GB,"tuberculosis therapy, Phage Genomics",39313,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2005-04-29 00:00:00,Searchlight Minerals Corp,29482,Discovery,2002-04-18 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,OTHER,Searchlight Minerals Corp,29482,UK,GB,"tuberculosis therapy, Phage Genomics",39313,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2005-04-29 00:00:00,Searchlight Minerals Corp,29482,Discontinued,2005-04-29 00:00:00,DX,3,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Medical Research Council Technology,1054893,UK,GB,"UvrD helicase inhibitors (Mycobacterium tuberculosis infection), MRCT",66922,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-06-21 00:00:00,Medical Research Council (MRC),18438,No Development Reported,2012-06-21 00:00:00,NDR,2,Respiratory disease,711
DNA vaccine,1879,LOCAL_AND_MAJOR,Yonsei University,25184,South Korea,KR,"therapeutic DNA vaccine (tuberculosis), Pohang/Yonsei Universities",53019,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2009-12-24 00:00:00,Yonsei University,25184,No Development Reported,2009-12-24 00:00:00,NDR,2,Respiratory disease,711
Leucyl tRNA synthetase modulator,36221,LOCAL_AND_MAJOR,GlaxoSmithKline plc,28355,US,US,"leucyl tRNA synthetase modulators (tuberculosis), GlaxoSmithKline",70581,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-10-17 00:00:00,GlaxoSmithKline plc,28355,Discovery,2013-10-17 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Genvax Ltd,1015643,UK,GB,"DNA vaccine (Mycobacterium tuberculosis infection), Genvax",57745,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2009-09-07 00:00:00,Medical Marketing International Group plc,1003702,Discovery,2007-07-30 00:00:00,DR,6,Respiratory disease,711
Recombinant viral vector vaccine,12370,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,"mucosal vaccines (rhPIV2 vector/nasal, tuberculosis), NIBIO/Aeras/Create Vaccine",89879,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-12-26 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Discovery,2013-12-26 00:00:00,DR,6,Respiratory disease,711
Topical antipruritic product,15180,LOCAL_AND_MAJOR,InterMune Inc,26430,US,US,Actimmune,3365,Biological,Launched,No Development Reported,NDR,L,Mycobacterium tuberculosis infection,221,false,2014-09-19 00:00:00,Roche Holding AG,19446,No Development Reported,2007-03-31 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,InterMune Inc,26430,US,US,Actimmune,3365,Biological,Launched,No Development Reported,NDR,L,Mycobacterium tuberculosis infection,221,false,2014-09-19 00:00:00,Roche Holding AG,19446,No Development Reported,2007-03-31 00:00:00,NDR,2,Respiratory disease,711
Fatty acid synthase inhibitor,6589,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"pyrazinamide analogs (tuberculosis infection), Yonsei University/TB Alliance",71894,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-03-28 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2011-03-28 00:00:00,DR,6,Respiratory disease,711
Antibacterial multidrug resistance inhibitor,4855,LOCAL_AND_MAJOR,Qurient Therapeutics,1062405,US,US,"Q-203, Qurient / Infectex",85970,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-02-06 00:00:00,Qurient Therapeutics,1062405,Discovery,2013-06-05 00:00:00,DR,6,Respiratory disease,711
Antiparasitic,2638,LOCAL_AND_MAJOR,InterMune Inc,26430,US,US,Actimmune,3365,Biological,Launched,No Development Reported,NDR,L,Mycobacterium tuberculosis infection,221,false,2014-09-19 00:00:00,Roche Holding AG,19446,No Development Reported,2007-03-31 00:00:00,NDR,2,Respiratory disease,711
RNA synthesis inhibitor,439,LOCAL_AND_MAJOR,InterMune Inc,26430,US,US,Actimmune,3365,Biological,Launched,No Development Reported,NDR,L,Mycobacterium tuberculosis infection,221,false,2014-09-19 00:00:00,Roche Holding AG,19446,No Development Reported,2007-03-31 00:00:00,NDR,2,Respiratory disease,711
Anticancer protein kinase inhibitor,62255,LOCAL_AND_MAJOR,InterMune Inc,26430,US,US,Actimmune,3365,Biological,Launched,No Development Reported,NDR,L,Mycobacterium tuberculosis infection,221,false,2014-09-19 00:00:00,Roche Holding AG,19446,No Development Reported,2007-03-31 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,National Institutes of Health,20518,US,US,"pharmacophores (Mycobacterium tuberculosis), NIH",86108,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-02-01 00:00:00,US Government,20516,Discovery,2012-02-01 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,iThemba Pharmaceuticals Pty Ltd,1049788,South Africa,ZA,"tuberculosis therapy, iThemba Pharmaceuticals/Southern Research Institute",67092,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-06-22 00:00:00,iThemba Pharmaceuticals Pty Ltd,1049788,No Development Reported,2012-06-22 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"pleuromutilin derivatives (tuberculosis), GlaxoSmithKline/The Global Alliance for TB Drug Development",56410,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-06-18 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2005-03-21 00:00:00,DR,6,Respiratory disease,711
Immunostimulant,393,LOCAL_AND_MAJOR,SciClone Pharmaceuticals Inc,19829,US,US,"golotimod (oral), SciClone/Verta",55521,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2011-10-10 00:00:00,SciClone Pharmaceuticals Inc,19829,No Development Reported,2011-10-10 00:00:00,NDR,2,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,T-Biovax,67683,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-10-17 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Discovery,2010-08-11 00:00:00,DR,6,Respiratory disease,711
Immunomodulator,1596,LOCAL_AND_MAJOR,Agenus Inc,23221,US,US,"tuberculosis vaccine (CD1), Antigenics",22778,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2002-10-15 00:00:00,Agenus Inc,23221,Discovery,2001-11-21 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Agenus Inc,23221,US,US,"tuberculosis vaccine (CD1), Antigenics",22778,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2002-10-15 00:00:00,Agenus Inc,23221,Discontinued,2002-10-15 00:00:00,DX,3,Respiratory disease,711
STAT3 gene inhibitor,19075,LOCAL_AND_MAJOR,Verta Ltd,1004196,Russian Federation,RU,"golotimod (oral), SciClone/Verta",55521,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2011-10-10 00:00:00,Verta Ltd,1004196,No Development Reported,2011-10-10 00:00:00,NDR,2,Respiratory disease,711
Live attenuated bacterial vaccine,12363,LOCAL_AND_MAJOR,Max-Planck-Gesellschaft zur Forderung der Wissenschaften eV,17962,Germany,DE,VPM-1002,55569,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2013-03-27 00:00:00,Max-Planck-Gesellschaft zur Forderung der Wissenschaften eV,17962,Discontinued,2004-03-24 00:00:00,DX,3,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Medical Research Council (MRC),18438,UK,GB,"GlgE inhibitors (tuberculosis), MCRT",78428,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-06-25 00:00:00,Medical Research Council (MRC),18438,No Development Reported,2013-06-25 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Pohang University of Science & Technology,25083,South Korea,KR,"therapeutic DNA vaccine (tuberculosis), Pohang/Yonsei Universities",53019,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2009-12-24 00:00:00,Pohang University of Science & Technology,25083,No Development Reported,2009-12-24 00:00:00,NDR,2,Respiratory disease,711
Glycosyltransferase inhibitor,1025,LOCAL_AND_MAJOR,Medical Research Council Technology,1054893,UK,GB,"GlgE inhibitors (tuberculosis), MCRT",78428,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-06-25 00:00:00,Medical Research Council (MRC),18438,No Development Reported,2013-06-25 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Sequella Inc,28087,US,US,sutezolid,11088,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-07-17 00:00:00,Sequella Inc,28087,Phase 1 Clinical,2013-07-17 00:00:00,C1,8,Respiratory disease,711
Ribosome binding agent,463,LOCAL_AND_MAJOR,Sequella Inc,28087,US,US,sutezolid,11088,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-07-17 00:00:00,Sequella Inc,28087,Phase 1 Clinical,2013-07-17 00:00:00,C1,8,Respiratory disease,711
Recombinant viral vector vaccine,12370,LOCAL_AND_MAJOR,Shanghai H&G Biotechnology Co,1066720,China,CN,HG856-SeV,75156,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-17 00:00:00,Shanghai H&G Biotechnology Co,1066720,Discovery,2009-12-31 00:00:00,DR,6,Respiratory disease,711
Mycobacterium early secretory antigen modulator,25527,LOCAL_AND_MAJOR,Shanghai H&G Biotechnology Co,1066720,China,CN,HG856-SeV,75156,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-17 00:00:00,Shanghai H&G Biotechnology Co,1066720,Discovery,2009-12-31 00:00:00,DR,6,Respiratory disease,711
Recombinant viral vector vaccine,12370,LOCAL_AND_MAJOR,Shanghai H&G Biotechnology Co,1066720,China,CN,HG856-SeV,75156,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-17 00:00:00,Shanghai H&G Biotechnology Co,1066720,No Development Reported,2013-01-17 00:00:00,NDR,2,Respiratory disease,711
Subunit vaccine,12371,LOCAL_AND_MAJOR,GlaxoSmithKline plc,28355,US,US,"MTB72F vaccine (tuberculosis), GSK/Aeras",9490,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-08-26 00:00:00,GlaxoSmithKline plc,28355,Discovery,2001-06-01 00:00:00,DR,6,Respiratory disease,711
Subunit vaccine,12371,OTHER,GlaxoSmithKline plc,28355,Belgium,BE,"MTB72F vaccine (tuberculosis), GSK/Aeras",9490,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-08-26 00:00:00,GlaxoSmithKline plc,28355,Phase 2 Clinical,2012-08-31 00:00:00,C2,9,Respiratory disease,711
Anticancer,1545,LOCAL_AND_MAJOR,Verta Ltd,1004196,Russian Federation,RU,golotimod,25023,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2013-11-12 00:00:00,Verta Ltd,1004196,Phase 2 Clinical,2002-09-28 00:00:00,C2,9,Respiratory disease,711
Immunostimulant,393,LOCAL_AND_MAJOR,Verta Ltd,1004196,Russian Federation,RU,golotimod,25023,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2013-11-12 00:00:00,Verta Ltd,1004196,Launched,2008-08-15 00:00:00,L,13,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Sequella Inc,28087,US,US,SQ-109,31010,Chemical,Phase 3 Clinical,Phase 3 Clinical,C3,C3,Mycobacterium tuberculosis infection,221,true,2012-12-19 00:00:00,Sequella Inc,28087,Discovery,2000-10-09 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Merck & Co Inc,18077,US,US,"vaccine (naked DNA, TB), Merck & Co",17424,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-03-03 00:00:00,Merck & Co Inc,18077,Discovery,1995-03-10 00:00:00,DR,6,Respiratory disease,711
DNA vaccine,1879,LOCAL_AND_MAJOR,Merck & Co Inc,18077,US,US,"vaccine (naked DNA, TB), Merck & Co",17424,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-03-03 00:00:00,Merck & Co Inc,18077,No Development Reported,2008-03-03 00:00:00,NDR,2,Respiratory disease,711
Anxiolytic,2942,LOCAL_AND_MAJOR,National University of Singapore,20633,Singapore,SG,pascolizumab,17132,Biological,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2014-06-23 00:00:00,National University of Singapore,20633,Phase 2 Clinical,2012-10-11 00:00:00,C2,9,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Demuris Ltd,1075252,UK,GB,"tuberculosis program, Demuris",81873,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-11-16 00:00:00,Demuris Ltd,1075252,Discovery,2012-11-16 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Demuris Ltd,1075252,UK,GB,"tuberculosis program, Demuris",81873,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-11-16 00:00:00,Demuris Ltd,1075252,Discovery,2012-11-16 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,Harbor Therapeutics Inc,24345,Mexico,MX,HE-2000,19980,Chemical,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2013-01-28 00:00:00,Harbor Therapeutics Inc,24345,Discovery,2002-11-22 00:00:00,DR,6,Respiratory disease,711
Immunomodulator,1596,OTHER,Harbor Therapeutics Inc,24345,Mexico,MX,HE-2000,19980,Chemical,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2013-01-28 00:00:00,Harbor Therapeutics Inc,24345,Discovery,2002-11-22 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,INSERM Transfert,1035636,France,FR,"L,D-transpeptidase inhibitors (Mycobacterium tuberculosis infection), INSERM",78290,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-05-24 00:00:00,INSERM,17229,Discovery,2012-05-24 00:00:00,DR,6,Respiratory disease,711
RNA polymerase inhibitor,347,LOCAL_AND_MAJOR,Shenyang Hongqi Pharmaceutical Co Ltd,1075626,China,CN,"rifampicin + isoniazid (fixed dose combination, tuberculosis), Shenyang Hongqi Pharmaceutical",82095,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2009-12-31 00:00:00,Shanghai Fosun Pharmaceutical (Group) Co Ltd,1015871,Registered,2009-05-22 00:00:00,R,12,Respiratory disease,711
Antibacterial,1594,OTHER,Institut Pasteur,17237,Sweden,SE,"multivalent vaccine (Bera-V, Mycobacterium tuberculosis infection), Abera Bioscience/Statens Serum/Institut Pasteur",89342,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-12-20 00:00:00,Institut Pasteur,17237,Discovery,2013-12-20 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Colorado State University,20562,US,US,"inhibitors of isoprenoid biosynthesis enzymes (tuberculosis infection), The Lilly TB Drug Discovery Initiative/Colorado State University",89970,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-08-30 00:00:00,Colorado State University,20562,Discovery,2005-12-31 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,GlaxoSmithKline plc,28355,Spain,ES,"isocitrate lyase inhibitors (tuberculosis), GlaxoSmithKline/The Global Alliance for TB Drug Developement",56373,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2007-05-31 00:00:00,GlaxoSmithKline plc,28355,No Development Reported,2007-05-31 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Qurient Therapeutics,1062405,South Korea,KR,"TB A series (tuberculosis infection), Qurient",77998,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-06-28 00:00:00,Qurient Therapeutics,1062405,No Development Reported,2013-06-28 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Finlay Institute,15912,Cuba,CU,"BCG/M smegmatis vector based live recombinant vaccine (tuberculosis infection), Finlay",73188,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2009-12-31 00:00:00,Finlay Institute,15912,Discovery,2009-12-31 00:00:00,DR,6,Respiratory disease,711
Respiratory system agent,1470,OTHER,Vivonyx Inc,1071865,World,WO,"V-001, Vivonyx",79997,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2012-06-21 00:00:00,Vivonyx Inc,1071865,Launched,2012-06-21 00:00:00,L,13,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,University of Lille,24385,France,FR,"EthR inhibitors (mycobacterium tuberculosis), BioVersys/ University of Lille/ GSK",92193,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-05-27 00:00:00,University of Lille,24385,Discovery,2014-05-27 00:00:00,DR,6,Respiratory disease,711
Mycolic acid synthase inhibitor,6542,LOCAL_AND_MAJOR,University of Lille,24385,France,FR,"EthR inhibitors (mycobacterium tuberculosis), BioVersys/ University of Lille/ GSK",92193,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-05-27 00:00:00,University of Lille,24385,Discovery,2014-05-27 00:00:00,DR,6,Respiratory disease,711
Recombinant viral vector vaccine,12370,OTHER,Aeras Global TB Vaccine Foundation,1007376,Kenya,KE,AERAS-402,53975,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2010-09-22 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 1 Clinical,2008-10-17 00:00:00,C1,8,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Aeras Global TB Vaccine Foundation,1007376,Kenya,KE,AERAS-402,53975,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2010-09-22 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 2 Clinical,2010-09-22 00:00:00,C2,9,Respiratory disease,711
Respiratory system agent,1470,OTHER,C&O Pharmaceutical Technology (Holdings) Ltd,1032379,Hong Kong,HK,CO-12,61340,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2007-08-31 00:00:00,Shionogi & Co Ltd,19898,Discovery,2007-08-31 00:00:00,DR,6,Respiratory disease,711
Interleukin-2 ligand,12481,LOCAL_AND_MAJOR,Shenzhen Neptunus Interlong Bio-Technique Co Ltd,1015704,China,CN,"recombinant human interleukin-2 (cancer/AIDS/autoimmune disorders/infections), Shenzhen Neptunus",80864,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2012-09-10 00:00:00,Shenzhen Neptunus Bioengineering Co Ltd,1031729,Launched,2012-09-10 00:00:00,L,13,Respiratory disease,711
Anti-inflammatory,2953,LOCAL_AND_MAJOR,Shenzhen Neptunus Interlong Bio-Technique Co Ltd,1015704,China,CN,"recombinant human interleukin-2 (cancer/AIDS/autoimmune disorders/infections), Shenzhen Neptunus",80864,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2012-09-10 00:00:00,Shenzhen Neptunus Bioengineering Co Ltd,1031729,Launched,2012-09-10 00:00:00,L,13,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,EyeGene Inc,1006553,South Korea,KR,"anti-tuberculosis vaccine, EyeGene",93723,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-06-30 00:00:00,EyeGene Inc,1006553,Discovery,2012-06-30 00:00:00,DR,6,Respiratory disease,711
Antiviral,991,LOCAL_AND_MAJOR,University of Georgia,20579,US,US,"small molecule therapeutics (tuberculosis/HIV), University of Georgia",95507,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2015-01-28 00:00:00,University of Georgia,20579,Discovery,2015-01-28 00:00:00,DR,6,Respiratory disease,711
Anticancer,1545,LOCAL_AND_MAJOR,SciClone Pharmaceuticals Inc,19829,US,US,golotimod,25023,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,false,2013-11-12 00:00:00,SciClone Pharmaceuticals Inc,19829,Phase 2 Clinical,2008-08-28 00:00:00,C2,9,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,SciClone Pharmaceuticals Inc,19829,US,US,golotimod,25023,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,false,2013-11-12 00:00:00,SciClone Pharmaceuticals Inc,19829,Discontinued,2013-11-12 00:00:00,DX,3,Respiratory disease,711
Cytokine synthesis stimulator,938,LOCAL_AND_MAJOR,SciClone Pharmaceuticals Inc,19829,US,US,golotimod,25023,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,false,2013-11-12 00:00:00,SciClone Pharmaceuticals Inc,19829,Discontinued,2013-11-12 00:00:00,DX,3,Respiratory disease,711
Topoisomerase I inhibitor,141,LOCAL_AND_MAJOR,New York Medical College,23270,US,US,"topoisomerase I inhibitors (tuberculosis infection), TB Alliance/NYMC/AZ",71897,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-06-27 00:00:00,New York University,20646,No Development Reported,2013-06-27 00:00:00,NDR,2,Respiratory disease,711
Collagenase stimulator,731,OTHER,Beech Tree Labs Inc,1052204,UK,GB,ML-05,69033,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-09-13 00:00:00,Beech Tree Labs Inc,1052204,Discovery,2011-09-13 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,PharmaPraxis,1061494,Brazil,BR,TB-001,77481,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-04-23 00:00:00,Axis Biotec Group,1061497,Discovery,2012-04-23 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,PharmaPraxis,1061494,Brazil,BR,TB-001,77481,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-04-23 00:00:00,Axis Biotec Group,1061497,Discovery,2012-04-23 00:00:00,DR,6,Respiratory disease,711
Antiviral,991,LOCAL_AND_MAJOR,Sarawak MediChem Pharmaceuticals Inc,24735,US,US,(+)-calanolide A,9539,Chemical,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2010-09-20 00:00:00,Sarawak State Government,29393,No Development Reported,2010-09-20 00:00:00,NDR,2,Respiratory disease,711
Live attenuated bacterial vaccine,12363,LOCAL_AND_MAJOR,ID Vaccine Corp,23373,US,US,"rBCG30, UCLA",9831,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,false,2014-07-07 00:00:00,GlaxoSmithKline plc,28355,No Development Reported,2003-06-14 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"isocitrate lyase inhibitors (tuberculosis), GlaxoSmithKline/The Global Alliance for TB Drug Developement",56373,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2007-05-31 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2005-03-21 00:00:00,DR,6,Respiratory disease,711
Lyase inhibitor,248,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"isocitrate lyase inhibitors (tuberculosis), GlaxoSmithKline/The Global Alliance for TB Drug Developement",56373,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2007-05-31 00:00:00,The Global Alliance for TB Drug Development,29411,No Development Reported,2007-05-31 00:00:00,NDR,2,Respiratory disease,711
Bacterial protein synthesis inhibitor,1538,OTHER,Pfizer Inc,18767,Europe,X5,sutezolid,11088,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2013-07-17 00:00:00,Pfizer Inc,18767,Discovery,2011-04-11 00:00:00,DR,6,Respiratory disease,711
Bacterial protein synthesis inhibitor,1538,OTHER,Pfizer Inc,18767,Europe,X5,sutezolid,11088,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2013-07-17 00:00:00,Pfizer Inc,18767,Discontinued,2013-07-17 00:00:00,DX,3,Respiratory disease,711
Bacterial protein synthesis inhibitor,1538,OTHER,Pfizer Inc,18767,South Africa,ZA,sutezolid,11088,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2013-07-17 00:00:00,Pfizer Inc,18767,Discontinued,2013-07-17 00:00:00,DX,3,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Maxwell Biotech Group,1061894,Russian Federation,RU,SQ-109,31010,Chemical,Phase 3 Clinical,Phase 3 Clinical,C3,C3,Mycobacterium tuberculosis infection,221,false,2012-12-19 00:00:00,Maxwell Biotech Group,1061894,Discovery,2011-04-25 00:00:00,DR,6,Respiratory disease,711
Fungicide,1748,LOCAL_AND_MAJOR,Maxwell Biotech Group,1061894,Russian Federation,RU,SQ-109,31010,Chemical,Phase 3 Clinical,Phase 3 Clinical,C3,C3,Mycobacterium tuberculosis infection,221,false,2012-12-19 00:00:00,Maxwell Biotech Group,1061894,Discovery,2011-04-25 00:00:00,DR,6,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,Genesis Research and Development Corp Ltd,25513,New Zealand,NZ,"MED-1 vaccine (tuberculosis), Genesis",40637,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2009-04-30 00:00:00,Genesis Research and Development Corp Ltd,25513,Discontinued,2009-04-30 00:00:00,DX,3,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Corixa Corp,15542,US,US,"MTB72F vaccine (tuberculosis), GSK/Aeras",9490,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-08-26 00:00:00,GlaxoSmithKline plc,28355,Phase 1 Clinical,2004-03-08 00:00:00,C1,8,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,TBI-166,57790,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2014-12-22 00:00:00,The Global Alliance for TB Drug Development,29411,No Development Reported,2014-12-22 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,TBI-166,57790,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2014-12-22 00:00:00,The Global Alliance for TB Drug Development,29411,No Development Reported,2014-12-22 00:00:00,NDR,2,Respiratory disease,711
Apoptosis stimulator,1589,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,AERAS-407 rBCG,62397,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-11-27 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 1 Clinical,2008-03-31 00:00:00,C1,8,Respiratory disease,711
Immunostimulant,393,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,AERAS-407 rBCG,62397,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-11-27 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Discovery,2008-03-31 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,AERAS-405,59144,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-09-18 00:00:00,Aeras Global TB Vaccine Foundation,1007376,No Development Reported,2012-09-18 00:00:00,NDR,2,Respiratory disease,711
Heat shock protein modulator,7992,LOCAL_AND_MAJOR,Medical Research Council (MRC),18438,UK,GB,"vaccine (tuberculosis), MRC",12867,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2009-03-16 00:00:00,Medical Research Council (MRC),18438,Discovery,1996-07-29 00:00:00,DR,6,Respiratory disease,711
DNA vaccine,1879,LOCAL_AND_MAJOR,Medical Research Council (MRC),18438,UK,GB,"vaccine (tuberculosis), MRC",12867,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2009-03-16 00:00:00,Medical Research Council (MRC),18438,No Development Reported,2009-03-16 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Sarawak MediChem Pharmaceuticals Inc,24735,US,US,(+)-calanolide A,9539,Chemical,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2010-09-20 00:00:00,Sarawak State Government,29393,Discovery,2002-06-20 00:00:00,DR,6,Respiratory disease,711
Putative membrane protein mmpL3 inhibitor,85843,OTHER,Novartis Institute for Tropical Diseases Pvt Ltd,1017949,Singapore,SG,"mycobacterial membrane protein large type 3 inhibitors (tuberculosis), TB Alliance",89552,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2014-08-20 00:00:00,Novartis AG,23137,Discovery,2013-08-19 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Albert Einstein College of Medicine,24282,US,US,KOA-18,10999,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,1995-09-26 14:53:02,Yeshiva University,20704,Discovery,1995-09-26 14:53:02,DR,6,Respiratory disease,711
Systemic antipsoriatic product,15184,OTHER,Silence Therapeutics plc,22356,Zambia,ZM,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Cytokine release modulator,1291,OTHER,Silence Therapeutics plc,22356,South Africa,ZA,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Systemic antipsoriatic product,15184,OTHER,Silence Therapeutics plc,22356,Nigeria,NG,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Antibacterial,1594,OTHER,Silence Therapeutics plc,22356,Gambia,GM,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Silence Therapeutics plc,22356,UK,GB,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Anticancer,1545,LOCAL_AND_MAJOR,Silence Therapeutics plc,22356,UK,GB,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Antiviral,991,OTHER,Silence Therapeutics plc,22356,Tanzania,TZ,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,2001-09-30 00:00:00,C2,9,Respiratory disease,711
Adjuvant,524,OTHER,Silence Therapeutics plc,22356,Tanzania,TZ,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,2001-09-30 00:00:00,C2,9,Respiratory disease,711
Cytokine release modulator,1291,OTHER,Silence Therapeutics plc,22356,Zambia,ZM,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 3 Clinical,1997-10-13 00:00:00,C3,10,Respiratory disease,711
Antiviral,991,OTHER,Silence Therapeutics plc,22356,Gambia,GM,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 3 Clinical,1997-10-13 00:00:00,C3,10,Respiratory disease,711
Antimicrobial,1593,OTHER,Silence Therapeutics plc,22356,Gambia,GM,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 3 Clinical,1997-10-13 00:00:00,C3,10,Respiratory disease,711
Therapeutic vaccine,12379,OTHER,Silence Therapeutics plc,22356,Gambia,GM,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 3 Clinical,1997-10-13 00:00:00,C3,10,Respiratory disease,711
Antibacterial,1594,OTHER,Silence Therapeutics plc,22356,South Africa,ZA,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 3 Clinical,1995-10-12 00:00:00,C3,10,Respiratory disease,711
Adjuvant,524,OTHER,Silence Therapeutics plc,22356,Nigeria,NG,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,1995-10-12 00:00:00,C2,9,Respiratory disease,711
Antimicrobial,1593,OTHER,Silence Therapeutics plc,22356,Nigeria,NG,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,1995-10-12 00:00:00,C2,9,Respiratory disease,711
Inactivated bacterial vaccine,12366,OTHER,Silence Therapeutics plc,22356,Nigeria,NG,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,1995-10-12 00:00:00,C2,9,Respiratory disease,711
Anticancer,1545,OTHER,Silence Therapeutics plc,22356,Gambia,GM,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,1995-10-12 00:00:00,C2,9,Respiratory disease,711
Cytokine release modulator,1291,OTHER,Silence Therapeutics plc,22356,Kuwait,KW,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,1995-10-12 00:00:00,C2,9,Respiratory disease,711
Adjuvant,524,OTHER,Silence Therapeutics plc,22356,Romania,RO,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,1995-10-12 00:00:00,C2,9,Respiratory disease,711
Therapeutic vaccine,12379,OTHER,Silence Therapeutics plc,22356,Romania,RO,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,1995-10-12 00:00:00,C2,9,Respiratory disease,711
Antiviral,991,LOCAL_AND_MAJOR,Farmabrasilis,1083670,Brazil,BR,P-MAPA,15596,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-06-18 00:00:00,Farmabrasilis,1083670,Discovery,2009-03-21 00:00:00,DR,6,Respiratory disease,711
TLR-4 agonist,7812,LOCAL_AND_MAJOR,Universidade Estadual de Campinas,24983,Brazil,BR,P-MAPA,15596,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-06-18 00:00:00,Universidade Estadual de Campinas,24983,Discovery,2009-03-21 00:00:00,DR,6,Respiratory disease,711
Immunostimulant,393,LOCAL_AND_MAJOR,Universidade Estadual de Campinas,24983,Brazil,BR,P-MAPA,15596,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-06-18 00:00:00,Universidade Estadual de Campinas,24983,Discovery,2009-03-21 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,VacTex Corp,25562,US,US,"vaccine (tuberculosis), Procept",15602,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2005-12-31 00:00:00,Agenus Inc,23221,No Development Reported,1999-10-14 00:00:00,NDR,2,Respiratory disease,711
Lipid subunit vaccine,12374,LOCAL_AND_MAJOR,VacTex Corp,25562,US,US,"vaccine (tuberculosis), Procept",15602,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2005-12-31 00:00:00,Agenus Inc,23221,No Development Reported,1999-10-14 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Indiana University,20593,US,US,"dihydrofolate reductase inhibitors, Duquesne/Indiana",12146,Chemical,Discovery,No Development Reported,NDR,DR,Mycobacterium tuberculosis infection,221,true,2011-01-04 00:00:00,Indiana University,20593,Discovery,2003-03-30 00:00:00,DR,6,Respiratory disease,711
Anticancer,1545,LOCAL_AND_MAJOR,Duquesne University,20569,US,US,"dihydrofolate reductase inhibitors, Duquesne/Indiana",12146,Chemical,Discovery,No Development Reported,NDR,DR,Mycobacterium tuberculosis infection,221,true,2011-01-04 00:00:00,Duquesne University,20569,No Development Reported,2011-01-04 00:00:00,NDR,2,Respiratory disease,711
DHFR inhibitor,135,LOCAL_AND_MAJOR,Duquesne University,20569,US,US,"dihydrofolate reductase inhibitors, Duquesne/Indiana",12146,Chemical,Discovery,No Development Reported,NDR,DR,Mycobacterium tuberculosis infection,221,true,2011-01-04 00:00:00,Duquesne University,20569,Discovery,2003-03-30 00:00:00,DR,6,Respiratory disease,711
Protein subunit vaccine,12372,OTHER,Nventa Biopharmaceuticals Corp,20265,Canada,CA,"vaccine (tuberculosis), StressGen",12954,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2000-05-18 00:00:00,Akela Pharma Inc,1011141,No Development Reported,2000-05-18 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,University of Illinois,20592,US,US,B-4157,12634,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2000-05-15 00:00:00,University of Illinois,20592,No Development Reported,2000-05-15 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Hoechst Marion Roussel Inc,25224,US,US,rifapentine,15102,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-12-02 00:00:00,Sanofi,1009547,Phase 3 Clinical,1997-05-08 17:17:42,C3,10,Respiratory disease,711
Antibacterial,1594,OTHER,The Global Alliance for TB Drug Development,29411,Asia,X2,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2014-10-14 00:00:00,DR,6,Respiratory disease,711
Bacterial nucleic acid synthesis inhibitor,3984,OTHER,The Global Alliance for TB Drug Development,29411,Haiti,HT,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2014-10-14 00:00:00,DR,6,Respiratory disease,711
DNA gyrase inhibitor,431,OTHER,The Global Alliance for TB Drug Development,29411,Peru,PE,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2014-10-14 00:00:00,DR,6,Respiratory disease,711
DNA gyrase inhibitor,431,OTHER,The Global Alliance for TB Drug Development,29411,Georgia,GE,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2014-10-14 00:00:00,DR,6,Respiratory disease,711
Systemic dermatological antibacterial product,15187,OTHER,The Global Alliance for TB Drug Development,29411,Georgia,GE,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2014-10-14 00:00:00,DR,6,Respiratory disease,711
Topoisomerase IV inhibitor,9320,OTHER,The Global Alliance for TB Drug Development,29411,South Africa,ZA,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,The Global Alliance for TB Drug Development,29411,Phase 3 Clinical,2015-02-10 00:00:00,C3,10,Respiratory disease,711
DNA gyrase inhibitor,431,OTHER,The Global Alliance for TB Drug Development,29411,South Africa,ZA,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,The Global Alliance for TB Drug Development,29411,Phase 3 Clinical,2015-02-10 00:00:00,C3,10,Respiratory disease,711
Systemic dermatological antibacterial product,15187,OTHER,The Global Alliance for TB Drug Development,29411,Malaysia,MY,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,The Global Alliance for TB Drug Development,29411,Phase 3 Clinical,2014-08-04 00:00:00,C3,10,Respiratory disease,711
Topoisomerase IV inhibitor,9320,OTHER,The Global Alliance for TB Drug Development,29411,Africa,X0,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,The Global Alliance for TB Drug Development,29411,Phase 3 Clinical,2007-11-08 00:00:00,C3,10,Respiratory disease,711
Antibacterial,1594,OTHER,The Global Alliance for TB Drug Development,29411,World,WO,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,The Global Alliance for TB Drug Development,29411,Phase 2 Clinical,2005-10-17 00:00:00,C2,9,Respiratory disease,711
Bacterial nucleic acid synthesis inhibitor,3984,OTHER,Bayer AG,14455,Brazil,BR,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,Bayer AG,14455,Phase 2 Clinical,2005-10-17 00:00:00,C2,9,Respiratory disease,711
Antiparasitic,2638,LOCAL_AND_MAJOR,Harbor Therapeutics Inc,24345,US,US,PP-29,15867,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2003-07-02 00:00:00,Harbor Therapeutics Inc,24345,No Development Reported,2003-07-02 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Wellesley College,25687,US,US,"antimycobacterials, Wellesley College",18382,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2001-11-28 00:00:00,Wellesley College,25687,Discovery,1998-07-24 15:57:33,DR,6,Respiratory disease,711
Antiparasitic,2638,LOCAL_AND_MAJOR,Georgia State University,21235,US,US,pafuramidine,16755,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2008-02-22 00:00:00,Georgia State University,21235,Discontinued,2000-01-28 00:00:00,DX,3,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,University of North Carolina,20634,US,US,pafuramidine,16755,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2008-02-22 00:00:00,University of North Carolina,20634,Discovery,2000-10-23 00:00:00,DR,6,Respiratory disease,711
Protease inhibitor,331,LOCAL_AND_MAJOR,Medivir AB,18015,Sweden,SE,"antibacterial protease inhibitors, Medivir/University of London",35747,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2003-08-19 00:00:00,Medivir AB,18015,Discovery,2001-08-28 12:25:25,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Sequella Inc,28087,US,US,"peptide vaccine (tuberculosis), Intercell/Sequella",32516,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2004-04-30 00:00:00,Sequella Inc,28087,Discovery,1999-12-01 00:00:00,DR,6,Respiratory disease,711
Neoplasm diagnostic agent,7220,LOCAL_AND_MAJOR,Navidea Biopharmaceuticals Inc,18471,US,US,technetium Tc 99m tilmanocept,34061,Chemical,Launched,Discovery,DR,L,Mycobacterium tuberculosis infection,221,true,2014-12-12 00:00:00,Navidea Biopharmaceuticals Inc,18471,Discovery,2013-09-19 00:00:00,DR,6,Respiratory disease,711
Endocrine diagnostic agent,7212,LOCAL_AND_MAJOR,Navidea Biopharmaceuticals Inc,18471,US,US,technetium Tc 99m tilmanocept,34061,Chemical,Launched,Discovery,DR,L,Mycobacterium tuberculosis infection,221,true,2014-12-12 00:00:00,Navidea Biopharmaceuticals Inc,18471,Discovery,2013-09-19 00:00:00,DR,6,Respiratory disease,711
Macrophage mannose receptor 1 modulator,53095,LOCAL_AND_MAJOR,Navidea Biopharmaceuticals Inc,18471,US,US,technetium Tc 99m tilmanocept,34061,Chemical,Launched,Discovery,DR,L,Mycobacterium tuberculosis infection,221,true,2014-12-12 00:00:00,Navidea Biopharmaceuticals Inc,18471,Discovery,2013-09-19 00:00:00,DR,6,Respiratory disease,711
Ultrasound contrast agent,4156,LOCAL_AND_MAJOR,Navidea Biopharmaceuticals Inc,18471,US,US,technetium Tc 99m tilmanocept,34061,Chemical,Launched,Discovery,DR,L,Mycobacterium tuberculosis infection,221,true,2014-12-12 00:00:00,Navidea Biopharmaceuticals Inc,18471,Discovery,2013-09-19 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,NicOx SA,23741,France,FR,NCX-976,47140,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2005-01-31 00:00:00,NicOx SA,23741,No Development Reported,2005-01-31 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,ANI Pharmaceuticals Inc,27120,US,US,"tuberculosis vaccine (BioVant), BioSante",39902,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-12-23 00:00:00,ANI Pharmaceuticals Inc,27120,Discovery,2002-05-30 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,UMeWorld Ltd,28431,Canada,CA,"rifampicin (nanoparticle encapsulated, tuberculosis), AlphaRx",53605,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2009-01-08 00:00:00,UMeWorld Ltd,28431,No Development Reported,2009-01-08 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Lupin Ltd,21932,India,IN,LL-3858,49162,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-07-24 00:00:00,Lupin Ltd,21932,No Development Reported,2012-07-24 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Lupin Ltd,21932,India,IN,LL-3858,49162,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-07-24 00:00:00,Lupin Ltd,21932,Discovery,2004-03-12 00:00:00,DR,6,Respiratory disease,711
Phospho MurNAc pentapeptide transferase inhibitor,64334,LOCAL_AND_MAJOR,Sequella Inc,28087,US,US,"capuramycin derivative translocase inhibitors (tuberculosis, Clostridium difficile infection, Chrons disease), Sequella",48440,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-05-03 00:00:00,Sequella Inc,28087,Discovery,2004-11-01 00:00:00,DR,6,Respiratory disease,711
Mycobacterial antigen complex 85B modulator,33970,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,"HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell",48499,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-07-29 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Discovery,2005-03-30 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,"HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell",48499,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-07-29 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Discovery,2005-03-30 00:00:00,DR,6,Respiratory disease,711
Mycobacterial antigen complex 85B modulator,33970,LOCAL_AND_MAJOR,Sanofi Pasteur,22127,France,FR,"HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell",48499,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-07-29 00:00:00,Sanofi,1009547,Phase 1 Clinical,2012-01-11 00:00:00,C1,8,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Intercell AG,28463,Tanzania,TZ,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2013-05-28 00:00:00,Valneva SE,1084202,Discontinued,2013-05-28 00:00:00,DX,3,Respiratory disease,711
Recombinant bacterial vector vaccine,12369,OTHER,Intercell AG,28463,Tanzania,TZ,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2013-05-28 00:00:00,Valneva SE,1084202,Discontinued,2013-05-28 00:00:00,DX,3,Respiratory disease,711
Protein subunit vaccine,12372,OTHER,Intercell AG,28463,Netherlands,NL,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2013-05-28 00:00:00,Valneva SE,1084202,Phase 1 Clinical,2005-11-18 00:00:00,C1,8,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Valneva SE,1084202,Tanzania,TZ,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-05-28 00:00:00,Valneva SE,1084202,Phase 2 Clinical,2013-05-28 00:00:00,C2,9,Respiratory disease,711
Glycosyltransferase inhibitor,1025,LOCAL_AND_MAJOR,Central Drug Research Institute,15350,India,IN,"galactopyranose derivatives (antifungal/antitubercular), Central Drug Research Institute",50637,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2005-01-24 00:00:00,Council of Scientific and Industrial Research (India),15561,Discovery,2003-07-24 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Aeras Global TB Vaccine Foundation,1007376,Netherlands,NL,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-05-28 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 2 Clinical,2009-03-02 00:00:00,C2,9,Respiratory disease,711
Protein subunit vaccine,12372,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-05-28 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Discovery,2005-06-27 00:00:00,DR,6,Respiratory disease,711
Recombinant bacterial vector vaccine,12369,OTHER,Aeras Global TB Vaccine Foundation,1007376,Netherlands,NL,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-05-28 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 1 Clinical,2005-11-18 00:00:00,C1,8,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Sanofi Pasteur,22127,Netherlands,NL,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-05-28 00:00:00,Sanofi,1009547,Phase 2 Clinical,2009-03-02 00:00:00,C2,9,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Statens Serum Institut,21502,Tanzania,TZ,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-05-28 00:00:00,Statens Serum Institut,21502,Phase 2 Clinical,2012-01-11 00:00:00,C2,9,Respiratory disease,711
Mycobacterial antigen complex 85A modulator,33967,OTHER,Oxford-Emergent Tuberculosis Consortium Ltd,1040955,Senegal,SN,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-07 00:00:00,Emergent BioSolutions Inc,1011990,Discontinued,2014-03-07 00:00:00,DX,3,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Oxford-Emergent Tuberculosis Consortium Ltd,1040955,UK,GB,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-07 00:00:00,Emergent BioSolutions Inc,1011990,Discontinued,2014-03-07 00:00:00,DX,3,Respiratory disease,711
Mycobacterial antigen complex 85A modulator,33967,OTHER,Oxford-Emergent Tuberculosis Consortium Ltd,1040955,South Africa,ZA,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-07 00:00:00,Emergent BioSolutions Inc,1011990,Discontinued,2014-03-07 00:00:00,DX,3,Respiratory disease,711
Mycobacterial antigen complex 85A modulator,33967,LOCAL_AND_MAJOR,University of Oxford,22182,UK,GB,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-07 00:00:00,University of Oxford,22182,Discontinued,2008-07-23 00:00:00,DX,3,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"gyrase inhibitors (Mycobacterium tuberculosis infection), GlaxoSmithKline/The Global Alliance for TB Drug Development",57733,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2006-12-31 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2006-12-31 00:00:00,DR,6,Respiratory disease,711
TLR-2 agonist,7806,LOCAL_AND_MAJOR,Cadila Pharmaceuticals Ltd,30025,India,IN,cadi-05,55173,Biological,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2014-12-03 00:00:00,Cadila Pharmaceuticals Ltd,30025,No Development Reported,2014-12-03 00:00:00,NDR,2,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,Cadila Pharmaceuticals Ltd,30025,India,IN,cadi-05,55173,Biological,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2014-12-03 00:00:00,Cadila Pharmaceuticals Ltd,30025,No Development Reported,2014-12-03 00:00:00,NDR,2,Respiratory disease,711
MAPK gene modulator,18476,LOCAL_AND_MAJOR,Cadila Pharmaceuticals Ltd,30025,India,IN,cadi-05,55173,Biological,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2014-12-03 00:00:00,Cadila Pharmaceuticals Ltd,30025,Phase 3 Clinical,2005-03-31 00:00:00,C3,10,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Hosp Germans Trias i Pujol,DOL1000424,Spain,ES,RUTI,57308,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2012-05-24 00:00:00,Hosp Germans Trias i Pujol,DOL1000424,Discovery,2004-04-17 00:00:00,DR,6,Respiratory disease,711
Mycolic acid synthase inhibitor,6542,LOCAL_AND_MAJOR,Institut Pasteur,17237,Western Europe,XW,"EthR inhibitors (mycobacterium tuberculosis), BioVersys",61115,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2012-07-10 00:00:00,Institut Pasteur,17237,Discovery,2008-08-27 00:00:00,DR,6,Respiratory disease,711
Bacterial protein synthesis inhibitor,1538,LOCAL_AND_MAJOR,Melinta Therapeutics Inc,29298,US,US,"radezolid (oral, CAP/uSSSI), Melinta",59067,Chemical,Phase 2 Clinical,Discovery,DR,C2,Mycobacterium tuberculosis infection,221,true,2010-09-15 00:00:00,Melinta Therapeutics Inc,29298,Discovery,2010-09-15 00:00:00,DR,6,Respiratory disease,711
Systemic dermatological antibacterial product,15187,LOCAL_AND_MAJOR,Melinta Therapeutics Inc,29298,US,US,"radezolid (oral, CAP/uSSSI), Melinta",59067,Chemical,Phase 2 Clinical,Discovery,DR,C2,Mycobacterium tuberculosis infection,221,true,2010-09-15 00:00:00,Melinta Therapeutics Inc,29298,Discovery,2010-09-15 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Tydockpharma Srl,1036974,Italy,IT,"ThyX inhibitors (Helicobacter pylori/Mycobacterium tuberculosis infections), Tydockpharma",59276,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2008-01-14 00:00:00,Tydockpharma Srl,1036974,Discovery,2008-01-14 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,University of Oxford,22182,UK,GB,FP-85A,63673,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2011-12-29 00:00:00,University of Oxford,22182,No Development Reported,2011-12-29 00:00:00,NDR,2,Respiratory disease,711
Anticancer,1545,LOCAL_AND_MAJOR,TVAX Biomedical LLC,1049288,US,US,"autologous therapeutic vaccine, TVAX Biomedical",64503,Biological,Phase 2 Clinical,Discovery,DR,C2,Mycobacterium tuberculosis infection,221,true,2014-12-03 00:00:00,TVAX Biomedical LLC,1049288,Discovery,2012-12-06 00:00:00,DR,6,Respiratory disease,711
CD40 ligand modulator,5486,LOCAL_AND_MAJOR,Adjuvantix Ltd,1002784,UK,GB,ADX40-TB,64522,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-10-21 00:00:00,Adjuvantix Ltd,1002784,Discovery,2009-10-05 00:00:00,DR,6,Respiratory disease,711
Protein subunit vaccine,12372,LOCAL_AND_MAJOR,Adjuvantix Ltd,1002784,UK,GB,ADX40-TB,64522,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-10-21 00:00:00,Adjuvantix Ltd,1002784,Discovery,2009-10-05 00:00:00,DR,6,Respiratory disease,711
Immunostimulant,393,LOCAL_AND_MAJOR,Wyeth BioPharma,20511,US,US,edodekin alfa,6934,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-06-27 00:00:00,Pfizer Inc,18767,Discontinued,2003-06-27 00:00:00,DX,3,Respiratory disease,711
Anticancer,1545,LOCAL_AND_MAJOR,Wyeth BioPharma,20511,US,US,edodekin alfa,6934,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-06-27 00:00:00,Pfizer Inc,18767,Discontinued,2003-06-27 00:00:00,DX,3,Respiratory disease,711
Anticancer protein kinase inhibitor,62255,LOCAL_AND_MAJOR,Aarden Pharmaceuticals Inc,1058608,US,US,"protein tyrosine phosphatase inhibitor (tuberculosis infection, cancer, autoimmune diseases), Aarden Pharmacueticals",69351,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2015-01-05 00:00:00,Aarden Pharmaceuticals Inc,1058608,Discovery,2009-11-10 00:00:00,DR,6,Respiratory disease,711
Protein tyrosine phosphatase-2C inhibitor,10327,LOCAL_AND_MAJOR,Aarden Pharmaceuticals Inc,1058608,US,US,"protein tyrosine phosphatase inhibitor (tuberculosis infection, cancer, autoimmune diseases), Aarden Pharmacueticals",69351,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2015-01-05 00:00:00,Aarden Pharmaceuticals Inc,1058608,Discovery,2009-11-10 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,TB Drug Boost,1054643,France,FR,"FurA inhibitors (Mycobacterium tuberculosis infection), TB Drug Boost",67299,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-06-20 00:00:00,TB Drug Boost,1054643,No Development Reported,2012-06-20 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,TB Drug Boost,1054643,France,FR,"FurA inhibitors (Mycobacterium tuberculosis infection), TB Drug Boost",67299,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-06-20 00:00:00,TB Drug Boost,1054643,Discovery,2010-05-06 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,ImCure Therapeutics,1014446,US,US,184045,70838,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-02-26 00:00:00,ImCure Therapeutics,1014446,No Development Reported,2013-02-26 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,ImCure Therapeutics,1014446,US,US,184045,70838,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-02-26 00:00:00,ImCure Therapeutics,1014446,No Development Reported,2013-02-26 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,ImCure Therapeutics,1014446,US,US,184045,70838,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-02-26 00:00:00,ImCure Therapeutics,1014446,Discovery,2011-03-28 00:00:00,DR,6,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,Finlay Institute,15912,Cuba,CU,"Streptomyces vector-based live recombinant vaccine (tuberculosis infection), Finlay Institute",73326,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-10-15 00:00:00,Finlay Institute,15912,No Development Reported,2013-10-15 00:00:00,NDR,2,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Finlay Institute,15912,Cuba,CU,"Streptomyces vector-based live recombinant vaccine (tuberculosis infection), Finlay Institute",73326,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-10-15 00:00:00,Finlay Institute,15912,Discovery,2009-12-31 00:00:00,DR,6,Respiratory disease,711
Folate synthesis inhibitor,553,LOCAL_AND_MAJOR,AstraZeneca plc,14190,UK,GB,"folate biosynthesis inhibitors (tuberculosis), AZ/TB Alliance",71614,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-11-30 00:00:00,AstraZeneca plc,14190,No Development Reported,2012-11-30 00:00:00,NDR,2,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,University of Pittsburgh,20659,US,US,H-56,69824,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-08-22 00:00:00,University of Pittsburgh,20659,No Development Reported,2013-08-22 00:00:00,NDR,2,Respiratory disease,711
DNA gyrase B inhibitor,71209,OTHER,The Global Alliance for TB Drug Development,29411,India,IN,"gyrase B inhibitors (tuberculosis infection), AZ/TB Alliance",71700,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-11-30 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2010-05-03 00:00:00,DR,6,Respiratory disease,711
Nitric oxide donor,698,LOCAL_AND_MAJOR,University of Illinois,20592,US,US,TBA-354,71742,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-01-30 00:00:00,University of Illinois,20592,Discovery,2009-10-02 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,B&C Biopharm,1004322,South Korea,KR,"tubercuslosis program, B&C Biopharm/Reyon Pharma/Wayne State University",67413,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2010-07-21 00:00:00,B&C Biopharm,1004322,Discovery,2008-03-31 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Aeras Global TB Vaccine Foundation,1007376,South Africa,ZA,ID-93,68617,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-09-20 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 1 Clinical,2013-09-20 00:00:00,C1,8,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,ID-93,68617,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-09-20 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 1 Clinical,2012-08-15 00:00:00,C1,8,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,ID-93,68617,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-09-20 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 1 Clinical,2012-08-15 00:00:00,C1,8,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Infectious Disease Research Institute,27376,South Africa,ZA,ID-93,68617,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-09-20 00:00:00,Infectious Disease Research Institute,27376,Phase 1 Clinical,2013-09-20 00:00:00,C1,8,Respiratory disease,711
Protein subunit vaccine,12372,OTHER,Infectious Disease Research Institute,27376,South Africa,ZA,ID-93,68617,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-09-20 00:00:00,Infectious Disease Research Institute,27376,Phase 1 Clinical,2013-09-20 00:00:00,C1,8,Respiratory disease,711
Protein subunit vaccine,12372,LOCAL_AND_MAJOR,Infectious Disease Research Institute,27376,US,US,ID-93,68617,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-09-20 00:00:00,Infectious Disease Research Institute,27376,Phase 1 Clinical,2012-08-15 00:00:00,C1,8,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Infectious Disease Research Institute,27376,US,US,ID-93,68617,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-09-20 00:00:00,Infectious Disease Research Institute,27376,Discovery,2009-12-31 00:00:00,DR,6,Respiratory disease,711
Unspecified vaccine,12380,LOCAL_AND_MAJOR,Medicine in Need,1054651,US,US,"BCG vaccine (inhalant/powder, tuberculosis), Medicine In Need",69074,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-09-24 00:00:00,Medicine in Need,1054651,No Development Reported,2014-09-24 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Medicine in Need,1054651,US,US,"BCG vaccine (inhalant/powder, tuberculosis), Medicine In Need",69074,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-09-24 00:00:00,Medicine in Need,1054651,Discovery,2010-11-18 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Ensoltek Co Ltd,1017455,South Korea,KR,Hesed-1000,71805,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-06-10 00:00:00,Ensoltek Co Ltd,1017455,Discovery,2011-06-10 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,Emory University,20573,South Africa,ZA,"isocitrate lyase prodrug inhibitors (tuberculosis), iThemba Pharmaceuticals",65567,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2008-03-31 00:00:00,Emory University,20573,Discovery,2007-08-31 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,iThemba Pharmaceuticals Pty Ltd,1049788,South Africa,ZA,"isocitrate lyase prodrug inhibitors (tuberculosis), iThemba Pharmaceuticals",65567,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2008-03-31 00:00:00,iThemba Pharmaceuticals Pty Ltd,1049788,Discovery,2008-03-31 00:00:00,DR,6,Respiratory disease,711
Recombinant bacterial vector vaccine,12369,OTHER,RecipharmCobra Biologics,20370,UK,GB,"tuberculosis DNA vaccine (ORT), RecipharmCobra Biologics",69165,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-03-13 00:00:00,Recipharm AB,1058217,Discovery,2010-02-04 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,THERAMetrics Holding AG,29586,Switzerland,CH,DasKloster 0249-01,71313,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2010-09-30 00:00:00,THERAMetrics Holding AG,29586,Discovery,2010-09-30 00:00:00,DR,6,Respiratory disease,711
Live attenuated bacterial vaccine,12363,LOCAL_AND_MAJOR,McMaster University,21238,Canada,CA,Ad5Ag85A,71323,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,false,2012-05-07 00:00:00,McMaster University,21238,Discontinued,2011-08-31 00:00:00,DX,3,Respiratory disease,711
Live attenuated bacterial vaccine,12363,LOCAL_AND_MAJOR,Tianjin CanSino Biotechnology Inc,1069870,China,CN,Ad5Ag85A,71323,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2012-05-07 00:00:00,Tianjin CanSino Biotechnology Inc,1069870,Discovery,2012-05-07 00:00:00,DR,6,Respiratory disease,711
Eukaryotic initiation 2 alpha kinase 2 inhibitor,51121,LOCAL_AND_MAJOR,Numerate Inc,1037610,US,US,"tuberculosis therapeutics, Numerate",73050,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-12-21 00:00:00,Numerate Inc,1037610,No Development Reported,2012-12-21 00:00:00,NDR,2,Respiratory disease,711
Anti-inflammatory,2953,LOCAL_AND_MAJOR,Chengdu Institute of Biological Products,1016340,China,CN,Ka Shu Ning,80062,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,1998-12-31 00:00:00,Sinopharm,1055632,Registered,1998-12-31 00:00:00,R,12,Respiratory disease,711
Unspecified drug target,59620,OTHER,Shanghai Sun-Sail Pharmaceutical Science & Technology Co Ltd,1049303,China,CN,"ethylenediamine derivative (mycobacterium tuberculosis), Shanghai Sun-Sail Pharmaceutical Science & Technology",81181,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-07-31 00:00:00,Shionogi & Co Ltd,19898,Discovery,2012-07-31 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,National Institute of Oceanography,1053325,India,IN,"anti-tuberculosis therapeutics, Shreya Life Sciences/NIO",76688,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2010-03-30 00:00:00,National Institute of Oceanography,1053325,Discovery,2010-03-30 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,VELES Pharma CJSC,1069315,US,US,"recombinant protein vaccine (nanoparticle, tuberculosis infection prevention/treatment), VELES Pharma",77247,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-04-12 00:00:00,VELES Pharma CJSC,1069315,Discovery,2012-04-12 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,ISA Pharmaceuticals BV,1032094,Netherlands,NL,TB-SLP,75383,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-04-12 00:00:00,ISA Pharmaceuticals BV,1032094,No Development Reported,2013-04-12 00:00:00,NDR,2,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,ISA Pharmaceuticals BV,1032094,Netherlands,NL,TB-SLP,75383,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-04-12 00:00:00,ISA Pharmaceuticals BV,1032094,Discovery,2009-04-24 00:00:00,DR,6,Respiratory disease,711
Interferon gamma modulator,922,LOCAL_AND_MAJOR,PHARMACLON LLC,1073552,Russian Federation,RU,"interferon gamma follow-on biologic, PHARMACLON LLC",81264,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2013-07-23 00:00:00,PHARMACLON LLC,1073552,Launched,2013-07-23 00:00:00,L,13,Respiratory disease,711
Anticancer,1545,LOCAL_AND_MAJOR,PHARMACLON LLC,1073552,Russian Federation,RU,"interferon gamma follow-on biologic, PHARMACLON LLC",81264,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2013-07-23 00:00:00,PHARMACLON LLC,1073552,Launched,2013-07-23 00:00:00,L,13,Respiratory disease,711
Systemic dermatological antiviral product,15190,LOCAL_AND_MAJOR,PHARMACLON LLC,1073552,Russian Federation,RU,"interferon gamma follow-on biologic, PHARMACLON LLC",81264,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2013-07-23 00:00:00,PHARMACLON LLC,1073552,Launched,2013-07-23 00:00:00,L,13,Respiratory disease,711
Unspecified drug target,59620,OTHER,Novartis Institute for Tropical Diseases Pvt Ltd,1017949,Singapore,SG,"tuberculosis therapy, NITD/TB Alliance",82584,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-11-30 00:00:00,Novartis AG,23137,Discovery,2012-11-30 00:00:00,DR,6,Respiratory disease,711
Vaccine,386,LOCAL_AND_MAJOR,National Institute for Food and Drug Control,1072842,China,CN,"primary immunization-booster TB vaccine, Chongqing Zhifei Biological Products",81359,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2012-05-04 00:00:00,National Institute for Food and Drug Control,1072842,Discontinued,2012-05-04 00:00:00,DX,3,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Chongqing Zhifei Biological Products Co Ltd,1062383,China,CN,AEC/BC02,81363,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-09-21 00:00:00,Chongqing Zhifei Biological Products Co Ltd,1062383,Discovery,2012-09-21 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Sphaera Pharma,1050976,India,IN,"repurposed mepenzolate bromide (tuberculosis), Sphaera/ICGEB",78319,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-05-07 00:00:00,Sphaera Pharma,1050976,Discovery,2012-05-07 00:00:00,DR,6,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,Statens Serum Institut,21502,Denmark,DK,"Ag85B-ESAT-6 fusion protein vaccine (CAF-01-adjuvanted, tuberculosis), Statens Serum Institut",75087,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2009-10-31 00:00:00,Statens Serum Institut,21502,Phase 1 Clinical,2009-10-31 00:00:00,C1,8,Respiratory disease,711
Protein subunit vaccine,12372,LOCAL_AND_MAJOR,Statens Serum Institut,21502,Denmark,DK,"Ag85B-ESAT-6 fusion protein vaccine (CAF-01-adjuvanted, tuberculosis), Statens Serum Institut",75087,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2009-10-31 00:00:00,Statens Serum Institut,21502,Phase 1 Clinical,2009-10-31 00:00:00,C1,8,Respiratory disease,711
Mycobacterium early secretory antigen modulator,25527,LOCAL_AND_MAJOR,Shanghai H&G Biotechnology Co,1066720,China,CN,"ESAT-6/Ag85A-expressing recombinant BCG vaccine (Mycobacterium tuberculosis), Shanghai H&G",75152,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-17 00:00:00,Shanghai H&G Biotechnology Co,1066720,No Development Reported,2013-01-17 00:00:00,NDR,2,Respiratory disease,711
Mycobacterial antigen complex 85A modulator,33967,LOCAL_AND_MAJOR,Shanghai H&G Biotechnology Co,1066720,China,CN,"ESAT-6/Ag85A-expressing recombinant BCG vaccine (Mycobacterium tuberculosis), Shanghai H&G",75152,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-17 00:00:00,Shanghai H&G Biotechnology Co,1066720,Discovery,2007-08-28 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Chongqing Zhifei Biological Products Co Ltd,1062383,China,CN,Wei Ka,81037,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2001-12-31 00:00:00,Chongqing Zhifei Biological Products Co Ltd,1062383,Registered,2001-12-31 00:00:00,R,12,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,National University of Singapore,20633,Singapore,SG,"miRNA-like molecules (tuberculosis), NUS",77116,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-06-20 00:00:00,National University of Singapore,20633,Discovery,2012-02-28 00:00:00,DR,6,Respiratory disease,711
Endopeptidase Clp inhibitor,79294,LOCAL_AND_MAJOR,NovoBiotic Pharmaceuticals LLC,1031362,US,US,lassomycin,81058,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-09-10 00:00:00,NovoBiotic Pharmaceuticals LLC,1031362,Discovery,2012-09-10 00:00:00,DR,6,Respiratory disease,711
Mycobacterial antigen complex 85A modulator,33967,LOCAL_AND_MAJOR,University of Oxford,22182,UK,GB,ChAdOx1-85A,84564,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-06-12 00:00:00,University of Oxford,22182,Phase 1 Clinical,2013-06-12 00:00:00,C1,8,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,University of Oxford,22182,UK,GB,ChAdOx1-85A,84564,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-06-12 00:00:00,University of Oxford,22182,Discovery,2012-07-31 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Sichuan Long March Pharmaceutical Co Ltd,1088430,China,CN,"ethambutol hydrochloride + pyrazinamide + rifampicin + isoniazid (oral tablet, tuberculosis), Sichuan Long March Pharmaceutical",96349,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-11-11 00:00:00,Sichuan Long March Pharmaceutical Co Ltd,1088430,No Development Reported,2008-11-11 00:00:00,NDR,2,Respiratory disease,711
Bacterial cell wall synthesis inhibitor,104,LOCAL_AND_MAJOR,Sichuan Long March Pharmaceutical Co Ltd,1088430,China,CN,"ethambutol hydrochloride + pyrazinamide + rifampicin + isoniazid (oral tablet, tuberculosis), Sichuan Long March Pharmaceutical",96349,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-11-11 00:00:00,Sichuan Long March Pharmaceutical Co Ltd,1088430,Discovery,2006-04-02 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Changchun ChangSheng Gene Pharmaceutical Co Ltd,1071244,China,CN,"accelular mycobacterium smegmatis vaccine (subcutaneous, mycobacterium tuberculosis infection), Changchun ChangSheng Gene Pharmaceutical",94475,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-10-30 00:00:00,Changchun ChangSheng Gene Pharmaceutical Co Ltd,1071244,No Development Reported,2008-10-30 00:00:00,NDR,2,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Changchun ChangSheng Gene Pharmaceutical Co Ltd,1071244,China,CN,"accelular mycobacterium smegmatis vaccine (subcutaneous, mycobacterium tuberculosis infection), Changchun ChangSheng Gene Pharmaceutical",94475,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-10-30 00:00:00,Changchun ChangSheng Gene Pharmaceutical Co Ltd,1071244,Discovery,2003-05-28 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,GlobalAcorn,1086420,UK,GB,GA4 NM-TB,86659,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2015-04-17 00:00:00,GlobalAcorn,1086420,No Development Reported,2015-04-17 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,University of Illinois at Urbana-Champaign,1073122,US,US,"pantothenate synthetase inhibitors (tuberculosis/bacterial infections), University of Illinois/University of Illinois at URBANA-CHAMPAIGN",88214,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-10-30 00:00:00,University of Illinois,20592,Discovery,2013-10-30 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Scripps Research Institute,21102,US,US,"ATP synthase inhibitors (tuberculosis), TB Alliance/California Institute for Biomedical Research",82643,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2013-06-30 00:00:00,Scripps Research Institute,21102,Discontinued,2013-06-30 00:00:00,DX,3,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,National Institute of Allergy and Infectious Diseases,20520,Tanzania,TZ,"vaccine (disseminated tuberculosis), NIAID",83281,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-02-11 00:00:00,US Government,20516,No Development Reported,2013-02-11 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Anacor Pharmaceuticals Inc,30118,US,US,"non-Leucyl-tRNA synthase inhibitors (tuberculosis infection), Anacor",84382,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2009-05-27 00:00:00,Anacor Pharmaceuticals Inc,30118,Discovery,2009-05-27 00:00:00,DR,6,Respiratory disease,711
Inhibin alpha chain inhibitor,33569,LOCAL_AND_MAJOR,State University of New York at Stony Brook,26884,US,US,"MTB fatty acid bio synthesis enzyme inhibitors (multi-drug resistant tuberculosis), State University of New York at Stony Brook",88952,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2006-02-17 00:00:00,State University of New York,26880,Discovery,2006-02-17 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Eli Lilly & Co,17810,US,US,"antibacterial compounds (tuberculosis), Eli Lilly & Co/The University of Notre Dame du Lac/Montana State University/University of Illinois/Infectious Disease Research Institute",87600,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-09-11 00:00:00,Eli Lilly & Co,17810,Discovery,2011-03-23 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,University of Auckland,20647,New Zealand,NZ,"diarylquinolines (tuberculosis), TB Alliance/J & J/University of Auckland/University of Illinois at Chicago",82662,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-06-30 00:00:00,University of Auckland,20647,Discovery,2012-11-30 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Harvard University Office of Technology Development,1085770,US,US,"small molecule VKOR inhibitors (Mycobacterium tuberculosis infection), Harvard University/Harvard University Office of Technology Development",86119,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-02-01 00:00:00,Harvard University,20584,Discovery,2012-02-01 00:00:00,DR,6,Respiratory disease,711
Vitamin K epoxide reductase inhibitor,10583,LOCAL_AND_MAJOR,Harvard University,20584,US,US,"small molecule VKOR inhibitors (Mycobacterium tuberculosis infection), Harvard University/Harvard University Office of Technology Development",86119,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-02-01 00:00:00,Harvard University,20584,Discovery,2012-02-01 00:00:00,DR,6,Respiratory disease,711
RNA polymerase inhibitor,347,LOCAL_AND_MAJOR,Shenyang Hongqi Pharmaceutical Co Ltd,1075626,China,CN,"ethambutol hydrochloride (150 mg) + pyrazinamide (300 mg) + rifampicin (90 mg) + isoniazid (60 mg) (oral tablet, tuberculosis), Shenyang Hongqi Pharmaceutical/Liaoning Hongwuxing Pharmaceutical",88505,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-11-15 00:00:00,Shanghai Fosun Pharmaceutical (Group) Co Ltd,1015871,Discovery,2009-02-01 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Liaoning Hongwuxing Pharmaceutical Co Ltd,1090092,China,CN,"ethambutol hydrochloride (200 mg) + pyrazinamide (300 mg) + rifampicin (120 mg) + isoniazid (100 mg) (oral tablet, tuberculosis), Shenyang Hongqi Pharmaceutical/Liaoning Hongwuxing Pharmaceutical",88507,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-11-15 00:00:00,Liaoning Hongwuxing Pharmaceutical Co Ltd,1090092,Discovery,2013-11-15 00:00:00,DR,6,Respiratory disease,711
Protein subunit vaccine,12372,LOCAL_AND_MAJOR,Johns Hopkins University,20596,US,US,"recombinant PknD subunit protein vaccine (Mycobacterium tuberculosis infection), Johns Hopkins University",89337,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-12-19 00:00:00,Johns Hopkins University,20596,Discovery,2013-06-11 00:00:00,DR,6,Respiratory disease,711
DNA gyrase B inhibitor,71209,LOCAL_AND_MAJOR,University of Pretoria,25323,South Africa,ZA,"naphthoquinone compounds (Mycobacterium tuberculosis infection, natural product), University of Pretoria",82839,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-01-15 00:00:00,University of Pretoria,25323,Discovery,2001-12-31 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,University of Pretoria,25323,South Africa,ZA,"naphthoquinone compounds (Mycobacterium tuberculosis infection, natural product), University of Pretoria",82839,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-01-15 00:00:00,University of Pretoria,25323,Discovery,2001-12-31 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,University of Illinois at Urbana-Champaign,1073122,US,US,"anti-tuberculosis agents, University of Illinois/University of Illinois at URBANA-CHAMPAIGN",87132,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-08-27 00:00:00,University of Illinois,20592,Discovery,2013-08-27 00:00:00,DR,6,Respiratory disease,711
Methionine aminopeptidase inhibitor,9287,LOCAL_AND_MAJOR,Johns Hopkins University Office of Technology Transfer,1083716,US,US,"Methionine aminopeptidase inhibitors (Mycobacterium tuberculosis), Johns Hopkins University",89387,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-12-19 00:00:00,Johns Hopkins University,20596,Discovery,2013-12-19 00:00:00,DR,6,Respiratory disease,711
Anticancer,1545,LOCAL_AND_MAJOR,Innate Immunotherapeutics Ltd,29958,US,US,"MIS-416/immunogen (anthrax/malaria/tuberculosis/neutropenia), Innate",60213,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-01-12 00:00:00,Innate Immunotherapeutics Ltd,29958,Discovery,2010-12-21 00:00:00,DR,6,Respiratory disease,711
Elastase inhibitor,154,LOCAL_AND_MAJOR,Omni Bio Pharmaceutical Inc,1047826,US,US,"p-ATT (type 1/2 diabetes/influenza/tuberculosis/anthrax/HIV infection/transplant rejection/GVHD), Omni Bio",66767,Chemical,Phase 2 Clinical,Discovery,DR,C2,Mycobacterium tuberculosis infection,221,true,2013-01-31 00:00:00,Omni Bio Pharmaceutical Inc,1047826,Discovery,2010-08-06 00:00:00,DR,6,Respiratory disease,711
Antiviral,991,LOCAL_AND_MAJOR,Omni Bio Pharmaceutical Inc,1047826,US,US,"p-ATT (type 1/2 diabetes/influenza/tuberculosis/anthrax/HIV infection/transplant rejection/GVHD), Omni Bio",66767,Chemical,Phase 2 Clinical,Discovery,DR,C2,Mycobacterium tuberculosis infection,221,true,2013-01-31 00:00:00,Omni Bio Pharmaceutical Inc,1047826,Discovery,2010-08-06 00:00:00,DR,6,Respiratory disease,711
Energy metabolism modulator,1732,LOCAL_AND_MAJOR,AstraZeneca plc,14190,UK,GB,"energy metabolism inhibitors (tuberculosis), AstraZeneca/University of Pennsylvania/TB Alliance",71615,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-03-28 00:00:00,AstraZeneca plc,14190,Discovery,2011-03-28 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,The Global Alliance for TB Drug Development,29411,UK,GB,"energy metabolism inhibitors (tuberculosis), AstraZeneca/University of Pennsylvania/TB Alliance",71615,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-03-28 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2011-03-17 00:00:00,DR,6,Respiratory disease,711
Bacterial protein synthesis inhibitor,1538,OTHER,Pfizer Inc,18767,Portugal,PT,rifabutin,4229,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2008-10-07 00:00:00,Pfizer Inc,18767,Launched,2007-03-21 00:00:00,L,13,Respiratory disease,711
Protein subunit vaccine,12372,LOCAL_AND_MAJOR,EpiVax Inc,1009858,US,US,"T-cell epitope-based DNA vaccine (tuberculosis), EpiVax",68339,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,1997-12-31 00:00:00,EpiVax Inc,1009858,Discovery,1997-12-31 00:00:00,DR,6,Respiratory disease,711
DNA vaccine,1879,LOCAL_AND_MAJOR,EpiVax Inc,1009858,US,US,"T-cell epitope-based DNA vaccine (tuberculosis), EpiVax",68339,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,1997-12-31 00:00:00,EpiVax Inc,1009858,Discovery,1997-12-31 00:00:00,DR,6,Respiratory disease,711
Antibacterial multidrug resistance inhibitor,4855,LOCAL_AND_MAJOR,Pfizer Inc,18767,US,US,"antibiotic (tuberculosis), MicuRx/Cumencor/Pfizer",68345,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2010-04-06 00:00:00,Pfizer Inc,18767,Discovery,2010-04-06 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,OTHER,MicuRx Pharmaceuticals Inc,1033227,China,CN,"antibiotic (tuberculosis), MicuRx/Cumencor/Pfizer",68345,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2010-04-06 00:00:00,MicuRx Pharmaceuticals Inc,1033227,Discovery,2010-04-06 00:00:00,DR,6,Respiratory disease,711
Antibacterial multidrug resistance inhibitor,4855,LOCAL_AND_MAJOR,Cumencor Pharmaceuticals,1053349,China,CN,"antibiotic (tuberculosis), MicuRx/Cumencor/Pfizer",68345,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2010-04-06 00:00:00,Cumencor Pharmaceuticals,1053349,Discovery,2010-04-06 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Vichem Chemie Ltd,1031147,Hungary,HU,"PknB inhibitor (tuberculosis), Vichem Chemie",68371,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2008-03-15 00:00:00,Vichem Chemie Ltd,1031147,Discovery,2008-03-15 00:00:00,DR,6,Respiratory disease,711
Protein kinase inhibitor,336,LOCAL_AND_MAJOR,Vichem Chemie Ltd,1031147,Hungary,HU,"PknB inhibitor (tuberculosis), Vichem Chemie",68371,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2008-03-15 00:00:00,Vichem Chemie Ltd,1031147,Discovery,2008-03-15 00:00:00,DR,6,Respiratory disease,711
Antibacterial multidrug resistance inhibitor,4855,OTHER,Janssen Research & Development LLC,1067538,China,CN,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Discovery,2009-12-17 00:00:00,DR,6,Respiratory disease,711
ATP synthase inhibitor,49687,OTHER,Janssen Research & Development LLC,1067538,South Korea,KR,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Discovery,2009-07-30 00:00:00,DR,6,Respiratory disease,711
Antibacterial multidrug resistance inhibitor,4855,OTHER,Janssen Research & Development LLC,1067538,Turkey,TR,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Discovery,2009-08-27 00:00:00,DR,6,Respiratory disease,711
ATP synthase inhibitor,49687,OTHER,Janssen Research & Development LLC,1067538,Thailand,TH,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Pre-registration,2013-06-17 00:00:00,PR,11,Respiratory disease,711
ATP synthase inhibitor,49687,OTHER,Janssen Research & Development LLC,1067538,Philippines,PH,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Registered,2014-11-06 00:00:00,R,12,Respiratory disease,711
Antibacterial multidrug resistance inhibitor,4855,OTHER,Janssen Research & Development LLC,1067538,Peru,PE,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Pre-registration,2014-11-06 00:00:00,PR,11,Respiratory disease,711
Antibacterial multidrug resistance inhibitor,4855,OTHER,Janssen Research & Development LLC,1067538,Vietnam,VN,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Pre-registration,2014-11-06 00:00:00,PR,11,Respiratory disease,711
Protein subunit vaccine,12372,OTHER,Statens Serum Institut,21502,South Africa,ZA,SSI H56-IC31,74849,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-11-08 00:00:00,Statens Serum Institut,21502,Phase 1 Clinical,2011-12-01 00:00:00,C1,8,Respiratory disease,711
Ribosome binding agent,463,LOCAL_AND_MAJOR,Microbiotix Inc,28907,US,US,MBX-600,76748,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-03-20 00:00:00,Microbiotix Inc,28907,Discovery,2012-03-20 00:00:00,DR,6,Respiratory disease,711
RNA vaccine,12377,OTHER,ID Pharma Co Ltd,27318,Japan,JP,"SeV gene vaccine (tuberculosis), DNAVEC",70034,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-02-08 00:00:00,Lupin Ltd,21932,Discovery,2011-02-08 00:00:00,DR,6,Respiratory disease,711
Nitric oxide donor,698,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,pretomanid,13323,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-09-05 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2002-02-04 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,pretomanid,13323,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-09-05 00:00:00,The Global Alliance for TB Drug Development,29411,Phase 1 Clinical,2005-06-14 00:00:00,C1,8,Respiratory disease,711
Antibacterial,1594,OTHER,The Global Alliance for TB Drug Development,29411,China,CN,pretomanid,13323,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-09-05 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2014-09-05 00:00:00,DR,6,Respiratory disease,711
Inactivated bacterial vaccine,12366,OTHER,Immunitor Inc,1006860,Ukraine,UA,"heat-killed Mycobacterium vaccae (tablet formulation, tuberculosis), Immunitor",70934,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-03-26 00:00:00,Immune Network Ltd,21412,Phase 2 Clinical,2011-08-31 00:00:00,C2,9,Respiratory disease,711
Antibacterial,1594,OTHER,Immunitor Inc,1006860,Ukraine,UA,"heat-killed Mycobacterium vaccae (tablet formulation, tuberculosis), Immunitor",70934,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-03-26 00:00:00,Immune Network Ltd,21412,Phase 2 Clinical,2011-08-31 00:00:00,C2,9,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Intercell AG,28463,South Africa,ZA,SSI H56-IC31,74849,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2013-11-08 00:00:00,Valneva SE,1084202,Phase 1 Clinical,2012-08-17 00:00:00,C1,8,Respiratory disease,711
Bacterial nucleic acid synthesis inhibitor,3984,LOCAL_AND_MAJOR,Nanosystem Ltd,1071336,Russian Federation,RU,"rifampicin nanoparticles (tuberculosis), NPK Nanosistema",81330,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-06-27 00:00:00,Nanosystem Ltd,1071336,Discovery,2010-07-01 00:00:00,DR,6,Respiratory disease,711
DPR oxidase inhibitor,78977,OTHER,New Medicines for Tuberculosis,1062637,Albania,AL,PBTZ-169,90085,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-08-27 00:00:00,New Medicines for Tuberculosis,1062637,Discovery,2012-08-27 00:00:00,DR,6,Respiratory disease,711
DNA vaccine,1879,LOCAL_AND_MAJOR,Shanghai H&G Biotechnology Co,1066720,China,CN,"ESAT-6/Ag85A DNA vaccine (Mycobacterium tuberculosis), Shanghai H&G",75153,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-17 00:00:00,Shanghai H&G Biotechnology Co,1066720,No Development Reported,2013-01-17 00:00:00,NDR,2,Respiratory disease,711
Mycobacterium early secretory antigen modulator,25527,LOCAL_AND_MAJOR,Shanghai H&G Biotechnology Co,1066720,China,CN,"ESAT-6/Ag85A DNA vaccine (Mycobacterium tuberculosis), Shanghai H&G",75153,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-17 00:00:00,Shanghai H&G Biotechnology Co,1066720,No Development Reported,2013-01-17 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Silvius Pharma,1068863,Russian Federation,RU,"small molecule therapeutics (Mycobacterium tuberculosis infection), ChemDiv Research Institute/Novartis Institute for Tropical Diseases/Silvius Pharma",76796,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2014-08-14 00:00:00,ChemRar,1050615,Discovery,2010-09-30 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Silvius Pharma,1068863,Russian Federation,RU,"small molecule therapeutics (Mycobacterium tuberculosis infection), ChemDiv Research Institute/Novartis Institute for Tropical Diseases/Silvius Pharma",76796,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2014-08-14 00:00:00,ChemRar,1050615,Discontinued,2014-08-14 00:00:00,DX,3,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,SEEK,1031545,UK,GB,TB-v,90650,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-03-12 00:00:00,SEEK,1031545,Discovery,2014-03-12 00:00:00,DR,6,Respiratory disease,711
Proteasome inhibitor,4917,LOCAL_AND_MAJOR,Harvard University,20584,US,US,"proteasome inhibitors (tuberculosis), Harvard University/Harvard University Office of Technology Development",86021,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-08-21 00:00:00,Harvard University,20584,No Development Reported,2014-08-21 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,St Jude Children's Research Hospital,21814,US,US,"thiolactomycin analog, GlaxoSmithKline",33073,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-08-08 00:00:00,St Jude Children's Research Hospital,21814,Discovery,2001-02-28 00:00:00,DR,6,Respiratory disease,711
Antibacterial multidrug resistance inhibitor,4855,OTHER,Janssen Diagnostics BVBA,30131,Belgium,BE,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,false,2015-03-18 00:00:00,Johnson & Johnson,17332,Phase 2 Clinical,2005-05-26 00:00:00,C2,9,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,LeukoMed Inc,30043,US,US,LMP-420,41819,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2009-03-16 00:00:00,LeukoMed Inc,30043,Discovery,2002-09-26 00:00:00,DR,6,Respiratory disease,711
Antiviral,991,LOCAL_AND_MAJOR,LeukoMed Inc,30043,US,US,LMP-420,41819,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2009-03-16 00:00:00,LeukoMed Inc,30043,No Development Reported,2009-03-16 00:00:00,NDR,2,Respiratory disease,711
Nitric oxide donor,698,LOCAL_AND_MAJOR,Chiron PathoGenesis,18741,US,US,pretomanid,13323,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-09-05 00:00:00,Novartis AG,23137,No Development Reported,2000-02-09 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Chiron PathoGenesis,18741,US,US,pretomanid,13323,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-09-05 00:00:00,Novartis AG,23137,Discontinued,2002-02-01 00:00:00,DX,3,Respiratory disease,711
Nitric oxide donor,698,LOCAL_AND_MAJOR,Chiron PathoGenesis,18741,US,US,pretomanid,13323,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-09-05 00:00:00,Novartis AG,23137,Discontinued,2002-02-01 00:00:00,DX,3,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Cincinnati Children's Hospital Medical Center,25631,US,US,"indoleamine 2,3-deoxygenase inhibitor (leishmaniasis/tuberculosis), Cincinnati Children's Hospital Medical Center",81141,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-10-13 00:00:00,Cincinnati Children's Hospital Medical Center,25631,Discovery,2011-10-13 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Procrysta Biologix Inc,1080144,US,US,PCB-101,83811,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-04-18 00:00:00,Procrysta Biologix Inc,1080144,No Development Reported,2014-04-18 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Microbion Corp,1055897,US,US,MBS-103,68316,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-09-25 00:00:00,Microbion Corp,1055897,Discovery,2010-09-27 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,Sequella Inc,28087,UK,GB,"DNA vaccine (tuberculosis), NIMR/Sequella",22154,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-10-13 00:00:00,Sequella Inc,28087,Discovery,2001-11-29 00:00:00,DR,6,Respiratory disease,711
DNA vaccine,1879,OTHER,Sequella Inc,28087,UK,GB,"DNA vaccine (tuberculosis), NIMR/Sequella",22154,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-10-13 00:00:00,Sequella Inc,28087,No Development Reported,2008-10-13 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,National Institutes of Health,20518,US,US,"thiolactomycin analog, GlaxoSmithKline",33073,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-08-08 00:00:00,US Government,20516,Discovery,2001-02-28 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Johns Hopkins University,20596,US,US,"tuberculosis therapy, TB Alliance/Johns Hopkins University",82716,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-06-30 00:00:00,Johns Hopkins University,20596,Discovery,2012-11-30 00:00:00,DR,6,Respiratory disease,711
Antiparasitic,2638,LOCAL_AND_MAJOR,National Institutes of Health,20518,US,US,"thiolactomycin analog, GlaxoSmithKline",33073,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-08-08 00:00:00,US Government,20516,No Development Reported,2008-08-08 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,UK National Institute of Medical Research,20466,UK,GB,"DNA vaccine (tuberculosis), NIMR/Sequella",22154,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-10-13 00:00:00,Medical Research Council (MRC),18438,No Development Reported,2008-10-13 00:00:00,NDR,2,Respiratory disease,711
Mycolic acid synthase inhibitor,6542,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Philippines,PH,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 2 Clinical,2008-04-30 00:00:00,C2,9,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Otsuka Pharmaceutical Co Ltd,18717,Japan,JP,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 2 Clinical,2008-04-30 00:00:00,C2,9,Respiratory disease,711
Angiogenesis inhibitor,61,LOCAL_AND_MAJOR,Otsuka Pharmaceutical Co Ltd,18717,Japan,JP,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Registered,2014-07-04 00:00:00,R,12,Respiratory disease,711
Antibacterial,1594,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Latvia,LV,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 2 Clinical,2008-04-30 00:00:00,C2,9,Respiratory disease,711
Anticancer,1545,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Egypt,EG,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 2 Clinical,2008-04-30 00:00:00,C2,9,Respiratory disease,711
Anti-inflammatory,2953,OTHER,Otsuka Pharmaceutical Co Ltd,18717,South Korea,KR,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Registered,2014-10-29 00:00:00,R,12,Respiratory disease,711
Anticancer,1545,OTHER,Otsuka Pharmaceutical Co Ltd,18717,South Africa,ZA,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 3 Clinical,2013-07-26 00:00:00,C3,10,Respiratory disease,711
Antibacterial,1594,OTHER,Otsuka Pharmaceutical Co Ltd,18717,South Africa,ZA,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 3 Clinical,2013-07-26 00:00:00,C3,10,Respiratory disease,711
Anti-inflammatory,2953,OTHER,Otsuka Pharmaceutical Co Ltd,18717,South Africa,ZA,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 3 Clinical,2013-07-26 00:00:00,C3,10,Respiratory disease,711
Anti-inflammatory,2953,OTHER,Otsuka Pharmaceutical Co Ltd,18717,UK,GB,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Launched,2014-05-31 00:00:00,L,13,Respiratory disease,711
Angiogenesis inhibitor,61,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Germany,DE,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Launched,2014-11-13 00:00:00,L,13,Respiratory disease,711
Anticancer,1545,LOCAL_AND_MAJOR,Otsuka Pharmaceutical Co Ltd,18717,Japan,JP,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Launched,2014-09-30 00:00:00,L,13,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Otsuka Pharmaceutical Co Ltd,18717,US,US,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 3 Clinical,2011-12-31 00:00:00,C3,10,Respiratory disease,711
Anti-inflammatory,2953,LOCAL_AND_MAJOR,Otsuka Pharmaceutical Co Ltd,18717,US,US,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 3 Clinical,2011-12-31 00:00:00,C3,10,Respiratory disease,711
Anticancer,1545,LOCAL_AND_MAJOR,Vakzine Projekt Management GmbH,1020740,Germany,DE,VPM-1002,55569,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-03-27 00:00:00,Vakzine Projekt Management GmbH,1020740,Phase 2 Clinical,2011-09-26 00:00:00,C2,9,Respiratory disease,711
Recombinant viral vector vaccine,12370,LOCAL_AND_MAJOR,GenomIdea Inc,1008113,Japan,JP,"DNA vaccines (HJV vector, tuberculosis), GenomIdea",60030,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2007-04-20 00:00:00,AnGes MG Inc,28514,Discovery,2007-04-20 00:00:00,DR,6,Respiratory disease,711
FGF-2 ligand modulator,3616,LOCAL_AND_MAJOR,GenomIdea Inc,1008113,Japan,JP,"DNA vaccines (HJV vector, tuberculosis), GenomIdea",60030,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2007-04-20 00:00:00,AnGes MG Inc,28514,Discovery,2007-04-20 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,University of Illinois,20592,US,US,"tuberculosis therapy, TB Alliance/Johns Hopkins University",82716,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2013-06-30 00:00:00,University of Illinois,20592,Discontinued,2013-06-30 00:00:00,DX,3,Respiratory disease,711
DNA binding protein inhibitor,18889,LOCAL_AND_MAJOR,BioVersys AG,1052531,Switzerland,CH,BV-6481,65858,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2008-01-22 00:00:00,BioVersys AG,1052531,Discovery,2008-01-22 00:00:00,DR,6,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,Vaxil BioTherapeutics Ltd,1036156,Israel,IL,MTbuVax,66172,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2009-02-25 00:00:00,Sheldonco Ltd,1095293,Discovery,2009-02-25 00:00:00,DR,6,Respiratory disease,711
Fatty acid synthase inhibitor,6589,LOCAL_AND_MAJOR,Yonsei University,25184,South Korea,KR,"pyrazinamide analogs (tuberculosis infection), Yonsei University/TB Alliance",71894,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-03-28 00:00:00,Yonsei University,25184,Discovery,2011-03-28 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Chiron PathoGenesis,18741,US,US,PA-647,11233,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,1996-10-01 00:00:00,Novartis AG,23137,Discontinued,1996-10-01 00:00:00,DX,3,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,Immunobiology Ltd,27371,UK,GB,T-Biovax,67683,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-10-17 00:00:00,Immunobiology Ltd,27371,Discovery,2010-08-11 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Lanzhou Institute of Biological Products,1061250,China,CN,T-Biovax,67683,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-10-17 00:00:00,Sinopharm,1055632,Discovery,2011-10-17 00:00:00,DR,6,Respiratory disease,711
Heat shock protein modulator,7992,LOCAL_AND_MAJOR,Lanzhou Institute of Biological Products,1061250,China,CN,T-Biovax,67683,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-10-17 00:00:00,Sinopharm,1055632,Discovery,2011-10-17 00:00:00,DR,6,Respiratory disease,711
Defensin modulator,14365,LOCAL_AND_MAJOR,Cellceutix Corp,1039453,US,US,PMX-10072,63306,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-09-09 00:00:00,Cellceutix Corp,1039453,Discovery,2013-09-09 00:00:00,DR,6,Respiratory disease,711
Ribosome binding agent,463,LOCAL_AND_MAJOR,AstraZeneca plc,14190,US,US,posizolid,26493,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2012-12-27 00:00:00,AstraZeneca plc,14190,Phase 1 Clinical,2009-12-22 00:00:00,C1,8,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,AstraZeneca plc,14190,US,US,posizolid,26493,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2012-12-27 00:00:00,AstraZeneca plc,14190,Phase 2 Clinical,2012-12-27 00:00:00,C2,9,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Cellceutix Corp,1039453,US,US,PMX-10072,63306,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-09-09 00:00:00,Cellceutix Corp,1039453,Discovery,2013-09-09 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Southern Research Institute,20226,US,US,"tuberculosis therapy, iThemba Pharmaceuticals/Southern Research Institute",67092,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-06-22 00:00:00,Southern Research Institute,20226,Discovery,2010-05-06 00:00:00,DR,6,Respiratory disease,711
Listeriolysin stimulator,14513,LOCAL_AND_MAJOR,Max-Planck-Gesellschaft zur Forderung der Wissenschaften eV,17962,Germany,DE,VPM-1002,55569,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2013-03-27 00:00:00,Max-Planck-Gesellschaft zur Forderung der Wissenschaften eV,17962,Discontinued,2004-03-24 00:00:00,DX,3,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,National Institutes of Health,20518,US,US,"pharmacophores (Mycobacterium tuberculosis), NIH",86108,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-02-01 00:00:00,US Government,20516,Discovery,2012-02-01 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Agenus Inc,23221,US,US,"tuberculosis vaccine (CD1), Antigenics",22778,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2002-10-15 00:00:00,Agenus Inc,23221,Discovery,2001-11-21 00:00:00,DR,6,Respiratory disease,711
Protein subunit vaccine,12372,LOCAL_AND_MAJOR,Shanghai H&G Biotechnology Co,1066720,China,CN,HG856-SeV,75156,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-17 00:00:00,Shanghai H&G Biotechnology Co,1066720,Discovery,2009-12-31 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Phage Therapeutics Inc,27485,US,US,"bacteriophage (Mycobacterium tuberculosis infection), Phage Therapeutics",34469,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-12-31 00:00:00,Phage Therapeutics Inc,27485,Discovery,2001-06-01 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,NeED Pharmaceuticals Srl,1013076,Italy,IT,ND-801,59776,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-03-21 00:00:00,NeED Pharmaceuticals Srl,1013076,No Development Reported,2014-03-21 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,iThemba Pharmaceuticals Pty Ltd,1049788,South Africa,ZA,"tuberculosis therapy, iThemba Pharmaceuticals/Southern Research Institute",67092,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-06-22 00:00:00,iThemba Pharmaceuticals Pty Ltd,1049788,Discovery,2010-05-06 00:00:00,DR,6,Respiratory disease,711
DNA vaccine,1879,LOCAL_AND_MAJOR,Genvax Ltd,1015643,UK,GB,"DNA vaccine (Mycobacterium tuberculosis infection), Genvax",57745,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2009-09-07 00:00:00,Medical Marketing International Group plc,1003702,Discovery,2007-07-30 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,OTHER,Pfizer Inc,18767,Philippines,PH,"rifampicin + isoniazid (fixed dose combination, tuberculosis), Pfizer",89460,Chemical,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-12-17 00:00:00,Pfizer Inc,18767,Phase 1 Clinical,2011-04-30 00:00:00,C1,8,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"pleuromutilin derivatives (tuberculosis), GlaxoSmithKline/The Global Alliance for TB Drug Development",56410,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-06-18 00:00:00,The Global Alliance for TB Drug Development,29411,No Development Reported,2012-06-18 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,SciClone Pharmaceuticals Inc,19829,US,US,"golotimod (oral), SciClone/Verta",55521,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2011-10-10 00:00:00,SciClone Pharmaceuticals Inc,19829,Discovery,1999-08-26 00:00:00,DR,6,Respiratory disease,711
STAT3 gene inhibitor,19075,LOCAL_AND_MAJOR,SciClone Pharmaceuticals Inc,19829,US,US,"golotimod (oral), SciClone/Verta",55521,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2011-10-10 00:00:00,SciClone Pharmaceuticals Inc,19829,Discovery,1999-08-26 00:00:00,DR,6,Respiratory disease,711
Live attenuated bacterial vaccine,12363,OTHER,Biofabri SL,1077737,Switzerland,CH,MTBVAC,89744,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-11-15 00:00:00,Biofabri SL,1077737,Phase 1 Clinical,2013-01-31 00:00:00,C1,8,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,National University of Singapore,20633,Singapore,SG,pascolizumab,17132,Biological,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2014-06-23 00:00:00,National University of Singapore,20633,Phase 2 Clinical,2012-10-11 00:00:00,C2,9,Respiratory disease,711
IL-4 antagonist,225,LOCAL_AND_MAJOR,National University of Singapore,20633,Singapore,SG,pascolizumab,17132,Biological,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2014-06-23 00:00:00,National University of Singapore,20633,Phase 2 Clinical,2012-10-11 00:00:00,C2,9,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,National University of Singapore,20633,Singapore,SG,pascolizumab,17132,Biological,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2014-06-23 00:00:00,National University of Singapore,20633,Discovery,2012-07-09 00:00:00,DR,6,Respiratory disease,711
IL-4 antagonist,225,LOCAL_AND_MAJOR,National University of Singapore,20633,Singapore,SG,pascolizumab,17132,Biological,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2014-06-23 00:00:00,National University of Singapore,20633,Discovery,2012-07-09 00:00:00,DR,6,Respiratory disease,711
Anxiolytic,2942,LOCAL_AND_MAJOR,National University of Singapore,20633,Singapore,SG,pascolizumab,17132,Biological,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2014-06-23 00:00:00,National University of Singapore,20633,Discovery,2012-07-09 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Medical Research Council Technology,1054893,UK,GB,"GlgE inhibitors (tuberculosis), MCRT",78428,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-06-25 00:00:00,Medical Research Council (MRC),18438,Discovery,2012-05-31 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,Sequella Inc,28087,Europe,X5,sutezolid,11088,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-07-17 00:00:00,Sequella Inc,28087,Discovery,2013-07-17 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,GlaxoSmithKline plc,28355,US,US,"MTB72F vaccine (tuberculosis), GSK/Aeras",9490,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-08-26 00:00:00,GlaxoSmithKline plc,28355,Discovery,2001-06-01 00:00:00,DR,6,Respiratory disease,711
Subunit vaccine,12371,OTHER,Aeras Global TB Vaccine Foundation,1007376,South Africa,ZA,"MTB72F vaccine (tuberculosis), GSK/Aeras",9490,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-08-26 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 2 Clinical,2014-08-26 00:00:00,C2,9,Respiratory disease,711
Immunostimulant,393,LOCAL_AND_MAJOR,Verta Ltd,1004196,Russian Federation,RU,golotimod,25023,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2013-11-12 00:00:00,Verta Ltd,1004196,Phase 2 Clinical,2002-09-28 00:00:00,C2,9,Respiratory disease,711
Fungicide,1748,LOCAL_AND_MAJOR,Infectex,1068619,Russian Federation,RU,SQ-109,31010,Chemical,Phase 3 Clinical,Phase 3 Clinical,C3,C3,Mycobacterium tuberculosis infection,221,true,2012-12-19 00:00:00,Maxwell Biotech Group,1061894,Discovery,2011-04-25 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Crucell NV,17254,Netherlands,NL,AERAS-402,53975,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2010-09-22 00:00:00,Johnson & Johnson,17332,Discovery,2004-03-24 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Crucell NV,17254,Kenya,KE,AERAS-402,53975,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2010-09-22 00:00:00,Johnson & Johnson,17332,Phase 1 Clinical,2008-10-17 00:00:00,C1,8,Respiratory disease,711
Recombinant viral vector vaccine,12370,LOCAL_AND_MAJOR,Crucell NV,17254,US,US,AERAS-402,53975,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2010-09-22 00:00:00,Johnson & Johnson,17332,Phase 1 Clinical,2006-10-25 00:00:00,C1,8,Respiratory disease,711
Recombinant viral vector vaccine,12370,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,AERAS-402,53975,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2010-09-22 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Discovery,2004-03-24 00:00:00,DR,6,Respiratory disease,711
Recombinant viral vector vaccine,12370,OTHER,Aeras Global TB Vaccine Foundation,1007376,South Africa,ZA,AERAS-402,53975,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2010-09-22 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 2 Clinical,2008-10-17 00:00:00,C2,9,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,AERAS-402,53975,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2010-09-22 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 1 Clinical,2006-10-25 00:00:00,C1,8,Respiratory disease,711
Recombinant viral vector vaccine,12370,OTHER,Aeras Global TB Vaccine Foundation,1007376,Kenya,KE,AERAS-402,53975,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2010-09-22 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 2 Clinical,2010-09-22 00:00:00,C2,9,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Polymun Scientific Immunobiologische Forschung GmbH,21851,Austria,AT,"tuberculosis vaccine (nasal, influenza virus carrier), Polymun",54201,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-06-10 00:00:00,Polymun Scientific Immunobiologische Forschung GmbH,21851,Phase 1 Clinical,2013-06-10 00:00:00,C1,8,Respiratory disease,711
T-cell surface glycoprotein CD8 stimulator,5039,LOCAL_AND_MAJOR,ApoVax Inc,29552,US,US,ApoVax104-TB,68211,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2015-01-05 00:00:00,ApoVax Inc,29552,Discovery,2008-08-31 00:00:00,DR,6,Respiratory disease,711
RNA interference agent,26034,LOCAL_AND_MAJOR,University of Georgia,20579,US,US,"small molecule therapeutics (tuberculosis/HIV), University of Georgia",95507,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2015-01-28 00:00:00,University of Georgia,20579,Discovery,2015-01-28 00:00:00,DR,6,Respiratory disease,711
Anti-inflammatory,2953,OTHER,Harbor Therapeutics Inc,24345,Mexico,MX,HE-2000,19980,Chemical,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2013-01-28 00:00:00,Harbor Therapeutics Inc,24345,Discovery,2002-11-22 00:00:00,DR,6,Respiratory disease,711
Antiviral,991,OTHER,Harbor Therapeutics Inc,24345,Mexico,MX,HE-2000,19980,Chemical,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2013-01-28 00:00:00,Harbor Therapeutics Inc,24345,No Development Reported,2013-01-28 00:00:00,NDR,2,Respiratory disease,711
Antimicrobial,1593,LOCAL_AND_MAJOR,Shenzhen Neptunus Interlong Bio-Technique Co Ltd,1015704,China,CN,"recombinant human interleukin-2 (cancer/AIDS/autoimmune disorders/infections), Shenzhen Neptunus",80864,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2012-09-10 00:00:00,Shenzhen Neptunus Bioengineering Co Ltd,1031729,Launched,2012-09-10 00:00:00,L,13,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,GlobeImmune Inc,28802,US,US,GI-19000,86853,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-08-22 00:00:00,GlobeImmune Inc,28802,Discovery,2013-06-13 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,University of Maryland Office of Technology Commercialization,1067932,US,US,"tuberculosis vaccine, University of Maryland",76032,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-02-10 00:00:00,University of Maryland,20611,Discovery,2012-02-10 00:00:00,DR,6,Respiratory disease,711
Alpha crystallin inhibitor,59382,LOCAL_AND_MAJOR,Finlay Institute,15912,Cuba,CU,"alpha crystallin inhibiting IgA mAbs (tuberculosis infection), Finlay Institute",72912,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-09-25 00:00:00,Finlay Institute,15912,No Development Reported,2013-09-25 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,SPA Societa Prodotti Antibiotici SpA,20228,Italy,IT,rifametane,9630,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2009-03-26 00:00:00,SPA Societa Prodotti Antibiotici SpA,20228,No Development Reported,2009-03-26 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"mycobacterial membrane protein large type 3 inhibitors (tuberculosis), TB Alliance",89552,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-08-20 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2014-08-20 00:00:00,DR,6,Respiratory disease,711
Lyase inhibitor,248,OTHER,GlaxoSmithKline plc,28355,Spain,ES,"isocitrate lyase inhibitors (tuberculosis), GlaxoSmithKline/The Global Alliance for TB Drug Developement",56373,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2007-05-31 00:00:00,GlaxoSmithKline plc,28355,Discovery,2005-03-21 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Qurient Therapeutics,1062405,South Korea,KR,"TB A series (tuberculosis infection), Qurient",77998,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-06-28 00:00:00,Qurient Therapeutics,1062405,Discovery,2012-04-17 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Shenyang Hongqi Pharmaceutical Co Ltd,1075626,China,CN,"rifampicin + isoniazid (fixed dose combination, tuberculosis), Shenyang Hongqi Pharmaceutical",82095,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2009-12-31 00:00:00,Shanghai Fosun Pharmaceutical (Group) Co Ltd,1015871,Registered,2009-05-22 00:00:00,R,12,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Shenyang Hongqi Pharmaceutical Co Ltd,1075626,China,CN,"rifampicin + isoniazid (fixed dose combination, tuberculosis), Shenyang Hongqi Pharmaceutical",82095,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2009-12-31 00:00:00,Shanghai Fosun Pharmaceutical (Group) Co Ltd,1015871,Launched,2009-12-31 00:00:00,L,13,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"DprE inhibitors (tuberculosis), TB Alliance/California Institute for Biomedical Research",82660,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-06-30 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2012-11-30 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,California Institute for Biomedical Research,1068758,US,US,"DprE inhibitors (tuberculosis), TB Alliance/California Institute for Biomedical Research",82660,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-06-30 00:00:00,California Institute for Biomedical Research,1068758,Discovery,2013-06-30 00:00:00,DR,6,Respiratory disease,711
DPR oxidase inhibitor,78977,LOCAL_AND_MAJOR,California Institute for Biomedical Research,1068758,US,US,"DprE inhibitors (tuberculosis), TB Alliance/California Institute for Biomedical Research",82660,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-06-30 00:00:00,California Institute for Biomedical Research,1068758,Discovery,2013-06-30 00:00:00,DR,6,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,Finlay Institute,15912,Cuba,CU,"BCG/M smegmatis vector based live recombinant vaccine (tuberculosis infection), Finlay",73188,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2009-12-31 00:00:00,Finlay Institute,15912,Discovery,2009-12-31 00:00:00,DR,6,Respiratory disease,711
Transcriptional regulator protein EthR inhibitor,74415,LOCAL_AND_MAJOR,University of Lille,24385,France,FR,"EthR inhibitors (mycobacterium tuberculosis), BioVersys/ University of Lille/ GSK",92193,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-05-27 00:00:00,University of Lille,24385,Discovery,2014-05-27 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,OTHER,C&O Pharmaceutical Technology (Holdings) Ltd,1032379,Hong Kong,HK,CO-12,61340,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2007-08-31 00:00:00,Shionogi & Co Ltd,19898,Discovery,2007-08-31 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,SciClone Pharmaceuticals Inc,19829,US,US,golotimod,25023,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,false,2013-11-12 00:00:00,SciClone Pharmaceuticals Inc,19829,Phase 1 Clinical,2005-08-08 00:00:00,C1,8,Respiratory disease,711
Antiviral,991,LOCAL_AND_MAJOR,SciClone Pharmaceuticals Inc,19829,US,US,golotimod,25023,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,false,2013-11-12 00:00:00,SciClone Pharmaceuticals Inc,19829,Discovery,1999-08-27 00:00:00,DR,6,Respiratory disease,711
Anticancer,1545,LOCAL_AND_MAJOR,SciClone Pharmaceuticals Inc,19829,US,US,golotimod,25023,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,false,2013-11-12 00:00:00,SciClone Pharmaceuticals Inc,19829,Discontinued,2013-11-12 00:00:00,DX,3,Respiratory disease,711
Antiviral,991,LOCAL_AND_MAJOR,SciClone Pharmaceuticals Inc,19829,US,US,golotimod,25023,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,false,2013-11-12 00:00:00,SciClone Pharmaceuticals Inc,19829,Discontinued,2013-11-12 00:00:00,DX,3,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,New York Medical College,23270,US,US,"topoisomerase I inhibitors (tuberculosis infection), TB Alliance/NYMC/AZ",71897,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-06-27 00:00:00,New York University,20646,Discovery,2009-05-27 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Medical Research Council (MRC),18438,UK,GB,"vaccine (tuberculosis), MRC",12867,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2009-03-16 00:00:00,Medical Research Council (MRC),18438,Discovery,1996-07-29 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Medical Research Council (MRC),18438,UK,GB,"vaccine (tuberculosis), MRC",12867,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2009-03-16 00:00:00,Medical Research Council (MRC),18438,No Development Reported,2009-03-16 00:00:00,NDR,2,Respiratory disease,711
Glutamine synthetase inhibitor,21014,LOCAL_AND_MAJOR,University of California Los Angeles,25623,US,US,"methionine sulfoximine (tuberculosis), UCLA",85542,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,1996-10-02 00:00:00,University of California,20547,Discovery,1996-10-02 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,University of Illinois,20592,US,US,TBI-166,57790,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2014-12-22 00:00:00,University of Illinois,20592,Discontinued,2013-06-30 00:00:00,DX,3,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,University of Illinois,20592,US,US,TBI-166,57790,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2014-12-22 00:00:00,University of Illinois,20592,Discontinued,2013-06-30 00:00:00,DX,3,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,BioDelivery Sciences International Inc,21164,US,US,"clofazimine (oral cochleate formulation), BioDelivery",48519,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-08-19 00:00:00,BioDelivery Sciences International Inc,21164,Discovery,2002-12-31 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,BioDelivery Sciences International Inc,21164,US,US,"clofazimine (oral cochleate formulation), BioDelivery",48519,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-08-19 00:00:00,BioDelivery Sciences International Inc,21164,No Development Reported,2008-08-19 00:00:00,NDR,2,Respiratory disease,711
Subunit vaccine,12371,LOCAL_AND_MAJOR,Corixa Corp,15542,US,US,"MTB72F vaccine (tuberculosis), GSK/Aeras",9490,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-08-26 00:00:00,GlaxoSmithKline plc,28355,Discovery,1995-10-01 00:00:00,DR,6,Respiratory disease,711
Apoptosis stimulator,1589,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,AERAS-407 rBCG,62397,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-11-27 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Discovery,2008-03-31 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,TBI-166,57790,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2014-12-22 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2007-01-11 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,Novartis Institute for Tropical Diseases Pvt Ltd,1017949,Singapore,SG,"mycobacterial membrane protein large type 3 inhibitors (tuberculosis), TB Alliance",89552,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2014-08-20 00:00:00,Novartis AG,23137,Discontinued,2014-08-20 00:00:00,DX,3,Respiratory disease,711
Bacterial nucleic acid synthesis inhibitor,3984,LOCAL_AND_MAJOR,Dong Wha Pharmaceutical Co Ltd,15745,South Korea,KR,DW-286,35974,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-04-27 00:00:00,Dong Wha Pharmaceutical Co Ltd,15745,No Development Reported,2006-08-13 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,OTHER,Pfizer Inc,18767,Europe,X5,sutezolid,11088,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2013-07-17 00:00:00,Pfizer Inc,18767,Discontinued,2013-07-17 00:00:00,DX,3,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Pfizer Inc,18767,US,US,sutezolid,11088,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2013-07-17 00:00:00,Pfizer Inc,18767,Discontinued,2013-07-17 00:00:00,DX,3,Respiratory disease,711
Antibacterial,1594,OTHER,Silence Therapeutics plc,22356,Zambia,ZM,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Anticancer,1545,OTHER,Silence Therapeutics plc,22356,Zambia,ZM,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Therapeutic vaccine,12379,OTHER,Silence Therapeutics plc,22356,South Africa,ZA,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Cytokine release modulator,1291,OTHER,Silence Therapeutics plc,22356,Romania,RO,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Adjuvant,524,OTHER,Silence Therapeutics plc,22356,Kuwait,KW,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Therapeutic vaccine,12379,OTHER,Silence Therapeutics plc,22356,Kuwait,KW,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Antimicrobial,1593,OTHER,Silence Therapeutics plc,22356,Gambia,GM,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Systemic antipsoriatic product,15184,LOCAL_AND_MAJOR,Silence Therapeutics plc,22356,UK,GB,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Antibacterial,1594,OTHER,Silence Therapeutics plc,22356,Tanzania,TZ,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,2001-09-30 00:00:00,C2,9,Respiratory disease,711
Systemic antipsoriatic product,15184,OTHER,Silence Therapeutics plc,22356,Tanzania,TZ,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,2001-09-30 00:00:00,C2,9,Respiratory disease,711
Inactivated bacterial vaccine,12366,OTHER,Silence Therapeutics plc,22356,Tanzania,TZ,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,2001-09-30 00:00:00,C2,9,Respiratory disease,711
Adjuvant,524,OTHER,Silence Therapeutics plc,22356,Zambia,ZM,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 3 Clinical,1997-10-13 00:00:00,C3,10,Respiratory disease,711
Antibacterial,1594,OTHER,Silence Therapeutics plc,22356,Zambia,ZM,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 3 Clinical,1997-10-13 00:00:00,C3,10,Respiratory disease,711
Antimicrobial,1593,OTHER,Silence Therapeutics plc,22356,Zambia,ZM,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 3 Clinical,1997-10-13 00:00:00,C3,10,Respiratory disease,711
Adjuvant,524,OTHER,Silence Therapeutics plc,22356,Gambia,GM,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 3 Clinical,1997-10-13 00:00:00,C3,10,Respiratory disease,711
Antiviral,991,OTHER,Silence Therapeutics plc,22356,South Africa,ZA,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 3 Clinical,1995-10-12 00:00:00,C3,10,Respiratory disease,711
Inactivated bacterial vaccine,12366,OTHER,Silence Therapeutics plc,22356,South Africa,ZA,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 3 Clinical,1995-10-12 00:00:00,C3,10,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Silence Therapeutics plc,22356,UK,GB,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,1995-10-12 00:00:00,C2,9,Respiratory disease,711
Antiviral,991,OTHER,Silence Therapeutics plc,22356,Nigeria,NG,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,1995-10-12 00:00:00,C2,9,Respiratory disease,711
Antibacterial,1594,OTHER,Silence Therapeutics plc,22356,Gambia,GM,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,1995-10-12 00:00:00,C2,9,Respiratory disease,711
Antimicrobial,1593,OTHER,Silence Therapeutics plc,22356,Gambia,GM,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,1995-10-12 00:00:00,C2,9,Respiratory disease,711
Antiviral,991,OTHER,Silence Therapeutics plc,22356,Romania,RO,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,1995-10-12 00:00:00,C2,9,Respiratory disease,711
Anticancer,1545,OTHER,Silence Therapeutics plc,22356,Romania,RO,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,1995-10-12 00:00:00,C2,9,Respiratory disease,711
Cytokine release modulator,1291,OTHER,Silence Therapeutics plc,22356,Romania,RO,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,1995-10-12 00:00:00,C2,9,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Chiron Corp,15385,US,US,"tobramycin (nebulized), Novartis",11232,Chemical,Launched,No Development Reported,NDR,L,Mycobacterium tuberculosis infection,221,false,2013-01-09 00:00:00,Novartis AG,23137,No Development Reported,2004-02-02 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Albert Einstein College of Medicine,24282,US,US,KOA-18,10999,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,1995-09-26 14:53:02,Yeshiva University,20704,No Development Reported,1995-09-26 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,CytRx Corporation,15585,US,US,CRL-1018,11007,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,1995-09-27 00:00:00,CytRx Corporation,15585,Discovery,1995-09-27 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,CytRx Corporation,15585,US,US,CRL-1018,11007,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,1995-09-27 00:00:00,CytRx Corporation,15585,Discovery,1995-09-27 00:00:00,DR,6,Respiratory disease,711
Protein subunit vaccine,12372,LOCAL_AND_MAJOR,Epimmune Inc,15573,US,US,Theradigm-tuberculosis,10406,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2001-12-09 00:00:00,Takeda Pharmaceutical Co Ltd,20300,No Development Reported,2001-12-09 00:00:00,NDR,2,Respiratory disease,711
Subunit vaccine,12371,LOCAL_AND_MAJOR,MaxPharma,26965,US,US,"M tuberculosis vaccine (LEAPS), CEL-SCI (MaxPharma)",11526,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2011-12-28 00:00:00,CEL-SCI Corp,15339,Discovery,1999-09-29 00:00:00,DR,6,Respiratory disease,711
Live attenuated bacterial vaccine,12363,LOCAL_AND_MAJOR,Whitehead Institute for Biomedical Research,20939,US,US,"vaccine (BCG), Connaught/Whitehead",12124,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2001-08-24 00:00:00,Whitehead Institute for Biomedical Research,20939,No Development Reported,2001-08-24 00:00:00,NDR,2,Respiratory disease,711
Live attenuated bacterial vaccine,12363,LOCAL_AND_MAJOR,Pasteur Merieux Connaught Canada,19267,US,US,"vaccine (BCG), Connaught/Whitehead",12124,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2001-08-24 00:00:00,Sanofi,1009547,No Development Reported,2001-08-24 00:00:00,NDR,2,Respiratory disease,711
Fungicide,1748,LOCAL_AND_MAJOR,University of North Carolina,20634,US,US,pafuramidine,16755,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2008-02-22 00:00:00,University of North Carolina,20634,Discontinued,2000-01-28 00:00:00,DX,3,Respiratory disease,711
Antiparasitic,2638,LOCAL_AND_MAJOR,University of North Carolina,20634,US,US,pafuramidine,16755,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2008-02-22 00:00:00,University of North Carolina,20634,Discovery,2000-10-23 00:00:00,DR,6,Respiratory disease,711
DNA gyrase inhibitor,431,OTHER,The Global Alliance for TB Drug Development,29411,Russian Federation,RU,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2014-10-14 00:00:00,DR,6,Respiratory disease,711
Topoisomerase IV inhibitor,9320,OTHER,The Global Alliance for TB Drug Development,29411,Asia,X2,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2014-10-14 00:00:00,DR,6,Respiratory disease,711
Systemic dermatological antibacterial product,15187,OTHER,The Global Alliance for TB Drug Development,29411,Asia,X2,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2014-10-14 00:00:00,DR,6,Respiratory disease,711
Systemic dermatological antibacterial product,15187,OTHER,The Global Alliance for TB Drug Development,29411,Haiti,HT,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2014-10-14 00:00:00,DR,6,Respiratory disease,711
Bacterial nucleic acid synthesis inhibitor,3984,OTHER,The Global Alliance for TB Drug Development,29411,Georgia,GE,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2014-10-14 00:00:00,DR,6,Respiratory disease,711
Systemic dermatological antibacterial product,15187,OTHER,The Global Alliance for TB Drug Development,29411,South Africa,ZA,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,The Global Alliance for TB Drug Development,29411,Phase 3 Clinical,2015-02-10 00:00:00,C3,10,Respiratory disease,711
Systemic dermatological antibacterial product,15187,OTHER,The Global Alliance for TB Drug Development,29411,World,WO,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,The Global Alliance for TB Drug Development,29411,Phase 2 Clinical,2005-10-17 00:00:00,C2,9,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Sanofi,1009547,US,US,rifapentine,15102,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-12-02 00:00:00,Sanofi,1009547,Registered,2014-12-02 00:00:00,R,12,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Sanofi,1009547,US,US,rifapentine,15102,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-12-02 00:00:00,Sanofi,1009547,Registered,2014-12-02 00:00:00,R,12,Respiratory disease,711
Bacterial nucleic acid synthesis inhibitor,3984,OTHER,Bayer AG,14455,Canada,CA,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,Bayer AG,14455,Phase 2 Clinical,2005-10-17 00:00:00,C2,9,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,OriGenix Technologies Inc,26201,Canada,CA,"Mycobacterium tuberculosis therapeutics, OriGenix",32998,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2002-09-13 00:00:00,Biowest Therapeutics Inc,18210,Discovery,2001-02-23 12:55:10,DR,6,Respiratory disease,711
Protein subunit vaccine,12372,OTHER,Intercell AG,28463,Austria,AT,"peptide vaccine (tuberculosis), Intercell/Sequella",32516,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2004-04-30 00:00:00,Valneva SE,1084202,No Development Reported,2004-04-30 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Medivir AB,18015,Sweden,SE,"antibacterial protease inhibitors, Medivir/University of London",35747,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2003-08-19 00:00:00,Medivir AB,18015,No Development Reported,2003-08-19 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Bristol-Myers Squibb Pharma Co,26864,US,US,DuP-105,2973,Chemical,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2004-03-02 00:00:00,Bristol-Myers Squibb Co,15065,No Development Reported,2001-06-27 00:00:00,NDR,2,Respiratory disease,711
Protein subunit vaccine,12372,OTHER,Intercell AG,28463,Tanzania,TZ,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2013-05-28 00:00:00,Valneva SE,1084202,Phase 2 Clinical,2012-08-17 00:00:00,C2,9,Respiratory disease,711
Protein subunit vaccine,12372,OTHER,Intercell AG,28463,Austria,AT,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2013-05-28 00:00:00,Valneva SE,1084202,Discovery,2004-03-17 00:00:00,DR,6,Respiratory disease,711
Recombinant bacterial vector vaccine,12369,OTHER,Valneva SE,1084202,South Africa,ZA,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-05-28 00:00:00,Valneva SE,1084202,Phase 2 Clinical,2013-05-28 00:00:00,C2,9,Respiratory disease,711
Protein subunit vaccine,12372,OTHER,Sanofi Pasteur,22127,Netherlands,NL,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-05-28 00:00:00,Sanofi,1009547,Phase 2 Clinical,2009-03-02 00:00:00,C2,9,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Sanofi Pasteur,22127,Switzerland,CH,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-05-28 00:00:00,Sanofi,1009547,Phase 1 Clinical,2010-12-31 00:00:00,C1,8,Respiratory disease,711
Protein subunit vaccine,12372,OTHER,Sanofi Pasteur,22127,Switzerland,CH,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-05-28 00:00:00,Sanofi,1009547,Phase 1 Clinical,2010-12-31 00:00:00,C1,8,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Sanofi Pasteur,22127,France,FR,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-05-28 00:00:00,Sanofi,1009547,Phase 1 Clinical,2008-02-12 00:00:00,C1,8,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Central Drug Research Institute,15350,India,IN,"galactopyranose derivatives (antifungal/antitubercular), Central Drug Research Institute",50637,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2005-01-24 00:00:00,Council of Scientific and Industrial Research (India),15561,Discovery,2003-07-24 00:00:00,DR,6,Respiratory disease,711
ATP synthase inhibitor,49687,LOCAL_AND_MAJOR,FASgen Inc,1006466,US,US,FAS-20013,49581,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-08-25 00:00:00,FASgen Inc,1006466,No Development Reported,2014-08-25 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,OTHER,UMeWorld Ltd,28431,Canada,CA,"rifampicin (nanoparticle encapsulated, tuberculosis), AlphaRx",53605,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2009-01-08 00:00:00,UMeWorld Ltd,28431,Discovery,2005-07-18 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Aeras Global TB Vaccine Foundation,1007376,South Africa,ZA,"HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell",48499,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-07-29 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 1 Clinical,2009-01-26 00:00:00,C1,8,Respiratory disease,711
Mycobacterial antigen complex 85B modulator,33970,OTHER,Sanofi Pasteur,22127,South Africa,ZA,"HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell",48499,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-07-29 00:00:00,Sanofi,1009547,Phase 2 Clinical,2013-07-29 00:00:00,C2,9,Respiratory disease,711
Mycobacterial antigen complex 85B modulator,33970,OTHER,Statens Serum Institut,21502,South Africa,ZA,"HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell",48499,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-07-29 00:00:00,Statens Serum Institut,21502,Phase 1 Clinical,2009-01-26 00:00:00,C1,8,Respiratory disease,711
Mycobacterial antigen complex 85B modulator,33970,LOCAL_AND_MAJOR,Statens Serum Institut,21502,Denmark,DK,"HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell",48499,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-07-29 00:00:00,Statens Serum Institut,21502,Discovery,2003-04-30 00:00:00,DR,6,Respiratory disease,711
Protein subunit vaccine,12372,LOCAL_AND_MAJOR,Statens Serum Institut,21502,Denmark,DK,"HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell",48499,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-07-29 00:00:00,Statens Serum Institut,21502,Discovery,2003-04-30 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"antibacterial compounds (Mycobacterium tuberculosis), Cumbre/The Global Alliance for TB Drug Development",57737,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2009-12-22 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2006-09-27 00:00:00,DR,6,Respiratory disease,711
Anticancer,1545,LOCAL_AND_MAJOR,Cadila Pharmaceuticals Ltd,30025,India,IN,cadi-05,55173,Biological,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2014-12-03 00:00:00,Cadila Pharmaceuticals Ltd,30025,No Development Reported,2014-12-03 00:00:00,NDR,2,Respiratory disease,711
Anticancer,1545,LOCAL_AND_MAJOR,Cadila Pharmaceuticals Ltd,30025,India,IN,cadi-05,55173,Biological,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2014-12-03 00:00:00,Cadila Pharmaceuticals Ltd,30025,Phase 3 Clinical,2005-03-31 00:00:00,C3,10,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Oxford-Emergent Tuberculosis Consortium Ltd,1040955,Senegal,SN,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-07 00:00:00,Emergent BioSolutions Inc,1011990,Discontinued,2014-03-07 00:00:00,DX,3,Respiratory disease,711
Mycobacterial antigen complex 85A modulator,33967,OTHER,Oxford-Emergent Tuberculosis Consortium Ltd,1040955,South Africa,ZA,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-07 00:00:00,Emergent BioSolutions Inc,1011990,Phase 1 Clinical,2008-07-23 00:00:00,C1,8,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Oxford-Emergent Tuberculosis Consortium Ltd,1040955,South Africa,ZA,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-07 00:00:00,Emergent BioSolutions Inc,1011990,Phase 1 Clinical,2008-07-23 00:00:00,C1,8,Respiratory disease,711
Recombinant viral vector vaccine,12370,OTHER,Oxford-Emergent Tuberculosis Consortium Ltd,1040955,South Africa,ZA,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-07 00:00:00,Emergent BioSolutions Inc,1011990,Phase 2 Clinical,2008-07-23 00:00:00,C2,9,Respiratory disease,711
Mycobacterial antigen complex 85A modulator,33967,OTHER,University of Oxford,22182,South Africa,ZA,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-07 00:00:00,University of Oxford,22182,Discontinued,2008-07-23 00:00:00,DX,3,Respiratory disease,711
Recombinant viral vector vaccine,12370,OTHER,University of Oxford,22182,South Africa,ZA,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-07 00:00:00,University of Oxford,22182,Discontinued,2008-07-23 00:00:00,DX,3,Respiratory disease,711
Mycobacterial antigen complex 85A modulator,33967,OTHER,TB-VAC,1020621,South Africa,ZA,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-03-07 00:00:00,TB-VAC,1020621,Phase 2 Clinical,2008-05-14 00:00:00,C2,9,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,TB-VAC,1020621,Senegal,SN,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-03-07 00:00:00,TB-VAC,1020621,Phase 2 Clinical,2011-08-08 00:00:00,C2,9,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,TB-VAC,1020621,UK,GB,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-03-07 00:00:00,TB-VAC,1020621,Phase 1 Clinical,2008-07-23 00:00:00,C1,8,Respiratory disease,711
Mycobacterial antigen complex 85A modulator,33967,OTHER,TB-VAC,1020621,Africa,X0,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-03-07 00:00:00,TB-VAC,1020621,Clinical,2007-03-25 00:00:00,CU,7,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,Hosp Germans Trias i Pujol,DOL1000424,Spain,ES,RUTI,57308,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2012-05-24 00:00:00,Hosp Germans Trias i Pujol,DOL1000424,Discovery,2004-04-17 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Archivel Farma SL,1014222,Spain,ES,RUTI,57308,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2012-05-24 00:00:00,Archivel Farma SL,1014222,Phase 1 Clinical,2007-05-06 00:00:00,C1,8,Respiratory disease,711
Recombinant viral vector vaccine,12370,LOCAL_AND_MAJOR,University of Oxford,22182,UK,GB,FP-85A,63673,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2011-12-29 00:00:00,University of Oxford,22182,No Development Reported,2011-12-29 00:00:00,NDR,2,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,University of Oxford,22182,UK,GB,FP-85A,63673,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2011-12-29 00:00:00,University of Oxford,22182,Phase 1 Clinical,2007-09-30 00:00:00,C1,8,Respiratory disease,711
Mycolic acid synthase inhibitor,6542,LOCAL_AND_MAJOR,Shaheed Beheshti Medical University,1034641,Iran,IR,KBF-611,65935,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-06-19 00:00:00,Shaheed Beheshti Medical University,1034641,Discovery,2009-12-31 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Colorado State University,20562,US,US,"menaquinone synthase inhibitors (tuberculosis infection), Colorado State University/TB Alliance",71664,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2009-05-27 00:00:00,Colorado State University,20562,Discovery,2009-05-27 00:00:00,DR,6,Respiratory disease,711
RNA polymerase inhibitor,347,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"RNA polymerase inhibitors (tuberculosis infection), TB Alliance/Rutgers",71698,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-07-10 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2009-01-27 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Rutgers University,21239,US,US,"RNA polymerase inhibitors (tuberculosis infection), TB Alliance/Rutgers",71698,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-07-10 00:00:00,Rutgers University,21239,Discovery,2009-01-27 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,AstraZeneca plc,14190,India,IN,"gyrase B inhibitors (tuberculosis infection), AZ/TB Alliance",71700,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-11-30 00:00:00,AstraZeneca plc,14190,No Development Reported,2012-11-30 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,TBA-354,71742,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-01-30 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2009-10-02 00:00:00,DR,6,Respiratory disease,711
Nitric oxide donor,698,LOCAL_AND_MAJOR,University of Auckland,20647,New Zealand,NZ,TBA-354,71742,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-01-30 00:00:00,University of Auckland,20647,Discovery,2009-10-02 00:00:00,DR,6,Respiratory disease,711
Nitric oxide donor,698,LOCAL_AND_MAJOR,Johns Hopkins University,20596,US,US,TBA-354,71742,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-01-30 00:00:00,Johns Hopkins University,20596,Discovery,2014-01-30 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"protease inhibitors (tuberculosis infection, TB Alliance/Institute of Microbiology Chinese Academy of Sciences",71743,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-18 00:00:00,The Global Alliance for TB Drug Development,29411,No Development Reported,2013-01-18 00:00:00,NDR,2,Respiratory disease,711
Protein subunit vaccine,12372,OTHER,Statens Serum Institut,21502,UK,GB,"protein subunit vaccine (Mycobacterium tuberculosis, intranasal), Novartis Vaccines & Diagnostics/Statens Serum Institut",66563,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2011-11-30 00:00:00,Statens Serum Institut,21502,Phase 1 Clinical,2007-02-26 00:00:00,C1,8,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Novartis Vaccines and Diagnostics Ltd,17976,UK,GB,"protein subunit vaccine (Mycobacterium tuberculosis, intranasal), Novartis Vaccines & Diagnostics/Statens Serum Institut",66563,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2011-11-30 00:00:00,Novartis AG,23137,No Development Reported,2011-11-30 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,NeED Pharmaceuticals Srl,1013076,Italy,IT,ND-601,71115,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-03-21 00:00:00,NeED Pharmaceuticals Srl,1013076,No Development Reported,2014-03-21 00:00:00,NDR,2,Respiratory disease,711
Unspecified vaccine,12380,LOCAL_AND_MAJOR,Medicine in Need,1054651,US,US,"BCG vaccine (inhalant/powder, tuberculosis), Medicine In Need",69074,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-09-24 00:00:00,Medicine in Need,1054651,Discovery,2010-11-18 00:00:00,DR,6,Respiratory disease,711
Protein subunit vaccine,12372,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,ID-93,68617,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-09-20 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 1 Clinical,2012-08-15 00:00:00,C1,8,Respiratory disease,711
Therapeutic vaccine,12379,OTHER,Infectious Disease Research Institute,27376,South Africa,ZA,ID-93,68617,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-09-20 00:00:00,Infectious Disease Research Institute,27376,Phase 1 Clinical,2013-09-20 00:00:00,C1,8,Respiratory disease,711
TLR-5 agonist,7815,LOCAL_AND_MAJOR,Bio Farma,19368,Indonesia,ID,Lipovax-Fg115-TB,68627,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2015-04-16 00:00:00,Bio Farma,19368,Discovery,2015-04-16 00:00:00,DR,6,Respiratory disease,711
DNA vaccine,1879,OTHER,RecipharmCobra Biologics,20370,UK,GB,"tuberculosis DNA vaccine (ORT), RecipharmCobra Biologics",69165,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-03-13 00:00:00,Recipharm AB,1058217,No Development Reported,2013-03-13 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Numerate Inc,1037610,US,US,"tuberculosis therapeutics, Numerate",73050,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-12-21 00:00:00,Numerate Inc,1037610,No Development Reported,2012-12-21 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,THERAMetrics Holding AG,29586,Switzerland,CH,DasKloster 0249-01,71313,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2010-09-30 00:00:00,THERAMetrics Holding AG,29586,Discovery,2010-09-30 00:00:00,DR,6,Respiratory disease,711
Respiratory system agent,1470,LOCAL_AND_MAJOR,THERAMetrics Holding AG,29586,Switzerland,CH,DasKloster 0249-01,71313,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2010-09-30 00:00:00,THERAMetrics Holding AG,29586,Discovery,2010-09-30 00:00:00,DR,6,Respiratory disease,711
Live attenuated bacterial vaccine,12363,LOCAL_AND_MAJOR,McMaster University,21238,Canada,CA,Ad5Ag85A,71323,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,false,2012-05-07 00:00:00,McMaster University,21238,Phase 1 Clinical,2009-07-31 00:00:00,C1,8,Respiratory disease,711
Recombinant bacterial vector vaccine,12369,OTHER,Aeras Global TB Vaccine Foundation,1007376,China,CN,Ad5Ag85A,71323,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2012-05-07 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Discovery,2012-05-07 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,PaxVax Inc,1032157,US,US,"adenovirus 4-based vaccine (oral, tuberculosis), PaxVax",72040,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-11-27 00:00:00,PaxVax Inc,1032157,No Development Reported,2012-11-27 00:00:00,NDR,2,Respiratory disease,711
Immunostimulant,393,LOCAL_AND_MAJOR,VIB,25058,Belgium,BE,"tuberculosis vaccine, VIB/Ghent University",70144,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-10-07 00:00:00,University of Antwerp,22741,No Development Reported,2014-10-07 00:00:00,NDR,2,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,VIB,25058,Belgium,BE,"tuberculosis vaccine, VIB/Ghent University",70144,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-10-07 00:00:00,University of Antwerp,22741,Discovery,2011-01-26 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,University of Ghent,24987,Belgium,BE,"tuberculosis vaccine, VIB/Ghent University",70144,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-10-07 00:00:00,University of Ghent,24987,Discovery,2011-01-26 00:00:00,DR,6,Respiratory disease,711
Anticancer hormone,62253,LOCAL_AND_MAJOR,Wyeth BioPharma,20511,US,US,edodekin alfa,6934,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-06-27 00:00:00,Pfizer Inc,18767,Discontinued,2003-06-27 00:00:00,DX,3,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Institute for Tuberculosis Research,1092461,US,US,"antituberculosis agents, LifePharms Inc/Institute for Tuberculosis Research",70763,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-01-24 00:00:00,Institute for Tuberculosis Research,1092461,Discovery,2014-01-24 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,TapImmune Inc,27762,US,US,"tuberculosis vaccine, TapImmune",74286,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-09-23 00:00:00,TapImmune Inc,27762,Discovery,2011-10-27 00:00:00,DR,6,Respiratory disease,711
Interleukin 12 ligand,51207,LOCAL_AND_MAJOR,Wyeth BioPharma,20511,US,US,edodekin alfa,6934,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-06-27 00:00:00,Pfizer Inc,18767,Discontinued,2003-06-27 00:00:00,DX,3,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Aarden Pharmaceuticals Inc,1058608,US,US,"protein tyrosine phosphatase inhibitor (tuberculosis infection, cancer, autoimmune diseases), Aarden Pharmacueticals",69351,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2015-01-05 00:00:00,Aarden Pharmaceuticals Inc,1058608,Discovery,2009-11-10 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Albert Einstein College of Medicine,24282,US,US,"tuberculosis ESX-3 gene expressing Mycobacterium smegmatis vaccine, Albert Einstein College of Medicine",73315,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2005-06-21 00:00:00,Yeshiva University,20704,Discovery,2005-06-21 00:00:00,DR,6,Respiratory disease,711
Protein subunit vaccine,12372,LOCAL_AND_MAJOR,Finlay Institute,15912,Cuba,CU,"Streptomyces vector-based live recombinant vaccine (tuberculosis infection), Finlay Institute",73326,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-10-15 00:00:00,Finlay Institute,15912,No Development Reported,2013-10-15 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Medical Research Council Technology,1054893,UK,GB,"PknB inhibitors (Mycobacterium tuberculosis infection), MRCT",66920,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-09-23 00:00:00,Medical Research Council (MRC),18438,Discovery,2008-12-31 00:00:00,DR,6,Respiratory disease,711
Epimerase inhibitor,520,LOCAL_AND_MAJOR,New Medicines for Tuberculosis,1062637,Switzerland,CH,"benzothiazinones (tuberculosis), Hans Knoell Institute",70901,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-09-25 00:00:00,New Medicines for Tuberculosis,1062637,Discovery,2009-03-19 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Heber Biotec SA,1062884,Cuba,CU,"interferon gamma follow-on biologic, CIGB/Heber Biotec",79519,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2009-12-31 00:00:00,Center for Genetic Engineering and Biotechnology,15353,Launched,2009-12-31 00:00:00,L,13,Respiratory disease,711
Antiviral,991,LOCAL_AND_MAJOR,Chengdu Institute of Biological Products,1016340,China,CN,Ka Shu Ning,80062,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,1998-12-31 00:00:00,Sinopharm,1055632,Registered,1998-12-31 00:00:00,R,12,Respiratory disease,711
Mycobacterial antigen complex 85B modulator,33970,LOCAL_AND_MAJOR,Shanghai H&G Biotechnology Co,1066720,China,CN,"Ag85A/B DNA vaccine (tuberculosis), Shanghai H&G Biotechnology",75084,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-17 00:00:00,Shanghai H&G Biotechnology Co,1066720,No Development Reported,2013-01-17 00:00:00,NDR,2,Respiratory disease,711
Mycobacterial antigen complex 85A modulator,33967,LOCAL_AND_MAJOR,Shanghai H&G Biotechnology Co,1066720,China,CN,"Ag85A/B DNA vaccine (tuberculosis), Shanghai H&G Biotechnology",75084,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-17 00:00:00,Shanghai H&G Biotechnology Co,1066720,No Development Reported,2013-01-17 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Nanosystem Ltd,1071336,Russian Federation,RU,"rifabutin nanoparticles (iv, Mycobacterium tuberculosis), Nanosystem",82299,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-12-07 00:00:00,Nanosystem Ltd,1071336,Discovery,2012-12-07 00:00:00,DR,6,Respiratory disease,711
Bacterial cell wall synthesis inhibitor,104,LOCAL_AND_MAJOR,George Washington University,26026,US,US,"Dxr inhibitors (Mycobacterium tuberculosis infection), George Washington University",79298,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-12-01 00:00:00,George Washington University,26026,Discovery,2011-12-01 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Anacor Pharmaceuticals Inc,30118,US,US,"benzoxaborole Leucyl-tRNA synthase inhibitors (bacterial infection), Anacor",78175,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-05-14 00:00:00,Anacor Pharmaceuticals Inc,30118,Discovery,2012-05-14 00:00:00,DR,6,Respiratory disease,711
Vaccine,386,LOCAL_AND_MAJOR,AnHui Longcom Biologic Pharmacy Co Ltd,1073327,China,CN,"primary immunization-booster TB vaccine, Chongqing Zhifei Biological Products",81359,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-05-04 00:00:00,Chongqing Zhifei Biological Products Co Ltd,1062383,Discovery,2012-05-04 00:00:00,DR,6,Respiratory disease,711
Protein subunit vaccine,12372,LOCAL_AND_MAJOR,AnHui Longcom Biologic Pharmacy Co Ltd,1073327,China,CN,AEC/BC02,81363,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-09-21 00:00:00,Chongqing Zhifei Biological Products Co Ltd,1062383,Discovery,2012-09-21 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Johnson & Johnson,17332,US,US,"diarylquinolines (tuberculosis), TB Alliance/J & J/University of Auckland/University of Illinois at Chicago",82662,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-06-30 00:00:00,Johnson & Johnson,17332,Discovery,2012-11-30 00:00:00,DR,6,Respiratory disease,711
Bacterial cell wall synthesis inhibitor,104,LOCAL_AND_MAJOR,Shenyang Hongqi Pharmaceutical Co Ltd,1075626,China,CN,"ethambutol hydrochloride + rifampicin + isoniazid (fixed dose combination, tuberculosis), Shenyang Hongqi Pharmaceutical",82091,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2008-12-31 00:00:00,Shanghai Fosun Pharmaceutical (Group) Co Ltd,1015871,Launched,2008-12-31 00:00:00,L,13,Respiratory disease,711
Leucyl tRNA synthetase inhibitor,36223,LOCAL_AND_MAJOR,Omnia Molecular,1065893,Spain,ES,"leucyl-tRNA synthetase inhibitors (Mycobacterium tuberculosis infection), Omnia Molecular",75760,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-10-14 00:00:00,Omnia Molecular,1065893,Discovery,2011-10-24 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,National University of Singapore,20633,Singapore,SG,"miRNA-like molecules (tuberculosis), NUS",77116,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-06-20 00:00:00,National University of Singapore,20633,No Development Reported,2014-06-20 00:00:00,NDR,2,Respiratory disease,711
Bacterial protein synthesis inhibitor,1538,LOCAL_AND_MAJOR,Kaneka Corp,17639,Japan,JP,rifalazil,8658,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2014-10-30 00:00:00,Kaneka Corp,17639,Discontinued,2001-12-01 00:00:00,DX,3,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,GlaxoSmithKline plc,28355,UK,GB,BM-212,89603,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-07-20 00:00:00,GlaxoSmithKline plc,28355,Discovery,2012-07-20 00:00:00,DR,6,Respiratory disease,711
Bacterial protein synthesis inhibitor,1538,LOCAL_AND_MAJOR,ActivBiotics Pharma LLC,1071434,US,US,rifalazil,8658,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2014-10-30 00:00:00,ActivBiotics Pharma LLC,1071434,No Development Reported,2014-10-30 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,GlobalAcorn,1086420,UK,GB,GA3 MEP-TB,86658,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2015-04-17 00:00:00,GlobalAcorn,1086420,Discovery,2012-11-14 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,BioNet-Asia Co Ltd,1049946,Thailand,TH,"anti-tuberculosis vaccine, BioNet-Asia",91450,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-05-26 00:00:00,BioNet-Asia Co Ltd,1049946,Launched,2014-05-26 00:00:00,L,13,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Science & Technology Corporation @ UNM,28506,US,US,modified formulation of isoniazid (drug-resistant tuberculosis) University of New Mexico/Science & Technology Corporation @ UNM,88285,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-05-05 00:00:00,University of New Mexico,20639,Discovery,2013-05-05 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,National Institutes of Health,20518,US,US,"thiatetracosanoate analogs (Mycobacterium tuberculosis), National Institutes of Health",86055,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-02-01 00:00:00,US Government,20516,Discovery,2012-02-01 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,National Institutes of Health,20518,US,US,"thiatetracosanoate analogs (Mycobacterium tuberculosis), National Institutes of Health",86055,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-02-01 00:00:00,US Government,20516,Discovery,2012-02-01 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Montana State University,1002785,US,US,"antibacterial compounds (tuberculosis), Eli Lilly & Co/The University of Notre Dame du Lac/Montana State University/University of Illinois/Infectious Disease Research Institute",87600,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-09-11 00:00:00,Montana State University,1002785,Discovery,2013-09-11 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Infectious Disease Research Institute,27376,US,US,"antibacterial compounds (tuberculosis), Eli Lilly & Co/The University of Notre Dame du Lac/Montana State University/University of Illinois/Infectious Disease Research Institute",87600,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-09-11 00:00:00,Infectious Disease Research Institute,27376,Discovery,2013-09-11 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Eli Lilly & Co,17810,US,US,"antibacterial compounds (tuberculosis), Eli Lilly & Co/The University of Notre Dame du Lac/Montana State University/University of Illinois/Infectious Disease Research Institute",87600,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-09-11 00:00:00,Eli Lilly & Co,17810,Discovery,2011-03-23 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Science & Technology Corporation @ UNM,28506,US,US,"peptides (tuberculosis), University of New Mexico/Science & Technology Corporation @ UNM",88384,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-01-24 00:00:00,University of New Mexico,20639,Discovery,2011-01-24 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Science & Technology Corporation @ UNM,28506,US,US,"peptides (tuberculosis), University of New Mexico/Science & Technology Corporation @ UNM",88384,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-01-24 00:00:00,University of New Mexico,20639,Discovery,2011-01-24 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,University of Tennessee Research Foundation Office of Technology Transfer,1089655,US,US,"menA inhibitors (Mycobacterium tuberculosis), University of Tennessee/University of Tennessee Research Foundation Office of Technology Transfer",88391,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-11-04 00:00:00,University of Tennessee,26292,Discovery,2013-11-04 00:00:00,DR,6,Respiratory disease,711
DHNA octaprenyltransferase inhibitor,74361,LOCAL_AND_MAJOR,University of Tennessee,26292,US,US,"menA inhibitors (Mycobacterium tuberculosis), University of Tennessee/University of Tennessee Research Foundation Office of Technology Transfer",88391,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-11-04 00:00:00,University of Tennessee,26292,Discovery,2013-11-04 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,OTHER,Amneal Pharmaceutical LLC,1027030,India,IN,"antitubercular agents (tuberculosis), Amneal Pharmaceutical LLC/ Saurashtra University/Maharaja Krishnakumarsinhji Bhavnagar University",95732,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-08-28 00:00:00,Amneal Pharmaceutical LLC,1027030,Discovery,2013-08-28 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,Amneal Pharmaceutical LLC,1027030,India,IN,"antitubercular agents (tuberculosis), Amneal Pharmaceutical LLC/ Saurashtra University/Maharaja Krishnakumarsinhji Bhavnagar University",95732,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-08-28 00:00:00,Amneal Pharmaceutical LLC,1027030,Discovery,2013-08-28 00:00:00,DR,6,Respiratory disease,711
Vitamin K epoxide reductase inhibitor,10583,LOCAL_AND_MAJOR,Harvard University Office of Technology Development,1085770,US,US,"small molecule VKOR inhibitors (Mycobacterium tuberculosis infection), Harvard University/Harvard University Office of Technology Development",86119,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-02-01 00:00:00,Harvard University,20584,Discovery,2012-02-01 00:00:00,DR,6,Respiratory disease,711
RNA polymerase inhibitor,347,LOCAL_AND_MAJOR,Shenyang Hongqi Pharmaceutical Co Ltd,1075626,China,CN,"ethambutol hydrochloride (200 mg) + pyrazinamide (300 mg) + rifampicin (120 mg) + isoniazid (100 mg) (oral tablet, tuberculosis), Shenyang Hongqi Pharmaceutical/Liaoning Hongwuxing Pharmaceutical",88507,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-11-15 00:00:00,Shanghai Fosun Pharmaceutical (Group) Co Ltd,1015871,Discovery,2009-02-01 00:00:00,DR,6,Respiratory disease,711
Bacterial cell wall synthesis inhibitor,104,LOCAL_AND_MAJOR,Shenyang Hongqi Pharmaceutical Co Ltd,1075626,China,CN,"ethambutol hydrochloride (200 mg) + pyrazinamide (300 mg) + rifampicin (120 mg) + isoniazid (100 mg) (oral tablet, tuberculosis), Shenyang Hongqi Pharmaceutical/Liaoning Hongwuxing Pharmaceutical",88507,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-11-15 00:00:00,Shanghai Fosun Pharmaceutical (Group) Co Ltd,1015871,Discovery,2009-02-01 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,AstraZeneca plc,14190,UK,GB,"DprE1 inhibitors (Mycobacterium tuberculosis infection), AstraZeneca",90122,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-09-10 00:00:00,AstraZeneca plc,14190,Discovery,2013-09-10 00:00:00,DR,6,Respiratory disease,711
Bacterial protein synthesis inhibitor,1538,LOCAL_AND_MAJOR,Pharmacia & Upjohn Co,18995,US,US,rifabutin,4229,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2008-10-07 00:00:00,Pfizer Inc,18767,Phase 3 Clinical,1996-12-09 00:00:00,C3,10,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Aeras Global TB Vaccine Foundation,1007376,Denmark,DK,SSI H56-IC31,74849,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-11-08 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Discovery,2011-04-27 00:00:00,DR,6,Respiratory disease,711
Therapeutic vaccine,12379,OTHER,Aeras Global TB Vaccine Foundation,1007376,Denmark,DK,SSI H56-IC31,74849,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-11-08 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Discovery,2011-04-27 00:00:00,DR,6,Respiratory disease,711
Protein subunit vaccine,12372,OTHER,Aeras Global TB Vaccine Foundation,1007376,South Africa,ZA,SSI H56-IC31,74849,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-11-08 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 1 Clinical,2011-12-01 00:00:00,C1,8,Respiratory disease,711
Therapeutic vaccine,12379,OTHER,Valneva SE,1084202,South Africa,ZA,SSI H56-IC31,74849,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-11-08 00:00:00,Valneva SE,1084202,Phase 1 Clinical,2013-05-28 00:00:00,C1,8,Respiratory disease,711
Antiparasitic,2638,LOCAL_AND_MAJOR,Genzyme Corp,16299,US,US,"enoyl reductase inhibitors (antimicrobial), Genzyme",47123,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2004-05-25 00:00:00,Sanofi,1009547,Discovery,2002-11-25 00:00:00,DR,6,Respiratory disease,711
Bacterial cell wall synthesis inhibitor,104,LOCAL_AND_MAJOR,Shenyang Hongqi Pharmaceutical Co Ltd,1075626,China,CN,"ethambutol hydrochloride (250 mg) + pyrazinamide (400 mg) + rifampicin (120 mg) + isoniazid (120 mg) (fixed dose combination, tuberculosis), Shenyang Hongqi Pharmaceutical",82062,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2009-12-31 00:00:00,Shanghai Fosun Pharmaceutical (Group) Co Ltd,1015871,Registered,2009-05-22 00:00:00,R,12,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Shenyang Hongqi Pharmaceutical Co Ltd,1075626,China,CN,"ethambutol hydrochloride (250 mg) + pyrazinamide (400 mg) + rifampicin (120 mg) + isoniazid (120 mg) (fixed dose combination, tuberculosis), Shenyang Hongqi Pharmaceutical",82062,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2009-12-31 00:00:00,Shanghai Fosun Pharmaceutical (Group) Co Ltd,1015871,Launched,2009-12-31 00:00:00,L,13,Respiratory disease,711
Antibacterial,1594,OTHER,Sequella Inc,28087,UK,GB,"DNA vaccine (tuberculosis), NIMR/Sequella",22154,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-10-13 00:00:00,Sequella Inc,28087,No Development Reported,2008-10-13 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,OTHER,The Global Alliance for TB Drug Development,29411,South Africa,ZA,pretomanid,13323,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-09-05 00:00:00,The Global Alliance for TB Drug Development,29411,Phase 2 Clinical,2007-11-08 00:00:00,C2,9,Respiratory disease,711
Trypsin inhibitor,379,LOCAL_AND_MAJOR,Omni Bio Pharmaceutical Inc,1047826,US,US,"p-ATT (type 1/2 diabetes/influenza/tuberculosis/anthrax/HIV infection/transplant rejection/GVHD), Omni Bio",66767,Chemical,Phase 2 Clinical,Discovery,DR,C2,Mycobacterium tuberculosis infection,221,true,2013-01-31 00:00:00,Omni Bio Pharmaceutical Inc,1047826,Discovery,2010-08-06 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,GlaxoSmithKline plc,28355,US,US,"thiolactomycin analog, GlaxoSmithKline",33073,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-08-08 00:00:00,GlaxoSmithKline plc,28355,Discovery,2001-02-28 00:00:00,DR,6,Respiratory disease,711
Antibacterial multidrug resistance inhibitor,4855,LOCAL_AND_MAJOR,Pharmstandard OJSC,1047078,Russian Federation,RU,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Pharmstandard OJSC,1047078,Discovery,2013-01-25 00:00:00,DR,6,Respiratory disease,711
Antibacterial multidrug resistance inhibitor,4855,OTHER,Janssen Research & Development LLC,1067538,Japan,JP,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Discovery,2015-02-13 00:00:00,DR,6,Respiratory disease,711
ATP synthase inhibitor,49687,OTHER,Janssen Research & Development LLC,1067538,Japan,JP,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Discovery,2015-02-13 00:00:00,DR,6,Respiratory disease,711
Antibacterial multidrug resistance inhibitor,4855,OTHER,Janssen Research & Development LLC,1067538,South Africa,ZA,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Pre-registration,2013-06-17 00:00:00,PR,11,Respiratory disease,711
ATP synthase inhibitor,49687,LOCAL_AND_MAJOR,Janssen Research & Development LLC,1067538,US,US,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Launched,2013-04-19 00:00:00,L,13,Respiratory disease,711
ATP synthase inhibitor,49687,OTHER,Janssen Research & Development LLC,1067538,China,CN,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Pre-registration,2013-06-17 00:00:00,PR,11,Respiratory disease,711
Antibacterial multidrug resistance inhibitor,4855,OTHER,Janssen Research & Development LLC,1067538,EU,EU,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Registered,2014-03-06 00:00:00,R,12,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Pfizer Inc,18767,US,US,"antibiotic (tuberculosis), MicuRx/Cumencor/Pfizer",68345,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2010-04-06 00:00:00,Pfizer Inc,18767,Discovery,2010-04-06 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,St Jude Children's Research Hospital,21814,US,US,"thiolactomycin analog, GlaxoSmithKline",33073,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-08-08 00:00:00,St Jude Children's Research Hospital,21814,No Development Reported,2008-08-08 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,University of Bristol,20544,UK,GB,"Mycobacterium chaperonin inhibitors, University of Bristol",30799,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-03-20 00:00:00,University of Bristol,20544,Discovery,2000-09-27 00:00:00,DR,6,Respiratory disease,711
Antibacterial multidrug resistance inhibitor,4855,OTHER,Johnson & Johnson Pharmaceutical Research & Development LLC,29481,Belgium,BE,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,false,2015-03-18 00:00:00,Johnson & Johnson,17332,Phase 1 Clinical,2004-10-30 00:00:00,C1,8,Respiratory disease,711
Antibacterial,1594,OTHER,Searchlight Minerals Corp,29482,UK,GB,"tuberculosis therapy, Phage Genomics",39313,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2005-04-29 00:00:00,Searchlight Minerals Corp,29482,Discontinued,2005-04-29 00:00:00,DX,3,Respiratory disease,711
Nitric oxide donor,698,LOCAL_AND_MAJOR,Chiron PathoGenesis,18741,US,US,pretomanid,13323,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-09-05 00:00:00,Novartis AG,23137,Discovery,2000-06-26 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Microbion Corp,1055897,US,US,MBS-103,68316,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-09-25 00:00:00,Microbion Corp,1055897,No Development Reported,2013-09-25 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Chiron PathoGenesis,18741,US,US,PA-647,11233,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,1996-10-01 00:00:00,Novartis AG,23137,Discontinued,1996-10-01 00:00:00,DX,3,Respiratory disease,711
Unspecified enzyme stimulator,1052,LOCAL_AND_MAJOR,Procrysta Biologix Inc,1080144,US,US,PCB-101,83811,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-04-18 00:00:00,Procrysta Biologix Inc,1080144,Discovery,2011-03-14 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,OTHER,Novartis Institute for Tropical Diseases Pvt Ltd,1017949,Singapore,SG,"small molecule therapeutics (Mycobacterium tuberculosis infection), ChemDiv Research Institute/Novartis Institute for Tropical Diseases/Silvius Pharma",76796,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2014-08-14 00:00:00,Novartis AG,23137,Discontinued,2014-08-14 00:00:00,DX,3,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,UK National Institute of Medical Research,20466,UK,GB,"DNA vaccine (tuberculosis), NIMR/Sequella",22154,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-10-13 00:00:00,Medical Research Council (MRC),18438,No Development Reported,2008-10-13 00:00:00,NDR,2,Respiratory disease,711
Aminoglycoside antibiotic,1541,OTHER,UMeWorld Ltd,28431,Canada,CA,"streptomycin (nanoparticle encapsulated, tuberculosis), AlphaRx",56894,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2011-08-02 00:00:00,UMeWorld Ltd,28431,No Development Reported,2011-08-02 00:00:00,NDR,2,Respiratory disease,711
Systemic antipsoriatic product,15184,LOCAL_AND_MAJOR,LeukoMed Inc,30043,US,US,LMP-420,41819,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2009-03-16 00:00:00,LeukoMed Inc,30043,Discovery,2002-09-26 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,University of Illinois,20592,US,US,"tuberculosis therapy, TB Alliance/Johns Hopkins University",82716,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2013-06-30 00:00:00,University of Illinois,20592,Discovery,2012-11-30 00:00:00,DR,6,Respiratory disease,711
Therapeutic vaccine,12379,OTHER,Immodulon Therapeutics Limited,1051823,Argentina,AR,"heat-killed Mycobacterium vaccae (tablet formulation, tuberculosis), Immunitor",70934,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-26 00:00:00,Immodulon Therapeutics Limited,1051823,Clinical,2010-03-31 00:00:00,CU,7,Respiratory disease,711
Inactivated bacterial vaccine,12366,OTHER,Immodulon Therapeutics Limited,1051823,Argentina,AR,"heat-killed Mycobacterium vaccae (tablet formulation, tuberculosis), Immunitor",70934,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-26 00:00:00,Immodulon Therapeutics Limited,1051823,No Development Reported,2014-03-26 00:00:00,NDR,2,Respiratory disease,711
RNA polymerase inhibitor,347,LOCAL_AND_MAJOR,Nanosystem Ltd,1071336,Russian Federation,RU,"rifampicin nanoparticles (tuberculosis), NPK Nanosistema",81330,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-06-27 00:00:00,Nanosystem Ltd,1071336,No Development Reported,2014-06-27 00:00:00,NDR,2,Respiratory disease,711
Bacterial nucleic acid synthesis inhibitor,3984,LOCAL_AND_MAJOR,Nanosystem Ltd,1071336,Russian Federation,RU,"rifampicin nanoparticles (tuberculosis), NPK Nanosistema",81330,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-06-27 00:00:00,Nanosystem Ltd,1071336,No Development Reported,2014-06-27 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Biowest Therapeutics Inc,18210,Canada,CA,Penetrin-A,9087,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2001-06-11 00:00:00,Biowest Therapeutics Inc,18210,Discovery,1994-07-01 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Biowest Therapeutics Inc,18210,Canada,CA,Penetrin-A,9087,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2001-06-11 00:00:00,Biowest Therapeutics Inc,18210,No Development Reported,2001-06-11 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Biowest Therapeutics Inc,18210,Canada,CA,Penetrin-A,9087,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2001-06-11 00:00:00,Biowest Therapeutics Inc,18210,No Development Reported,2001-06-11 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Sequella Inc,28087,US,US,"TL1 inhibitors (tuberculosis infection), Sequella",71741,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2009-11-13 00:00:00,Sequella Inc,28087,Discovery,2009-11-13 00:00:00,DR,6,Respiratory disease,711
DNA gyrase inhibitor,431,OTHER,Dainippon Pharmaceutical Co Ltd,15606,China,CN,sparfloxacin,4439,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,1999-12-31 00:00:00,Sumitomo Chemical Co Ltd,20268,Registered,1999-11-20 00:00:00,R,12,Respiratory disease,711
Ubiquinol cytochrome C reductase 14 kDa inhibitor,30365,LOCAL_AND_MAJOR,Qurient Therapeutics,1062405,US,US,"Q-203, Qurient / Infectex",85970,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-02-06 00:00:00,Qurient Therapeutics,1062405,Discovery,2013-06-05 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Finlay Institute,15912,Cuba,CU,"polyclonal antibodies (Mycobacterium tuberculosis infection), Finlay Institute",73038,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-08-09 00:00:00,Finlay Institute,15912,Discovery,2011-08-09 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,T-Biovax,67683,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-10-17 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Discovery,2010-08-11 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Medical Research Council Technology,1054893,UK,GB,"UvrD helicase inhibitors (Mycobacterium tuberculosis infection), MRCT",66922,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-06-21 00:00:00,Medical Research Council (MRC),18438,Discovery,2010-06-17 00:00:00,DR,6,Respiratory disease,711
Anticancer,1545,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Philippines,PH,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 2 Clinical,2008-04-30 00:00:00,C2,9,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Otsuka Pharmaceutical Co Ltd,18717,Japan,JP,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 1 Clinical,2005-12-19 00:00:00,C1,8,Respiratory disease,711
Angiogenesis inhibitor,61,LOCAL_AND_MAJOR,Otsuka Pharmaceutical Co Ltd,18717,Japan,JP,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 1 Clinical,2005-12-19 00:00:00,C1,8,Respiratory disease,711
Mycolic acid synthase inhibitor,6542,LOCAL_AND_MAJOR,Otsuka Pharmaceutical Co Ltd,18717,Japan,JP,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 3 Clinical,2011-12-31 00:00:00,C3,10,Respiratory disease,711
Angiogenesis inhibitor,61,LOCAL_AND_MAJOR,Otsuka Pharmaceutical Co Ltd,18717,Japan,JP,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Pre-registration,2013-03-27 00:00:00,PR,11,Respiratory disease,711
Anti-inflammatory,2953,LOCAL_AND_MAJOR,Otsuka Pharmaceutical Co Ltd,18717,Japan,JP,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 2 Clinical,2008-04-30 00:00:00,C2,9,Respiratory disease,711
Angiogenesis inhibitor,61,LOCAL_AND_MAJOR,Otsuka Pharmaceutical Co Ltd,18717,Japan,JP,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 2 Clinical,2008-04-30 00:00:00,C2,9,Respiratory disease,711
Angiogenesis inhibitor,61,OTHER,Otsuka Pharmaceutical Co Ltd,18717,South Africa,ZA,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 2 Clinical,2006-11-30 00:00:00,C2,9,Respiratory disease,711
Mycolic acid synthase inhibitor,6542,OTHER,Otsuka Pharmaceutical Co Ltd,18717,South Africa,ZA,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 2 Clinical,2006-11-30 00:00:00,C2,9,Respiratory disease,711
Anticancer,1545,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Estonia,EE,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 2 Clinical,2008-04-30 00:00:00,C2,9,Respiratory disease,711
Antibacterial,1594,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Estonia,EE,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 2 Clinical,2008-04-30 00:00:00,C2,9,Respiratory disease,711
Angiogenesis inhibitor,61,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Lithuania,LT,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 3 Clinical,2011-09-19 00:00:00,C3,10,Respiratory disease,711
Antibacterial,1594,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Estonia,EE,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 3 Clinical,2011-09-19 00:00:00,C3,10,Respiratory disease,711
Antibacterial,1594,OTHER,Otsuka Pharmaceutical Co Ltd,18717,EU,EU,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Registered,2014-04-28 00:00:00,R,12,Respiratory disease,711
Antibacterial,1594,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Philippines,PH,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 3 Clinical,2013-07-26 00:00:00,C3,10,Respiratory disease,711
Angiogenesis inhibitor,61,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Philippines,PH,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 3 Clinical,2013-07-26 00:00:00,C3,10,Respiratory disease,711
Antibacterial,1594,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Egypt,EG,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 2 Clinical,2008-04-30 00:00:00,C2,9,Respiratory disease,711
Mycolic acid synthase inhibitor,6542,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Egypt,EG,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 2 Clinical,2008-04-30 00:00:00,C2,9,Respiratory disease,711
Antibacterial,1594,OTHER,Otsuka Pharmaceutical Co Ltd,18717,UK,GB,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Launched,2014-05-31 00:00:00,L,13,Respiratory disease,711
Angiogenesis inhibitor,61,OTHER,Otsuka Pharmaceutical Co Ltd,18717,UK,GB,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Launched,2014-05-31 00:00:00,L,13,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Vakzine Projekt Management GmbH,1020740,Germany,DE,VPM-1002,55569,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-03-27 00:00:00,Vakzine Projekt Management GmbH,1020740,No Development Reported,2013-03-27 00:00:00,NDR,2,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Vakzine Projekt Management GmbH,1020740,Germany,DE,VPM-1002,55569,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-03-27 00:00:00,Vakzine Projekt Management GmbH,1020740,Discovery,2004-03-24 00:00:00,DR,6,Respiratory disease,711
Listeriolysin stimulator,14513,LOCAL_AND_MAJOR,Vakzine Projekt Management GmbH,1020740,Germany,DE,VPM-1002,55569,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-03-27 00:00:00,Vakzine Projekt Management GmbH,1020740,Discovery,2004-03-24 00:00:00,DR,6,Respiratory disease,711
Hsp 60 family stimulator,7996,LOCAL_AND_MAJOR,GenomIdea Inc,1008113,Japan,JP,"DNA vaccines (HJV vector, tuberculosis), GenomIdea",60030,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2007-04-20 00:00:00,AnGes MG Inc,28514,Discovery,2007-04-20 00:00:00,DR,6,Respiratory disease,711
Live attenuated bacterial vaccine,12363,LOCAL_AND_MAJOR,Universidad de Zaragoza,25210,Spain,ES,MTBVAC,89744,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-11-15 00:00:00,Universidad de Zaragoza,25210,Discovery,2011-05-25 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Universidad de Zaragoza,25210,Spain,ES,MTBVAC,89744,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-11-15 00:00:00,Universidad de Zaragoza,25210,Discovery,2011-05-25 00:00:00,DR,6,Respiratory disease,711
Live attenuated bacterial vaccine,12363,OTHER,Universidad de Zaragoza,25210,Switzerland,CH,MTBVAC,89744,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-11-15 00:00:00,Universidad de Zaragoza,25210,Phase 1 Clinical,2013-01-31 00:00:00,C1,8,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,"mucosal vaccines (rhPIV2 vector/nasal, tuberculosis), NIBIO/Aeras/Create Vaccine",89879,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-12-26 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Discovery,2013-12-26 00:00:00,DR,6,Respiratory disease,711
Recombinant viral vector vaccine,12370,LOCAL_AND_MAJOR,National Institute of Biomedical Innovation,1031352,Japan,JP,"mucosal vaccines (rhPIV2 vector/nasal, tuberculosis), NIBIO/Aeras/Create Vaccine",89879,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-12-26 00:00:00,National Institute of Biomedical Innovation,1031352,Discovery,2013-12-26 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,The Vavilov Institute of General Genetics,1073514,Russian Federation,RU,"microbacterial protein kinase inhibitors (tuberculosis infection), The Vavilov Institute of General Genetics",81211,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-09-24 00:00:00,The Vavilov Institute of General Genetics,1073514,Discovery,2012-06-21 00:00:00,DR,6,Respiratory disease,711
Protein kinase inhibitor,336,LOCAL_AND_MAJOR,The Vavilov Institute of General Genetics,1073514,Russian Federation,RU,"microbacterial protein kinase inhibitors (tuberculosis infection), The Vavilov Institute of General Genetics",81211,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-09-24 00:00:00,The Vavilov Institute of General Genetics,1073514,Discovery,2012-06-21 00:00:00,DR,6,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,Pohang University of Science & Technology,25083,South Korea,KR,"therapeutic DNA vaccine (tuberculosis), Pohang/Yonsei Universities",53019,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2009-12-24 00:00:00,Pohang University of Science & Technology,25083,Discovery,2003-09-30 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,OTHER,PharMida AG,1043700,Switzerland,CH,"targeted gold nanoparticle (Mycobacterium tuberculosis infection), Midatech",66235,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-02-06 00:00:00,Midatech Ltd,1011432,No Development Reported,2013-02-06 00:00:00,NDR,2,Respiratory disease,711
Mycobacterial antigen complex 85A modulator,33967,LOCAL_AND_MAJOR,Shanghai H&G Biotechnology Co,1066720,China,CN,HG856-SeV,75156,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-17 00:00:00,Shanghai H&G Biotechnology Co,1066720,Discovery,2009-12-31 00:00:00,DR,6,Respiratory disease,711
Protein subunit vaccine,12372,LOCAL_AND_MAJOR,Shanghai H&G Biotechnology Co,1066720,China,CN,HG856-SeV,75156,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-17 00:00:00,Shanghai H&G Biotechnology Co,1066720,No Development Reported,2013-01-17 00:00:00,NDR,2,Respiratory disease,711
DNA vaccine,1879,LOCAL_AND_MAJOR,Yonsei University,25184,South Korea,KR,"therapeutic DNA vaccine (tuberculosis), Pohang/Yonsei Universities",53019,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2009-12-24 00:00:00,Yonsei University,25184,Discovery,2003-09-30 00:00:00,DR,6,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,Yonsei University,25184,South Korea,KR,"therapeutic DNA vaccine (tuberculosis), Pohang/Yonsei Universities",53019,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2009-12-24 00:00:00,Yonsei University,25184,No Development Reported,2009-12-24 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,PolyMedix Inc,1011746,US,US,"SMAMPs (malaria), Fox Chase Chemical Diversity Center",62968,Chemical,Discovery,No Development Reported,NDR,DR,Mycobacterium tuberculosis infection,221,false,2013-09-09 00:00:00,PolyMedix Inc,1011746,No Development Reported,2011-02-09 00:00:00,NDR,2,Respiratory disease,711
Antiparasitic,2638,LOCAL_AND_MAJOR,PolyMedix Inc,1011746,US,US,"SMAMPs (malaria), Fox Chase Chemical Diversity Center",62968,Chemical,Discovery,No Development Reported,NDR,DR,Mycobacterium tuberculosis infection,221,false,2013-09-09 00:00:00,PolyMedix Inc,1011746,No Development Reported,2011-02-09 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Genvax Ltd,1015643,UK,GB,"DNA vaccine (Mycobacterium tuberculosis infection), Genvax",57745,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2009-09-07 00:00:00,Medical Marketing International Group plc,1003702,No Development Reported,2009-09-07 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"pleuromutilin derivatives (tuberculosis), GlaxoSmithKline/The Global Alliance for TB Drug Development",56410,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-06-18 00:00:00,The Global Alliance for TB Drug Development,29411,No Development Reported,2012-06-18 00:00:00,NDR,2,Respiratory disease,711
Immunostimulant,393,LOCAL_AND_MAJOR,SciClone Pharmaceuticals Inc,19829,US,US,"golotimod (oral), SciClone/Verta",55521,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2011-10-10 00:00:00,SciClone Pharmaceuticals Inc,19829,Phase 1 Clinical,2006-05-25 00:00:00,C1,8,Respiratory disease,711
Immunostimulant,393,LOCAL_AND_MAJOR,SciClone Pharmaceuticals Inc,19829,US,US,"golotimod (oral), SciClone/Verta",55521,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2011-10-10 00:00:00,SciClone Pharmaceuticals Inc,19829,Discovery,1999-08-26 00:00:00,DR,6,Respiratory disease,711
Fungicide,1748,LOCAL_AND_MAJOR,InterMune Inc,26430,US,US,Actimmune,3365,Biological,Launched,No Development Reported,NDR,L,Mycobacterium tuberculosis infection,221,false,2014-09-19 00:00:00,Roche Holding AG,19446,No Development Reported,2007-03-31 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Chiron PathoGenesis,18741,US,US,PA-342,10997,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,1996-11-01 00:00:00,Novartis AG,23137,Discontinued,1996-11-01 00:00:00,DX,3,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,GlaxoSmithKline plc,28355,UK,GB,"pleuromutilin derivatives (tuberculosis), GlaxoSmithKline/The Global Alliance for TB Drug Development",56410,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-06-18 00:00:00,GlaxoSmithKline plc,28355,Discovery,2005-03-21 00:00:00,DR,6,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,ApoVax Inc,29552,US,US,ApoVax104-TB,68211,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2015-01-05 00:00:00,ApoVax Inc,29552,Discovery,2008-08-31 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,ApoVax Inc,29552,US,US,ApoVax104-TB,68211,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2015-01-05 00:00:00,ApoVax Inc,29552,No Development Reported,2015-01-05 00:00:00,NDR,2,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Merck & Co Inc,18077,US,US,"vaccine (naked DNA, TB), Merck & Co",17424,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-03-03 00:00:00,Merck & Co Inc,18077,No Development Reported,2008-03-03 00:00:00,NDR,2,Respiratory disease,711
Ribosome binding agent,463,OTHER,Sequella Inc,28087,South Africa,ZA,sutezolid,11088,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-07-17 00:00:00,Sequella Inc,28087,Phase 2 Clinical,2013-07-17 00:00:00,C2,9,Respiratory disease,711
Subunit vaccine,12371,OTHER,GlaxoSmithKline plc,28355,Switzerland,CH,"MTB72F vaccine (tuberculosis), GSK/Aeras",9490,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-08-26 00:00:00,GlaxoSmithKline plc,28355,Phase 2 Clinical,2000-09-30 00:00:00,C2,9,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,"MTB72F vaccine (tuberculosis), GSK/Aeras",9490,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-08-26 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Discovery,2005-10-20 00:00:00,DR,6,Respiratory disease,711
Subunit vaccine,12371,LOCAL_AND_MAJOR,TB-VAC,1020621,Netherlands,NL,"MTB72F vaccine (tuberculosis), GSK/Aeras",9490,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-08-26 00:00:00,TB-VAC,1020621,Discovery,2006-04-22 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Verta Ltd,1004196,Russian Federation,RU,golotimod,25023,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2013-11-12 00:00:00,Verta Ltd,1004196,Phase 2 Clinical,2002-09-28 00:00:00,C2,9,Respiratory disease,711
Cytokine synthesis stimulator,938,LOCAL_AND_MAJOR,Verta Ltd,1004196,Russian Federation,RU,golotimod,25023,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2013-11-12 00:00:00,Verta Ltd,1004196,Phase 2 Clinical,2002-09-28 00:00:00,C2,9,Respiratory disease,711
Antiviral,991,LOCAL_AND_MAJOR,Verta Ltd,1004196,Russian Federation,RU,golotimod,25023,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2013-11-12 00:00:00,Verta Ltd,1004196,Phase 2 Clinical,2002-09-28 00:00:00,C2,9,Respiratory disease,711
Fungicide,1748,LOCAL_AND_MAJOR,Sequella Inc,28087,US,US,SQ-109,31010,Chemical,Phase 3 Clinical,Phase 3 Clinical,C3,C3,Mycobacterium tuberculosis infection,221,true,2012-12-19 00:00:00,Sequella Inc,28087,Phase 1 Clinical,2006-09-30 00:00:00,C1,8,Respiratory disease,711
Cell wall synthesis inhibitor,7052,LOCAL_AND_MAJOR,Infectex,1068619,Russian Federation,RU,SQ-109,31010,Chemical,Phase 3 Clinical,Phase 3 Clinical,C3,C3,Mycobacterium tuberculosis infection,221,true,2012-12-19 00:00:00,Maxwell Biotech Group,1061894,Discovery,2011-04-25 00:00:00,DR,6,Respiratory disease,711
Fungicide,1748,LOCAL_AND_MAJOR,Infectex,1068619,Russian Federation,RU,SQ-109,31010,Chemical,Phase 3 Clinical,Phase 3 Clinical,C3,C3,Mycobacterium tuberculosis infection,221,true,2012-12-19 00:00:00,Maxwell Biotech Group,1061894,Phase 3 Clinical,2012-12-19 00:00:00,C3,10,Respiratory disease,711
Recombinant viral vector vaccine,12370,OTHER,Crucell NV,17254,South Africa,ZA,AERAS-402,53975,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2010-09-22 00:00:00,Johnson & Johnson,17332,Phase 1 Clinical,2007-05-11 00:00:00,C1,8,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Aeras Global TB Vaccine Foundation,1007376,South Africa,ZA,AERAS-402,53975,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2010-09-22 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 1 Clinical,2007-05-11 00:00:00,C1,8,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Aeras Global TB Vaccine Foundation,1007376,South Africa,ZA,AERAS-402,53975,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2010-09-22 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 2 Clinical,2008-10-17 00:00:00,C2,9,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Polymun Scientific Immunobiologische Forschung GmbH,21851,Austria,AT,"tuberculosis vaccine (nasal, influenza virus carrier), Polymun",54201,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-06-10 00:00:00,Polymun Scientific Immunobiologische Forschung GmbH,21851,Discovery,2005-09-15 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,GlobeImmune Inc,28802,US,US,GI-19000,86853,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-08-22 00:00:00,GlobeImmune Inc,28802,Discovery,2013-06-13 00:00:00,DR,6,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,GlobeImmune Inc,28802,US,US,GI-19000,86853,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-08-22 00:00:00,GlobeImmune Inc,28802,Discovery,2013-06-13 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,GlobeImmune Inc,28802,US,US,GI-19000,86853,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-08-22 00:00:00,GlobeImmune Inc,28802,Discovery,2013-06-13 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,SciClone Pharmaceuticals Inc,19829,US,US,golotimod,25023,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,false,2013-11-12 00:00:00,SciClone Pharmaceuticals Inc,19829,Phase 2 Clinical,2008-08-28 00:00:00,C2,9,Respiratory disease,711
Antiviral,991,LOCAL_AND_MAJOR,SciClone Pharmaceuticals Inc,19829,US,US,golotimod,25023,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,false,2013-11-12 00:00:00,SciClone Pharmaceuticals Inc,19829,Phase 2 Clinical,2008-08-28 00:00:00,C2,9,Respiratory disease,711
Antiviral,991,LOCAL_AND_MAJOR,SciClone Pharmaceuticals Inc,19829,US,US,golotimod,25023,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,false,2013-11-12 00:00:00,SciClone Pharmaceuticals Inc,19829,Phase 1 Clinical,2005-08-08 00:00:00,C1,8,Respiratory disease,711
Androgen receptor agonist,59,OTHER,Harbor Therapeutics Inc,24345,Mexico,MX,HE-2000,19980,Chemical,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2013-01-28 00:00:00,Harbor Therapeutics Inc,24345,No Development Reported,2013-01-28 00:00:00,NDR,2,Respiratory disease,711
Topoisomerase I inhibitor,141,LOCAL_AND_MAJOR,New York Medical College,23270,US,US,"topoisomerase I inhibitors (tuberculosis infection), TB Alliance/NYMC/AZ",71897,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-06-27 00:00:00,New York University,20646,Discovery,2009-05-27 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,AERAS-405,59144,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-09-18 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Discovery,2006-04-21 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Korea Research Institute of Chemical Technology,17684,South Korea,KR,"quinolone analogs (Mycobacterium tuberculosis), KRICT/TB Alliance",57730,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-11-30 00:00:00,Korea Research Institute of Chemical Technology,17684,No Development Reported,2012-11-30 00:00:00,NDR,2,Respiratory disease,711
DNA gyrase inhibitor,431,LOCAL_AND_MAJOR,Korea Research Institute of Chemical Technology,17684,South Korea,KR,"quinolone analogs (Mycobacterium tuberculosis), KRICT/TB Alliance",57730,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-11-30 00:00:00,Korea Research Institute of Chemical Technology,17684,No Development Reported,2012-11-30 00:00:00,NDR,2,Respiratory disease,711
Bacterial cell wall synthesis inhibitor,104,LOCAL_AND_MAJOR,INSERM Transfert,1035636,France,FR,"L,D-transpeptidase inhibitors (Mycobacterium tuberculosis infection), INSERM",78290,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-05-24 00:00:00,INSERM,17229,Discovery,2012-05-24 00:00:00,DR,6,Respiratory disease,711
Topoisomerase I inhibitor,141,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"topoisomerase I inhibitors (tuberculosis infection), TB Alliance/NYMC/AZ",71897,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-06-27 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2009-05-27 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Pro Bono Bio,1068320,UK,GB,"anti-tuberculosis therapeutics, Pro Bono Bio",76813,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-07-17 00:00:00,Pro Bono Bio,1068320,No Development Reported,2014-07-17 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Pro Bono Bio,1068320,UK,GB,"anti-tuberculosis therapeutics, Pro Bono Bio",76813,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-07-17 00:00:00,Pro Bono Bio,1068320,No Development Reported,2014-07-17 00:00:00,NDR,2,Respiratory disease,711
Therapeutic vaccine,12379,OTHER,Institut Pasteur,17237,Sweden,SE,"multivalent vaccine (Bera-V, Mycobacterium tuberculosis infection), Abera Bioscience/Statens Serum/Institut Pasteur",89342,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-12-20 00:00:00,Institut Pasteur,17237,Discovery,2013-12-20 00:00:00,DR,6,Respiratory disease,711
Therapeutic vaccine,12379,OTHER,Statens Serum Institut,21502,Sweden,SE,"multivalent vaccine (Bera-V, Mycobacterium tuberculosis infection), Abera Bioscience/Statens Serum/Institut Pasteur",89342,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-12-20 00:00:00,Statens Serum Institut,21502,Discovery,2013-12-20 00:00:00,DR,6,Respiratory disease,711
Antiviral,991,LOCAL_AND_MAJOR,Sarawak MediChem Pharmaceuticals Inc,24735,US,US,(+)-calanolide A,9539,Chemical,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2010-09-20 00:00:00,Sarawak State Government,29393,Discovery,2002-06-20 00:00:00,DR,6,Respiratory disease,711
Non-nucleoside reverse transcriptase inhibitor,1833,LOCAL_AND_MAJOR,Sarawak MediChem Pharmaceuticals Inc,24735,US,US,(+)-calanolide A,9539,Chemical,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2010-09-20 00:00:00,Sarawak State Government,29393,No Development Reported,2010-09-20 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Vertex Pharmaceuticals Inc,20739,US,US,"anti-tuberculosis therapeutics, Vertex Pharmaceuticals",89966,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-06-12 00:00:00,Vertex Pharmaceuticals Inc,20739,Discovery,2013-06-12 00:00:00,DR,6,Respiratory disease,711
DXP reductoisomerase inhibitor,6324,LOCAL_AND_MAJOR,The Lilly TB Drug Discovery Initiative,1042702,US,US,"inhibitors of isoprenoid biosynthesis enzymes (tuberculosis infection), The Lilly TB Drug Discovery Initiative/Colorado State University",89970,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-08-30 00:00:00,The Lilly TB Drug Discovery Initiative,1042702,Discovery,2011-08-30 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Finlay Institute,15912,Cuba,CU,"alpha crystallin inhibiting IgA mAbs (tuberculosis infection), Finlay Institute",72912,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-09-25 00:00:00,Finlay Institute,15912,No Development Reported,2013-09-25 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,BioVersys AG,1052531,Switzerland,CH,"EthR inhibitors (mycobacterium tuberculosis), BioVersys/ University of Lille/ GSK",92193,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-05-27 00:00:00,BioVersys AG,1052531,Discovery,2014-05-27 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,"Indian Institute of Integrative Medicine, Jammu",1058778,India,IN,"rifampicin + isoniazid + piperine (fixed dose combination, tuberculosis), Cadila Pharmaceuticals",69440,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,false,2009-10-31 00:00:00,Council of Scientific and Industrial Research (India),15561,Discontinued,2009-10-31 00:00:00,DX,3,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,University of Illinois,20592,US,US,TBI-166,57790,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2014-12-22 00:00:00,University of Illinois,20592,Discovery,2011-03-28 00:00:00,DR,6,Respiratory disease,711
Arabinosyltransferase inhibitor,6676,LOCAL_AND_MAJOR,Ohio State University,20649,US,US,"tuberculosis therapy, Ohio State University",17342,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2009-12-24 00:00:00,Ohio State University,20649,Discovery,1998-03-03 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Ohio State University,20649,US,US,"tuberculosis therapy, Ohio State University",17342,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2009-12-24 00:00:00,Ohio State University,20649,No Development Reported,2009-12-24 00:00:00,NDR,2,Respiratory disease,711
Putative membrane protein mmpL3 inhibitor,85843,OTHER,Novartis Institute for Tropical Diseases Pvt Ltd,1017949,Singapore,SG,"mycobacterial membrane protein large type 3 inhibitors (tuberculosis), TB Alliance",89552,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2014-08-20 00:00:00,Novartis AG,23137,Discontinued,2014-08-20 00:00:00,DX,3,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,"rBCG30, UCLA",9831,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,false,2014-07-07 00:00:00,Aeras Global TB Vaccine Foundation,1007376,No Development Reported,2012-09-21 00:00:00,NDR,2,Respiratory disease,711
Ribosome binding agent,463,OTHER,Pfizer Inc,18767,Europe,X5,sutezolid,11088,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2013-07-17 00:00:00,Pfizer Inc,18767,Discovery,2011-04-11 00:00:00,DR,6,Respiratory disease,711
Ribosome binding agent,463,OTHER,Pfizer Inc,18767,South Africa,ZA,sutezolid,11088,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2013-07-17 00:00:00,Pfizer Inc,18767,Phase 2 Clinical,2011-08-11 00:00:00,C2,9,Respiratory disease,711
Ribosome binding agent,463,OTHER,Pfizer Inc,18767,South Africa,ZA,sutezolid,11088,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2013-07-17 00:00:00,Pfizer Inc,18767,Discontinued,2013-07-17 00:00:00,DX,3,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,SRI International,20234,US,US,"replicating and nonreplicating Mycobacterium tuberculosis inhibitors (tuberculosis), SRI International/University of Illinois",82340,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-07-25 00:00:00,SRI International,20234,Discovery,2012-01-27 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,University of Illinois,20592,US,US,"replicating and nonreplicating Mycobacterium tuberculosis inhibitors (tuberculosis), SRI International/University of Illinois",82340,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-07-25 00:00:00,University of Illinois,20592,Discovery,2012-01-27 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,Silence Therapeutics plc,22356,Tanzania,TZ,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,2003-05-06 00:00:00,DX,3,Respiratory disease,711
Antimicrobial,1593,OTHER,Silence Therapeutics plc,22356,Tanzania,TZ,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,2003-05-06 00:00:00,DX,3,Respiratory disease,711
Cytokine release modulator,1291,OTHER,Silence Therapeutics plc,22356,Tanzania,TZ,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,2003-05-06 00:00:00,DX,3,Respiratory disease,711
Antiviral,991,OTHER,Silence Therapeutics plc,22356,Romania,RO,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Antibacterial,1594,OTHER,Silence Therapeutics plc,22356,Romania,RO,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Anticancer,1545,OTHER,Silence Therapeutics plc,22356,Romania,RO,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Inactivated bacterial vaccine,12366,OTHER,Silence Therapeutics plc,22356,Romania,RO,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Anticancer,1545,OTHER,Silence Therapeutics plc,22356,Nigeria,NG,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Antimicrobial,1593,OTHER,Silence Therapeutics plc,22356,Kuwait,KW,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Inactivated bacterial vaccine,12366,OTHER,Silence Therapeutics plc,22356,Kuwait,KW,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Therapeutic vaccine,12379,OTHER,Silence Therapeutics plc,22356,Gambia,GM,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Antimicrobial,1593,OTHER,Silence Therapeutics plc,22356,Tanzania,TZ,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,2001-09-30 00:00:00,C2,9,Respiratory disease,711
Inactivated bacterial vaccine,12366,OTHER,Silence Therapeutics plc,22356,Gambia,GM,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 3 Clinical,1997-10-13 00:00:00,C3,10,Respiratory disease,711
Adjuvant,524,OTHER,Silence Therapeutics plc,22356,South Africa,ZA,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 3 Clinical,1995-10-12 00:00:00,C3,10,Respiratory disease,711
Antimicrobial,1593,LOCAL_AND_MAJOR,Silence Therapeutics plc,22356,UK,GB,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,1995-10-12 00:00:00,C2,9,Respiratory disease,711
Anticancer,1545,LOCAL_AND_MAJOR,Silence Therapeutics plc,22356,UK,GB,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,1995-10-12 00:00:00,C2,9,Respiratory disease,711
Cytokine release modulator,1291,LOCAL_AND_MAJOR,Silence Therapeutics plc,22356,UK,GB,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,1995-10-12 00:00:00,C2,9,Respiratory disease,711
Inactivated bacterial vaccine,12366,LOCAL_AND_MAJOR,Silence Therapeutics plc,22356,UK,GB,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,1995-10-12 00:00:00,C2,9,Respiratory disease,711
Antiviral,991,OTHER,Silence Therapeutics plc,22356,Kuwait,KW,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,1995-10-12 00:00:00,C2,9,Respiratory disease,711
Antibacterial,1594,OTHER,Silence Therapeutics plc,22356,Kuwait,KW,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,1995-10-12 00:00:00,C2,9,Respiratory disease,711
Antimicrobial,1593,OTHER,Silence Therapeutics plc,22356,Kuwait,KW,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,1995-10-12 00:00:00,C2,9,Respiratory disease,711
Systemic antipsoriatic product,15184,OTHER,Silence Therapeutics plc,22356,Romania,RO,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,1995-10-12 00:00:00,C2,9,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Trustees of Health & Hospitals of The City of Boston,21398,US,US,"vaccine (BCG), Connaught/Whitehead",12124,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2001-08-24 00:00:00,Trustees of Health & Hospitals of The City of Boston,21398,No Development Reported,2001-08-24 00:00:00,NDR,2,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Massachusetts Institute of Technology,18225,US,US,"vaccine (BCG), Connaught/Whitehead",12124,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2001-08-24 00:00:00,Massachusetts Institute of Technology,18225,No Development Reported,2001-08-24 00:00:00,NDR,2,Respiratory disease,711
Aminoglycoside antibiotic,1541,LOCAL_AND_MAJOR,Chiron Corp,15385,US,US,"tobramycin (nebulized), Novartis",11232,Chemical,Launched,No Development Reported,NDR,L,Mycobacterium tuberculosis infection,221,false,2013-01-09 00:00:00,Novartis AG,23137,No Development Reported,2004-02-02 00:00:00,NDR,2,Respiratory disease,711
Surfactant,1610,LOCAL_AND_MAJOR,CytRx Corporation,15585,US,US,CRL-1018,11007,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,1995-09-27 00:00:00,CytRx Corporation,15585,Discontinued,1995-09-27 00:00:00,DX,3,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,CytRx Corporation,15585,US,US,CRL-1018,11007,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,1995-09-27 00:00:00,CytRx Corporation,15585,Discontinued,1995-09-27 00:00:00,DX,3,Respiratory disease,711
Ribosome binding agent,463,LOCAL_AND_MAJOR,PathoGenesis Ltd,24982,US,US,"tobramycin (nebulized), Novartis",11232,Chemical,Launched,No Development Reported,NDR,L,Mycobacterium tuberculosis infection,221,true,2013-01-09 00:00:00,Novartis AG,23137,Phase 2 Clinical,1997-10-14 00:00:00,C2,9,Respiratory disease,711
DHFR inhibitor,135,LOCAL_AND_MAJOR,Duquesne University,20569,US,US,"dihydrofolate reductase inhibitors, Duquesne/Indiana",12146,Chemical,Discovery,No Development Reported,NDR,DR,Mycobacterium tuberculosis infection,221,true,2011-01-04 00:00:00,Duquesne University,20569,No Development Reported,2011-01-04 00:00:00,NDR,2,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,Epimmune Inc,15573,US,US,Theradigm-tuberculosis,10406,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2001-12-09 00:00:00,Takeda Pharmaceutical Co Ltd,20300,No Development Reported,2001-12-09 00:00:00,NDR,2,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,MaxPharma,26965,US,US,"M tuberculosis vaccine (LEAPS), CEL-SCI (MaxPharma)",11526,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2011-12-28 00:00:00,CEL-SCI Corp,15339,No Development Reported,2011-12-28 00:00:00,NDR,2,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,CEL-SCI Corp,15339,US,US,"M tuberculosis vaccine (LEAPS), CEL-SCI (MaxPharma)",11526,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2011-12-28 00:00:00,CEL-SCI Corp,15339,Discovery,1996-01-08 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,University of Illinois,20592,US,US,B-4154,12633,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-08-08 00:00:00,University of Illinois,20592,No Development Reported,2008-08-08 00:00:00,NDR,2,Respiratory disease,711
RNA synthesis inhibitor,439,LOCAL_AND_MAJOR,Harbor Therapeutics Inc,24345,US,US,PP-29,15867,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2003-07-02 00:00:00,Harbor Therapeutics Inc,24345,Discovery,1997-03-01 00:00:00,DR,6,Respiratory disease,711
Bacterial nucleic acid synthesis inhibitor,3984,LOCAL_AND_MAJOR,Harbor Therapeutics Inc,24345,US,US,PP-29,15867,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2003-07-02 00:00:00,Harbor Therapeutics Inc,24345,Discovery,1997-03-01 00:00:00,DR,6,Respiratory disease,711
Fungicide,1748,LOCAL_AND_MAJOR,Georgia State University,21235,US,US,pafuramidine,16755,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2008-02-22 00:00:00,Georgia State University,21235,Discontinued,2000-01-28 00:00:00,DX,3,Respiratory disease,711
Topoisomerase II inhibitor,142,LOCAL_AND_MAJOR,Georgia State University,21235,US,US,pafuramidine,16755,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2008-02-22 00:00:00,Georgia State University,21235,Discontinued,2000-01-28 00:00:00,DX,3,Respiratory disease,711
Fungicide,1748,LOCAL_AND_MAJOR,Georgia State University,21235,US,US,pafuramidine,16755,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2008-02-22 00:00:00,Georgia State University,21235,Discovery,2000-10-23 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,University of Illinois,20592,US,US,pafuramidine,16755,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2008-02-22 00:00:00,University of Illinois,20592,Discontinued,2000-01-28 00:00:00,DX,3,Respiratory disease,711
Topoisomerase II inhibitor,142,LOCAL_AND_MAJOR,University of Illinois,20592,US,US,pafuramidine,16755,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2008-02-22 00:00:00,University of Illinois,20592,Discontinued,2000-01-28 00:00:00,DX,3,Respiratory disease,711
Fungicide,1748,LOCAL_AND_MAJOR,University of Illinois,20592,US,US,pafuramidine,16755,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2008-02-22 00:00:00,University of Illinois,20592,Discovery,2000-10-23 00:00:00,DR,6,Respiratory disease,711
Nuclease inhibitor,9166,LOCAL_AND_MAJOR,University of North Carolina,20634,US,US,pafuramidine,16755,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2008-02-22 00:00:00,University of North Carolina,20634,Discovery,2000-10-23 00:00:00,DR,6,Respiratory disease,711
Topoisomerase II inhibitor,142,LOCAL_AND_MAJOR,University of North Carolina,20634,US,US,pafuramidine,16755,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2008-02-22 00:00:00,University of North Carolina,20634,Discovery,2000-10-23 00:00:00,DR,6,Respiratory disease,711
Topoisomerase IV inhibitor,9320,OTHER,The Global Alliance for TB Drug Development,29411,Peru,PE,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2014-10-14 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,The Global Alliance for TB Drug Development,29411,Georgia,GE,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2014-10-14 00:00:00,DR,6,Respiratory disease,711
Bacterial nucleic acid synthesis inhibitor,3984,OTHER,The Global Alliance for TB Drug Development,29411,South Africa,ZA,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,The Global Alliance for TB Drug Development,29411,Phase 3 Clinical,2015-02-10 00:00:00,C3,10,Respiratory disease,711
Antibacterial,1594,OTHER,The Global Alliance for TB Drug Development,29411,South Africa,ZA,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,The Global Alliance for TB Drug Development,29411,Phase 3 Clinical,2015-02-10 00:00:00,C3,10,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Immtech Pharmaceuticals Inc,17195,US,US,pafuramidine,16755,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2008-02-22 00:00:00,Immtech Pharmaceuticals Inc,17195,Discovery,2000-10-23 00:00:00,DR,6,Respiratory disease,711
Topoisomerase II inhibitor,142,LOCAL_AND_MAJOR,Immtech Pharmaceuticals Inc,17195,US,US,pafuramidine,16755,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2008-02-22 00:00:00,Immtech Pharmaceuticals Inc,17195,No Development Reported,2003-10-23 00:00:00,NDR,2,Respiratory disease,711
Immunostimulant,393,LOCAL_AND_MAJOR,Farmabrasilis,1083670,Brazil,BR,P-MAPA,15596,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-06-18 00:00:00,Farmabrasilis,1083670,Discovery,2009-03-21 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Farmabrasilis,1083670,Brazil,BR,P-MAPA,15596,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-06-18 00:00:00,Farmabrasilis,1083670,Discovery,2009-03-21 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,Bayer AG,14455,Brazil,BR,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,Bayer AG,14455,Phase 2 Clinical,2005-10-17 00:00:00,C2,9,Respiratory disease,711
Antibacterial,1594,OTHER,Bayer AG,14455,Tanzania,TZ,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,Bayer AG,14455,Phase 2 Clinical,2005-10-17 00:00:00,C2,9,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Hoechst Marion Roussel Inc,25224,US,US,rifapentine,15102,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-12-02 00:00:00,Sanofi,1009547,Launched,1998-10-31 00:00:00,L,13,Respiratory disease,711
3-Oxoacyl-ACP synthase inhibitor,6565,LOCAL_AND_MAJOR,Johns Hopkins University,20596,US,US,"antituberculosis agents, Johns Hopkins",30452,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-06-20 00:00:00,Johns Hopkins University,20596,No Development Reported,2008-06-20 00:00:00,NDR,2,Respiratory disease,711
3-Oxoacyl-ACP synthase inhibitor,6565,LOCAL_AND_MAJOR,Johns Hopkins University,20596,US,US,"antituberculosis agents, Johns Hopkins",30452,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-06-20 00:00:00,Johns Hopkins University,20596,Discovery,2000-09-05 00:00:00,DR,6,Respiratory disease,711
Cardiovascular diagnostic agent,7210,LOCAL_AND_MAJOR,Navidea Biopharmaceuticals Inc,18471,US,US,technetium Tc 99m tilmanocept,34061,Chemical,Launched,Discovery,DR,L,Mycobacterium tuberculosis infection,221,true,2014-12-12 00:00:00,Navidea Biopharmaceuticals Inc,18471,Discovery,2013-09-19 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Intercell AG,28463,Austria,AT,"peptide vaccine (tuberculosis), Intercell/Sequella",32516,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2004-04-30 00:00:00,Valneva SE,1084202,No Development Reported,2004-04-30 00:00:00,NDR,2,Respiratory disease,711
Protein subunit vaccine,12372,LOCAL_AND_MAJOR,Sequella Inc,28087,US,US,"peptide vaccine (tuberculosis), Intercell/Sequella",32516,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2004-04-30 00:00:00,Sequella Inc,28087,No Development Reported,2004-04-30 00:00:00,NDR,2,Respiratory disease,711
Nitric oxide donor,698,LOCAL_AND_MAJOR,NicOx SA,23741,France,FR,NCX-976,47140,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2005-01-31 00:00:00,NicOx SA,23741,No Development Reported,2005-01-31 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Sankyo Co Ltd,19658,Japan,JP,"capuramycin derivative translocase inhibitors (tuberculosis, Clostridium difficile infection, Chrons disease), Sequella",48440,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2012-05-03 00:00:00,Daiichi Sankyo Co Ltd,1017506,Discontinued,2004-11-01 00:00:00,DX,3,Respiratory disease,711
Anti-inflammatory,2953,LOCAL_AND_MAJOR,Sankyo Co Ltd,19658,Japan,JP,"capuramycin derivative translocase inhibitors (tuberculosis, Clostridium difficile infection, Chrons disease), Sequella",48440,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2012-05-03 00:00:00,Daiichi Sankyo Co Ltd,1017506,Discovery,2003-09-01 00:00:00,DR,6,Respiratory disease,711
Bacterial cell wall synthesis inhibitor,104,LOCAL_AND_MAJOR,Sankyo Co Ltd,19658,Japan,JP,"capuramycin derivative translocase inhibitors (tuberculosis, Clostridium difficile infection, Chrons disease), Sequella",48440,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2012-05-03 00:00:00,Daiichi Sankyo Co Ltd,1017506,Discovery,2003-09-01 00:00:00,DR,6,Respiratory disease,711
Anti-inflammatory,2953,LOCAL_AND_MAJOR,Sequella Inc,28087,US,US,"capuramycin derivative translocase inhibitors (tuberculosis, Clostridium difficile infection, Chrons disease), Sequella",48440,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-05-03 00:00:00,Sequella Inc,28087,Discovery,2004-11-01 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Aeras Global TB Vaccine Foundation,1007376,Sweden,SE,"HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell",48499,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-07-29 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 1 Clinical,2007-12-04 00:00:00,C1,8,Respiratory disease,711
Mycobacterial antigen complex 85B modulator,33970,OTHER,Aeras Global TB Vaccine Foundation,1007376,Finland,FI,"HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell",48499,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-07-29 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 1 Clinical,2009-01-26 00:00:00,C1,8,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Aeras Global TB Vaccine Foundation,1007376,South Africa,ZA,"HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell",48499,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-07-29 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 2 Clinical,2013-07-29 00:00:00,C2,9,Respiratory disease,711
Protein subunit vaccine,12372,OTHER,Aeras Global TB Vaccine Foundation,1007376,South Africa,ZA,"HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell",48499,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-07-29 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 2 Clinical,2013-07-29 00:00:00,C2,9,Respiratory disease,711
Mycobacterial antigen complex 85B modulator,33970,OTHER,Statens Serum Institut,21502,Sweden,SE,"HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell",48499,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-07-29 00:00:00,Statens Serum Institut,21502,Phase 1 Clinical,2007-12-04 00:00:00,C1,8,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Statens Serum Institut,21502,Sweden,SE,"HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell",48499,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-07-29 00:00:00,Statens Serum Institut,21502,Phase 1 Clinical,2007-12-04 00:00:00,C1,8,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Lupin Ltd,21932,India,IN,LL-4858,51319,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2010-03-26 00:00:00,Lupin Ltd,21932,No Development Reported,2010-03-26 00:00:00,NDR,2,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Intercell AG,28463,Tanzania,TZ,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2013-05-28 00:00:00,Valneva SE,1084202,Phase 2 Clinical,2012-08-17 00:00:00,C2,9,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-05-28 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Discovery,2005-06-27 00:00:00,DR,6,Respiratory disease,711
Protein subunit vaccine,12372,OTHER,Aeras Global TB Vaccine Foundation,1007376,Netherlands,NL,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-05-28 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 1 Clinical,2005-11-18 00:00:00,C1,8,Respiratory disease,711
TLR-2 agonist,7806,LOCAL_AND_MAJOR,Cadila Pharmaceuticals Ltd,30025,India,IN,cadi-05,55173,Biological,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2014-12-03 00:00:00,Cadila Pharmaceuticals Ltd,30025,Phase 3 Clinical,2005-03-31 00:00:00,C3,10,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Central Drug Research Institute,15350,India,IN,"galactopyranose derivatives (antifungal/antitubercular), Central Drug Research Institute",50637,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2005-01-24 00:00:00,Council of Scientific and Industrial Research (India),15561,No Development Reported,2005-01-24 00:00:00,NDR,2,Respiratory disease,711
Fungicide,1748,LOCAL_AND_MAJOR,Central Drug Research Institute,15350,India,IN,"galactopyranose derivatives (antifungal/antitubercular), Central Drug Research Institute",50637,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2005-01-24 00:00:00,Council of Scientific and Industrial Research (India),15561,Discovery,2003-07-24 00:00:00,DR,6,Respiratory disease,711
6-aminoglycoside N-acetyltransferase inhibitor,23008,LOCAL_AND_MAJOR,The Lilly TB Drug Discovery Initiative,1042702,US,US,"N-acetyltransferase inhibitors (tuberculosis), Summit/Lilly TB Drug Discovery Initiative",57219,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2008-10-07 00:00:00,The Lilly TB Drug Discovery Initiative,1042702,Discovery,2008-10-07 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Hosp Germans Trias i Pujol,DOL1000424,Spain,ES,RUTI,57308,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2012-05-24 00:00:00,Hosp Germans Trias i Pujol,DOL1000424,Discovery,2004-04-17 00:00:00,DR,6,Respiratory disease,711
Subunit vaccine,12371,LOCAL_AND_MAJOR,Hosp Germans Trias i Pujol,DOL1000424,Spain,ES,RUTI,57308,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2012-05-24 00:00:00,Hosp Germans Trias i Pujol,DOL1000424,Discovery,2004-04-17 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,Archivel Farma SL,1014222,Europe,X5,RUTI,57308,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2012-05-24 00:00:00,Archivel Farma SL,1014222,Phase 2 Clinical,2012-05-24 00:00:00,C2,9,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Archivel Farma SL,1014222,Europe,X5,RUTI,57308,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2012-05-24 00:00:00,Archivel Farma SL,1014222,Phase 2 Clinical,2012-05-24 00:00:00,C2,9,Respiratory disease,711
Subunit vaccine,12371,LOCAL_AND_MAJOR,Archivel Farma SL,1014222,Spain,ES,RUTI,57308,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2012-05-24 00:00:00,Archivel Farma SL,1014222,Phase 1 Clinical,2007-05-06 00:00:00,C1,8,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,The Lilly TB Drug Discovery Initiative,1042702,US,US,CPZEN-45,59885,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2008-10-07 00:00:00,The Lilly TB Drug Discovery Initiative,1042702,Discovery,2008-10-07 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,GlaxoSmithKline plc,28355,UK,GB,"gyrase inhibitors (Mycobacterium tuberculosis infection), GlaxoSmithKline/The Global Alliance for TB Drug Development",57733,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2006-12-31 00:00:00,GlaxoSmithKline plc,28355,Discovery,2006-12-31 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Cumbre Pharmaceuticals Inc,29103,US,US,"antibacterial compounds (Mycobacterium tuberculosis), Cumbre/The Global Alliance for TB Drug Development",57737,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2009-12-22 00:00:00,Cumbre Pharmaceuticals Inc,29103,Discontinued,2006-09-27 00:00:00,DX,3,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Oxford-Emergent Tuberculosis Consortium Ltd,1040955,South Africa,ZA,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-07 00:00:00,Emergent BioSolutions Inc,1011990,Discontinued,2014-03-07 00:00:00,DX,3,Respiratory disease,711
Recombinant viral vector vaccine,12370,OTHER,Oxford-Emergent Tuberculosis Consortium Ltd,1040955,South Africa,ZA,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-07 00:00:00,Emergent BioSolutions Inc,1011990,Discontinued,2014-03-07 00:00:00,DX,3,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Oxford-Emergent Tuberculosis Consortium Ltd,1040955,UK,GB,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-07 00:00:00,Emergent BioSolutions Inc,1011990,Phase 1 Clinical,2008-07-23 00:00:00,C1,8,Respiratory disease,711
Mycobacterial antigen complex 85A modulator,33967,LOCAL_AND_MAJOR,University of Oxford,22182,UK,GB,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-07 00:00:00,University of Oxford,22182,Discovery,2000-12-31 00:00:00,DR,6,Respiratory disease,711
Recombinant viral vector vaccine,12370,LOCAL_AND_MAJOR,University of Oxford,22182,UK,GB,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-07 00:00:00,University of Oxford,22182,Discovery,2000-12-31 00:00:00,DR,6,Respiratory disease,711
Recombinant viral vector vaccine,12370,LOCAL_AND_MAJOR,University of Oxford,22182,UK,GB,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-07 00:00:00,University of Oxford,22182,Phase 1 Clinical,2002-09-30 00:00:00,C1,8,Respiratory disease,711
Recombinant viral vector vaccine,12370,OTHER,University of Oxford,22182,Africa,X0,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-07 00:00:00,University of Oxford,22182,Phase 1 Clinical,2002-09-30 00:00:00,C1,8,Respiratory disease,711
Recombinant viral vector vaccine,12370,OTHER,TB-VAC,1020621,South Africa,ZA,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-03-07 00:00:00,TB-VAC,1020621,Phase 2 Clinical,2008-05-14 00:00:00,C2,9,Respiratory disease,711
Recombinant viral vector vaccine,12370,OTHER,TB-VAC,1020621,Africa,X0,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-03-07 00:00:00,TB-VAC,1020621,Clinical,2007-03-25 00:00:00,CU,7,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Emergent BioSolutions Inc,1011990,UK,GB,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-03-07 00:00:00,Emergent BioSolutions Inc,1011990,Phase 1 Clinical,2014-03-07 00:00:00,C1,8,Respiratory disease,711
Recombinant viral vector vaccine,12370,OTHER,Emergent BioSolutions Inc,1011990,Senegal,SN,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-03-07 00:00:00,Emergent BioSolutions Inc,1011990,Phase 2 Clinical,2014-03-07 00:00:00,C2,9,Respiratory disease,711
Antiviral,991,LOCAL_AND_MAJOR,TVAX Biomedical LLC,1049288,US,US,"autologous therapeutic vaccine, TVAX Biomedical",64503,Biological,Phase 2 Clinical,Discovery,DR,C2,Mycobacterium tuberculosis infection,221,true,2014-12-03 00:00:00,TVAX Biomedical LLC,1049288,Discovery,2012-12-06 00:00:00,DR,6,Respiratory disease,711
Anti-inflammatory,2953,LOCAL_AND_MAJOR,TVAX Biomedical LLC,1049288,US,US,"autologous therapeutic vaccine, TVAX Biomedical",64503,Biological,Phase 2 Clinical,Discovery,DR,C2,Mycobacterium tuberculosis infection,221,true,2014-12-03 00:00:00,TVAX Biomedical LLC,1049288,Discovery,2012-12-06 00:00:00,DR,6,Respiratory disease,711
Isocitrate lyase inhibitor,68490,OTHER,Emory University,20573,South Africa,ZA,"isocitrate lyase prodrug inhibitors (tuberculosis), iThemba Pharmaceuticals",65567,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2008-03-31 00:00:00,Emory University,20573,Discontinued,2008-03-31 00:00:00,DX,3,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Adjuvantix Ltd,1002784,UK,GB,ADX40-TB,64522,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-10-21 00:00:00,Adjuvantix Ltd,1002784,No Development Reported,2014-10-21 00:00:00,NDR,2,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Adjuvantix Ltd,1002784,UK,GB,ADX40-TB,64522,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-10-21 00:00:00,Adjuvantix Ltd,1002784,Discovery,2009-10-05 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,TB Drug Boost,1054643,France,FR,"EthR inhibitors (Mycobacterium tuberculosis), TB Drug Boost",67295,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-06-20 00:00:00,TB Drug Boost,1054643,Discovery,2010-05-06 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,TB Drug Boost,1054643,France,FR,"FurA inhibitors (Mycobacterium tuberculosis infection), TB Drug Boost",67299,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-06-20 00:00:00,TB Drug Boost,1054643,Discovery,2010-05-06 00:00:00,DR,6,Respiratory disease,711
Protein kinase inhibitor,336,LOCAL_AND_MAJOR,Reyon Pharmaceuticals Co Ltd,1022208,South Korea,KR,"tubercuslosis program, B&C Biopharm/Reyon Pharma/Wayne State University",67413,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2010-07-21 00:00:00,Reyon Pharmaceuticals Co Ltd,1022208,Discovery,2008-03-31 00:00:00,DR,6,Respiratory disease,711
Mycolic acid synthase inhibitor,6542,LOCAL_AND_MAJOR,BioVersys AG,1052531,Switzerland,CH,"EthR inhibitors (mycobacterium tuberculosis), BioVersys",61115,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-07-10 00:00:00,BioVersys AG,1052531,Discovery,2012-07-10 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,BioVersys AG,1052531,Switzerland,CH,"EthR inhibitors (mycobacterium tuberculosis), BioVersys",61115,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-07-10 00:00:00,BioVersys AG,1052531,Discovery,2012-07-10 00:00:00,DR,6,Respiratory disease,711
Mycobacterial antigen complex 85A modulator,33967,OTHER,Imaxio,1007058,UK,GB,IMX-461,66409,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-08-01 00:00:00,Imaxio,1007058,Phase 1 Clinical,2013-08-01 00:00:00,C1,8,Respiratory disease,711
Mycobacterial antigen complex 85A modulator,33967,LOCAL_AND_MAJOR,Imaxio,1007058,France,FR,IMX-461,66409,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-08-01 00:00:00,Imaxio,1007058,Phase 1 Clinical,2010-05-06 00:00:00,C1,8,Respiratory disease,711
Unspecified protein kinase inhibitor,9671,LOCAL_AND_MAJOR,Medical Research Council Technology,1054893,UK,GB,"PknB inhibitors (Mycobacterium tuberculosis infection), MRCT",66920,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-09-23 00:00:00,Medical Research Council (MRC),18438,No Development Reported,2014-09-23 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Medical Research Council Technology,1054893,UK,GB,"Mut Y inhibitors (Mycobacterium tuberculosis infection), MRCT",66921,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-06-21 00:00:00,Medical Research Council (MRC),18438,Discovery,2010-06-17 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"menaquinone synthase inhibitors (tuberculosis infection), Colorado State University/TB Alliance",71664,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2009-05-27 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2009-05-27 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"malate synthase (tuberculosis infection), GSK/TB Alliance/Texas A&M University",71667,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2007-12-31 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2007-12-31 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,GlaxoSmithKline plc,28355,UK,GB,"malate synthase (tuberculosis infection), GSK/TB Alliance/Texas A&M University",71667,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2007-12-31 00:00:00,GlaxoSmithKline plc,28355,Discovery,2007-12-31 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Texas A&M University System,23290,US,US,"malate synthase (tuberculosis infection), GSK/TB Alliance/Texas A&M University",71667,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2007-12-31 00:00:00,Texas A&M University System,23290,Discovery,2007-12-31 00:00:00,DR,6,Respiratory disease,711
Adjuvant,524,OTHER,Aeras Global TB Vaccine Foundation,1007376,South Africa,ZA,ID-93,68617,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-09-20 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 1 Clinical,2013-09-20 00:00:00,C1,8,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,ID-93,68617,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-09-20 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Discovery,2012-05-09 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,ID-93,68617,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-09-20 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Discovery,2012-05-09 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,AstraZeneca plc,14190,UK,GB,"RNA polymerase inhibitors (tuberculosis infection), TB Alliance/Rutgers",71698,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2013-07-10 00:00:00,AstraZeneca plc,14190,No Development Reported,2013-07-10 00:00:00,NDR,2,Respiratory disease,711
RNA polymerase inhibitor,347,LOCAL_AND_MAJOR,AstraZeneca plc,14190,UK,GB,"RNA polymerase inhibitors (tuberculosis infection), TB Alliance/Rutgers",71698,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2013-07-10 00:00:00,AstraZeneca plc,14190,Discovery,2010-05-03 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,AstraZeneca plc,14190,UK,GB,"RNA polymerase inhibitors (tuberculosis infection), TB Alliance/Rutgers",71698,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2013-07-10 00:00:00,AstraZeneca plc,14190,Discovery,2010-05-03 00:00:00,DR,6,Respiratory disease,711
DNA gyrase B inhibitor,71209,OTHER,AstraZeneca plc,14190,India,IN,"gyrase B inhibitors (tuberculosis infection), AZ/TB Alliance",71700,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-11-30 00:00:00,AstraZeneca plc,14190,No Development Reported,2012-11-30 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Quantum Pharmaceuticals LLC,1072312,Russian Federation,RU,QP-42,76732,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-07-24 00:00:00,Quantum Pharmaceuticals LLC,1072312,No Development Reported,2013-07-24 00:00:00,NDR,2,Respiratory disease,711
Protease inhibitor,331,LOCAL_AND_MAJOR,The Institute of Microbiology Chinese Academy of Sciences,1015456,China,CN,"protease inhibitors (tuberculosis infection, TB Alliance/Institute of Microbiology Chinese Academy of Sciences",71743,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-18 00:00:00,Chinese Academy of Sciences,23863,No Development Reported,2013-01-18 00:00:00,NDR,2,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,Shanghai H&G Biotechnology Co,1066720,China,CN,"ESAT-6/Ag85A-expressing recombinant BCG vaccine (Mycobacterium tuberculosis), Shanghai H&G",75152,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-17 00:00:00,Shanghai H&G Biotechnology Co,1066720,Discovery,2007-08-28 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Fundacao de Amparo a Pesquisa do Estado Sao Paulo,1003225,Brazil,BR,"ruthenium (II) based organic complexes (tuberculosis infection), FAPESP",71902,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2009-06-10 00:00:00,Fundacao de Amparo a Pesquisa do Estado Sao Paulo,1003225,Discovery,2009-06-10 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,National Institute of Oceanography,1053325,India,IN,"anti-tuberculosis therapeutics, Shreya Life Sciences/NIO",76688,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2010-03-30 00:00:00,National Institute of Oceanography,1053325,Discovery,2010-03-30 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Shreya Life Sciences Pvt Ltd,1028690,India,IN,"anti-tuberculosis therapeutics, Shreya Life Sciences/NIO",76688,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2010-03-30 00:00:00,Shreya Life Sciences Pvt Ltd,1028690,Discovery,2010-03-30 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,VIB,25058,Belgium,BE,"tuberculosis vaccine, VIB/Ghent University",70144,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-10-07 00:00:00,University of Antwerp,22741,No Development Reported,2014-10-07 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,PaxVax Inc,1032157,US,US,"adenovirus 4-based vaccine (oral, tuberculosis), PaxVax",72040,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-11-27 00:00:00,PaxVax Inc,1032157,Discovery,2011-06-21 00:00:00,DR,6,Respiratory disease,711
Recombinant viral vector vaccine,12370,LOCAL_AND_MAJOR,PaxVax Inc,1032157,US,US,"adenovirus 4-based vaccine (oral, tuberculosis), PaxVax",72040,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-11-27 00:00:00,PaxVax Inc,1032157,Discovery,2011-06-21 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,SRI International,20234,US,US,"gyrase B inhibitors (tuberculosis), SRI",74814,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-11-02 00:00:00,SRI International,20234,Discovery,2011-11-02 00:00:00,DR,6,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,Transgene SA,23924,France,FR,"Mycobacterium tuberculosis vaccine, Transgene",67820,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2010-07-29 00:00:00,ACCRA,1020515,Discovery,2010-07-29 00:00:00,DR,6,Respiratory disease,711
Antiviral,991,LOCAL_AND_MAJOR,Wyeth BioPharma,20511,US,US,edodekin alfa,6934,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-06-27 00:00:00,Pfizer Inc,18767,Discontinued,2003-06-27 00:00:00,DX,3,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Institute for Tuberculosis Research,1092461,US,US,"antituberculosis agents, LifePharms Inc/Institute for Tuberculosis Research",70763,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-01-24 00:00:00,Institute for Tuberculosis Research,1092461,Discovery,2014-01-24 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,LifePharms Inc,1060609,US,US,"antituberculosis agents, LifePharms Inc/Institute for Tuberculosis Research",70763,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-01-24 00:00:00,LifePharms Inc,1060609,Discovery,2010-03-26 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Medicine in Need,1054651,US,US,"capreomycin (inhalant/powder, tuberculosis), Medicines in Need",70827,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-09-24 00:00:00,Medicine in Need,1054651,No Development Reported,2014-09-24 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Medicine in Need,1054651,US,US,"capreomycin (inhalant/powder, tuberculosis), Medicines in Need",70827,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-09-24 00:00:00,Medicine in Need,1054651,No Development Reported,2014-09-24 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Medicine in Need,1054651,US,US,"capreomycin (inhalant/powder, tuberculosis), Medicines in Need",70827,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-09-24 00:00:00,Medicine in Need,1054651,Phase 2 Clinical,2008-10-16 00:00:00,C2,9,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Intervet Innovation GmbH,1061424,Germany,DE,"thioredoxin reductase inhibitors (tuberculosis), Intervet Innovation",70840,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-02-26 00:00:00,Intervet Innovation GmbH,1061424,No Development Reported,2013-02-26 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Intervet Innovation GmbH,1061424,Germany,DE,"thioredoxin reductase inhibitors (tuberculosis), Intervet Innovation",70840,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-02-26 00:00:00,Intervet Innovation GmbH,1061424,Discovery,2010-05-04 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,New Medicines for Tuberculosis,1062637,Switzerland,CH,"benzothiazinones (tuberculosis), Hans Knoell Institute",70901,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-09-25 00:00:00,New Medicines for Tuberculosis,1062637,No Development Reported,2013-09-25 00:00:00,NDR,2,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,Finlay Institute,15912,Cuba,CU,"Streptomyces vector-based live recombinant vaccine (tuberculosis infection), Finlay Institute",73326,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-10-15 00:00:00,Finlay Institute,15912,Discovery,2009-12-31 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Orient Pharma Co Ltd,1042436,Taiwan,TW,"tuberculosis therapeutics (capsule), Orient",75681,Chemical,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2012-01-19 00:00:00,Orient Europharma,DOL1000087,Phase 1 Clinical,2012-01-19 00:00:00,C1,8,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"folate biosynthesis inhibitors (tuberculosis), AZ/TB Alliance",71614,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-11-30 00:00:00,The Global Alliance for TB Drug Development,29411,No Development Reported,2012-11-30 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,University of California San Diego,25451,US,US,NTF-1836,72331,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-02-05 00:00:00,University of California,20547,No Development Reported,2013-02-05 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Statens Serum Institut,21502,Denmark,DK,"Ag85B-ESAT-6 fusion protein vaccine (CAF-01-adjuvanted, tuberculosis), Statens Serum Institut",75087,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2009-10-31 00:00:00,Statens Serum Institut,21502,Phase 1 Clinical,2009-10-31 00:00:00,C1,8,Respiratory disease,711
Leucyl tRNA synthetase inhibitor,36223,LOCAL_AND_MAJOR,Omnia Molecular,1065893,Spain,ES,"leucyl-tRNA synthetase inhibitors (Mycobacterium tuberculosis infection), Omnia Molecular",75760,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-10-14 00:00:00,Omnia Molecular,1065893,No Development Reported,2014-10-14 00:00:00,NDR,2,Respiratory disease,711
Bifunctional aminoacyl tRNA synthetase inhibitor,33999,LOCAL_AND_MAJOR,Omnia Molecular,1065893,Spain,ES,"leucyl-tRNA synthetase inhibitors (Mycobacterium tuberculosis infection), Omnia Molecular",75760,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-10-14 00:00:00,Omnia Molecular,1065893,Discovery,2011-10-24 00:00:00,DR,6,Respiratory disease,711
Interferon gamma ligand,51201,LOCAL_AND_MAJOR,Heber Biotec SA,1062884,Cuba,CU,"interferon gamma follow-on biologic, CIGB/Heber Biotec",79519,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2009-12-31 00:00:00,Center for Genetic Engineering and Biotechnology,15353,Launched,2009-12-31 00:00:00,L,13,Respiratory disease,711
Anti-inflammatory,2953,LOCAL_AND_MAJOR,Center for Genetic Engineering and Biotechnology,15353,Cuba,CU,"interferon gamma follow-on biologic, CIGB/Heber Biotec",79519,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2009-12-31 00:00:00,Center for Genetic Engineering and Biotechnology,15353,Clinical,2008-02-11 00:00:00,CU,7,Respiratory disease,711
RNA polymerase inhibitor,347,LOCAL_AND_MAJOR,Nanosystem Ltd,1071336,Russian Federation,RU,"rifabutin nanoparticles (iv, Mycobacterium tuberculosis), Nanosystem",82299,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-12-07 00:00:00,Nanosystem Ltd,1071336,Discovery,2012-12-07 00:00:00,DR,6,Respiratory disease,711
Recombinant bacterial vector vaccine,12369,LOCAL_AND_MAJOR,VELES Pharma CJSC,1069315,US,US,"recombinant protein vaccine (nanoparticle, tuberculosis infection prevention/treatment), VELES Pharma",77247,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-04-12 00:00:00,VELES Pharma CJSC,1069315,Discovery,2012-04-12 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Anacor Pharmaceuticals Inc,30118,US,US,"non-Leucyl-tRNA synthase inhibitors (tuberculosis infection), Anacor",84382,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2009-05-27 00:00:00,Anacor Pharmaceuticals Inc,30118,Discovery,2009-05-27 00:00:00,DR,6,Respiratory disease,711
Immunostimulant,393,LOCAL_AND_MAJOR,Savine Therapeutics Pty Ltd,1066884,Australia,AU,"TB SAVINE (cDNA vaccine, tuberculosis), Savine",77428,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-12-14 00:00:00,BioDiem Ltd,30212,Discovery,2011-12-14 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Scripps Research Institute,21102,US,US,"ATP synthase inhibitors (tuberculosis), TB Alliance/California Institute for Biomedical Research",82643,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2013-06-30 00:00:00,Scripps Research Institute,21102,Discovery,2012-11-30 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"diarylquinolines (tuberculosis), TB Alliance/J & J/University of Auckland/University of Illinois at Chicago",82662,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-06-30 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2012-11-30 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,University of Auckland,20647,New Zealand,NZ,"diarylquinolines (tuberculosis), TB Alliance/J & J/University of Auckland/University of Illinois at Chicago",82662,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-06-30 00:00:00,University of Auckland,20647,Discovery,2012-11-30 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,University of Illinois,20592,US,US,"diarylquinolines (tuberculosis), TB Alliance/J & J/University of Auckland/University of Illinois at Chicago",82662,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-06-30 00:00:00,University of Illinois,20592,Discovery,2013-06-30 00:00:00,DR,6,Respiratory disease,711
Recombinant viral vector vaccine,12370,LOCAL_AND_MAJOR,University of Oxford,22182,UK,GB,ChAdOx1-85A,84564,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-06-12 00:00:00,University of Oxford,22182,Discovery,2012-07-31 00:00:00,DR,6,Respiratory disease,711
RNA polymerase inhibitor,347,LOCAL_AND_MAJOR,Shenyang Hongqi Pharmaceutical Co Ltd,1075626,China,CN,"ethambutol hydrochloride + rifampicin + isoniazid (fixed dose combination, tuberculosis), Shenyang Hongqi Pharmaceutical",82091,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2008-12-31 00:00:00,Shanghai Fosun Pharmaceutical (Group) Co Ltd,1015871,Launched,2008-12-31 00:00:00,L,13,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Shenyang Hongqi Pharmaceutical Co Ltd,1075626,China,CN,"ethambutol hydrochloride + rifampicin + isoniazid (fixed dose combination, tuberculosis), Shenyang Hongqi Pharmaceutical",82091,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2008-12-31 00:00:00,Shanghai Fosun Pharmaceutical (Group) Co Ltd,1015871,Launched,2008-12-31 00:00:00,L,13,Respiratory disease,711
Antiviral,991,LOCAL_AND_MAJOR,Chengdu Institute of Biological Products,1016340,China,CN,Ka Shu Ning,80062,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,1998-12-31 00:00:00,Sinopharm,1055632,Launched,1998-12-31 00:00:00,L,13,Respiratory disease,711
Anti-inflammatory,2953,LOCAL_AND_MAJOR,Chengdu Institute of Biological Products,1016340,China,CN,Ka Shu Ning,80062,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,1998-12-31 00:00:00,Sinopharm,1055632,Launched,1998-12-31 00:00:00,L,13,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Chengdu Institute of Biological Products,1016340,China,CN,Ka Shu Ning,80062,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,1998-12-31 00:00:00,Sinopharm,1055632,Launched,1998-12-31 00:00:00,L,13,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,New York University,20646,US,US,"modified Pup modulators (Mycobacterium tuberculosis infection), New York University",88848,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-09-24 00:00:00,New York University,20646,Discovery,2013-09-24 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,University of Illinois,20592,US,US,"pantothenate synthetase inhibitors (tuberculosis/bacterial infections), University of Illinois/University of Illinois at URBANA-CHAMPAIGN",88214,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-10-30 00:00:00,University of Illinois,20592,Discovery,2008-04-10 00:00:00,DR,6,Respiratory disease,711
Enoyl ACP reductase Fabl inhibitor,79288,LOCAL_AND_MAJOR,State University of New York at Stony Brook,26884,US,US,"MTB fatty acid bio synthesis enzyme inhibitors (multi-drug resistant tuberculosis), State University of New York at Stony Brook",88952,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2006-02-17 00:00:00,State University of New York,26880,Discovery,2006-02-17 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Eli Lilly & Co,17810,US,US,"Mycobacterium tuberculosis inhibitors (Mycobacterium tuberculosis infection), Eli Lilly",87565,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-09-12 00:00:00,Eli Lilly & Co,17810,Discovery,2013-09-12 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Saurashtra University,1034429,India,IN,"antitubercular agents (tuberculosis), Amneal Pharmaceutical LLC/ Saurashtra University/Maharaja Krishnakumarsinhji Bhavnagar University",95732,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-08-28 00:00:00,Saurashtra University,1034429,Discovery,2013-08-28 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,The Global Alliance for TB Drug Development,29411,Malaysia,MY,pretomanid,13323,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-09-05 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2014-08-04 00:00:00,DR,6,Respiratory disease,711
Bacterial cell wall synthesis inhibitor,104,LOCAL_AND_MAJOR,Liaoning Hongwuxing Pharmaceutical Co Ltd,1090092,China,CN,"ethambutol hydrochloride (150 mg) + pyrazinamide (300 mg) + rifampicin (90 mg) + isoniazid (60 mg) (oral tablet, tuberculosis), Shenyang Hongqi Pharmaceutical/Liaoning Hongwuxing Pharmaceutical",88505,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-11-15 00:00:00,Liaoning Hongwuxing Pharmaceutical Co Ltd,1090092,Discovery,2013-11-15 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Shenyang Hongqi Pharmaceutical Co Ltd,1075626,China,CN,"ethambutol hydrochloride (150 mg) + pyrazinamide (300 mg) + rifampicin (90 mg) + isoniazid (60 mg) (oral tablet, tuberculosis), Shenyang Hongqi Pharmaceutical/Liaoning Hongwuxing Pharmaceutical",88505,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-11-15 00:00:00,Shanghai Fosun Pharmaceutical (Group) Co Ltd,1015871,Discovery,2009-02-01 00:00:00,DR,6,Respiratory disease,711
RNA polymerase inhibitor,347,LOCAL_AND_MAJOR,Sichuan Long March Pharmaceutical Co Ltd,1088430,China,CN,"ethambutol hydrochloride + pyrazinamide + rifampicin + isoniazid (oral tablet, tuberculosis), Sichuan Long March Pharmaceutical",96349,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-11-11 00:00:00,Sichuan Long March Pharmaceutical Co Ltd,1088430,Discovery,2006-04-02 00:00:00,DR,6,Respiratory disease,711
Unspecified vaccine,12380,LOCAL_AND_MAJOR,Bio Farma,19368,Indonesia,ID,Lipovax-FliC-TB,96406,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2015-04-16 00:00:00,Bio Farma,19368,Discovery,2015-04-16 00:00:00,DR,6,Respiratory disease,711
Ribosome binding agent,463,OTHER,Pfizer Inc,18767,Portugal,PT,rifabutin,4229,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2008-10-07 00:00:00,Pfizer Inc,18767,Launched,2007-03-21 00:00:00,L,13,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Pharmacia & Upjohn Co,18995,US,US,rifabutin,4229,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2008-10-07 00:00:00,Pfizer Inc,18767,Phase 3 Clinical,1996-12-09 00:00:00,C3,10,Respiratory disease,711
Ribosome binding agent,463,LOCAL_AND_MAJOR,Pharmacia & Upjohn Co,18995,US,US,rifabutin,4229,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2008-10-07 00:00:00,Pfizer Inc,18767,Phase 3 Clinical,1996-12-09 00:00:00,C3,10,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Changchun ChangSheng Gene Pharmaceutical Co Ltd,1071244,China,CN,"accelular mycobacterium smegmatis vaccine (subcutaneous, mycobacterium tuberculosis infection), Changchun ChangSheng Gene Pharmaceutical",94475,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-10-30 00:00:00,Changchun ChangSheng Gene Pharmaceutical Co Ltd,1071244,Phase 1 Clinical,2007-04-30 00:00:00,C1,8,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Only For Children Pharmaceuticals,1047869,France,FR,"isoniazid (oral/solution, tuberculosis), O4CP",91937,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-07-08 00:00:00,Only For Children Pharmaceuticals,1047869,Discovery,2014-07-08 00:00:00,DR,6,Respiratory disease,711
ATP synthase inhibitor,49687,LOCAL_AND_MAJOR,Pharmstandard OJSC,1047078,Russian Federation,RU,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Pharmstandard OJSC,1047078,Discovery,2013-01-25 00:00:00,DR,6,Respiratory disease,711
Antibacterial multidrug resistance inhibitor,4855,OTHER,Janssen Research & Development LLC,1067538,EU,EU,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Pre-registration,2012-08-31 00:00:00,PR,11,Respiratory disease,711
ATP synthase inhibitor,49687,OTHER,Janssen Research & Development LLC,1067538,EU,EU,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Pre-registration,2012-08-31 00:00:00,PR,11,Respiratory disease,711
ATP synthase inhibitor,49687,OTHER,Janssen Research & Development LLC,1067538,Peru,PE,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Discovery,2009-07-30 00:00:00,DR,6,Respiratory disease,711
ATP synthase inhibitor,49687,OTHER,Janssen Research & Development LLC,1067538,South Korea,KR,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Phase 2 Clinical,2009-12-17 00:00:00,C2,9,Respiratory disease,711
Antibacterial multidrug resistance inhibitor,4855,OTHER,Janssen Research & Development LLC,1067538,Philippines,PH,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Discovery,2009-07-30 00:00:00,DR,6,Respiratory disease,711
ATP synthase inhibitor,49687,OTHER,Janssen Research & Development LLC,1067538,Philippines,PH,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Discovery,2009-07-30 00:00:00,DR,6,Respiratory disease,711
ATP synthase inhibitor,49687,OTHER,Janssen Research & Development LLC,1067538,South Africa,ZA,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Discovery,2009-07-30 00:00:00,DR,6,Respiratory disease,711
ATP synthase inhibitor,49687,OTHER,Janssen Research & Development LLC,1067538,Thailand,TH,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Discovery,2009-07-30 00:00:00,DR,6,Respiratory disease,711
ATP synthase inhibitor,49687,OTHER,Janssen Research & Development LLC,1067538,South Korea,KR,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Registered,2014-11-06 00:00:00,R,12,Respiratory disease,711
Antibacterial multidrug resistance inhibitor,4855,OTHER,Janssen Research & Development LLC,1067538,Kenya,KE,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Discovery,2009-07-30 00:00:00,DR,6,Respiratory disease,711
Antibacterial multidrug resistance inhibitor,4855,OTHER,Janssen Research & Development LLC,1067538,Japan,JP,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Phase 2 Clinical,2015-03-18 00:00:00,C2,9,Respiratory disease,711
Antibacterial multidrug resistance inhibitor,4855,OTHER,Janssen Research & Development LLC,1067538,Colombia,CO,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Pre-registration,2014-11-06 00:00:00,PR,11,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Statens Serum Institut,21502,South Africa,ZA,SSI H56-IC31,74849,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-11-08 00:00:00,Statens Serum Institut,21502,Phase 1 Clinical,2011-12-01 00:00:00,C1,8,Respiratory disease,711
Protein subunit vaccine,12372,OTHER,Valneva SE,1084202,South Africa,ZA,SSI H56-IC31,74849,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-11-08 00:00:00,Valneva SE,1084202,Phase 1 Clinical,2013-05-28 00:00:00,C1,8,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,National Institutes of Health,20518,US,US,"mycothiol-S-conjugate amidase inhibitors (Mycobacterium tuberculosis infection), National Institutes of Health",86146,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-02-01 00:00:00,US Government,20516,Discovery,2012-02-01 00:00:00,DR,6,Respiratory disease,711
Mycothiol conjugate amidase inhibitor,30242,LOCAL_AND_MAJOR,National Institutes of Health,20518,US,US,"mycothiol-S-conjugate amidase inhibitors (Mycobacterium tuberculosis infection), National Institutes of Health",86146,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-02-01 00:00:00,US Government,20516,Discovery,2012-02-01 00:00:00,DR,6,Respiratory disease,711
"Indoleamine-pyrrole-2,3-dioxygenase inhibitor",6366,LOCAL_AND_MAJOR,Cincinnati Children's Hospital Medical Center,25631,US,US,"indoleamine 2,3-deoxygenase inhibitor (leishmaniasis/tuberculosis), Cincinnati Children's Hospital Medical Center",81141,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-10-13 00:00:00,Cincinnati Children's Hospital Medical Center,25631,Discovery,2011-10-13 00:00:00,DR,6,Respiratory disease,711
RNA polymerase inhibitor,347,LOCAL_AND_MAJOR,Shenyang Hongqi Pharmaceutical Co Ltd,1075626,China,CN,"ethambutol hydrochloride (250 mg) + pyrazinamide (400 mg) + rifampicin (120 mg) + isoniazid (120 mg) (fixed dose combination, tuberculosis), Shenyang Hongqi Pharmaceutical",82062,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2009-12-31 00:00:00,Shanghai Fosun Pharmaceutical (Group) Co Ltd,1015871,Launched,2009-12-31 00:00:00,L,13,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Harvard University Office of Technology Development,1085770,US,US,"proteasome inhibitors (tuberculosis), Harvard University/Harvard University Office of Technology Development",86021,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-08-21 00:00:00,Harvard University,20584,Discovery,2012-02-01 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Harvard University Office of Technology Development,1085770,US,US,"proteasome inhibitors (tuberculosis), Harvard University/Harvard University Office of Technology Development",86021,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-08-21 00:00:00,Harvard University,20584,No Development Reported,2014-08-21 00:00:00,NDR,2,Respiratory disease,711
Therapeutic vaccine,12379,OTHER,Immunitor Inc,1006860,Ukraine,UA,"heat-killed Mycobacterium vaccae (tablet formulation, tuberculosis), Immunitor",70934,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-03-26 00:00:00,Immune Network Ltd,21412,Phase 2 Clinical,2011-08-31 00:00:00,C2,9,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Genzyme Corp,16299,US,US,"enoyl reductase inhibitors (antimicrobial), Genzyme",47123,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2004-05-25 00:00:00,Sanofi,1009547,No Development Reported,2004-05-25 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Harvard University,20584,US,US,"proteasome inhibitors (tuberculosis), Harvard University/Harvard University Office of Technology Development",86021,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-08-21 00:00:00,Harvard University,20584,No Development Reported,2014-08-21 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,University of Bristol,20544,UK,GB,"Mycobacterium chaperonin inhibitors, University of Bristol",30799,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-03-20 00:00:00,University of Bristol,20544,Discovery,2000-09-27 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,University of Bristol,20544,UK,GB,"Mycobacterium chaperonin inhibitors, University of Bristol",30799,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-03-20 00:00:00,University of Bristol,20544,No Development Reported,2008-03-20 00:00:00,NDR,2,Respiratory disease,711
Energy metabolism modulator,1732,LOCAL_AND_MAJOR,University of Pennsylvania,20658,US,US,"energy metabolism inhibitors (tuberculosis), AstraZeneca/University of Pennsylvania/TB Alliance",71615,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-03-28 00:00:00,University of Pennsylvania,20658,Discovery,2011-03-17 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Innate Immunotherapeutics Ltd,29958,US,US,"MIS-416/immunogen (anthrax/malaria/tuberculosis/neutropenia), Innate",60213,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-01-12 00:00:00,Innate Immunotherapeutics Ltd,29958,Discovery,2010-12-21 00:00:00,DR,6,Respiratory disease,711
TLR-9 modulator,7826,LOCAL_AND_MAJOR,Innate Immunotherapeutics Ltd,29958,US,US,"MIS-416/immunogen (anthrax/malaria/tuberculosis/neutropenia), Innate",60213,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-01-12 00:00:00,Innate Immunotherapeutics Ltd,29958,Discovery,2010-12-21 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,GlaxoSmithKline plc,28355,US,US,"thiolactomycin analog, GlaxoSmithKline",33073,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-08-08 00:00:00,GlaxoSmithKline plc,28355,Discovery,2001-02-28 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Shanghai H&G Biotechnology Co,1066720,China,CN,"ESAT-6/Ag85A DNA vaccine (Mycobacterium tuberculosis), Shanghai H&G",75153,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-17 00:00:00,Shanghai H&G Biotechnology Co,1066720,No Development Reported,2013-01-17 00:00:00,NDR,2,Respiratory disease,711
Antibacterial multidrug resistance inhibitor,4855,OTHER,MicuRx Pharmaceuticals Inc,1033227,China,CN,"antibiotic (tuberculosis), MicuRx/Cumencor/Pfizer",68345,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2010-04-06 00:00:00,MicuRx Pharmaceuticals Inc,1033227,Discovery,2010-04-06 00:00:00,DR,6,Respiratory disease,711
Antibacterial multidrug resistance inhibitor,4855,OTHER,Janssen Diagnostics BVBA,30131,Belgium,BE,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,false,2015-03-18 00:00:00,Johnson & Johnson,17332,Phase 1 Clinical,2005-03-31 00:00:00,C1,8,Respiratory disease,711
ATP synthase inhibitor,49687,OTHER,Johnson & Johnson Pharmaceutical Research & Development LLC,29481,Belgium,BE,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,false,2015-03-18 00:00:00,Johnson & Johnson,17332,Phase 1 Clinical,2004-10-30 00:00:00,C1,8,Respiratory disease,711
Helicase inhibitor,5552,LOCAL_AND_MAJOR,Medical Research Council Technology,1054893,UK,GB,"UvrD helicase inhibitors (Mycobacterium tuberculosis infection), MRCT",66922,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-06-21 00:00:00,Medical Research Council (MRC),18438,No Development Reported,2012-06-21 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,St Jude Children's Research Hospital,21814,US,US,"thiolactomycin analog, GlaxoSmithKline",33073,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-08-08 00:00:00,St Jude Children's Research Hospital,21814,Discovery,2001-02-28 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Chimerix Inc,30079,US,US,"Mycobacterium tuberculosis infection targeting compounds, Chimerix",69571,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-09-16 00:00:00,Chimerix Inc,30079,Discovery,2011-01-04 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,OTHER,Novartis Institute for Tropical Diseases Pvt Ltd,1017949,Singapore,SG,"small molecule therapeutics (Mycobacterium tuberculosis infection), ChemDiv Research Institute/Novartis Institute for Tropical Diseases/Silvius Pharma",76796,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2014-08-14 00:00:00,Novartis AG,23137,Discovery,2010-09-30 00:00:00,DR,6,Respiratory disease,711
Aminoglycoside antibiotic,1541,OTHER,Gilead Sciences Inc,16450,UK,GB,"amikacin (liposomal formulation), NeXstar",10211,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2001-06-25 00:00:00,Gilead Sciences Inc,16450,Discontinued,2001-06-25 00:00:00,DX,3,Respiratory disease,711
Antibacterial,1594,OTHER,Chemical Diversity Research Institute Ltd,1009877,Russian Federation,RU,"small molecule therapeutics (Mycobacterium tuberculosis infection), ChemDiv Research Institute/Novartis Institute for Tropical Diseases/Silvius Pharma",76796,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2014-08-14 00:00:00,ChemDiv Inc,1012947,Discontinued,2014-08-14 00:00:00,DX,3,Respiratory disease,711
Anticancer,1545,OTHER,Immodulon Therapeutics Limited,1051823,Argentina,AR,"heat-killed Mycobacterium vaccae (tablet formulation, tuberculosis), Immunitor",70934,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-26 00:00:00,Immodulon Therapeutics Limited,1051823,No Development Reported,2014-03-26 00:00:00,NDR,2,Respiratory disease,711
Mycobacterial antigen complex 85A modulator,33967,LOCAL_AND_MAJOR,Shanghai H&G Biotechnology Co,1066720,China,CN,"Ag85A DNA vaccine (Mycobacterium tuberculosis), Shanghai H&G",75158,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-17 00:00:00,Shanghai H&G Biotechnology Co,1066720,No Development Reported,2013-01-17 00:00:00,NDR,2,Respiratory disease,711
Systemic antipsoriatic product,15184,LOCAL_AND_MAJOR,LeukoMed Inc,30043,US,US,LMP-420,41819,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2009-03-16 00:00:00,LeukoMed Inc,30043,No Development Reported,2009-03-16 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,National Institutes of Health,20518,US,US,"thiolactomycin analog, GlaxoSmithKline",33073,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-08-08 00:00:00,US Government,20516,No Development Reported,2008-08-08 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,University of Illinois,20592,US,US,"tuberculosis therapy, TB Alliance/Johns Hopkins University",82716,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2013-06-30 00:00:00,University of Illinois,20592,Discovery,2012-11-30 00:00:00,DR,6,Respiratory disease,711
DNA vaccine,1879,LOCAL_AND_MAJOR,UK National Institute of Medical Research,20466,UK,GB,"DNA vaccine (tuberculosis), NIMR/Sequella",22154,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-10-13 00:00:00,Medical Research Council (MRC),18438,Discovery,1999-02-19 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Chiron PathoGenesis,18741,US,US,PA-647,11233,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,1996-10-01 00:00:00,Novartis AG,23137,Discovery,1995-11-02 15:31:09,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Silvius Pharma,1068863,Russian Federation,RU,"small molecule therapeutics (Mycobacterium tuberculosis infection), ChemDiv Research Institute/Novartis Institute for Tropical Diseases/Silvius Pharma",76796,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2014-08-14 00:00:00,ChemRar,1050615,Discontinued,2014-08-14 00:00:00,DX,3,Respiratory disease,711
Unspecified drug target,59620,OTHER,The Global Alliance for TB Drug Development,29411,World,WO,"indazole derivatives (Mycobacterium tuberculosis infection), GlaxoSmithKline/The Global Alliance for TB Drug Development",86639,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-07-31 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2013-07-31 00:00:00,DR,6,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,Yonsei University,25184,South Korea,KR,"therapeutic DNA vaccine (tuberculosis), Pohang/Yonsei Universities",53019,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2009-12-24 00:00:00,Yonsei University,25184,Discovery,2003-09-30 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,AstraZeneca plc,14190,US,US,posizolid,26493,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2012-12-27 00:00:00,AstraZeneca plc,14190,Phase 1 Clinical,2009-12-22 00:00:00,C1,8,Respiratory disease,711
Macrolide antibiotic,1540,LOCAL_AND_MAJOR,Helmholtz Zentrum fur Infektionsforschung GmbH,16277,Germany,DE,"thuggacines (tuberculosis), Helmholtz",82363,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-11-14 00:00:00,Helmholtz Zentrum fur Infektionsforschung GmbH,16277,Discovery,2007-05-15 00:00:00,DR,6,Respiratory disease,711
Fibrosuppressant,664,LOCAL_AND_MAJOR,InterMune Inc,26430,US,US,Actimmune,3365,Biological,Launched,No Development Reported,NDR,L,Mycobacterium tuberculosis infection,221,false,2014-09-19 00:00:00,Roche Holding AG,19446,No Development Reported,2007-03-31 00:00:00,NDR,2,Respiratory disease,711
Collagen synthesis modulator,858,LOCAL_AND_MAJOR,InterMune Inc,26430,US,US,Actimmune,3365,Biological,Launched,No Development Reported,NDR,L,Mycobacterium tuberculosis infection,221,false,2014-09-19 00:00:00,Roche Holding AG,19446,No Development Reported,2007-03-31 00:00:00,NDR,2,Respiratory disease,711
Bacterial protein synthesis inhibitor,1538,LOCAL_AND_MAJOR,Sanofi,1009547,US,US,"macrolides (tuberculosis), TB Alliance/Sanofi",82709,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-11-30 00:00:00,Sanofi,1009547,Discovery,2012-11-30 00:00:00,DR,6,Respiratory disease,711
Anticancer,1545,LOCAL_AND_MAJOR,Vakzine Projekt Management GmbH,1020740,Germany,DE,VPM-1002,55569,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-03-27 00:00:00,Vakzine Projekt Management GmbH,1020740,No Development Reported,2013-03-27 00:00:00,NDR,2,Respiratory disease,711
Live attenuated bacterial vaccine,12363,LOCAL_AND_MAJOR,Vakzine Projekt Management GmbH,1020740,Germany,DE,VPM-1002,55569,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-03-27 00:00:00,Vakzine Projekt Management GmbH,1020740,Phase 1 Clinical,2008-09-05 00:00:00,C1,8,Respiratory disease,711
Unspecified drug target,59620,OTHER,Pfizer Inc,18767,Singapore,SG,"rifampicin + isoniazid (fixed dose combination, tuberculosis), Pfizer",89460,Chemical,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-12-17 00:00:00,Pfizer Inc,18767,Phase 1 Clinical,2013-12-17 00:00:00,C1,8,Respiratory disease,711
Antibacterial,1594,OTHER,Pfizer Inc,18767,Philippines,PH,"rifampicin + isoniazid (fixed dose combination, tuberculosis), Pfizer",89460,Chemical,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-12-17 00:00:00,Pfizer Inc,18767,Phase 1 Clinical,2011-04-30 00:00:00,C1,8,Respiratory disease,711
Anticancer,1545,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Europe,X5,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Discovery,2007-12-06 00:00:00,DR,6,Respiratory disease,711
Angiogenesis inhibitor,61,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Europe,X5,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Discovery,2007-12-06 00:00:00,DR,6,Respiratory disease,711
Mycolic acid synthase inhibitor,6542,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Europe,X5,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Discovery,2007-12-06 00:00:00,DR,6,Respiratory disease,711
Anticancer,1545,LOCAL_AND_MAJOR,Otsuka Pharmaceutical Co Ltd,18717,Japan,JP,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 2 Clinical,2008-04-30 00:00:00,C2,9,Respiratory disease,711
Anticancer,1545,LOCAL_AND_MAJOR,Otsuka Pharmaceutical Co Ltd,18717,Japan,JP,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Registered,2014-07-04 00:00:00,R,12,Respiratory disease,711
Anti-inflammatory,2953,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Latvia,LV,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 2 Clinical,2008-04-30 00:00:00,C2,9,Respiratory disease,711
Mycolic acid synthase inhibitor,6542,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Latvia,LV,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 2 Clinical,2008-04-30 00:00:00,C2,9,Respiratory disease,711
Anti-inflammatory,2953,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Latvia,LV,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 3 Clinical,2011-09-19 00:00:00,C3,10,Respiratory disease,711
Angiogenesis inhibitor,61,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Latvia,LV,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 3 Clinical,2011-09-19 00:00:00,C3,10,Respiratory disease,711
Mycolic acid synthase inhibitor,6542,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Latvia,LV,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 3 Clinical,2011-09-19 00:00:00,C3,10,Respiratory disease,711
IL12 gene stimulator,4965,LOCAL_AND_MAJOR,GenomIdea Inc,1008113,Japan,JP,"DNA vaccines (HJV vector, tuberculosis), GenomIdea",60030,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2007-04-20 00:00:00,AnGes MG Inc,28514,Discovery,2007-04-20 00:00:00,DR,6,Respiratory disease,711
Anti-inflammatory,2953,OTHER,Otsuka Pharmaceutical Co Ltd,18717,EU,EU,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Registered,2014-04-28 00:00:00,R,12,Respiratory disease,711
Anti-inflammatory,2953,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Philippines,PH,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 3 Clinical,2013-07-26 00:00:00,C3,10,Respiratory disease,711
Angiogenesis inhibitor,61,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Egypt,EG,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 2 Clinical,2008-04-30 00:00:00,C2,9,Respiratory disease,711
Anticancer,1545,OTHER,Otsuka Pharmaceutical Co Ltd,18717,China,CN,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 2 Clinical,2008-04-30 00:00:00,C2,9,Respiratory disease,711
Mycolic acid synthase inhibitor,6542,OTHER,Otsuka Pharmaceutical Co Ltd,18717,South Africa,ZA,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 3 Clinical,2013-07-26 00:00:00,C3,10,Respiratory disease,711
Mycolic acid synthase inhibitor,6542,OTHER,Otsuka Pharmaceutical Co Ltd,18717,UK,GB,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Launched,2014-05-31 00:00:00,L,13,Respiratory disease,711
Mycolic acid synthase inhibitor,6542,LOCAL_AND_MAJOR,Otsuka Pharmaceutical Co Ltd,18717,US,US,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 3 Clinical,2011-12-31 00:00:00,C3,10,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Biofabri SL,1077737,Switzerland,CH,MTBVAC,89744,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-11-15 00:00:00,Biofabri SL,1077737,Phase 1 Clinical,2013-01-31 00:00:00,C1,8,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Agenus Inc,23221,US,US,"tuberculosis vaccine (CD1), Antigenics",22778,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2002-10-15 00:00:00,Agenus Inc,23221,Discontinued,2002-10-15 00:00:00,DX,3,Respiratory disease,711
Antibacterial multidrug resistance inhibitor,4855,LOCAL_AND_MAJOR,BioVersys AG,1052531,Switzerland,CH,BV-6481,65858,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2008-01-22 00:00:00,BioVersys AG,1052531,Discovery,2008-01-22 00:00:00,DR,6,Respiratory disease,711
Antibacterial multidrug resistance inhibitor,4855,LOCAL_AND_MAJOR,Infectex,1068619,Russian Federation,RU,"Q-203, Qurient / Infectex",85970,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-02-06 00:00:00,Maxwell Biotech Group,1061894,Discovery,2014-02-06 00:00:00,DR,6,Respiratory disease,711
Immunomodulator,1596,LOCAL_AND_MAJOR,Aquila Biopharmaceuticals Inc,24317,US,US,"tuberculosis vaccine (CD1), Antigenics",22778,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2002-10-15 00:00:00,Agenus Inc,23221,Discovery,1999-03-30 00:00:00,DR,6,Respiratory disease,711
Leucyl tRNA synthetase modulator,36221,LOCAL_AND_MAJOR,Anacor Pharmaceuticals Inc,30118,US,US,"leucyl tRNA synthetase modulators (tuberculosis), GlaxoSmithKline",70581,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2013-10-17 00:00:00,Anacor Pharmaceuticals Inc,30118,Discovery,2009-05-27 00:00:00,DR,6,Respiratory disease,711
Leucyl tRNA synthetase modulator,36221,LOCAL_AND_MAJOR,Anacor Pharmaceuticals Inc,30118,US,US,"leucyl tRNA synthetase modulators (tuberculosis), GlaxoSmithKline",70581,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2013-10-17 00:00:00,Anacor Pharmaceuticals Inc,30118,Discontinued,2013-10-17 00:00:00,DX,3,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,NeED Pharmaceuticals Srl,1013076,Italy,IT,ND-801,59776,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-03-21 00:00:00,NeED Pharmaceuticals Srl,1013076,Discovery,2007-04-25 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,PolyMedix Inc,1011746,US,US,"SMAMPs (malaria), Fox Chase Chemical Diversity Center",62968,Chemical,Discovery,No Development Reported,NDR,DR,Mycobacterium tuberculosis infection,221,false,2013-09-09 00:00:00,PolyMedix Inc,1011746,Discovery,2008-10-27 00:00:00,DR,6,Respiratory disease,711
Antiparasitic,2638,LOCAL_AND_MAJOR,PolyMedix Inc,1011746,US,US,"SMAMPs (malaria), Fox Chase Chemical Diversity Center",62968,Chemical,Discovery,No Development Reported,NDR,DR,Mycobacterium tuberculosis infection,221,false,2013-09-09 00:00:00,PolyMedix Inc,1011746,Discovery,2008-10-27 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,PolyMedix Inc,1011746,US,US,"SMAMPs (malaria), Fox Chase Chemical Diversity Center",62968,Chemical,Discovery,No Development Reported,NDR,DR,Mycobacterium tuberculosis infection,221,false,2013-09-09 00:00:00,PolyMedix Inc,1011746,Discovery,2008-10-27 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,iThemba Pharmaceuticals Pty Ltd,1049788,South Africa,ZA,"tuberculosis therapy, iThemba Pharmaceuticals/Southern Research Institute",67092,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-06-22 00:00:00,iThemba Pharmaceuticals Pty Ltd,1049788,Discovery,2010-05-06 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,University of Pretoria,25323,South Africa,ZA,B-4128,33132,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-07-08 00:00:00,University of Pretoria,25323,Discovery,2001-03-05 00:00:00,DR,6,Respiratory disease,711
Phospholipase A2 stimulator,1885,LOCAL_AND_MAJOR,University of Pretoria,25323,South Africa,ZA,B-4128,33132,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-07-08 00:00:00,University of Pretoria,25323,No Development Reported,2008-07-08 00:00:00,NDR,2,Respiratory disease,711
Defensin modulator,14365,LOCAL_AND_MAJOR,PolyMedix Inc,1011746,US,US,PMX-10072,63306,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2013-09-09 00:00:00,PolyMedix Inc,1011746,Discovery,2008-12-31 00:00:00,DR,6,Respiratory disease,711
Subunit vaccine,12371,LOCAL_AND_MAJOR,ApoVax Inc,29552,US,US,ApoVax104-TB,68211,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2015-01-05 00:00:00,ApoVax Inc,29552,Discovery,2008-08-31 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,ApoVax Inc,29552,US,US,ApoVax104-TB,68211,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2015-01-05 00:00:00,ApoVax Inc,29552,Discovery,2008-08-31 00:00:00,DR,6,Respiratory disease,711
T-cell surface glycoprotein CD8 stimulator,5039,LOCAL_AND_MAJOR,ApoVax Inc,29552,US,US,ApoVax104-TB,68211,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2015-01-05 00:00:00,ApoVax Inc,29552,No Development Reported,2015-01-05 00:00:00,NDR,2,Respiratory disease,711
Immunostimulant,393,LOCAL_AND_MAJOR,Verta Ltd,1004196,Russian Federation,RU,"golotimod (oral), SciClone/Verta",55521,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2011-10-10 00:00:00,Verta Ltd,1004196,No Development Reported,2011-10-10 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Medical Research Council (MRC),18438,UK,GB,"GlgE inhibitors (tuberculosis), MCRT",78428,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-06-25 00:00:00,Medical Research Council (MRC),18438,Discovery,2012-05-31 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Phage Therapeutics Inc,27485,US,US,"bacteriophage (Mycobacterium tuberculosis infection), Phage Therapeutics",34469,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-12-31 00:00:00,Phage Therapeutics Inc,27485,Discontinued,2003-12-31 00:00:00,DX,3,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,University of Illinois,20592,US,US,"actinomycetes metabolites (multi-drug resistant tuberculosis infection), Univeristy of Illinois/Institute for Tuberculosis Research/Univeristy of Illinois at Urbana-Champaign",71899,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-01-24 00:00:00,University of Illinois,20592,Discovery,2009-11-30 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,University of Illinois at Urbana-Champaign,1073122,US,US,"actinomycetes metabolites (multi-drug resistant tuberculosis infection), Univeristy of Illinois/Institute for Tuberculosis Research/Univeristy of Illinois at Urbana-Champaign",71899,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-01-24 00:00:00,University of Illinois,20592,Discovery,2013-10-30 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,University of Illinois at Urbana-Champaign,1073122,US,US,"actinomycetes metabolites (multi-drug resistant tuberculosis infection), Univeristy of Illinois/Institute for Tuberculosis Research/Univeristy of Illinois at Urbana-Champaign",71899,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-01-24 00:00:00,University of Illinois,20592,Discovery,2013-10-30 00:00:00,DR,6,Respiratory disease,711
Subunit vaccine,12371,OTHER,GlaxoSmithKline plc,28355,Belgium,BE,"MTB72F vaccine (tuberculosis), GSK/Aeras",9490,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-08-26 00:00:00,GlaxoSmithKline plc,28355,Discovery,2004-06-15 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,GlaxoSmithKline plc,28355,US,US,"MTB72F vaccine (tuberculosis), GSK/Aeras",9490,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-08-26 00:00:00,GlaxoSmithKline plc,28355,Phase 1 Clinical,2004-03-08 00:00:00,C1,8,Respiratory disease,711
Subunit vaccine,12371,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,"MTB72F vaccine (tuberculosis), GSK/Aeras",9490,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-08-26 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Discovery,2005-10-20 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,C&O Pharmaceutical Technology (Holdings) Ltd,1032379,Hong Kong,HK,CO-12,61340,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2007-08-31 00:00:00,Shionogi & Co Ltd,19898,Discovery,2007-08-31 00:00:00,DR,6,Respiratory disease,711
T-lymphocyte stimulator,7761,LOCAL_AND_MAJOR,Shenzhen Neptunus Interlong Bio-Technique Co Ltd,1015704,China,CN,"recombinant human interleukin-2 (cancer/AIDS/autoimmune disorders/infections), Shenzhen Neptunus",80864,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2012-09-10 00:00:00,Shenzhen Neptunus Bioengineering Co Ltd,1031729,Launched,2012-09-10 00:00:00,L,13,Respiratory disease,711
Recombinant viral vector vaccine,12370,OTHER,Crucell NV,17254,South Africa,ZA,AERAS-402,53975,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2010-09-22 00:00:00,Johnson & Johnson,17332,Phase 2 Clinical,2008-10-17 00:00:00,C2,9,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,AERAS-402,53975,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2010-09-22 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Discovery,2004-03-24 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Aeras Global TB Vaccine Foundation,1007376,Kenya,KE,AERAS-402,53975,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2010-09-22 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 1 Clinical,2008-10-17 00:00:00,C1,8,Respiratory disease,711
Recombinant viral vector vaccine,12370,LOCAL_AND_MAJOR,Polymun Scientific Immunobiologische Forschung GmbH,21851,Austria,AT,"tuberculosis vaccine (nasal, influenza virus carrier), Polymun",54201,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-06-10 00:00:00,Polymun Scientific Immunobiologische Forschung GmbH,21851,Discovery,2005-09-15 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Colorado State University,20562,US,US,GI-19000,86853,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-08-22 00:00:00,Colorado State University,20562,Discovery,2013-08-22 00:00:00,DR,6,Respiratory disease,711
Cell wall synthesis inhibitor,7052,LOCAL_AND_MAJOR,Sequella Inc,28087,US,US,SQ-109,31010,Chemical,Phase 3 Clinical,Phase 3 Clinical,C3,C3,Mycobacterium tuberculosis infection,221,true,2012-12-19 00:00:00,Sequella Inc,28087,Discovery,2000-10-09 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Sequella Inc,28087,US,US,SQ-109,31010,Chemical,Phase 3 Clinical,Phase 3 Clinical,C3,C3,Mycobacterium tuberculosis infection,221,true,2012-12-19 00:00:00,Sequella Inc,28087,Phase 1 Clinical,2006-09-30 00:00:00,C1,8,Respiratory disease,711
Antibacterial,1594,OTHER,Sequella Inc,28087,South Africa,ZA,sutezolid,11088,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-07-17 00:00:00,Sequella Inc,28087,Phase 2 Clinical,2013-07-17 00:00:00,C2,9,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Statens Serum Institut,21502,Sweden,SE,"multivalent vaccine (Bera-V, Mycobacterium tuberculosis infection), Abera Bioscience/Statens Serum/Institut Pasteur",89342,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-12-20 00:00:00,Statens Serum Institut,21502,Discovery,2013-12-20 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Abera Bioscience AB,1091260,Sweden,SE,"multivalent vaccine (Bera-V, Mycobacterium tuberculosis infection), Abera Bioscience/Statens Serum/Institut Pasteur",89342,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-12-20 00:00:00,Abera Bioscience AB,1091260,Discovery,2013-12-20 00:00:00,DR,6,Respiratory disease,711
Ribosome binding agent,463,LOCAL_AND_MAJOR,Microbiotix Inc,28907,US,US,"spectinamides (Mycobacterium tuberculosis infection), St Jude Children's Research Hospital/Microbiotix",78400,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-02-26 00:00:00,Microbiotix Inc,28907,Discovery,2014-02-26 00:00:00,DR,6,Respiratory disease,711
DNA gyrase inhibitor,431,LOCAL_AND_MAJOR,Dong Wha Pharmaceutical Co Ltd,15745,South Korea,KR,DW-286,35974,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-04-27 00:00:00,Dong Wha Pharmaceutical Co Ltd,15745,Discovery,2001-09-13 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Dong Wha Pharmaceutical Co Ltd,15745,South Korea,KR,DW-286,35974,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-04-27 00:00:00,Dong Wha Pharmaceutical Co Ltd,15745,No Development Reported,2006-08-13 00:00:00,NDR,2,Respiratory disease,711
Subunit vaccine,12371,LOCAL_AND_MAJOR,SmithKline Beecham plc,19962,US,US,"MTB72F vaccine (tuberculosis), GSK/Aeras",9490,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-08-26 00:00:00,GlaxoSmithKline plc,28355,Discovery,1995-10-01 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,AstraZeneca plc,14190,India,IN,"topoisomerase I inhibitors (tuberculosis infection), TB Alliance/NYMC/AZ",71897,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-06-27 00:00:00,AstraZeneca plc,14190,Discovery,2010-05-03 00:00:00,DR,6,Respiratory disease,711
Topoisomerase I inhibitor,141,OTHER,AstraZeneca plc,14190,India,IN,"topoisomerase I inhibitors (tuberculosis infection), TB Alliance/NYMC/AZ",71897,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-06-27 00:00:00,AstraZeneca plc,14190,No Development Reported,2013-06-27 00:00:00,NDR,2,Respiratory disease,711
Bacterial protein synthesis inhibitor,1538,LOCAL_AND_MAJOR,Pfizer Inc,18767,US,US,sutezolid,11088,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2013-07-17 00:00:00,Pfizer Inc,18767,Phase 1 Clinical,2009-05-19 00:00:00,C1,8,Respiratory disease,711
Immunostimulant,393,LOCAL_AND_MAJOR,SciClone Pharmaceuticals Inc,19829,US,US,golotimod,25023,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,false,2013-11-12 00:00:00,SciClone Pharmaceuticals Inc,19829,Phase 2 Clinical,2008-08-28 00:00:00,C2,9,Respiratory disease,711
Immunostimulant,393,LOCAL_AND_MAJOR,SciClone Pharmaceuticals Inc,19829,US,US,golotimod,25023,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,false,2013-11-12 00:00:00,SciClone Pharmaceuticals Inc,19829,Phase 1 Clinical,2005-08-08 00:00:00,C1,8,Respiratory disease,711
Cytokine synthesis stimulator,938,LOCAL_AND_MAJOR,SciClone Pharmaceuticals Inc,19829,US,US,golotimod,25023,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,false,2013-11-12 00:00:00,SciClone Pharmaceuticals Inc,19829,Discovery,1999-08-27 00:00:00,DR,6,Respiratory disease,711
Immunostimulant,393,LOCAL_AND_MAJOR,SciClone Pharmaceuticals Inc,19829,US,US,golotimod,25023,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,false,2013-11-12 00:00:00,SciClone Pharmaceuticals Inc,19829,Discontinued,2013-11-12 00:00:00,DX,3,Respiratory disease,711
Recombinant bacterial vector vaccine,12369,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,AERAS-405,59144,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-09-18 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Discovery,2006-04-21 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,SRI International,20234,US,US,"replicating and nonreplicating Mycobacterium tuberculosis inhibitors (tuberculosis), SRI International/University of Illinois",82340,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-07-25 00:00:00,SRI International,20234,No Development Reported,2013-07-25 00:00:00,NDR,2,Respiratory disease,711
DNA vaccine,1879,LOCAL_AND_MAJOR,Medical Research Council (MRC),18438,UK,GB,"vaccine (tuberculosis), MRC",12867,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2009-03-16 00:00:00,Medical Research Council (MRC),18438,Discovery,1996-07-29 00:00:00,DR,6,Respiratory disease,711
Energy metabolism modulator,1732,OTHER,Harbor Therapeutics Inc,24345,Mexico,MX,HE-2000,19980,Chemical,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2013-01-28 00:00:00,Harbor Therapeutics Inc,24345,Discovery,2002-11-22 00:00:00,DR,6,Respiratory disease,711
Androgen receptor agonist,59,OTHER,Harbor Therapeutics Inc,24345,Mexico,MX,HE-2000,19980,Chemical,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2013-01-28 00:00:00,Harbor Therapeutics Inc,24345,Discovery,2002-11-22 00:00:00,DR,6,Respiratory disease,711
Immunomodulator,1596,OTHER,Harbor Therapeutics Inc,24345,Mexico,MX,HE-2000,19980,Chemical,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2013-01-28 00:00:00,Harbor Therapeutics Inc,24345,No Development Reported,2013-01-28 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,BioDelivery Sciences International Inc,21164,US,US,"clofazimine (oral cochleate formulation), BioDelivery",48519,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-08-19 00:00:00,BioDelivery Sciences International Inc,21164,No Development Reported,2008-08-19 00:00:00,NDR,2,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Sanofi Pasteur,22127,France,FR,"rBCG30, UCLA",9831,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,false,2014-07-07 00:00:00,Sanofi,1009547,No Development Reported,2003-06-14 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,OTHER,Novartis Institute for Tropical Diseases Pvt Ltd,1017949,Singapore,SG,"mycobacterial membrane protein large type 3 inhibitors (tuberculosis), TB Alliance",89552,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2014-08-20 00:00:00,Novartis AG,23137,Discovery,2013-08-19 00:00:00,DR,6,Respiratory disease,711
Lyase inhibitor,248,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"isocitrate lyase inhibitors (tuberculosis), GlaxoSmithKline/The Global Alliance for TB Drug Developement",56373,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2007-05-31 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2005-03-21 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,AERAS-407 rBCG,62397,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-11-27 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 1 Clinical,2008-03-31 00:00:00,C1,8,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Institute of Materia Medica Chinese Academy of Medical Sciences & Peking Union Medical College,19595,China,CN,TBI-166,57790,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2014-12-22 00:00:00,Chinese Academy of Medical Sciences & Peking Union Medical College,1066199,Discovery,2007-01-11 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Scripps Research Institute,21102,US,US,"DprE inhibitors (tuberculosis), TB Alliance/California Institute for Biomedical Research",82660,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2013-06-30 00:00:00,Scripps Research Institute,21102,Discovery,2012-11-30 00:00:00,DR,6,Respiratory disease,711
DPR oxidase inhibitor,78977,LOCAL_AND_MAJOR,Scripps Research Institute,21102,US,US,"DprE inhibitors (tuberculosis), TB Alliance/California Institute for Biomedical Research",82660,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2013-06-30 00:00:00,Scripps Research Institute,21102,Discovery,2012-11-30 00:00:00,DR,6,Respiratory disease,711
Live attenuated bacterial vaccine,12363,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,"rBCG30, UCLA",9831,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,false,2014-07-07 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 1 Clinical,2004-02-17 00:00:00,C1,8,Respiratory disease,711
Live attenuated bacterial vaccine,12363,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,"rBCG30, UCLA",9831,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,false,2014-07-07 00:00:00,Aeras Global TB Vaccine Foundation,1007376,No Development Reported,2012-09-21 00:00:00,NDR,2,Respiratory disease,711
Bacterial nucleic acid synthesis inhibitor,3984,OTHER,Bayer AG,14455,China,CN,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,Bayer AG,14455,Phase 3 Clinical,2011-10-19 00:00:00,C3,10,Respiratory disease,711
Antibacterial,1594,OTHER,Bayer AG,14455,China,CN,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,Bayer AG,14455,Phase 3 Clinical,2011-10-19 00:00:00,C3,10,Respiratory disease,711
Antibacterial,1594,OTHER,Bayer AG,14455,Spain,ES,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,Bayer AG,14455,Phase 2 Clinical,2005-10-17 00:00:00,C2,9,Respiratory disease,711
Topoisomerase IV inhibitor,9320,LOCAL_AND_MAJOR,Bayer AG,14455,US,US,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,Bayer AG,14455,Phase 2 Clinical,2005-10-17 00:00:00,C2,9,Respiratory disease,711
DNA gyrase inhibitor,431,LOCAL_AND_MAJOR,Bayer AG,14455,US,US,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,Bayer AG,14455,Phase 2 Clinical,2005-10-17 00:00:00,C2,9,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Bayer AG,14455,US,US,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,Bayer AG,14455,Phase 2 Clinical,2005-10-17 00:00:00,C2,9,Respiratory disease,711
Antibacterial,1594,OTHER,Bayer AG,14455,Canada,CA,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,Bayer AG,14455,Phase 2 Clinical,2005-10-17 00:00:00,C2,9,Respiratory disease,711
Systemic dermatological antibacterial product,15187,OTHER,Bayer AG,14455,Brazil,BR,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,Bayer AG,14455,Phase 2 Clinical,2005-10-17 00:00:00,C2,9,Respiratory disease,711
Antiviral,991,OTHER,Silence Therapeutics plc,22356,Tanzania,TZ,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,2003-05-06 00:00:00,DX,3,Respiratory disease,711
Cytokine release modulator,1291,OTHER,Silence Therapeutics plc,22356,Zambia,ZM,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Systemic antipsoriatic product,15184,OTHER,Silence Therapeutics plc,22356,Romania,RO,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Antiviral,991,OTHER,Silence Therapeutics plc,22356,Nigeria,NG,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Antiviral,991,OTHER,Silence Therapeutics plc,22356,Kuwait,KW,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Live attenuated bacterial vaccine,12363,LOCAL_AND_MAJOR,Massachusetts Institute of Technology,18225,US,US,"vaccine (BCG), Connaught/Whitehead",12124,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2001-08-24 00:00:00,Massachusetts Institute of Technology,18225,No Development Reported,2001-08-24 00:00:00,NDR,2,Respiratory disease,711
Live attenuated bacterial vaccine,12363,LOCAL_AND_MAJOR,Massachusetts Institute of Technology,18225,US,US,"vaccine (BCG), Connaught/Whitehead",12124,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2001-08-24 00:00:00,Massachusetts Institute of Technology,18225,Discovery,1996-04-18 00:00:00,DR,6,Respiratory disease,711
Cytokine release modulator,1291,OTHER,Silence Therapeutics plc,22356,Kuwait,KW,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Inactivated bacterial vaccine,12366,LOCAL_AND_MAJOR,Silence Therapeutics plc,22356,UK,GB,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Anticancer,1545,OTHER,Silence Therapeutics plc,22356,Tanzania,TZ,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,2001-09-30 00:00:00,C2,9,Respiratory disease,711
Systemic antipsoriatic product,15184,OTHER,Silence Therapeutics plc,22356,Zambia,ZM,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 3 Clinical,1997-10-13 00:00:00,C3,10,Respiratory disease,711
Anticancer,1545,OTHER,Silence Therapeutics plc,22356,Gambia,GM,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 3 Clinical,1997-10-13 00:00:00,C3,10,Respiratory disease,711
Antimicrobial,1593,OTHER,Silence Therapeutics plc,22356,South Africa,ZA,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 3 Clinical,1995-10-12 00:00:00,C3,10,Respiratory disease,711
Anticancer,1545,OTHER,Silence Therapeutics plc,22356,South Africa,ZA,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 3 Clinical,1995-10-12 00:00:00,C3,10,Respiratory disease,711
Therapeutic vaccine,12379,OTHER,Silence Therapeutics plc,22356,South Africa,ZA,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 3 Clinical,1995-10-12 00:00:00,C3,10,Respiratory disease,711
Antibacterial,1594,OTHER,Silence Therapeutics plc,22356,Nigeria,NG,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,1995-10-12 00:00:00,C2,9,Respiratory disease,711
Inactivated bacterial vaccine,12366,OTHER,Silence Therapeutics plc,22356,Romania,RO,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,1995-10-12 00:00:00,C2,9,Respiratory disease,711
Fungicide,1748,LOCAL_AND_MAJOR,Indiana University,20593,US,US,"dihydrofolate reductase inhibitors, Duquesne/Indiana",12146,Chemical,Discovery,No Development Reported,NDR,DR,Mycobacterium tuberculosis infection,221,true,2011-01-04 00:00:00,Indiana University,20593,Discovery,2003-03-30 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Duquesne University,20569,US,US,"dihydrofolate reductase inhibitors, Duquesne/Indiana",12146,Chemical,Discovery,No Development Reported,NDR,DR,Mycobacterium tuberculosis infection,221,true,2011-01-04 00:00:00,Duquesne University,20569,No Development Reported,2011-01-04 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Duquesne University,20569,US,US,"dihydrofolate reductase inhibitors, Duquesne/Indiana",12146,Chemical,Discovery,No Development Reported,NDR,DR,Mycobacterium tuberculosis infection,221,true,2011-01-04 00:00:00,Duquesne University,20569,Discovery,2003-03-30 00:00:00,DR,6,Respiratory disease,711
Ribosome binding agent,463,LOCAL_AND_MAJOR,Chiron Corp,15385,US,US,"tobramycin (nebulized), Novartis",11232,Chemical,Launched,No Development Reported,NDR,L,Mycobacterium tuberculosis infection,221,false,2013-01-09 00:00:00,Novartis AG,23137,No Development Reported,2004-02-02 00:00:00,NDR,2,Respiratory disease,711
Aminoglycoside antibiotic,1541,LOCAL_AND_MAJOR,PathoGenesis Ltd,24982,US,US,"tobramycin (nebulized), Novartis",11232,Chemical,Launched,No Development Reported,NDR,L,Mycobacterium tuberculosis infection,221,true,2013-01-09 00:00:00,Novartis AG,23137,Phase 2 Clinical,1997-10-14 00:00:00,C2,9,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Albert Einstein College of Medicine,24282,US,US,KOA-18,10999,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,1995-09-26 14:53:02,Yeshiva University,20704,Discovery,1995-09-26 14:53:02,DR,6,Respiratory disease,711
Antimicrobial permeability enhancer,955,LOCAL_AND_MAJOR,CytRx Corporation,15585,US,US,CRL-1018,11007,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,1995-09-27 00:00:00,CytRx Corporation,15585,Discovery,1995-09-27 00:00:00,DR,6,Respiratory disease,711
Protein subunit vaccine,12372,LOCAL_AND_MAJOR,Epimmune Inc,15573,US,US,Theradigm-tuberculosis,10406,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2001-12-09 00:00:00,Takeda Pharmaceutical Co Ltd,20300,Discontinued,1997-09-23 00:00:00,DX,3,Respiratory disease,711
Systemic dermatological antibacterial product,15187,OTHER,The Global Alliance for TB Drug Development,29411,Russian Federation,RU,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2014-10-14 00:00:00,DR,6,Respiratory disease,711
DNA gyrase inhibitor,431,OTHER,The Global Alliance for TB Drug Development,29411,Malaysia,MY,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,The Global Alliance for TB Drug Development,29411,Phase 3 Clinical,2014-08-04 00:00:00,C3,10,Respiratory disease,711
Antibacterial,1594,OTHER,The Global Alliance for TB Drug Development,29411,Africa,X0,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,The Global Alliance for TB Drug Development,29411,Phase 3 Clinical,2007-11-08 00:00:00,C3,10,Respiratory disease,711
Nuclease inhibitor,9166,LOCAL_AND_MAJOR,Georgia State University,21235,US,US,pafuramidine,16755,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2008-02-22 00:00:00,Georgia State University,21235,Discovery,2000-10-23 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Georgia State University,21235,US,US,pafuramidine,16755,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2008-02-22 00:00:00,Georgia State University,21235,Discovery,2000-10-23 00:00:00,DR,6,Respiratory disease,711
Nuclease inhibitor,9166,LOCAL_AND_MAJOR,Immtech Pharmaceuticals Inc,17195,US,US,pafuramidine,16755,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2008-02-22 00:00:00,Immtech Pharmaceuticals Inc,17195,No Development Reported,2003-10-23 00:00:00,NDR,2,Respiratory disease,711
TLR-2 agonist,7806,LOCAL_AND_MAJOR,Farmabrasilis,1083670,Brazil,BR,P-MAPA,15596,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-06-18 00:00:00,Farmabrasilis,1083670,Discovery,2009-03-21 00:00:00,DR,6,Respiratory disease,711
Anticancer,1545,LOCAL_AND_MAJOR,Farmabrasilis,1083670,Brazil,BR,P-MAPA,15596,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-06-18 00:00:00,Farmabrasilis,1083670,Discovery,2009-03-21 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Universidade Estadual de Campinas,24983,Brazil,BR,P-MAPA,15596,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-06-18 00:00:00,Universidade Estadual de Campinas,24983,Discovery,2009-03-21 00:00:00,DR,6,Respiratory disease,711
Anticancer,1545,LOCAL_AND_MAJOR,Universidade Estadual de Campinas,24983,Brazil,BR,P-MAPA,15596,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-06-18 00:00:00,Universidade Estadual de Campinas,24983,Discovery,2009-03-21 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Paligent Inc,19142,US,US,"vaccine (tuberculosis), Procept",15602,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2005-12-31 00:00:00,Paligent Inc,19142,Discontinued,2005-12-31 00:00:00,DX,3,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Paligent Inc,19142,US,US,"vaccine (tuberculosis), Procept",15602,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2005-12-31 00:00:00,Paligent Inc,19142,Discovery,1997-07-30 00:00:00,DR,6,Respiratory disease,711
Lipid subunit vaccine,12374,LOCAL_AND_MAJOR,VacTex Corp,25562,US,US,"vaccine (tuberculosis), Procept",15602,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2005-12-31 00:00:00,Agenus Inc,23221,Discovery,1997-07-30 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,OriGenix Technologies Inc,26201,Canada,CA,"Mycobacterium tuberculosis therapeutics, OriGenix",32998,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2002-09-13 00:00:00,Biowest Therapeutics Inc,18210,Discontinued,2002-09-13 00:00:00,DX,3,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Intercell AG,28463,Austria,AT,"peptide vaccine (tuberculosis), Intercell/Sequella",32516,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2004-04-30 00:00:00,Valneva SE,1084202,Discovery,1999-12-01 00:00:00,DR,6,Respiratory disease,711
Protein subunit vaccine,12372,OTHER,Intercell AG,28463,Austria,AT,"peptide vaccine (tuberculosis), Intercell/Sequella",32516,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2004-04-30 00:00:00,Valneva SE,1084202,Discovery,1999-12-01 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Johns Hopkins University,20596,US,US,"antituberculosis agents, Johns Hopkins",30452,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-06-20 00:00:00,Johns Hopkins University,20596,No Development Reported,2008-06-20 00:00:00,NDR,2,Respiratory disease,711
DNA vaccine,1879,LOCAL_AND_MAJOR,Oxxon Therapeutics Ltd,27753,UK,GB,"TB vaccine (prophylactic, Prime-Boost), Oxxon Therapeutics",42764,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2009-01-02 00:00:00,Oxford BioMedica plc,23434,Phase 1 Clinical,2002-11-28 00:00:00,C1,8,Respiratory disease,711
Subunit vaccine,12371,LOCAL_AND_MAJOR,ANI Pharmaceuticals Inc,27120,US,US,"tuberculosis vaccine (BioVant), BioSante",39902,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-12-23 00:00:00,ANI Pharmaceuticals Inc,27120,No Development Reported,2008-12-23 00:00:00,NDR,2,Respiratory disease,711
Nitric oxide donor,698,LOCAL_AND_MAJOR,NicOx SA,23741,France,FR,NCX-976,47140,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2005-01-31 00:00:00,NicOx SA,23741,Discovery,2003-07-31 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Sequella Inc,28087,US,US,"capuramycin derivative translocase inhibitors (tuberculosis, Clostridium difficile infection, Chrons disease), Sequella",48440,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-05-03 00:00:00,Sequella Inc,28087,Discovery,2004-11-01 00:00:00,DR,6,Respiratory disease,711
Protein subunit vaccine,12372,OTHER,Aeras Global TB Vaccine Foundation,1007376,South Africa,ZA,"HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell",48499,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-07-29 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 1 Clinical,2009-01-26 00:00:00,C1,8,Respiratory disease,711
Protein subunit vaccine,12372,LOCAL_AND_MAJOR,Sanofi Pasteur,22127,France,FR,"HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell",48499,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-07-29 00:00:00,Sanofi,1009547,Phase 1 Clinical,2012-01-11 00:00:00,C1,8,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Sanofi Pasteur,22127,South Africa,ZA,"HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell",48499,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-07-29 00:00:00,Sanofi,1009547,Phase 2 Clinical,2013-07-29 00:00:00,C2,9,Respiratory disease,711
Protein subunit vaccine,12372,OTHER,Statens Serum Institut,21502,Sweden,SE,"HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell",48499,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-07-29 00:00:00,Statens Serum Institut,21502,Phase 1 Clinical,2007-12-04 00:00:00,C1,8,Respiratory disease,711
Mycobacterial antigen complex 85B modulator,33970,OTHER,Statens Serum Institut,21502,South Africa,ZA,"HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell",48499,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-07-29 00:00:00,Statens Serum Institut,21502,Phase 2 Clinical,2013-07-29 00:00:00,C2,9,Respiratory disease,711
Protein subunit vaccine,12372,OTHER,Statens Serum Institut,21502,South Africa,ZA,"HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell",48499,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-07-29 00:00:00,Statens Serum Institut,21502,Phase 2 Clinical,2013-07-29 00:00:00,C2,9,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Statens Serum Institut,21502,Denmark,DK,"HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell",48499,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-07-29 00:00:00,Statens Serum Institut,21502,Discovery,2003-04-30 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,FASgen Inc,1006466,US,US,FAS-20013,49581,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-08-25 00:00:00,FASgen Inc,1006466,No Development Reported,2014-08-25 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Lupin Ltd,21932,India,IN,LL-3858,49162,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-07-24 00:00:00,Lupin Ltd,21932,No Development Reported,2012-07-24 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Lupin Ltd,21932,India,IN,LL-4858,51319,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2010-03-26 00:00:00,Lupin Ltd,21932,Phase 1 Clinical,2006-05-17 00:00:00,C1,8,Respiratory disease,711
Recombinant bacterial vector vaccine,12369,LOCAL_AND_MAJOR,Sanofi Pasteur,22127,France,FR,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-05-28 00:00:00,Sanofi,1009547,Phase 1 Clinical,2008-02-12 00:00:00,C1,8,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Statens Serum Institut,21502,Netherlands,NL,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-05-28 00:00:00,Statens Serum Institut,21502,Phase 2 Clinical,2009-03-02 00:00:00,C2,9,Respiratory disease,711
TLR-9 antagonist,7828,LOCAL_AND_MAJOR,Cadila Pharmaceuticals Ltd,30025,India,IN,cadi-05,55173,Biological,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2014-12-03 00:00:00,Cadila Pharmaceuticals Ltd,30025,No Development Reported,2014-12-03 00:00:00,NDR,2,Respiratory disease,711
Adjuvant,524,LOCAL_AND_MAJOR,Cadila Pharmaceuticals Ltd,30025,India,IN,cadi-05,55173,Biological,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2014-12-03 00:00:00,Cadila Pharmaceuticals Ltd,30025,No Development Reported,2014-12-03 00:00:00,NDR,2,Respiratory disease,711
Interferon gamma receptor agonist,215,LOCAL_AND_MAJOR,Cadila Pharmaceuticals Ltd,30025,India,IN,cadi-05,55173,Biological,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2014-12-03 00:00:00,Cadila Pharmaceuticals Ltd,30025,No Development Reported,2014-12-03 00:00:00,NDR,2,Respiratory disease,711
TLR-9 antagonist,7828,LOCAL_AND_MAJOR,Cadila Pharmaceuticals Ltd,30025,India,IN,cadi-05,55173,Biological,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2014-12-03 00:00:00,Cadila Pharmaceuticals Ltd,30025,Phase 3 Clinical,2005-03-31 00:00:00,C3,10,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,Cadila Pharmaceuticals Ltd,30025,India,IN,cadi-05,55173,Biological,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2014-12-03 00:00:00,Cadila Pharmaceuticals Ltd,30025,Phase 3 Clinical,2005-03-31 00:00:00,C3,10,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,University of Oxford,22182,UK,GB,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-07 00:00:00,University of Oxford,22182,Discontinued,2008-07-23 00:00:00,DX,3,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,University of Oxford,22182,South Africa,ZA,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-07 00:00:00,University of Oxford,22182,Discontinued,2008-07-23 00:00:00,DX,3,Respiratory disease,711
Mycobacterial antigen complex 85A modulator,33967,OTHER,University of Oxford,22182,Africa,X0,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-07 00:00:00,University of Oxford,22182,Phase 1 Clinical,2002-09-30 00:00:00,C1,8,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,University of Oxford,22182,South Africa,ZA,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-07 00:00:00,University of Oxford,22182,Phase 2 Clinical,2007-12-31 00:00:00,C2,9,Respiratory disease,711
Mycobacterial antigen complex 85A modulator,33967,OTHER,Emergent BioSolutions Inc,1011990,UK,GB,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-03-07 00:00:00,Emergent BioSolutions Inc,1011990,Phase 1 Clinical,2014-03-07 00:00:00,C1,8,Respiratory disease,711
Therapeutic vaccine,12379,OTHER,Archivel Farma SL,1014222,Europe,X5,RUTI,57308,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2012-05-24 00:00:00,Archivel Farma SL,1014222,Phase 2 Clinical,2012-05-24 00:00:00,C2,9,Respiratory disease,711
Therapeutic vaccine,12379,OTHER,Archivel Farma SL,1014222,South Africa,ZA,RUTI,57308,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2012-05-24 00:00:00,Archivel Farma SL,1014222,Phase 2 Clinical,2010-06-30 00:00:00,C2,9,Respiratory disease,711
Cytochrome P450 reductase inhibitor,416,LOCAL_AND_MAJOR,NeED Pharmaceuticals Srl,1013076,Italy,IT,ND-701,59777,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-03-21 00:00:00,NeED Pharmaceuticals Srl,1013076,No Development Reported,2014-03-21 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,NeED Pharmaceuticals Srl,1013076,Italy,IT,ND-701,59777,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-03-21 00:00:00,NeED Pharmaceuticals Srl,1013076,No Development Reported,2014-03-21 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,NeED Pharmaceuticals Srl,1013076,Italy,IT,ND-201,59784,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-03-21 00:00:00,NeED Pharmaceuticals Srl,1013076,No Development Reported,2014-03-21 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,NeED Pharmaceuticals Srl,1013076,Italy,IT,ND-201,59784,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-03-21 00:00:00,NeED Pharmaceuticals Srl,1013076,No Development Reported,2014-03-21 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Microbial Chemistry Research Foundation,14851,Japan,JP,CPZEN-45,59885,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2008-10-07 00:00:00,Microbial Chemistry Research Foundation,14851,Discovery,2008-04-09 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Institut Pasteur,17237,Western Europe,XW,"EthR inhibitors (mycobacterium tuberculosis), BioVersys",61115,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2012-07-10 00:00:00,Institut Pasteur,17237,Discontinued,2012-07-10 00:00:00,DX,3,Respiratory disease,711
Transcriptional regulator protein EthR inhibitor,74415,LOCAL_AND_MAJOR,Institut Pasteur,17237,Western Europe,XW,"EthR inhibitors (mycobacterium tuberculosis), BioVersys",61115,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2012-07-10 00:00:00,Institut Pasteur,17237,Discovery,2008-08-27 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Genexine Co Ltd,29830,South Korea,KR,GX-140,61171,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2010-06-19 00:00:00,Genexine Co Ltd,29830,No Development Reported,2010-06-19 00:00:00,NDR,2,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,Genexine Co Ltd,29830,South Korea,KR,GX-140,61171,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2010-06-19 00:00:00,Genexine Co Ltd,29830,Discovery,2008-06-30 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,SinoBiomed Inc,1032007,China,CN,"recombinant multivalent tuberculosis vaccine, SinoBiomed",61931,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2011-01-06 00:00:00,SinoBiomed Inc,1032007,No Development Reported,2011-01-06 00:00:00,NDR,2,Respiratory disease,711
Therapeutic vaccine,12379,OTHER,SinoBiomed Inc,1032007,China,CN,"recombinant multivalent tuberculosis vaccine, SinoBiomed",61931,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2011-01-06 00:00:00,SinoBiomed Inc,1032007,No Development Reported,2011-01-06 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,TB Drug Boost,1054643,France,FR,"EthR inhibitors (Mycobacterium tuberculosis), TB Drug Boost",67295,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-06-20 00:00:00,TB Drug Boost,1054643,No Development Reported,2012-06-20 00:00:00,NDR,2,Respiratory disease,711
Non receptor tyrosine phosphatase 22 inhibitor,40557,LOCAL_AND_MAJOR,Aarden Pharmaceuticals Inc,1058608,US,US,"protein tyrosine phosphatase inhibitor (tuberculosis infection, cancer, autoimmune diseases), Aarden Pharmacueticals",69351,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2015-01-05 00:00:00,Aarden Pharmaceuticals Inc,1058608,Discovery,2009-11-10 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,University of Pittsburgh,20659,US,US,H-56,69824,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-08-22 00:00:00,University of Pittsburgh,20659,Discovery,2011-12-01 00:00:00,DR,6,Respiratory disease,711
Protein subunit vaccine,12372,LOCAL_AND_MAJOR,Infectious Disease Research Institute,27376,US,US,ID-93,68617,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-09-20 00:00:00,Infectious Disease Research Institute,27376,Discovery,2009-12-31 00:00:00,DR,6,Respiratory disease,711
Unspecified vaccine,12380,LOCAL_AND_MAJOR,Bio Farma,19368,Indonesia,ID,Lipovax-Fg115-TB,68627,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2015-04-16 00:00:00,Bio Farma,19368,Discovery,2015-04-16 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Dafra Pharma R&D,1040827,Belgium,BE,"DF-152 series (Mycobacterium tuberculosis infection), Dafra Pharma R&D",69801,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-01-25 00:00:00,Dafra Pharma International,1031290,Discovery,2011-01-25 00:00:00,DR,6,Respiratory disease,711
Unspecified protein kinase inhibitor,9671,LOCAL_AND_MAJOR,Medical Research Council Technology,1054893,UK,GB,"PknB inhibitors (Mycobacterium tuberculosis infection), MRCT",66920,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-09-23 00:00:00,Medical Research Council (MRC),18438,Discovery,2008-12-31 00:00:00,DR,6,Respiratory disease,711
Bacterial cell wall synthesis inhibitor,104,LOCAL_AND_MAJOR,Shaheed Beheshti Medical University,1034641,Iran,IR,KBF-611,65935,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-06-19 00:00:00,Shaheed Beheshti Medical University,1034641,Discovery,2009-12-31 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,Imaxio,1007058,UK,GB,IMX-461,66409,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-08-01 00:00:00,Imaxio,1007058,Phase 1 Clinical,2013-08-01 00:00:00,C1,8,Respiratory disease,711
Recombinant viral vector vaccine,12370,LOCAL_AND_MAJOR,Imaxio,1007058,France,FR,IMX-461,66409,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-08-01 00:00:00,Imaxio,1007058,Phase 1 Clinical,2010-05-06 00:00:00,C1,8,Respiratory disease,711
Antibacterial,1594,OTHER,RecipharmCobra Biologics,20370,UK,GB,"tuberculosis DNA vaccine (ORT), RecipharmCobra Biologics",69165,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-03-13 00:00:00,Recipharm AB,1058217,Discovery,2010-02-04 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Statens Serum Institut,21502,UK,GB,"protein subunit vaccine (Mycobacterium tuberculosis, intranasal), Novartis Vaccines & Diagnostics/Statens Serum Institut",66563,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2011-11-30 00:00:00,Statens Serum Institut,21502,Phase 1 Clinical,2007-02-26 00:00:00,C1,8,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Vichem Chemie Ltd,1031147,Hungary,HU,"PknG inhibitors (Mycobacterium tuberculosis infection), Vichem Chemie",68370,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2015-04-24 00:00:00,Vichem Chemie Ltd,1031147,Discovery,2008-03-15 00:00:00,DR,6,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,University of Oxford,22182,UK,GB,FP-85A,63673,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2011-12-29 00:00:00,University of Oxford,22182,No Development Reported,2011-12-29 00:00:00,NDR,2,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,TVAX Biomedical LLC,1049288,US,US,"autologous therapeutic vaccine, TVAX Biomedical",64503,Biological,Phase 2 Clinical,Discovery,DR,C2,Mycobacterium tuberculosis infection,221,true,2014-12-03 00:00:00,TVAX Biomedical LLC,1049288,Discovery,2012-12-06 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Medicine in Need,1054651,US,US,"capreomycin (inhalant/powder, tuberculosis), Medicines in Need",70827,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-09-24 00:00:00,Medicine in Need,1054651,Phase 2 Clinical,2008-10-16 00:00:00,C2,9,Respiratory disease,711
Epimerase inhibitor,520,LOCAL_AND_MAJOR,Hans Knoell Institute of Natural Products Research,24984,Germany,DE,"benzothiazinones (tuberculosis), Hans Knoell Institute",70901,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-09-25 00:00:00,Hans Knoell Institute of Natural Products Research,24984,No Development Reported,2013-09-25 00:00:00,NDR,2,Respiratory disease,711
Live attenuated bacterial vaccine,12363,LOCAL_AND_MAJOR,Albert Einstein College of Medicine,24282,US,US,"tuberculosis ESX-3 gene expressing Mycobacterium smegmatis vaccine, Albert Einstein College of Medicine",73315,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2005-06-21 00:00:00,Yeshiva University,20704,Discovery,2005-06-21 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Finlay Institute,15912,Cuba,CU,"Streptomyces vector-based live recombinant vaccine (tuberculosis infection), Finlay Institute",73326,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-10-15 00:00:00,Finlay Institute,15912,No Development Reported,2013-10-15 00:00:00,NDR,2,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Finlay Institute,15912,Cuba,CU,"Streptomyces vector-based live recombinant vaccine (tuberculosis infection), Finlay Institute",73326,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-10-15 00:00:00,Finlay Institute,15912,No Development Reported,2013-10-15 00:00:00,NDR,2,Respiratory disease,711
Recombinant fungal vector vaccine,33963,LOCAL_AND_MAJOR,Finlay Institute,15912,Cuba,CU,"Streptomyces vector-based live recombinant vaccine (tuberculosis infection), Finlay Institute",73326,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-10-15 00:00:00,Finlay Institute,15912,Discovery,2009-12-31 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,University of California San Diego,25451,US,US,NTF-1836,72331,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-02-05 00:00:00,University of California,20547,No Development Reported,2013-02-05 00:00:00,NDR,2,Respiratory disease,711
RNA polymerase inhibitor,347,LOCAL_AND_MAJOR,AstraZeneca plc,14190,UK,GB,"RNA polymerase inhibitors (tuberculosis infection), TB Alliance/Rutgers",71698,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2013-07-10 00:00:00,AstraZeneca plc,14190,No Development Reported,2013-07-10 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"RNA polymerase inhibitors (tuberculosis infection), TB Alliance/Rutgers",71698,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-07-10 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2009-01-27 00:00:00,DR,6,Respiratory disease,711
DNA gyrase B inhibitor,71209,OTHER,The Global Alliance for TB Drug Development,29411,India,IN,"gyrase B inhibitors (tuberculosis infection), AZ/TB Alliance",71700,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-11-30 00:00:00,The Global Alliance for TB Drug Development,29411,No Development Reported,2012-11-30 00:00:00,NDR,2,Respiratory disease,711
Carbapenem,73547,LOCAL_AND_MAJOR,Albert Einstein College of Medicine,24282,US,US,"carbapenem + beta lactamase inhibitor (Mycobacterium tuberculosis infection), Albert Einstein College of Medicine",79321,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-05-28 00:00:00,Yeshiva University,20704,No Development Reported,2014-05-28 00:00:00,NDR,2,Respiratory disease,711
Antibacterial multidrug resistance inhibitor,4855,LOCAL_AND_MAJOR,Albert Einstein College of Medicine,24282,US,US,"carbapenem + beta lactamase inhibitor (Mycobacterium tuberculosis infection), Albert Einstein College of Medicine",79321,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-05-28 00:00:00,Yeshiva University,20704,Discovery,2007-10-04 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,University of Auckland,20647,New Zealand,NZ,TBA-354,71742,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-01-30 00:00:00,University of Auckland,20647,Discovery,2009-10-02 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Shanghai H&G Biotechnology Co,1066720,China,CN,"Ag85A/B DNA vaccine (tuberculosis), Shanghai H&G Biotechnology",75084,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-17 00:00:00,Shanghai H&G Biotechnology Co,1066720,Discovery,2006-12-31 00:00:00,DR,6,Respiratory disease,711
Mycobacterial antigen complex 85A modulator,33967,LOCAL_AND_MAJOR,Shanghai H&G Biotechnology Co,1066720,China,CN,"ESAT-6/Ag85A-expressing recombinant BCG vaccine (Mycobacterium tuberculosis), Shanghai H&G",75152,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-17 00:00:00,Shanghai H&G Biotechnology Co,1066720,No Development Reported,2013-01-17 00:00:00,NDR,2,Respiratory disease,711
Recombinant bacterial vector vaccine,12369,LOCAL_AND_MAJOR,Shanghai H&G Biotechnology Co,1066720,China,CN,"ESAT-6/Ag85A-expressing recombinant BCG vaccine (Mycobacterium tuberculosis), Shanghai H&G",75152,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-17 00:00:00,Shanghai H&G Biotechnology Co,1066720,No Development Reported,2013-01-17 00:00:00,NDR,2,Respiratory disease,711
Mycobacterium early secretory antigen modulator,25527,LOCAL_AND_MAJOR,Shanghai H&G Biotechnology Co,1066720,China,CN,"ESAT-6/Ag85A-expressing recombinant BCG vaccine (Mycobacterium tuberculosis), Shanghai H&G",75152,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-17 00:00:00,Shanghai H&G Biotechnology Co,1066720,Discovery,2007-08-28 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Shanghai H&G Biotechnology Co,1066720,China,CN,"ESAT-6/Ag85A-expressing recombinant BCG vaccine (Mycobacterium tuberculosis), Shanghai H&G",75152,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-17 00:00:00,Shanghai H&G Biotechnology Co,1066720,Discovery,2007-08-28 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Microbion Corp,1055897,US,US,"MB-11, Microbion",77124,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-01-17 00:00:00,Microbion Corp,1055897,No Development Reported,2014-01-17 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Microbion Corp,1055897,US,US,"MB-11, Microbion",77124,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-01-17 00:00:00,Microbion Corp,1055897,No Development Reported,2014-01-17 00:00:00,NDR,2,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,VELES Pharma CJSC,1069315,US,US,"recombinant protein vaccine (nanoparticle, tuberculosis infection prevention/treatment), VELES Pharma",77247,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-04-12 00:00:00,VELES Pharma CJSC,1069315,Discovery,2012-04-12 00:00:00,DR,6,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,Universidade Federal de Minas Gerais,25676,Brazil,BR,"sMTL-13 vaccine (Mycobacterium tuberculosis infection), Universidade Federal de Minas Gerais",79289,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-08-25 00:00:00,Universidade Federal de Minas Gerais,25676,Discovery,2012-06-21 00:00:00,DR,6,Respiratory disease,711
Recombinant bacterial vector vaccine,12369,LOCAL_AND_MAJOR,VIB,25058,Belgium,BE,"tuberculosis vaccine, VIB/Ghent University",70144,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-10-07 00:00:00,University of Antwerp,22741,Discovery,2011-01-26 00:00:00,DR,6,Respiratory disease,711
Respiratory system agent,1470,OTHER,Pharmarare SA,1062315,World,WO,DasKloster 0249-01,71313,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2010-09-30 00:00:00,Pharmarare SA,1062315,Discovery,2010-09-30 00:00:00,DR,6,Respiratory disease,711
Recombinant bacterial vector vaccine,12369,OTHER,Tianjin CanSino Biotechnology Inc,1069870,Canada,CA,Ad5Ag85A,71323,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2012-05-07 00:00:00,Tianjin CanSino Biotechnology Inc,1069870,Phase 1 Clinical,2011-08-31 00:00:00,C1,8,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Nagoya City University,1022846,Japan,JP,"glucopyranoside derivatives (Mycobacterium tuberculosis infection), Nagoya City University",70208,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-02-18 00:00:00,Nagoya City University,1022846,Discovery,2009-11-30 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Nagoya City University,1022846,Japan,JP,"glucopyranoside derivatives (Mycobacterium tuberculosis infection), Nagoya City University",70208,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-02-18 00:00:00,Nagoya City University,1022846,Discovery,2009-11-30 00:00:00,DR,6,Respiratory disease,711
Recombinant viral vector vaccine,12370,LOCAL_AND_MAJOR,PaxVax Inc,1032157,US,US,"adenovirus 4-based vaccine (oral, tuberculosis), PaxVax",72040,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-11-27 00:00:00,PaxVax Inc,1032157,No Development Reported,2012-11-27 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,GlobalAcorn,1086420,UK,GB,GA3 MEP-TB,86658,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2015-04-17 00:00:00,GlobalAcorn,1086420,No Development Reported,2015-04-17 00:00:00,NDR,2,Respiratory disease,711
Protein subunit vaccine,12372,LOCAL_AND_MAJOR,Chongqing Zhifei Biological Products Co Ltd,1062383,China,CN,AEC/BC02,81363,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-09-21 00:00:00,Chongqing Zhifei Biological Products Co Ltd,1062383,Discovery,2012-09-21 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,The University of Notre Dame du Lac,20642,US,US,"antibacterial compounds (tuberculosis), Eli Lilly & Co/The University of Notre Dame du Lac/Montana State University/University of Illinois/Infectious Disease Research Institute",87600,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-09-11 00:00:00,The University of Notre Dame du Lac,20642,Discovery,2011-03-23 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,University of Illinois,20592,US,US,"antibacterial compounds (tuberculosis), Eli Lilly & Co/The University of Notre Dame du Lac/Montana State University/University of Illinois/Infectious Disease Research Institute",87600,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-09-11 00:00:00,University of Illinois,20592,Discovery,2011-03-23 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,University of California Los Angeles,25623,US,US,"rBCG30 vaccine (improved version, tuberculosis), UCLA",89141,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-11-29 00:00:00,University of California,20547,Discovery,2013-11-29 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,Novartis Institute for Tropical Diseases Pvt Ltd,1017949,Singapore,SG,"tuberculosis therapy, NITD/TB Alliance",82584,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-11-30 00:00:00,Novartis AG,23137,Discovery,2012-11-30 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"tuberculosis therapy, NITD/TB Alliance",82584,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-11-30 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2012-11-30 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"tuberculosis therapy, NITD/TB Alliance",82584,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-11-30 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2012-11-30 00:00:00,DR,6,Respiratory disease,711
ATP synthase inhibitor,49687,LOCAL_AND_MAJOR,Scripps Research Institute,21102,US,US,"ATP synthase inhibitors (tuberculosis), TB Alliance/California Institute for Biomedical Research",82643,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2013-06-30 00:00:00,Scripps Research Institute,21102,Discontinued,2013-06-30 00:00:00,DX,3,Respiratory disease,711
DPR oxidase inhibitor,78977,LOCAL_AND_MAJOR,Sichuan University,1003379,China,CN,SKLB-TB37,87680,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-06-16 00:00:00,Sichuan University,1003379,Discovery,2011-06-16 00:00:00,DR,6,Respiratory disease,711
Bacterial cell wall synthesis inhibitor,104,LOCAL_AND_MAJOR,Sichuan University,1003379,China,CN,SKLB-TB37,87680,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-06-16 00:00:00,Sichuan University,1003379,Discovery,2011-06-16 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,University of New Mexico,20639,US,US,"peptides (tuberculosis), University of New Mexico/Science & Technology Corporation @ UNM",88384,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-01-24 00:00:00,University of New Mexico,20639,Discovery,2011-01-24 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,University of New Mexico,20639,US,US,"peptides (tuberculosis), University of New Mexico/Science & Technology Corporation @ UNM",88384,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-01-24 00:00:00,University of New Mexico,20639,Discovery,2011-01-24 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Harvard University,20584,US,US,"small molecule VKOR inhibitors (Mycobacterium tuberculosis infection), Harvard University/Harvard University Office of Technology Development",86119,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-02-01 00:00:00,Harvard University,20584,Discovery,2012-02-01 00:00:00,DR,6,Respiratory disease,711
RNA polymerase inhibitor,347,LOCAL_AND_MAJOR,Liaoning Hongwuxing Pharmaceutical Co Ltd,1090092,China,CN,"ethambutol hydrochloride (150 mg) + pyrazinamide (300 mg) + rifampicin (90 mg) + isoniazid (60 mg) (oral tablet, tuberculosis), Shenyang Hongqi Pharmaceutical/Liaoning Hongwuxing Pharmaceutical",88505,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-11-15 00:00:00,Liaoning Hongwuxing Pharmaceutical Co Ltd,1090092,Discovery,2013-11-15 00:00:00,DR,6,Respiratory disease,711
Bacterial cell wall synthesis inhibitor,104,LOCAL_AND_MAJOR,Liaoning Hongwuxing Pharmaceutical Co Ltd,1090092,China,CN,"ethambutol hydrochloride (200 mg) + pyrazinamide (300 mg) + rifampicin (120 mg) + isoniazid (100 mg) (oral tablet, tuberculosis), Shenyang Hongqi Pharmaceutical/Liaoning Hongwuxing Pharmaceutical",88507,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-11-15 00:00:00,Liaoning Hongwuxing Pharmaceutical Co Ltd,1090092,Discovery,2013-11-15 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Sanofi,1009547,US,US,"urea compounds (tuberculosis), TB Alliance/Sanofi",89824,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-01-23 00:00:00,Sanofi,1009547,Discovery,2014-01-23 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Johns Hopkins University Office of Technology Transfer,1083716,US,US,"Methionine aminopeptidase inhibitors (Mycobacterium tuberculosis), Johns Hopkins University",89387,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-12-19 00:00:00,Johns Hopkins University,20596,Discovery,2013-12-19 00:00:00,DR,6,Respiratory disease,711
Methionine aminopeptidase inhibitor,9287,LOCAL_AND_MAJOR,Johns Hopkins University,20596,US,US,"Methionine aminopeptidase inhibitors (Mycobacterium tuberculosis), Johns Hopkins University",89387,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-12-19 00:00:00,Johns Hopkins University,20596,Discovery,2010-01-31 00:00:00,DR,6,Respiratory disease,711
Acetolactate synthase inhibitor,83093,OTHER,AstraZeneca plc,14190,India,IN,"antimycobacterials (Mycobacterium tuberculsosis infection), Astrazeneca",89914,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-04-15 00:00:00,AstraZeneca plc,14190,Discovery,2013-04-15 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Shanghai Zerun Biotechnology Co Ltd,1044432,China,CN,"tuberculosis vaccine, Shanghai Zerun Biotech",81607,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-09-07 00:00:00,Yunnan Walvax Biotech Co Ltd,1048098,Discovery,2012-09-07 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,University of Illinois,20592,US,US,"anti-tuberculosis agents, University of Illinois/University of Illinois at URBANA-CHAMPAIGN",87132,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-08-27 00:00:00,University of Illinois,20592,Discovery,2013-08-27 00:00:00,DR,6,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,Chongqing Zhifei Biological Products Co Ltd,1062383,China,CN,Wei Ka,81037,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2001-12-31 00:00:00,Chongqing Zhifei Biological Products Co Ltd,1062383,Launched,2001-12-31 00:00:00,L,13,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Chongqing Zhifei Biological Products Co Ltd,1062383,China,CN,Wei Ka,81037,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2001-12-31 00:00:00,Chongqing Zhifei Biological Products Co Ltd,1062383,Launched,2001-12-31 00:00:00,L,13,Respiratory disease,711
Inactivated bacterial vaccine,12366,LOCAL_AND_MAJOR,Chongqing Zhifei Biological Products Co Ltd,1062383,China,CN,Wei Ka,81037,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2001-12-31 00:00:00,Chongqing Zhifei Biological Products Co Ltd,1062383,Launched,2001-12-31 00:00:00,L,13,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Chengdu Institute of Biological Products,1016340,China,CN,Ka Shu Ning,80062,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,1998-12-31 00:00:00,Sinopharm,1055632,Registered,1998-12-31 00:00:00,R,12,Respiratory disease,711
Live attenuated bacterial vaccine,12363,LOCAL_AND_MAJOR,Shanghai Institute of Biological Products Co Ltd,1071897,China,CN,"BCG vaccine (intradermal), Shanghai Institute of Biological Products",80067,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2001-12-31 00:00:00,Sinopharm,1055632,Registered,2001-12-31 00:00:00,R,12,Respiratory disease,711
Bacterial protein synthesis inhibitor,1538,LOCAL_AND_MAJOR,Kaneka Corp,17639,Japan,JP,rifalazil,8658,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2014-10-30 00:00:00,Kaneka Corp,17639,No Development Reported,2000-02-22 00:00:00,NDR,2,Respiratory disease,711
Ribosome binding agent,463,LOCAL_AND_MAJOR,Nanosystem Ltd,1071336,Russian Federation,RU,"rifabutin nanoparticles (iv, Mycobacterium tuberculosis), Nanosystem",82299,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-12-07 00:00:00,Nanosystem Ltd,1071336,Discovery,2012-12-07 00:00:00,DR,6,Respiratory disease,711
Unspecified enzyme modulator,1051,LOCAL_AND_MAJOR,Albert Einstein College of Medicine,24282,US,US,"TCA1 analogs (Mycobacterium tuberculosis infection), SRI/HHMI/AECM",85774,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-06-17 00:00:00,Yeshiva University,20704,Discovery,2013-06-17 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Howard Hughes Medical Institute,21084,US,US,"TCA1 analogs (Mycobacterium tuberculosis infection), SRI/HHMI/AECM",85774,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-06-17 00:00:00,Howard Hughes Medical Institute,21084,Discovery,2013-06-17 00:00:00,DR,6,Respiratory disease,711
Antiviral,991,LOCAL_AND_MAJOR,PHARMACLON LLC,1073552,Russian Federation,RU,"interferon gamma follow-on biologic, PHARMACLON LLC",81264,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2013-07-23 00:00:00,PHARMACLON LLC,1073552,Launched,2013-07-23 00:00:00,L,13,Respiratory disease,711
RNA polymerase inhibitor,347,LOCAL_AND_MAJOR,Pharmacia & Upjohn Co,18995,US,US,rifabutin,4229,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2008-10-07 00:00:00,Pfizer Inc,18767,Phase 3 Clinical,1996-12-09 00:00:00,C3,10,Respiratory disease,711
Antibacterial multidrug resistance inhibitor,4855,OTHER,Janssen Research & Development LLC,1067538,Russian Federation,RU,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Discovery,2009-10-30 00:00:00,DR,6,Respiratory disease,711
ATP synthase inhibitor,49687,OTHER,Janssen Research & Development LLC,1067538,South Africa,ZA,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Registered,2014-11-06 00:00:00,R,12,Respiratory disease,711
Antibacterial multidrug resistance inhibitor,4855,LOCAL_AND_MAJOR,Janssen Research & Development LLC,1067538,US,US,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Launched,2013-04-19 00:00:00,L,13,Respiratory disease,711
ATP synthase inhibitor,49687,OTHER,Janssen Research & Development LLC,1067538,Kenya,KE,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Discovery,2009-07-30 00:00:00,DR,6,Respiratory disease,711
ATP synthase inhibitor,49687,OTHER,Janssen Research & Development LLC,1067538,Japan,JP,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Phase 2 Clinical,2015-03-18 00:00:00,C2,9,Respiratory disease,711
ATP synthase inhibitor,49687,OTHER,Janssen Research & Development LLC,1067538,Colombia,CO,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Pre-registration,2014-11-06 00:00:00,PR,11,Respiratory disease,711
Antibacterial multidrug resistance inhibitor,4855,OTHER,Janssen Research & Development LLC,1067538,India,IN,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Pre-registration,2013-06-17 00:00:00,PR,11,Respiratory disease,711
DPR oxidase inhibitor,78977,LOCAL_AND_MAJOR,AstraZeneca plc,14190,UK,GB,"DprE1 inhibitors (Mycobacterium tuberculosis infection), AstraZeneca",90122,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-09-10 00:00:00,AstraZeneca plc,14190,Discovery,2013-09-10 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Sichuan University,1003379,China,CN,antituberculosis agents (tuberculosis) Sichuan University,95733,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-12-27 00:00:00,Sichuan University,1003379,Discovery,2013-12-27 00:00:00,DR,6,Respiratory disease,711
Nitric oxide donor,698,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,pretomanid,13323,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-09-05 00:00:00,The Global Alliance for TB Drug Development,29411,Phase 1 Clinical,2005-06-14 00:00:00,C1,8,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Okklo Life Sciences BV,1098970,Netherlands,NL,OKL-3018,92087,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-07-31 00:00:00,Okklo Life Sciences BV,1098970,Discovery,2014-07-31 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,GlaxoSmithKline plc,28355,UK,GB,"anti-tuberculosis drugs (Mycobacterium tuberculosis infection), GlaxoSmithKline",90381,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-03-16 00:00:00,GlaxoSmithKline plc,28355,Discovery,2014-03-16 00:00:00,DR,6,Respiratory disease,711
DNA vaccine,1879,LOCAL_AND_MAJOR,FIT Biotech Oyj Plc,26400,Finland,FI,GTU-TB vaccine,66880,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2009-02-09 00:00:00,FIT Biotech Oyj Plc,26400,Discovery,2009-02-09 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Chiron PathoGenesis,18741,US,US,pretomanid,13323,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-09-05 00:00:00,Novartis AG,23137,No Development Reported,2000-02-09 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,OTHER,Chemical Diversity Research Institute Ltd,1009877,Russian Federation,RU,"small molecule therapeutics (Mycobacterium tuberculosis infection), ChemDiv Research Institute/Novartis Institute for Tropical Diseases/Silvius Pharma",76796,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2014-08-14 00:00:00,ChemDiv Inc,1012947,Discovery,2010-09-30 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Cornell University,24136,US,US,"proteosome inhibitors (mycobacterium tuberculosis), Cornell University",86500,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2009-10-01 00:00:00,Cornell University,24136,Discovery,2009-10-01 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,National Institutes of Health,20518,US,US,"thiolactomycin analog, GlaxoSmithKline",33073,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-08-08 00:00:00,US Government,20516,Discovery,2001-02-28 00:00:00,DR,6,Respiratory disease,711
Protein subunit vaccine,12372,LOCAL_AND_MAJOR,Statens Serum Institut,21502,Denmark,DK,SSI H56-IC31,74849,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-11-08 00:00:00,Statens Serum Institut,21502,Discovery,2011-04-27 00:00:00,DR,6,Respiratory disease,711
Therapeutic vaccine,12379,OTHER,Statens Serum Institut,21502,South Africa,ZA,SSI H56-IC31,74849,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-11-08 00:00:00,Statens Serum Institut,21502,Phase 1 Clinical,2011-12-01 00:00:00,C1,8,Respiratory disease,711
DNA vaccine,1879,OTHER,Sequella Inc,28087,UK,GB,"DNA vaccine (tuberculosis), NIMR/Sequella",22154,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-10-13 00:00:00,Sequella Inc,28087,Discovery,2001-11-29 00:00:00,DR,6,Respiratory disease,711
Therapeutic vaccine,12379,OTHER,Sequella Inc,28087,UK,GB,"DNA vaccine (tuberculosis), NIMR/Sequella",22154,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-10-13 00:00:00,Sequella Inc,28087,No Development Reported,2008-10-13 00:00:00,NDR,2,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,UK National Institute of Medical Research,20466,UK,GB,"DNA vaccine (tuberculosis), NIMR/Sequella",22154,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-10-13 00:00:00,Medical Research Council (MRC),18438,Discovery,1999-02-19 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Johns Hopkins University,20596,US,US,"tuberculosis therapy, TB Alliance/Johns Hopkins University",82716,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-06-30 00:00:00,Johns Hopkins University,20596,Discovery,2012-11-30 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"tuberculosis therapy, TB Alliance/Johns Hopkins University",82716,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-06-30 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2012-11-30 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,GlaxoSmithKline plc,28355,US,US,"thiolactomycin analog, GlaxoSmithKline",33073,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-08-08 00:00:00,GlaxoSmithKline plc,28355,No Development Reported,2008-08-08 00:00:00,NDR,2,Respiratory disease,711
Antiparasitic,2638,LOCAL_AND_MAJOR,GlaxoSmithKline plc,28355,US,US,"thiolactomycin analog, GlaxoSmithKline",33073,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-08-08 00:00:00,GlaxoSmithKline plc,28355,No Development Reported,2008-08-08 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Karolinska Institutet,21110,Sweden,SE,"XDR-TB RNA-based therapeutics (tuberculosis), Sarepta therapeutics/Karolinska Institute",71453,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-01-05 00:00:00,Karolinska Institutet,21110,Discovery,2011-01-05 00:00:00,DR,6,Respiratory disease,711
Antisense oligonucleotide inhibitor,7294,LOCAL_AND_MAJOR,Karolinska Institutet,21110,Sweden,SE,"XDR-TB RNA-based therapeutics (tuberculosis), Sarepta therapeutics/Karolinska Institute",71453,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-01-05 00:00:00,Karolinska Institutet,21110,Discovery,2011-01-05 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Dartmouth-Hitchcock Medical Center,30837,US,US,DAR-901,90231,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2014-02-28 00:00:00,Dartmouth-Hitchcock Medical Center,30837,Phase 1 Clinical,2014-02-28 00:00:00,C1,8,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Cellworks Group Inc,1071272,US,US,CWGNC-4_1,90432,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-07-02 00:00:00,Cellworks Group Inc,1071272,Discovery,2012-07-02 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,AstraZeneca plc,14190,UK,GB,"energy metabolism inhibitors (tuberculosis), AstraZeneca/University of Pennsylvania/TB Alliance",71615,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-03-28 00:00:00,AstraZeneca plc,14190,Discovery,2011-03-28 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,University of Pennsylvania,20658,US,US,"energy metabolism inhibitors (tuberculosis), AstraZeneca/University of Pennsylvania/TB Alliance",71615,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-03-28 00:00:00,University of Pennsylvania,20658,Discovery,2011-03-17 00:00:00,DR,6,Respiratory disease,711
Energy metabolism modulator,1732,OTHER,The Global Alliance for TB Drug Development,29411,UK,GB,"energy metabolism inhibitors (tuberculosis), AstraZeneca/University of Pennsylvania/TB Alliance",71615,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-03-28 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2011-03-17 00:00:00,DR,6,Respiratory disease,711
Glutamate receptor modulator,870,LOCAL_AND_MAJOR,Johns Hopkins University,20596,US,US,"L-homoserine, Johns Hopkins",18364,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2001-01-30 00:00:00,Johns Hopkins University,20596,No Development Reported,2001-01-30 00:00:00,NDR,2,Respiratory disease,711
Antiparasitic,2638,LOCAL_AND_MAJOR,St Jude Children's Research Hospital,21814,US,US,"thiolactomycin analog, GlaxoSmithKline",33073,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-08-08 00:00:00,St Jude Children's Research Hospital,21814,Discovery,2001-02-28 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,St Jude Children's Research Hospital,21814,US,US,"thiolactomycin analog, GlaxoSmithKline",33073,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-08-08 00:00:00,St Jude Children's Research Hospital,21814,No Development Reported,2008-08-08 00:00:00,NDR,2,Respiratory disease,711
Helicase inhibitor,5552,LOCAL_AND_MAJOR,Medical Research Council Technology,1054893,UK,GB,"UvrD helicase inhibitors (Mycobacterium tuberculosis infection), MRCT",66922,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-06-21 00:00:00,Medical Research Council (MRC),18438,Discovery,2010-06-17 00:00:00,DR,6,Respiratory disease,711
Anti-inflammatory,2953,LOCAL_AND_MAJOR,Otsuka Pharmaceutical Co Ltd,18717,Japan,JP,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Discovery,2005-03-16 00:00:00,DR,6,Respiratory disease,711
Anticancer,1545,OTHER,Otsuka Pharmaceutical Co Ltd,18717,South Korea,KR,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 2 Clinical,2008-04-30 00:00:00,C2,9,Respiratory disease,711
Anti-inflammatory,2953,OTHER,Otsuka Pharmaceutical Co Ltd,18717,South Korea,KR,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 2 Clinical,2008-04-30 00:00:00,C2,9,Respiratory disease,711
Angiogenesis inhibitor,61,OTHER,Otsuka Pharmaceutical Co Ltd,18717,South Korea,KR,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 2 Clinical,2008-04-30 00:00:00,C2,9,Respiratory disease,711
Antibacterial,1594,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Europe,X5,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Discovery,2007-12-06 00:00:00,DR,6,Respiratory disease,711
Anti-inflammatory,2953,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Europe,X5,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Discovery,2007-12-06 00:00:00,DR,6,Respiratory disease,711
Anticancer,1545,LOCAL_AND_MAJOR,Otsuka Pharmaceutical Co Ltd,18717,Japan,JP,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 1 Clinical,2005-12-19 00:00:00,C1,8,Respiratory disease,711
Anticancer,1545,LOCAL_AND_MAJOR,Otsuka Pharmaceutical Co Ltd,18717,Japan,JP,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Pre-registration,2013-03-27 00:00:00,PR,11,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Otsuka Pharmaceutical Co Ltd,18717,Japan,JP,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Pre-registration,2013-03-27 00:00:00,PR,11,Respiratory disease,711
Anti-inflammatory,2953,LOCAL_AND_MAJOR,Otsuka Pharmaceutical Co Ltd,18717,Japan,JP,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Pre-registration,2013-03-27 00:00:00,PR,11,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Otsuka Pharmaceutical Co Ltd,18717,Japan,JP,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Registered,2014-07-04 00:00:00,R,12,Respiratory disease,711
Anti-inflammatory,2953,OTHER,Otsuka Pharmaceutical Co Ltd,18717,South Africa,ZA,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 2 Clinical,2006-11-30 00:00:00,C2,9,Respiratory disease,711
Mycolic acid synthase inhibitor,6542,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Estonia,EE,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 2 Clinical,2008-04-30 00:00:00,C2,9,Respiratory disease,711
Anti-inflammatory,2953,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Lithuania,LT,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 3 Clinical,2011-09-19 00:00:00,C3,10,Respiratory disease,711
Anti-inflammatory,2953,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Estonia,EE,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 3 Clinical,2011-09-19 00:00:00,C3,10,Respiratory disease,711
Angiogenesis inhibitor,61,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Estonia,EE,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 3 Clinical,2011-09-19 00:00:00,C3,10,Respiratory disease,711
Anti-inflammatory,2953,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Egypt,EG,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 2 Clinical,2008-04-30 00:00:00,C2,9,Respiratory disease,711
Anticancer,1545,OTHER,Otsuka Pharmaceutical Co Ltd,18717,South Korea,KR,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Registered,2014-10-29 00:00:00,R,12,Respiratory disease,711
Anti-inflammatory,2953,OTHER,Otsuka Pharmaceutical Co Ltd,18717,China,CN,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 2 Clinical,2008-04-30 00:00:00,C2,9,Respiratory disease,711
Angiogenesis inhibitor,61,OTHER,Otsuka Pharmaceutical Co Ltd,18717,South Africa,ZA,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 3 Clinical,2013-07-26 00:00:00,C3,10,Respiratory disease,711
Anti-inflammatory,2953,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Peru,PE,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 3 Clinical,2013-07-26 00:00:00,C3,10,Respiratory disease,711
Antibacterial,1594,OTHER,Immodulon Therapeutics Limited,1051823,Argentina,AR,"heat-killed Mycobacterium vaccae (tablet formulation, tuberculosis), Immunitor",70934,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-26 00:00:00,Immodulon Therapeutics Limited,1051823,Clinical,2010-03-31 00:00:00,CU,7,Respiratory disease,711
Antiviral,991,LOCAL_AND_MAJOR,LeukoMed Inc,30043,US,US,LMP-420,41819,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2009-03-16 00:00:00,LeukoMed Inc,30043,Discovery,2002-09-26 00:00:00,DR,6,Respiratory disease,711
Immunomodulator,1596,LOCAL_AND_MAJOR,LeukoMed Inc,30043,US,US,LMP-420,41819,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2009-03-16 00:00:00,LeukoMed Inc,30043,No Development Reported,2009-03-16 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,University of Illinois,20592,US,US,"tuberculosis therapy, TB Alliance/Johns Hopkins University",82716,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2013-06-30 00:00:00,University of Illinois,20592,Discontinued,2013-06-30 00:00:00,DX,3,Respiratory disease,711
Bacterial protein synthesis inhibitor,1538,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"macrolides (tuberculosis), TB Alliance/Sanofi",82709,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-11-30 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2012-11-30 00:00:00,DR,6,Respiratory disease,711
IL-4 antagonist,225,LOCAL_AND_MAJOR,InterMune Inc,26430,US,US,Actimmune,3365,Biological,Launched,No Development Reported,NDR,L,Mycobacterium tuberculosis infection,221,false,2014-09-19 00:00:00,Roche Holding AG,19446,No Development Reported,2007-03-31 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Chiron PathoGenesis,18741,US,US,PA-342,10997,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,1996-11-01 00:00:00,Novartis AG,23137,Discovery,1995-09-26 13:55:49,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Verta Ltd,1004196,Russian Federation,RU,"golotimod (oral), SciClone/Verta",55521,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2011-10-10 00:00:00,Verta Ltd,1004196,Discovery,1999-08-26 00:00:00,DR,6,Respiratory disease,711
Immunostimulant,393,LOCAL_AND_MAJOR,Verta Ltd,1004196,Russian Federation,RU,"golotimod (oral), SciClone/Verta",55521,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2011-10-10 00:00:00,Verta Ltd,1004196,Discovery,1999-08-26 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Universidad de Zaragoza,25210,South Africa,ZA,MTBVAC,89744,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-11-15 00:00:00,Universidad de Zaragoza,25210,Discovery,2013-11-15 00:00:00,DR,6,Respiratory disease,711
Alanine racemase inhibitor,48741,LOCAL_AND_MAJOR,L2 Diagnostics Llc,1007281,US,US,"alanine racemase inhibitors (Mycobacterium tuberculosis infection), L2 Diagnostics",72479,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2015-01-02 00:00:00,L2 Diagnostics Llc,1007281,Discovery,2011-05-26 00:00:00,DR,6,Respiratory disease,711
Alanine racemase inhibitor,48741,LOCAL_AND_MAJOR,L2 Diagnostics Llc,1007281,US,US,"alanine racemase inhibitors (Mycobacterium tuberculosis infection), L2 Diagnostics",72479,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2015-01-02 00:00:00,L2 Diagnostics Llc,1007281,No Development Reported,2015-01-02 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Southern Research Institute,20226,US,US,"tuberculosis therapy, iThemba Pharmaceuticals/Southern Research Institute",67092,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-06-22 00:00:00,Southern Research Institute,20226,Discovery,2010-05-06 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Southern Research Institute,20226,US,US,"tuberculosis therapy, iThemba Pharmaceuticals/Southern Research Institute",67092,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-06-22 00:00:00,Southern Research Institute,20226,No Development Reported,2012-06-22 00:00:00,NDR,2,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Max-Planck-Gesellschaft zur Forderung der Wissenschaften eV,17962,Germany,DE,VPM-1002,55569,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2013-03-27 00:00:00,Max-Planck-Gesellschaft zur Forderung der Wissenschaften eV,17962,Discontinued,2004-03-24 00:00:00,DX,3,Respiratory disease,711
Anticancer,1545,LOCAL_AND_MAJOR,Max-Planck-Gesellschaft zur Forderung der Wissenschaften eV,17962,Germany,DE,VPM-1002,55569,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2013-03-27 00:00:00,Max-Planck-Gesellschaft zur Forderung der Wissenschaften eV,17962,Discontinued,2004-03-24 00:00:00,DX,3,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Vakzine Projekt Management GmbH,1020740,Germany,DE,VPM-1002,55569,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-03-27 00:00:00,Vakzine Projekt Management GmbH,1020740,Phase 1 Clinical,2008-09-05 00:00:00,C1,8,Respiratory disease,711
Live attenuated bacterial vaccine,12363,LOCAL_AND_MAJOR,Vakzine Projekt Management GmbH,1020740,Germany,DE,VPM-1002,55569,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-03-27 00:00:00,Vakzine Projekt Management GmbH,1020740,Phase 2 Clinical,2011-09-26 00:00:00,C2,9,Respiratory disease,711
DNA vaccine,1879,LOCAL_AND_MAJOR,GenomIdea Inc,1008113,Japan,JP,"DNA vaccines (HJV vector, tuberculosis), GenomIdea",60030,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2007-04-20 00:00:00,AnGes MG Inc,28514,Discovery,2007-04-20 00:00:00,DR,6,Respiratory disease,711
Ubiquinol cytochrome C reductase 14 kDa inhibitor,30365,LOCAL_AND_MAJOR,Infectex,1068619,Russian Federation,RU,"Q-203, Qurient / Infectex",85970,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-02-06 00:00:00,Maxwell Biotech Group,1061894,Discovery,2014-02-06 00:00:00,DR,6,Respiratory disease,711
Phospholipase A2 stimulator,1885,LOCAL_AND_MAJOR,University of Pretoria,25323,South Africa,ZA,B-4128,33132,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-07-08 00:00:00,University of Pretoria,25323,Discovery,2001-03-05 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,University of Pretoria,25323,South Africa,ZA,B-4128,33132,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-07-08 00:00:00,University of Pretoria,25323,No Development Reported,2008-07-08 00:00:00,NDR,2,Respiratory disease,711
Immunomodulator,1596,LOCAL_AND_MAJOR,Finlay Institute,15912,Cuba,CU,"polyclonal antibodies (Mycobacterium tuberculosis infection), Finlay Institute",73038,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-08-09 00:00:00,Finlay Institute,15912,Discovery,2011-08-09 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,NeED Pharmaceuticals Srl,1013076,Italy,IT,ND-801,59776,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-03-21 00:00:00,NeED Pharmaceuticals Srl,1013076,Discovery,2007-04-25 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,NeED Pharmaceuticals Srl,1013076,Italy,IT,ND-801,59776,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-03-21 00:00:00,NeED Pharmaceuticals Srl,1013076,No Development Reported,2014-03-21 00:00:00,NDR,2,Respiratory disease,711
T-lymphocyte stimulator,7761,LOCAL_AND_MAJOR,Vaxil BioTherapeutics Ltd,1036156,Israel,IL,MTbuVax,66172,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2009-02-25 00:00:00,Sheldonco Ltd,1095293,Discovery,2009-02-25 00:00:00,DR,6,Respiratory disease,711
Defensin modulator,14365,LOCAL_AND_MAJOR,PolyMedix Inc,1011746,US,US,PMX-10072,63306,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2013-09-09 00:00:00,PolyMedix Inc,1011746,Discontinued,2013-09-09 00:00:00,DX,3,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,ApoVax Inc,29552,US,US,ApoVax104-TB,68211,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2015-01-05 00:00:00,ApoVax Inc,29552,No Development Reported,2015-01-05 00:00:00,NDR,2,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,ApoVax Inc,29552,US,US,ApoVax104-TB,68211,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2015-01-05 00:00:00,ApoVax Inc,29552,No Development Reported,2015-01-05 00:00:00,NDR,2,Respiratory disease,711
DNA vaccine,1879,LOCAL_AND_MAJOR,Pohang University of Science & Technology,25083,South Korea,KR,"therapeutic DNA vaccine (tuberculosis), Pohang/Yonsei Universities",53019,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2009-12-24 00:00:00,Pohang University of Science & Technology,25083,Discovery,2003-09-30 00:00:00,DR,6,Respiratory disease,711
DNA vaccine,1879,LOCAL_AND_MAJOR,Pohang University of Science & Technology,25083,South Korea,KR,"therapeutic DNA vaccine (tuberculosis), Pohang/Yonsei Universities",53019,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2009-12-24 00:00:00,Pohang University of Science & Technology,25083,No Development Reported,2009-12-24 00:00:00,NDR,2,Respiratory disease,711
Glycosyltransferase inhibitor,1025,LOCAL_AND_MAJOR,Medical Research Council Technology,1054893,UK,GB,"GlgE inhibitors (tuberculosis), MCRT",78428,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-06-25 00:00:00,Medical Research Council (MRC),18438,Discovery,2012-05-31 00:00:00,DR,6,Respiratory disease,711
Antidepressant,2941,LOCAL_AND_MAJOR,National University of Singapore,20633,Singapore,SG,pascolizumab,17132,Biological,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2014-06-23 00:00:00,National University of Singapore,20633,Discovery,2012-07-09 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Phage Therapeutics Inc,27485,US,US,"bacteriophage (Mycobacterium tuberculosis infection), Phage Therapeutics",34469,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-12-31 00:00:00,Phage Therapeutics Inc,27485,Discovery,2001-06-01 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Shanghai H&G Biotechnology Co,1066720,China,CN,HG856-SeV,75156,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-17 00:00:00,Shanghai H&G Biotechnology Co,1066720,Discovery,2009-12-31 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Shanghai H&G Biotechnology Co,1066720,China,CN,HG856-SeV,75156,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-17 00:00:00,Shanghai H&G Biotechnology Co,1066720,No Development Reported,2013-01-17 00:00:00,NDR,2,Respiratory disease,711
Mycobacterial antigen complex 85A modulator,33967,LOCAL_AND_MAJOR,Shanghai H&G Biotechnology Co,1066720,China,CN,HG856-SeV,75156,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-17 00:00:00,Shanghai H&G Biotechnology Co,1066720,No Development Reported,2013-01-17 00:00:00,NDR,2,Respiratory disease,711
Subunit vaccine,12371,OTHER,GlaxoSmithKline plc,28355,South Africa,ZA,"MTB72F vaccine (tuberculosis), GSK/Aeras",9490,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-08-26 00:00:00,GlaxoSmithKline plc,28355,Phase 2 Clinical,2014-08-26 00:00:00,C2,9,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,GlaxoSmithKline plc,28355,Switzerland,CH,"MTB72F vaccine (tuberculosis), GSK/Aeras",9490,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-08-26 00:00:00,GlaxoSmithKline plc,28355,Phase 2 Clinical,2000-09-30 00:00:00,C2,9,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Anacor Pharmaceuticals Inc,30118,US,US,"leucyl tRNA synthetase modulators (tuberculosis), GlaxoSmithKline",70581,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2013-10-17 00:00:00,Anacor Pharmaceuticals Inc,30118,Discovery,2009-05-27 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Anacor Pharmaceuticals Inc,30118,US,US,"leucyl tRNA synthetase modulators (tuberculosis), GlaxoSmithKline",70581,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2013-10-17 00:00:00,Anacor Pharmaceuticals Inc,30118,Discontinued,2013-10-17 00:00:00,DX,3,Respiratory disease,711
Hyaluronic acid agonist,476,OTHER,Beech Tree Labs Inc,1052204,UK,GB,ML-05,69033,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-09-13 00:00:00,Beech Tree Labs Inc,1052204,Discovery,2011-09-13 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"topoisomerase I inhibitors (tuberculosis infection), TB Alliance/NYMC/AZ",71897,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-06-27 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2009-05-27 00:00:00,DR,6,Respiratory disease,711
RNA polymerase inhibitor,347,LOCAL_AND_MAJOR,Cadila Pharmaceuticals Ltd,30025,India,IN,"rifampicin + isoniazid + piperine (fixed dose combination, tuberculosis), Cadila Pharmaceuticals",69440,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2009-10-31 00:00:00,Cadila Pharmaceuticals Ltd,30025,Launched,2009-10-31 00:00:00,L,13,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Pro Bono Bio,1068320,UK,GB,"anti-tuberculosis therapeutics, Pro Bono Bio",76813,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-07-17 00:00:00,Pro Bono Bio,1068320,Discovery,2012-03-19 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Pro Bono Bio,1068320,UK,GB,"anti-tuberculosis therapeutics, Pro Bono Bio",76813,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-07-17 00:00:00,Pro Bono Bio,1068320,Discovery,2012-03-19 00:00:00,DR,6,Respiratory disease,711
Carbapenem,73547,LOCAL_AND_MAJOR,INSERM,17229,France,FR,"L,D-transpeptidase inhibitors (Mycobacterium tuberculosis infection), INSERM",78290,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-05-24 00:00:00,INSERM,17229,Discovery,2008-04-11 00:00:00,DR,6,Respiratory disease,711
DPR oxidase inhibitor,78977,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"DprE inhibitors (tuberculosis), TB Alliance/California Institute for Biomedical Research",82660,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-06-30 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2012-11-30 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"cyclopeptides (oral, tuberculosis), TB Alliance/Sanofi",82710,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-11-30 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2012-11-30 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Sanofi,1009547,US,US,"cyclopeptides (oral, tuberculosis), TB Alliance/Sanofi",82710,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-11-30 00:00:00,Sanofi,1009547,Discovery,2012-11-30 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Finlay Institute,15912,Cuba,CU,"alpha crystallin inhibiting IgA mAbs (tuberculosis infection), Finlay Institute",72912,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-09-25 00:00:00,Finlay Institute,15912,Discovery,2003-09-24 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Institute for Tuberculosis Research,1092461,US,US,"anti-TB antibiotics (Mycobacterium tuberculosis), Mycosynthetix/Institute for Tuberculosis Research",70759,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2009-02-12 00:00:00,Institute for Tuberculosis Research,1092461,Discovery,2009-02-12 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Sanofi,1009547,US,US,"cyclopeptides (oral, tuberculosis), TB Alliance/Sanofi",82710,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-11-30 00:00:00,Sanofi,1009547,Discovery,2012-11-30 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Anacor Pharmaceuticals Inc,30118,US,US,"anti-tuberculosis therapeutics, Anacor/Infectious Disease Research Institute",89753,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-12-31 00:00:00,Anacor Pharmaceuticals Inc,30118,Discovery,2009-05-27 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,The Lilly TB Drug Discovery Initiative,1042702,US,US,"inhibitors of isoprenoid biosynthesis enzymes (tuberculosis infection), The Lilly TB Drug Discovery Initiative/Colorado State University",89970,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-08-30 00:00:00,The Lilly TB Drug Discovery Initiative,1042702,Discovery,2011-08-30 00:00:00,DR,6,Respiratory disease,711
Lyase inhibitor,248,OTHER,GlaxoSmithKline plc,28355,Spain,ES,"isocitrate lyase inhibitors (tuberculosis), GlaxoSmithKline/The Global Alliance for TB Drug Developement",56373,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2007-05-31 00:00:00,GlaxoSmithKline plc,28355,No Development Reported,2007-05-31 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Institute for Tuberculosis Research,1092461,US,US,"actinomycetes metabolites (multi-drug resistant tuberculosis infection), Univeristy of Illinois/Institute for Tuberculosis Research/Univeristy of Illinois at Urbana-Champaign",71899,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-01-24 00:00:00,Institute for Tuberculosis Research,1092461,Discovery,2014-01-24 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,GlaxoSmithKline plc,28355,UK,GB,"EthR inhibitors (mycobacterium tuberculosis), BioVersys/ University of Lille/ GSK",92193,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-05-27 00:00:00,GlaxoSmithKline plc,28355,Discovery,2014-05-27 00:00:00,DR,6,Respiratory disease,711
Unspecified vaccine,12380,LOCAL_AND_MAJOR,EyeGene Inc,1006553,South Korea,KR,"anti-tuberculosis vaccine, EyeGene",93723,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-06-30 00:00:00,EyeGene Inc,1006553,Discovery,2012-06-30 00:00:00,DR,6,Respiratory disease,711
Cytokine synthesis stimulator,938,LOCAL_AND_MAJOR,Verta Ltd,1004196,Russian Federation,RU,golotimod,25023,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2013-11-12 00:00:00,Verta Ltd,1004196,Launched,2008-08-15 00:00:00,L,13,Respiratory disease,711
Recombinant viral vector vaccine,12370,OTHER,Crucell NV,17254,Kenya,KE,AERAS-402,53975,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2010-09-22 00:00:00,Johnson & Johnson,17332,Phase 2 Clinical,2010-09-22 00:00:00,C2,9,Respiratory disease,711
Recombinant viral vector vaccine,12370,OTHER,Aeras Global TB Vaccine Foundation,1007376,South Africa,ZA,AERAS-402,53975,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2010-09-22 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 1 Clinical,2007-05-11 00:00:00,C1,8,Respiratory disease,711
esaT6 gene modulator,25530,LOCAL_AND_MAJOR,Polymun Scientific Immunobiologische Forschung GmbH,21851,Austria,AT,"tuberculosis vaccine (nasal, influenza virus carrier), Polymun",54201,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-06-10 00:00:00,Polymun Scientific Immunobiologische Forschung GmbH,21851,Phase 1 Clinical,2013-06-10 00:00:00,C1,8,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,University of Georgia,20579,US,US,"small molecule therapeutics (tuberculosis/HIV), University of Georgia",95507,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2015-01-28 00:00:00,University of Georgia,20579,Discovery,2015-01-28 00:00:00,DR,6,Respiratory disease,711
Anticancer,1545,LOCAL_AND_MAJOR,SciClone Pharmaceuticals Inc,19829,US,US,golotimod,25023,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,false,2013-11-12 00:00:00,SciClone Pharmaceuticals Inc,19829,Phase 1 Clinical,2005-08-08 00:00:00,C1,8,Respiratory disease,711
Cytokine synthesis stimulator,938,LOCAL_AND_MAJOR,SciClone Pharmaceuticals Inc,19829,US,US,golotimod,25023,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,false,2013-11-12 00:00:00,SciClone Pharmaceuticals Inc,19829,Phase 1 Clinical,2005-08-08 00:00:00,C1,8,Respiratory disease,711
Anticancer,1545,LOCAL_AND_MAJOR,SciClone Pharmaceuticals Inc,19829,US,US,golotimod,25023,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,false,2013-11-12 00:00:00,SciClone Pharmaceuticals Inc,19829,Discovery,1999-08-27 00:00:00,DR,6,Respiratory disease,711
Fungicide,1748,OTHER,Sequella Inc,28087,Africa,X0,SQ-109,31010,Chemical,Phase 3 Clinical,Phase 3 Clinical,C3,C3,Mycobacterium tuberculosis infection,221,true,2012-12-19 00:00:00,Sequella Inc,28087,Phase 2 Clinical,2010-12-06 00:00:00,C2,9,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Infectex,1068619,Russian Federation,RU,SQ-109,31010,Chemical,Phase 3 Clinical,Phase 3 Clinical,C3,C3,Mycobacterium tuberculosis infection,221,true,2012-12-19 00:00:00,Maxwell Biotech Group,1061894,Discovery,2011-04-25 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Infectex,1068619,Russian Federation,RU,SQ-109,31010,Chemical,Phase 3 Clinical,Phase 3 Clinical,C3,C3,Mycobacterium tuberculosis infection,221,true,2012-12-19 00:00:00,Maxwell Biotech Group,1061894,Discovery,2011-04-25 00:00:00,DR,6,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,Colorado State University,20562,US,US,GI-19000,86853,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-08-22 00:00:00,Colorado State University,20562,Discovery,2013-08-22 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Colorado State University,20562,US,US,GI-19000,86853,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-08-22 00:00:00,Colorado State University,20562,Discovery,2013-08-22 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,Harbor Therapeutics Inc,24345,Mexico,MX,HE-2000,19980,Chemical,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2013-01-28 00:00:00,Harbor Therapeutics Inc,24345,No Development Reported,2013-01-28 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Scripps Research Institute,21102,US,US,"DprE inhibitors (tuberculosis), TB Alliance/California Institute for Biomedical Research",82660,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2013-06-30 00:00:00,Scripps Research Institute,21102,Discontinued,2013-06-30 00:00:00,DX,3,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Korea Research Institute of Chemical Technology,17684,South Korea,KR,"quinolone analogs (Mycobacterium tuberculosis), KRICT/TB Alliance",57730,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-11-30 00:00:00,Korea Research Institute of Chemical Technology,17684,Discovery,2003-04-25 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Dong Wha Pharmaceutical Co Ltd,15745,South Korea,KR,DW-286,35974,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-04-27 00:00:00,Dong Wha Pharmaceutical Co Ltd,15745,Discovery,2001-09-13 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,University of Illinois,20592,US,US,TBI-166,57790,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2014-12-22 00:00:00,University of Illinois,20592,Discovery,2011-03-28 00:00:00,DR,6,Respiratory disease,711
Bacterial protein synthesis inhibitor,1538,LOCAL_AND_MAJOR,Pfizer Inc,18767,US,US,sutezolid,11088,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2013-07-17 00:00:00,Pfizer Inc,18767,Discontinued,2013-07-17 00:00:00,DX,3,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,SRI International,20234,US,US,"replicating and nonreplicating Mycobacterium tuberculosis inhibitors (tuberculosis), SRI International/University of Illinois",82340,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-07-25 00:00:00,SRI International,20234,Discovery,2012-01-27 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"quinolone analogs (Mycobacterium tuberculosis), KRICT/TB Alliance",57730,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-11-30 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2003-04-25 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"quinolone analogs (Mycobacterium tuberculosis), KRICT/TB Alliance",57730,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-11-30 00:00:00,The Global Alliance for TB Drug Development,29411,No Development Reported,2012-11-30 00:00:00,NDR,2,Respiratory disease,711
Topoisomerase I inhibitor,141,OTHER,AstraZeneca plc,14190,India,IN,"topoisomerase I inhibitors (tuberculosis infection), TB Alliance/NYMC/AZ",71897,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-06-27 00:00:00,AstraZeneca plc,14190,Discovery,2010-05-03 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,AstraZeneca plc,14190,India,IN,"topoisomerase I inhibitors (tuberculosis infection), TB Alliance/NYMC/AZ",71897,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-06-27 00:00:00,AstraZeneca plc,14190,No Development Reported,2013-06-27 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Genesis Research and Development Corp Ltd,25513,New Zealand,NZ,"MED-1 vaccine (tuberculosis), Genesis",40637,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2009-04-30 00:00:00,Genesis Research and Development Corp Ltd,25513,Discovery,2002-01-29 00:00:00,DR,6,Respiratory disease,711
DNA vaccine,1879,LOCAL_AND_MAJOR,Genesis Research and Development Corp Ltd,25513,New Zealand,NZ,"MED-1 vaccine (tuberculosis), Genesis",40637,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2009-04-30 00:00:00,Genesis Research and Development Corp Ltd,25513,Discontinued,2009-04-30 00:00:00,DX,3,Respiratory disease,711
Antibacterial multidrug resistance inhibitor,4855,OTHER,Janssen Research & Development LLC,1067538,Thailand,TH,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Discovery,2009-07-30 00:00:00,DR,6,Respiratory disease,711
Antibacterial multidrug resistance inhibitor,4855,OTHER,Janssen Research & Development LLC,1067538,South Korea,KR,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Discovery,2009-07-30 00:00:00,DR,6,Respiratory disease,711
Antibacterial multidrug resistance inhibitor,4855,OTHER,Janssen Research & Development LLC,1067538,South Korea,KR,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Registered,2014-11-06 00:00:00,R,12,Respiratory disease,711
ATP synthase inhibitor,49687,OTHER,Janssen Research & Development LLC,1067538,Turkey,TR,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Discovery,2009-08-27 00:00:00,DR,6,Respiratory disease,711
Antibacterial multidrug resistance inhibitor,4855,OTHER,Janssen Research & Development LLC,1067538,South Africa,ZA,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Registered,2014-11-06 00:00:00,R,12,Respiratory disease,711
Antibacterial multidrug resistance inhibitor,4855,OTHER,Janssen Research & Development LLC,1067538,China,CN,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Pre-registration,2013-06-17 00:00:00,PR,11,Respiratory disease,711
ATP synthase inhibitor,49687,OTHER,Janssen Research & Development LLC,1067538,EU,EU,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Registered,2014-03-06 00:00:00,R,12,Respiratory disease,711
Protein subunit vaccine,12372,LOCAL_AND_MAJOR,Johns Hopkins University Office of Technology Transfer,1083716,US,US,"recombinant PknD subunit protein vaccine (Mycobacterium tuberculosis infection), Johns Hopkins University",89337,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-12-19 00:00:00,Johns Hopkins University,20596,Discovery,2013-12-19 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Johns Hopkins University,20596,US,US,"recombinant PknD subunit protein vaccine (Mycobacterium tuberculosis infection), Johns Hopkins University",89337,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-12-19 00:00:00,Johns Hopkins University,20596,Discovery,2013-06-11 00:00:00,DR,6,Respiratory disease,711
Pantoate beta alanine ligase inhibitor,19060,LOCAL_AND_MAJOR,University of Illinois,20592,US,US,"pantothenate synthetase inhibitors (tuberculosis/bacterial infections), University of Illinois/University of Illinois at URBANA-CHAMPAIGN",88214,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-10-30 00:00:00,University of Illinois,20592,Discovery,2008-04-10 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Shenyang Hongqi Pharmaceutical Co Ltd,1075626,China,CN,"ethambutol hydrochloride (200 mg) + pyrazinamide (300 mg) + rifampicin (120 mg) + isoniazid (100 mg) (oral tablet, tuberculosis), Shenyang Hongqi Pharmaceutical/Liaoning Hongwuxing Pharmaceutical",88507,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-11-15 00:00:00,Shanghai Fosun Pharmaceutical (Group) Co Ltd,1015871,Discovery,2009-02-01 00:00:00,DR,6,Respiratory disease,711
ATP synthase inhibitor,49687,OTHER,Janssen Diagnostics BVBA,30131,Belgium,BE,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,false,2015-03-18 00:00:00,Johnson & Johnson,17332,Phase 2 Clinical,2005-05-26 00:00:00,C2,9,Respiratory disease,711
ATP synthase inhibitor,49687,OTHER,Janssen Diagnostics BVBA,30131,Belgium,BE,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,false,2015-03-18 00:00:00,Johnson & Johnson,17332,Phase 1 Clinical,2005-03-31 00:00:00,C1,8,Respiratory disease,711
DNA gyrase B inhibitor,71209,LOCAL_AND_MAJOR,SRI International,20234,US,US,"gyrase B inhibitors (tuberculosis), SRI",74814,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-11-02 00:00:00,SRI International,20234,Discovery,2011-11-02 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Shanghai H&G Biotechnology Co,1066720,China,CN,"Ag85A/B DNA vaccine (tuberculosis), Shanghai H&G Biotechnology",75084,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-17 00:00:00,Shanghai H&G Biotechnology Co,1066720,No Development Reported,2013-01-17 00:00:00,NDR,2,Respiratory disease,711
Mycobacterial antigen complex 85B modulator,33970,LOCAL_AND_MAJOR,Statens Serum Institut,21502,Denmark,DK,"Ag85B-ESAT-6 fusion protein vaccine (CAF-01-adjuvanted, tuberculosis), Statens Serum Institut",75087,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2009-10-31 00:00:00,Statens Serum Institut,21502,Phase 1 Clinical,2009-10-31 00:00:00,C1,8,Respiratory disease,711
Protein subunit vaccine,12372,LOCAL_AND_MAJOR,Savine Therapeutics Pty Ltd,1066884,Australia,AU,"TB SAVINE (cDNA vaccine, tuberculosis), Savine",77428,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-12-14 00:00:00,BioDiem Ltd,30212,Discovery,2011-12-14 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,OTHER,Institut Pasteur,17237,South Korea,KR,"TB I series (tuberculosis infection), Qurient Therapeutics",78036,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2013-06-28 00:00:00,Institut Pasteur,17237,Discontinued,2010-03-31 00:00:00,DX,3,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,National University of Singapore,20633,Singapore,SG,"miRNA-like molecules (tuberculosis), NUS",77116,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-06-20 00:00:00,National University of Singapore,20633,No Development Reported,2014-06-20 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Microbion Corp,1055897,US,US,"MB-11, Microbion",77124,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-01-17 00:00:00,Microbion Corp,1055897,Discovery,2012-02-28 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Epimmune Inc,15573,US,US,Theradigm-tuberculosis,10406,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2001-12-09 00:00:00,Takeda Pharmaceutical Co Ltd,20300,Discontinued,1997-09-23 00:00:00,DX,3,Respiratory disease,711
Protein subunit vaccine,12372,LOCAL_AND_MAJOR,Epimmune Inc,15573,US,US,Theradigm-tuberculosis,10406,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2001-12-09 00:00:00,Takeda Pharmaceutical Co Ltd,20300,Discovery,1995-06-22 14:36:07,DR,6,Respiratory disease,711
Bacterial protein synthesis inhibitor,1538,LOCAL_AND_MAJOR,Chiron Corp,15385,US,US,"tobramycin (nebulized), Novartis",11232,Chemical,Launched,No Development Reported,NDR,L,Mycobacterium tuberculosis infection,221,false,2013-01-09 00:00:00,Novartis AG,23137,No Development Reported,2004-02-02 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Antibiotic Co,24897,Bulgaria,BG,T9,10994,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2002-01-02 00:00:00,Antibiotic Co,24897,Discovery,1995-09-26 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Antibiotic Co,24897,Bulgaria,BG,T9,10994,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2002-01-02 00:00:00,Antibiotic Co,24897,Discovery,1995-09-26 00:00:00,DR,6,Respiratory disease,711
Bacterial protein synthesis inhibitor,1538,LOCAL_AND_MAJOR,PathoGenesis Ltd,24982,US,US,"tobramycin (nebulized), Novartis",11232,Chemical,Launched,No Development Reported,NDR,L,Mycobacterium tuberculosis infection,221,true,2013-01-09 00:00:00,Novartis AG,23137,Phase 2 Clinical,1997-10-14 00:00:00,C2,9,Respiratory disease,711
Aminoglycoside antibiotic,1541,LOCAL_AND_MAJOR,PathoGenesis Ltd,24982,US,US,"tobramycin (nebulized), Novartis",11232,Chemical,Launched,No Development Reported,NDR,L,Mycobacterium tuberculosis infection,221,true,2013-01-09 00:00:00,Novartis AG,23137,Discovery,1996-05-01 00:00:00,DR,6,Respiratory disease,711
Bacterial protein synthesis inhibitor,1538,LOCAL_AND_MAJOR,PathoGenesis Ltd,24982,US,US,"tobramycin (nebulized), Novartis",11232,Chemical,Launched,No Development Reported,NDR,L,Mycobacterium tuberculosis infection,221,true,2013-01-09 00:00:00,Novartis AG,23137,Discovery,1996-05-01 00:00:00,DR,6,Respiratory disease,711
DHFR inhibitor,135,LOCAL_AND_MAJOR,Indiana University,20593,US,US,"dihydrofolate reductase inhibitors, Duquesne/Indiana",12146,Chemical,Discovery,No Development Reported,NDR,DR,Mycobacterium tuberculosis infection,221,true,2011-01-04 00:00:00,Indiana University,20593,No Development Reported,2011-01-04 00:00:00,NDR,2,Respiratory disease,711
DHFR inhibitor,135,LOCAL_AND_MAJOR,Indiana University,20593,US,US,"dihydrofolate reductase inhibitors, Duquesne/Indiana",12146,Chemical,Discovery,No Development Reported,NDR,DR,Mycobacterium tuberculosis infection,221,true,2011-01-04 00:00:00,Indiana University,20593,Discovery,2003-03-30 00:00:00,DR,6,Respiratory disease,711
Fungicide,1748,LOCAL_AND_MAJOR,Duquesne University,20569,US,US,"dihydrofolate reductase inhibitors, Duquesne/Indiana",12146,Chemical,Discovery,No Development Reported,NDR,DR,Mycobacterium tuberculosis infection,221,true,2011-01-04 00:00:00,Duquesne University,20569,No Development Reported,2011-01-04 00:00:00,NDR,2,Respiratory disease,711
Fungicide,1748,LOCAL_AND_MAJOR,Duquesne University,20569,US,US,"dihydrofolate reductase inhibitors, Duquesne/Indiana",12146,Chemical,Discovery,No Development Reported,NDR,DR,Mycobacterium tuberculosis infection,221,true,2011-01-04 00:00:00,Duquesne University,20569,Discovery,2003-03-30 00:00:00,DR,6,Respiratory disease,711
Protein subunit vaccine,12372,OTHER,Nventa Biopharmaceuticals Corp,20265,Canada,CA,"vaccine (tuberculosis), StressGen",12954,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2000-05-18 00:00:00,Akela Pharma Inc,1011141,Discovery,1996-08-08 02:46:32,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,The Global Alliance for TB Drug Development,29411,Russian Federation,RU,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2014-10-14 00:00:00,DR,6,Respiratory disease,711
DNA gyrase inhibitor,431,OTHER,The Global Alliance for TB Drug Development,29411,Asia,X2,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2014-10-14 00:00:00,DR,6,Respiratory disease,711
Bacterial nucleic acid synthesis inhibitor,3984,OTHER,The Global Alliance for TB Drug Development,29411,Asia,X2,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2014-10-14 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,The Global Alliance for TB Drug Development,29411,Peru,PE,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2014-10-14 00:00:00,DR,6,Respiratory disease,711
Systemic dermatological antibacterial product,15187,OTHER,The Global Alliance for TB Drug Development,29411,Africa,X0,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,The Global Alliance for TB Drug Development,29411,Phase 3 Clinical,2007-11-08 00:00:00,C3,10,Respiratory disease,711
DNA gyrase inhibitor,431,OTHER,Bayer AG,14455,Spain,ES,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,Bayer AG,14455,Phase 2 Clinical,2005-10-17 00:00:00,C2,9,Respiratory disease,711
Bacterial nucleic acid synthesis inhibitor,3984,LOCAL_AND_MAJOR,Bayer AG,14455,US,US,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,Bayer AG,14455,Phase 2 Clinical,2005-10-17 00:00:00,C2,9,Respiratory disease,711
Systemic dermatological antibacterial product,15187,LOCAL_AND_MAJOR,Bayer AG,14455,US,US,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,Bayer AG,14455,Phase 2 Clinical,2005-10-17 00:00:00,C2,9,Respiratory disease,711
Systemic dermatological antibacterial product,15187,OTHER,Bayer AG,14455,Canada,CA,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,Bayer AG,14455,Phase 2 Clinical,2005-10-17 00:00:00,C2,9,Respiratory disease,711
DNA gyrase inhibitor,431,OTHER,Bayer AG,14455,Brazil,BR,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,Bayer AG,14455,Phase 2 Clinical,2005-10-17 00:00:00,C2,9,Respiratory disease,711
DNA gyrase inhibitor,431,OTHER,Bayer AG,14455,Tanzania,TZ,moxifloxacin,12978,Chemical,Launched,Phase 3 Clinical,C3,L,Mycobacterium tuberculosis infection,221,true,2015-02-10 00:00:00,Bayer AG,14455,Phase 2 Clinical,2005-10-17 00:00:00,C2,9,Respiratory disease,711
Therapeutic vaccine,12379,OTHER,Silence Therapeutics plc,22356,Tanzania,TZ,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,2003-05-06 00:00:00,DX,3,Respiratory disease,711
Inactivated bacterial vaccine,12366,OTHER,Silence Therapeutics plc,22356,Tanzania,TZ,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,2003-05-06 00:00:00,DX,3,Respiratory disease,711
Antiviral,991,OTHER,Silence Therapeutics plc,22356,South Africa,ZA,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Therapeutic vaccine,12379,OTHER,Silence Therapeutics plc,22356,Nigeria,NG,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Inactivated bacterial vaccine,12366,OTHER,Silence Therapeutics plc,22356,Nigeria,NG,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Anticancer,1545,OTHER,Silence Therapeutics plc,22356,Gambia,GM,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,Silence Therapeutics plc,22356,UK,GB,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Discontinued,1998-03-01 00:00:00,DX,3,Respiratory disease,711
Therapeutic vaccine,12379,OTHER,Silence Therapeutics plc,22356,Zambia,ZM,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 3 Clinical,1997-10-13 00:00:00,C3,10,Respiratory disease,711
Inactivated bacterial vaccine,12366,OTHER,Silence Therapeutics plc,22356,Zambia,ZM,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 3 Clinical,1997-10-13 00:00:00,C3,10,Respiratory disease,711
Systemic antipsoriatic product,15184,OTHER,Silence Therapeutics plc,22356,Gambia,GM,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 3 Clinical,1997-10-13 00:00:00,C3,10,Respiratory disease,711
Systemic antipsoriatic product,15184,LOCAL_AND_MAJOR,Silence Therapeutics plc,22356,UK,GB,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,1995-10-12 00:00:00,C2,9,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,Silence Therapeutics plc,22356,UK,GB,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,1995-10-12 00:00:00,C2,9,Respiratory disease,711
Anticancer,1545,OTHER,Silence Therapeutics plc,22356,Kuwait,KW,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,1995-10-12 00:00:00,C2,9,Respiratory disease,711
Antibacterial,1594,OTHER,Silence Therapeutics plc,22356,Romania,RO,SRL-172,11115,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2003-05-07 00:00:00,Silence Therapeutics plc,22356,Phase 2 Clinical,1995-10-12 00:00:00,C2,9,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Whitehead Institute for Biomedical Research,20939,US,US,"vaccine (BCG), Connaught/Whitehead",12124,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2001-08-24 00:00:00,Whitehead Institute for Biomedical Research,20939,No Development Reported,2001-08-24 00:00:00,NDR,2,Respiratory disease,711
Live attenuated bacterial vaccine,12363,LOCAL_AND_MAJOR,Pasteur Merieux Connaught Canada,19267,US,US,"vaccine (BCG), Connaught/Whitehead",12124,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2001-08-24 00:00:00,Sanofi,1009547,Discovery,1996-04-18 00:00:00,DR,6,Respiratory disease,711
RNA synthesis inhibitor,439,LOCAL_AND_MAJOR,Harbor Therapeutics Inc,24345,US,US,PP-29,15867,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2003-07-02 00:00:00,Harbor Therapeutics Inc,24345,No Development Reported,2003-07-02 00:00:00,NDR,2,Respiratory disease,711
Nuclease inhibitor,9166,LOCAL_AND_MAJOR,University of Illinois,20592,US,US,pafuramidine,16755,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2008-02-22 00:00:00,University of Illinois,20592,Discovery,2000-10-23 00:00:00,DR,6,Respiratory disease,711
Topoisomerase II inhibitor,142,LOCAL_AND_MAJOR,University of Illinois,20592,US,US,pafuramidine,16755,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2008-02-22 00:00:00,University of Illinois,20592,Discovery,2000-10-23 00:00:00,DR,6,Respiratory disease,711
Topoisomerase II inhibitor,142,LOCAL_AND_MAJOR,University of North Carolina,20634,US,US,pafuramidine,16755,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2008-02-22 00:00:00,University of North Carolina,20634,Discontinued,2000-01-28 00:00:00,DX,3,Respiratory disease,711
Fungicide,1748,LOCAL_AND_MAJOR,University of North Carolina,20634,US,US,pafuramidine,16755,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2008-02-22 00:00:00,University of North Carolina,20634,Discovery,2000-10-23 00:00:00,DR,6,Respiratory disease,711
Nuclease inhibitor,9166,LOCAL_AND_MAJOR,Immtech Pharmaceuticals Inc,17195,US,US,pafuramidine,16755,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2008-02-22 00:00:00,Immtech Pharmaceuticals Inc,17195,Discovery,2000-10-23 00:00:00,DR,6,Respiratory disease,711
Antiparasitic,2638,LOCAL_AND_MAJOR,Immtech Pharmaceuticals Inc,17195,US,US,pafuramidine,16755,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2008-02-22 00:00:00,Immtech Pharmaceuticals Inc,17195,No Development Reported,2003-10-23 00:00:00,NDR,2,Respiratory disease,711
Fungicide,1748,LOCAL_AND_MAJOR,Immtech Pharmaceuticals Inc,17195,US,US,pafuramidine,16755,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2008-02-22 00:00:00,Immtech Pharmaceuticals Inc,17195,No Development Reported,2003-10-23 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Immtech Pharmaceuticals Inc,17195,US,US,pafuramidine,16755,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2008-02-22 00:00:00,Immtech Pharmaceuticals Inc,17195,No Development Reported,2003-10-23 00:00:00,NDR,2,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Brigham & Women's Hospital,21048,US,US,"vaccine (tuberculosis), Procept",15602,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2005-12-31 00:00:00,Brigham & Women's Hospital,21048,No Development Reported,1999-12-15 00:00:00,NDR,2,Respiratory disease,711
Lipid subunit vaccine,12374,LOCAL_AND_MAJOR,Brigham & Women's Hospital,21048,US,US,"vaccine (tuberculosis), Procept",15602,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2005-12-31 00:00:00,Brigham & Women's Hospital,21048,No Development Reported,1999-12-15 00:00:00,NDR,2,Respiratory disease,711
Lipid subunit vaccine,12374,LOCAL_AND_MAJOR,Brigham & Women's Hospital,21048,US,US,"vaccine (tuberculosis), Procept",15602,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2005-12-31 00:00:00,Brigham & Women's Hospital,21048,Discovery,1997-07-30 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,VacTex Corp,25562,US,US,"vaccine (tuberculosis), Procept",15602,Biological,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2005-12-31 00:00:00,Agenus Inc,23221,Discovery,1997-07-30 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,OriGenix Technologies Inc,26201,Canada,CA,"Mycobacterium tuberculosis therapeutics, OriGenix",32998,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2002-09-13 00:00:00,Biowest Therapeutics Inc,18210,Discontinued,2002-09-13 00:00:00,DX,3,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,OriGenix Technologies Inc,26201,Canada,CA,"Mycobacterium tuberculosis therapeutics, OriGenix",32998,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2002-09-13 00:00:00,Biowest Therapeutics Inc,18210,Discovery,2001-02-23 12:55:10,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,University of London,20607,UK,GB,"antibacterial protease inhibitors, Medivir/University of London",35747,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2003-08-19 00:00:00,University of London,20607,No Development Reported,2003-08-19 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Panacea Biotec Ltd,25333,India,IN,Panacea-0394,29616,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-02-20 00:00:00,Panacea Biotec Ltd,25333,Discovery,2000-07-13 00:00:00,DR,6,Respiratory disease,711
Protein subunit vaccine,12372,LOCAL_AND_MAJOR,Sequella Inc,28087,US,US,"peptide vaccine (tuberculosis), Intercell/Sequella",32516,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2004-04-30 00:00:00,Sequella Inc,28087,Discovery,1999-12-01 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Oxxon Therapeutics Ltd,27753,UK,GB,"TB vaccine (prophylactic, Prime-Boost), Oxxon Therapeutics",42764,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2009-01-02 00:00:00,Oxford BioMedica plc,23434,No Development Reported,2009-01-02 00:00:00,NDR,2,Respiratory disease,711
ATP synthase inhibitor,49687,LOCAL_AND_MAJOR,FASgen Inc,1006466,US,US,FAS-20013,49581,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-08-25 00:00:00,FASgen Inc,1006466,Discovery,2003-09-24 00:00:00,DR,6,Respiratory disease,711
Mycobacterial antigen complex 85B modulator,33970,OTHER,Aeras Global TB Vaccine Foundation,1007376,South Africa,ZA,"HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell",48499,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-07-29 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 1 Clinical,2009-01-26 00:00:00,C1,8,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Sanofi Pasteur,22127,France,FR,"HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell",48499,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-07-29 00:00:00,Sanofi,1009547,Phase 1 Clinical,2012-01-11 00:00:00,C1,8,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Statens Serum Institut,21502,South Africa,ZA,"HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell",48499,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-07-29 00:00:00,Statens Serum Institut,21502,Phase 1 Clinical,2009-01-26 00:00:00,C1,8,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Lupin Ltd,21932,India,IN,LL-3858,49162,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-07-24 00:00:00,Lupin Ltd,21932,Phase 1 Clinical,2005-04-01 00:00:00,C1,8,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Lupin Ltd,21932,India,IN,LL-3858,49162,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-07-24 00:00:00,Lupin Ltd,21932,Phase 2 Clinical,2010-03-26 00:00:00,C2,9,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Lupin Ltd,21932,India,IN,LL-4858,51319,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2010-03-26 00:00:00,Lupin Ltd,21932,No Development Reported,2010-03-26 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Lupin Ltd,21932,India,IN,LL-4858,51319,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2010-03-26 00:00:00,Lupin Ltd,21932,Discovery,2004-04-01 00:00:00,DR,6,Respiratory disease,711
Bacterial protein synthesis inhibitor,1538,OTHER,Ranbaxy Laboratories Ltd,21266,India,IN,RBx-8700,46560,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2004-04-05 00:00:00,Daiichi Sankyo Co Ltd,1017506,No Development Reported,2004-04-05 00:00:00,NDR,2,Respiratory disease,711
Bacterial cell wall synthesis inhibitor,104,LOCAL_AND_MAJOR,Sequella Inc,28087,US,US,"capuramycin derivative translocase inhibitors (tuberculosis, Clostridium difficile infection, Chrons disease), Sequella",48440,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-05-03 00:00:00,Sequella Inc,28087,Discovery,2004-11-01 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,The Lilly TB Drug Discovery Initiative,1042702,US,US,"N-acetyltransferase inhibitors (tuberculosis), Summit/Lilly TB Drug Discovery Initiative",57219,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2008-10-07 00:00:00,The Lilly TB Drug Discovery Initiative,1042702,Discovery,2008-10-07 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"InhA inhibitors (oral/tuberculosis), GlaxoSmithKline/The Global Alliance for TB Drug Development",56371,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2005-03-21 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2005-03-21 00:00:00,DR,6,Respiratory disease,711
MAPK gene modulator,18476,LOCAL_AND_MAJOR,Cadila Pharmaceuticals Ltd,30025,India,IN,cadi-05,55173,Biological,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2014-12-03 00:00:00,Cadila Pharmaceuticals Ltd,30025,No Development Reported,2014-12-03 00:00:00,NDR,2,Respiratory disease,711
TLR-4 antagonist,7813,LOCAL_AND_MAJOR,Cadila Pharmaceuticals Ltd,30025,India,IN,cadi-05,55173,Biological,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2014-12-03 00:00:00,Cadila Pharmaceuticals Ltd,30025,Phase 3 Clinical,2005-03-31 00:00:00,C3,10,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Cadila Pharmaceuticals Ltd,30025,India,IN,cadi-05,55173,Biological,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2014-12-03 00:00:00,Cadila Pharmaceuticals Ltd,30025,Phase 3 Clinical,2005-03-31 00:00:00,C3,10,Respiratory disease,711
Antibacterial,1594,OTHER,Archivel Farma SL,1014222,South Africa,ZA,RUTI,57308,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2012-05-24 00:00:00,Archivel Farma SL,1014222,Phase 2 Clinical,2010-06-30 00:00:00,C2,9,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Archivel Farma SL,1014222,South Africa,ZA,RUTI,57308,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2012-05-24 00:00:00,Archivel Farma SL,1014222,Phase 2 Clinical,2010-06-30 00:00:00,C2,9,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,Archivel Farma SL,1014222,Spain,ES,RUTI,57308,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2012-05-24 00:00:00,Archivel Farma SL,1014222,Phase 1 Clinical,2007-05-06 00:00:00,C1,8,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Archivel Farma SL,1014222,Spain,ES,RUTI,57308,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2012-05-24 00:00:00,Archivel Farma SL,1014222,Phase 1 Clinical,2007-05-06 00:00:00,C1,8,Respiratory disease,711
RNA polymerase inhibitor,347,OTHER,UMeWorld Ltd,28431,Canada,CA,"rifampicin (nanoparticle encapsulated, tuberculosis), AlphaRx",53605,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2009-01-08 00:00:00,UMeWorld Ltd,28431,Discovery,2005-07-18 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Oxford-Emergent Tuberculosis Consortium Ltd,1040955,Senegal,SN,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-07 00:00:00,Emergent BioSolutions Inc,1011990,Phase 2 Clinical,2011-08-08 00:00:00,C2,9,Respiratory disease,711
Mycobacterial antigen complex 85A modulator,33967,OTHER,University of Oxford,22182,South Africa,ZA,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-07 00:00:00,University of Oxford,22182,Phase 2 Clinical,2007-12-31 00:00:00,C2,9,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,TB-VAC,1020621,South Africa,ZA,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-03-07 00:00:00,TB-VAC,1020621,Phase 2 Clinical,2008-05-14 00:00:00,C2,9,Respiratory disease,711
Mycobacterial antigen complex 85A modulator,33967,OTHER,TB-VAC,1020621,Senegal,SN,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-03-07 00:00:00,TB-VAC,1020621,Phase 2 Clinical,2011-08-08 00:00:00,C2,9,Respiratory disease,711
Mycobacterial antigen complex 85A modulator,33967,OTHER,Emergent BioSolutions Inc,1011990,South Africa,ZA,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-03-07 00:00:00,Emergent BioSolutions Inc,1011990,Phase 2 Clinical,2014-03-07 00:00:00,C2,9,Respiratory disease,711
Mycobacterial antigen complex 85A modulator,33967,OTHER,Emergent BioSolutions Inc,1011990,Senegal,SN,MVA-85A,55317,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-03-07 00:00:00,Emergent BioSolutions Inc,1011990,Phase 2 Clinical,2014-03-07 00:00:00,C2,9,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Intercell AG,28463,South Africa,ZA,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2013-05-28 00:00:00,Valneva SE,1084202,Discontinued,2013-05-28 00:00:00,DX,3,Respiratory disease,711
Recombinant bacterial vector vaccine,12369,OTHER,Intercell AG,28463,South Africa,ZA,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2013-05-28 00:00:00,Valneva SE,1084202,Discontinued,2013-05-28 00:00:00,DX,3,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Intercell AG,28463,South Africa,ZA,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2013-05-28 00:00:00,Valneva SE,1084202,Phase 2 Clinical,2012-08-17 00:00:00,C2,9,Respiratory disease,711
Protein subunit vaccine,12372,OTHER,Intercell AG,28463,South Africa,ZA,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2013-05-28 00:00:00,Valneva SE,1084202,Phase 2 Clinical,2012-08-17 00:00:00,C2,9,Respiratory disease,711
Recombinant bacterial vector vaccine,12369,OTHER,Intercell AG,28463,Netherlands,NL,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2013-05-28 00:00:00,Valneva SE,1084202,Phase 1 Clinical,2005-11-18 00:00:00,C1,8,Respiratory disease,711
Recombinant bacterial vector vaccine,12369,OTHER,Valneva SE,1084202,Tanzania,TZ,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-05-28 00:00:00,Valneva SE,1084202,Phase 2 Clinical,2013-05-28 00:00:00,C2,9,Respiratory disease,711
Recombinant bacterial vector vaccine,12369,OTHER,Aeras Global TB Vaccine Foundation,1007376,Netherlands,NL,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-05-28 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 2 Clinical,2009-03-02 00:00:00,C2,9,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Aeras Global TB Vaccine Foundation,1007376,Netherlands,NL,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-05-28 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 1 Clinical,2005-11-18 00:00:00,C1,8,Respiratory disease,711
Protein subunit vaccine,12372,OTHER,Statens Serum Institut,21502,South Africa,ZA,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-05-28 00:00:00,Statens Serum Institut,21502,Phase 2 Clinical,2012-01-11 00:00:00,C2,9,Respiratory disease,711
Recombinant bacterial vector vaccine,12369,OTHER,Statens Serum Institut,21502,South Africa,ZA,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-05-28 00:00:00,Statens Serum Institut,21502,Phase 2 Clinical,2012-01-11 00:00:00,C2,9,Respiratory disease,711
Recombinant bacterial vector vaccine,12369,OTHER,Statens Serum Institut,21502,Tanzania,TZ,"Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva",53784,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-05-28 00:00:00,Statens Serum Institut,21502,Phase 2 Clinical,2012-01-11 00:00:00,C2,9,Respiratory disease,711
Antibacterial,1594,OTHER,Upstream Biosciences Inc,1035256,Canada,CA,"antibacterial therapies (tuberculosis), Upstream Biosciences",62917,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-01-10 00:00:00,Upstream Biosciences Inc,1035256,Discovery,2009-01-31 00:00:00,DR,6,Respiratory disease,711
DNA gyrase inhibitor,431,LOCAL_AND_MAJOR,GlaxoSmithKline plc,28355,UK,GB,"gyrase inhibitors (Mycobacterium tuberculosis infection), GlaxoSmithKline/The Global Alliance for TB Drug Development",57733,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2006-12-31 00:00:00,GlaxoSmithKline plc,28355,Discovery,2006-12-31 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"antibacterial compounds (Mycobacterium tuberculosis), Cumbre/The Global Alliance for TB Drug Development",57737,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2009-12-22 00:00:00,The Global Alliance for TB Drug Development,29411,No Development Reported,2009-12-22 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"antibacterial compounds (Mycobacterium tuberculosis), Cumbre/The Global Alliance for TB Drug Development",57737,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2009-12-22 00:00:00,The Global Alliance for TB Drug Development,29411,No Development Reported,2009-12-22 00:00:00,NDR,2,Respiratory disease,711
Mycolic acid synthase inhibitor,6542,LOCAL_AND_MAJOR,Institut Pasteur,17237,Western Europe,XW,"EthR inhibitors (mycobacterium tuberculosis), BioVersys",61115,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2012-07-10 00:00:00,Institut Pasteur,17237,Discontinued,2012-07-10 00:00:00,DX,3,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Institut Pasteur,17237,Western Europe,XW,"EthR inhibitors (mycobacterium tuberculosis), BioVersys",61115,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2012-07-10 00:00:00,Institut Pasteur,17237,Discovery,2008-08-27 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,Avanti Therapeutics,1045576,World,WO,"tuberculosis vaccine, Avanti Therapeutics",62573,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-09-25 00:00:00,Avanti Therapeutics,1045576,No Development Reported,2013-09-25 00:00:00,NDR,2,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,Genexine Co Ltd,29830,South Korea,KR,GX-140,61171,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2010-06-19 00:00:00,Genexine Co Ltd,29830,No Development Reported,2010-06-19 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,OTHER,SinoBiomed Inc,1032007,China,CN,"recombinant multivalent tuberculosis vaccine, SinoBiomed",61931,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2011-01-06 00:00:00,SinoBiomed Inc,1032007,Discovery,2008-08-21 00:00:00,DR,6,Respiratory disease,711
Mycobacterial antigen complex 85A modulator,33967,LOCAL_AND_MAJOR,Shanghai H&G Biotechnology Co,1066720,China,CN,"ESAT-6/Ag85A DNA vaccine (Mycobacterium tuberculosis), Shanghai H&G",75153,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-17 00:00:00,Shanghai H&G Biotechnology Co,1066720,Discovery,2011-12-20 00:00:00,DR,6,Respiratory disease,711
Antisense oligonucleotide inhibitor,7294,LOCAL_AND_MAJOR,Sarepta Therapeutics Inc,14240,US,US,"XDR-TB RNA-based therapeutics (tuberculosis), Sarepta therapeutics/Karolinska Institute",71453,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-01-05 00:00:00,Sarepta Therapeutics Inc,14240,Discovery,2011-01-05 00:00:00,DR,6,Respiratory disease,711
Hypoglycemic agent,399,LOCAL_AND_MAJOR,Omni Bio Pharmaceutical Inc,1047826,US,US,"p-ATT (type 1/2 diabetes/influenza/tuberculosis/anthrax/HIV infection/transplant rejection/GVHD), Omni Bio",66767,Chemical,Phase 2 Clinical,Discovery,DR,C2,Mycobacterium tuberculosis infection,221,true,2013-01-31 00:00:00,Omni Bio Pharmaceutical Inc,1047826,Discovery,2010-08-06 00:00:00,DR,6,Respiratory disease,711
Interleukin-1 converting enzyme inhibitor,791,LOCAL_AND_MAJOR,Omni Bio Pharmaceutical Inc,1047826,US,US,"p-ATT (type 1/2 diabetes/influenza/tuberculosis/anthrax/HIV infection/transplant rejection/GVHD), Omni Bio",66767,Chemical,Phase 2 Clinical,Discovery,DR,C2,Mycobacterium tuberculosis infection,221,true,2013-01-31 00:00:00,Omni Bio Pharmaceutical Inc,1047826,Discovery,2010-08-06 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Cellworks Group Inc,1071272,US,US,CWGNC-4_1,90432,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-07-02 00:00:00,Cellworks Group Inc,1071272,Discovery,2012-07-02 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Silvius Pharma,1068863,Russian Federation,RU,"small molecule therapeutics (Mycobacterium tuberculosis infection), ChemDiv Research Institute/Novartis Institute for Tropical Diseases/Silvius Pharma",76796,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2014-08-14 00:00:00,ChemRar,1050615,Discovery,2010-09-30 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,University of Bristol,20544,UK,GB,"Mycobacterium chaperonin inhibitors, University of Bristol",30799,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-03-20 00:00:00,University of Bristol,20544,No Development Reported,2008-03-20 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Chiron PathoGenesis,18741,US,US,pretomanid,13323,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-09-05 00:00:00,Novartis AG,23137,Suspended,2000-02-14 00:00:00,S,5,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Fudan University,DOL1000375,China,CN,I-2906,67739,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-02-01 00:00:00,Fudan University,DOL1000375,No Development Reported,2013-02-01 00:00:00,NDR,2,Respiratory disease,711
Proteasome inhibitor,4917,LOCAL_AND_MAJOR,Harvard University Office of Technology Development,1085770,US,US,"proteasome inhibitors (tuberculosis), Harvard University/Harvard University Office of Technology Development",86021,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-08-21 00:00:00,Harvard University,20584,Discovery,2012-02-01 00:00:00,DR,6,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,Statens Serum Institut,21502,Denmark,DK,SSI H56-IC31,74849,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-11-08 00:00:00,Statens Serum Institut,21502,Discovery,2011-04-27 00:00:00,DR,6,Respiratory disease,711
Protein subunit vaccine,12372,OTHER,Statens Serum Institut,21502,South Africa,ZA,SSI H56-IC31,74849,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-11-08 00:00:00,Statens Serum Institut,21502,Phase 2 Clinical,2013-11-08 00:00:00,C2,9,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Valneva SE,1084202,South Africa,ZA,SSI H56-IC31,74849,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-11-08 00:00:00,Valneva SE,1084202,Phase 1 Clinical,2013-05-28 00:00:00,C1,8,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,Shanghai H&G Biotechnology Co,1066720,China,CN,"Ag85A DNA vaccine (Mycobacterium tuberculosis), Shanghai H&G",75158,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-17 00:00:00,Shanghai H&G Biotechnology Co,1066720,Discovery,2011-12-20 00:00:00,DR,6,Respiratory disease,711
RNA polymerase inhibitor,347,LOCAL_AND_MAJOR,Shenyang Hongqi Pharmaceutical Co Ltd,1075626,China,CN,"ethambutol hydrochloride (250 mg) + pyrazinamide (400 mg) + rifampicin (120 mg) + isoniazid (120 mg) (fixed dose combination, tuberculosis), Shenyang Hongqi Pharmaceutical",82062,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2009-12-31 00:00:00,Shanghai Fosun Pharmaceutical (Group) Co Ltd,1015871,Registered,2009-05-22 00:00:00,R,12,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Microbiotix Inc,28907,US,US,MBX-600,76748,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-03-20 00:00:00,Microbiotix Inc,28907,Discovery,2012-03-20 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,pretomanid,13323,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-09-05 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2002-02-04 00:00:00,DR,6,Respiratory disease,711
Nitric oxide donor,698,OTHER,The Global Alliance for TB Drug Development,29411,Malaysia,MY,pretomanid,13323,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-09-05 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2014-08-04 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Saurashtra University,1034429,India,IN,"antitubercular agents (tuberculosis), Amneal Pharmaceutical LLC/ Saurashtra University/Maharaja Krishnakumarsinhji Bhavnagar University",95732,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-08-28 00:00:00,Saurashtra University,1034429,Discovery,2013-08-28 00:00:00,DR,6,Respiratory disease,711
ATP synthase inhibitor,49687,LOCAL_AND_MAJOR,Pharmstandard OJSC,1047078,Russian Federation,RU,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Pharmstandard OJSC,1047078,Registered,2013-12-19 00:00:00,R,12,Respiratory disease,711
ATP synthase inhibitor,49687,OTHER,Janssen Research & Development LLC,1067538,China,CN,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Discovery,2009-12-17 00:00:00,DR,6,Respiratory disease,711
Antibacterial multidrug resistance inhibitor,4855,OTHER,Janssen Research & Development LLC,1067538,South Africa,ZA,bedaquiline,51310,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2015-03-18 00:00:00,Johnson & Johnson,17332,Discovery,2009-07-30 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Novartis AG,23137,US,US,"clofazimine (active tuberculosis), Novartis",91861,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-06-25 00:00:00,Novartis AG,23137,Discovery,2014-06-25 00:00:00,DR,6,Respiratory disease,711
RNA polymerase inhibitor,347,LOCAL_AND_MAJOR,Sichuan Long March Pharmaceutical Co Ltd,1088430,China,CN,"ethambutol hydrochloride + pyrazinamide + rifampicin + isoniazid (oral tablet, tuberculosis), Sichuan Long March Pharmaceutical",96349,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-11-11 00:00:00,Sichuan Long March Pharmaceutical Co Ltd,1088430,No Development Reported,2008-11-11 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Bio Farma,19368,Indonesia,ID,Lipovax-FliC-TB,96406,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2015-04-16 00:00:00,Bio Farma,19368,Discovery,2015-04-16 00:00:00,DR,6,Respiratory disease,711
Ribosome binding agent,463,OTHER,Pfizer Inc,18767,Netherlands,NL,rifabutin,4229,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2008-10-07 00:00:00,Pfizer Inc,18767,Registered,1995-07-17 00:00:00,R,12,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Pharmacia & Upjohn Co,18995,US,US,rifabutin,4229,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2008-10-07 00:00:00,Pfizer Inc,18767,No Development Reported,2002-09-02 00:00:00,NDR,2,Respiratory disease,711
Ribosome binding agent,463,LOCAL_AND_MAJOR,Pharmacia & Upjohn Co,18995,US,US,rifabutin,4229,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2008-10-07 00:00:00,Pfizer Inc,18767,No Development Reported,2002-09-02 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Okklo Life Sciences BV,1098970,Netherlands,NL,OKL-3018,92087,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-07-31 00:00:00,Okklo Life Sciences BV,1098970,Discovery,2014-07-31 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Sanofi,1009547,France,FR,"FtsZ inhibitors (Mycobacterium tuberculosis infection), Sanofi/Colorado State University/Stony Brook University",92356,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-04-15 00:00:00,Sanofi,1009547,Discovery,2014-04-15 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Sanofi,1009547,US,US,"urea compounds (tuberculosis), TB Alliance/Sanofi",89824,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-01-23 00:00:00,Sanofi,1009547,Discovery,2014-01-23 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"urea compounds (tuberculosis), TB Alliance/Sanofi",89824,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-01-23 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2014-01-23 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,AstraZeneca plc,14190,India,IN,"antimycobacterials (Mycobacterium tuberculsosis infection), Astrazeneca",89914,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-04-15 00:00:00,AstraZeneca plc,14190,Discovery,2013-04-15 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,California Institute for Biomedical Research,1068758,US,US,"ATP synthase inhibitors (tuberculosis), TB Alliance/California Institute for Biomedical Research",82643,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-06-30 00:00:00,California Institute for Biomedical Research,1068758,Discovery,2013-06-30 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,University of Illinois,20592,US,US,"diarylquinolines (tuberculosis), TB Alliance/J & J/University of Auckland/University of Illinois at Chicago",82662,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-06-30 00:00:00,University of Illinois,20592,Discovery,2013-06-30 00:00:00,DR,6,Respiratory disease,711
RNA polymerase inhibitor,347,LOCAL_AND_MAJOR,Shenyang Hongqi Pharmaceutical Co Ltd,1075626,China,CN,"ethambutol hydrochloride + rifampicin + isoniazid (fixed dose combination, tuberculosis), Shenyang Hongqi Pharmaceutical",82091,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2008-12-31 00:00:00,Shanghai Fosun Pharmaceutical (Group) Co Ltd,1015871,Registered,2008-03-03 00:00:00,R,12,Respiratory disease,711
Bacterial cell wall synthesis inhibitor,104,LOCAL_AND_MAJOR,Shenyang Hongqi Pharmaceutical Co Ltd,1075626,China,CN,"ethambutol hydrochloride + rifampicin + isoniazid (fixed dose combination, tuberculosis), Shenyang Hongqi Pharmaceutical",82091,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2008-12-31 00:00:00,Shanghai Fosun Pharmaceutical (Group) Co Ltd,1015871,Registered,2008-03-03 00:00:00,R,12,Respiratory disease,711
Interferon gamma ligand,51201,LOCAL_AND_MAJOR,Center for Genetic Engineering and Biotechnology,15353,Cuba,CU,"interferon gamma follow-on biologic, CIGB/Heber Biotec",79519,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2009-12-31 00:00:00,Center for Genetic Engineering and Biotechnology,15353,Clinical,2008-02-11 00:00:00,CU,7,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Shanghai Institute of Biological Products Co Ltd,1071897,China,CN,"BCG vaccine (intradermal), Shanghai Institute of Biological Products",80067,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2001-12-31 00:00:00,Sinopharm,1055632,Registered,2001-12-31 00:00:00,R,12,Respiratory disease,711
ATP-dependent Clp protease 1 inhibitor,26617,LOCAL_AND_MAJOR,NovoBiotic Pharmaceuticals LLC,1031362,US,US,lassomycin,81058,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-09-10 00:00:00,NovoBiotic Pharmaceuticals LLC,1031362,Discovery,2012-09-10 00:00:00,DR,6,Respiratory disease,711
Beta lactamase inhibitor,86,LOCAL_AND_MAJOR,Albert Einstein College of Medicine,24282,US,US,"carbapenem + beta lactamase inhibitor (Mycobacterium tuberculosis infection), Albert Einstein College of Medicine",79321,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-05-28 00:00:00,Yeshiva University,20704,No Development Reported,2014-05-28 00:00:00,NDR,2,Respiratory disease,711
Carbapenem,73547,LOCAL_AND_MAJOR,Albert Einstein College of Medicine,24282,US,US,"carbapenem + beta lactamase inhibitor (Mycobacterium tuberculosis infection), Albert Einstein College of Medicine",79321,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-05-28 00:00:00,Yeshiva University,20704,Discovery,2007-10-04 00:00:00,DR,6,Respiratory disease,711
Bacterial protein synthesis inhibitor,1538,LOCAL_AND_MAJOR,Chiron PathoGenesis,18741,US,US,rifalazil,8658,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2014-10-30 00:00:00,Novartis AG,23137,Phase 1 Clinical,1995-04-01 00:00:00,C1,8,Respiratory disease,711
Bacterial protein synthesis inhibitor,1538,LOCAL_AND_MAJOR,Kaneka Corp,17639,Japan,JP,rifalazil,8658,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2014-10-30 00:00:00,Kaneka Corp,17639,Phase 1 Clinical,1996-11-04 00:00:00,C1,8,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,GlobalAcorn,1086420,UK,GB,GA4 NM-TB,86659,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2015-04-17 00:00:00,GlobalAcorn,1086420,Discovery,2012-11-14 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Scripps Research Institute,21102,US,US,"TCA1 analogs (Mycobacterium tuberculosis infection), SRI/HHMI/AECM",85774,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-06-17 00:00:00,Scripps Research Institute,21102,Discovery,2013-06-17 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Syntrix Biosystems Inc,1023036,US,US,"Mtb-DHFS inhibitor analogs (Mycobacterium tuberculosis infection), Syntrix",78586,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-09-01 00:00:00,Syntrix Biosystems Inc,1023036,Discovery,2011-09-01 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Syntrix Biosystems Inc,1023036,US,US,"Mtb-DHFS inhibitor analogs (Mycobacterium tuberculosis infection), Syntrix",78586,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-09-01 00:00:00,Syntrix Biosystems Inc,1023036,Discovery,2011-09-01 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,iThemba Pharmaceuticals Pty Ltd,1049788,South Africa,ZA,"NBTIs (Mycobacterium tuberculosis infection), iThemba",79395,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-03-13 00:00:00,iThemba Pharmaceuticals Pty Ltd,1049788,No Development Reported,2014-03-13 00:00:00,NDR,2,Respiratory disease,711
ATP synthase inhibitor,49687,LOCAL_AND_MAJOR,Scripps Research Institute,21102,US,US,"ATP synthase inhibitors (tuberculosis), TB Alliance/California Institute for Biomedical Research",82643,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2013-06-30 00:00:00,Scripps Research Institute,21102,Discovery,2012-11-30 00:00:00,DR,6,Respiratory disease,711
ATP synthase inhibitor,49687,LOCAL_AND_MAJOR,California Institute for Biomedical Research,1068758,US,US,"ATP synthase inhibitors (tuberculosis), TB Alliance/California Institute for Biomedical Research",82643,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-06-30 00:00:00,California Institute for Biomedical Research,1068758,Discovery,2013-06-30 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,The University of Notre Dame du Lac,20642,US,US,"antibacterial compounds (tuberculosis), Eli Lilly & Co/The University of Notre Dame du Lac/Montana State University/University of Illinois/Infectious Disease Research Institute",87600,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-09-11 00:00:00,The University of Notre Dame du Lac,20642,Discovery,2011-03-23 00:00:00,DR,6,Respiratory disease,711
Isocitrate lyase inhibitor,68490,LOCAL_AND_MAJOR,iThemba Pharmaceuticals Pty Ltd,1049788,South Africa,ZA,"isocitrate lyase prodrug inhibitors (tuberculosis), iThemba Pharmaceuticals",65567,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2008-03-31 00:00:00,iThemba Pharmaceuticals Pty Ltd,1049788,Discovery,2008-03-31 00:00:00,DR,6,Respiratory disease,711
Adjuvant,524,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,ID-93,68617,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-09-20 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 1 Clinical,2012-08-15 00:00:00,C1,8,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,ID-93,68617,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-09-20 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 1 Clinical,2012-08-15 00:00:00,C1,8,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Infectious Disease Research Institute,27376,US,US,ID-93,68617,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-09-20 00:00:00,Infectious Disease Research Institute,27376,Phase 1 Clinical,2012-08-15 00:00:00,C1,8,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,Infectious Disease Research Institute,27376,US,US,ID-93,68617,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-09-20 00:00:00,Infectious Disease Research Institute,27376,Discovery,2009-12-31 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Medicine in Need,1054651,US,US,"BCG vaccine (inhalant/powder, tuberculosis), Medicine In Need",69074,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-09-24 00:00:00,Medicine in Need,1054651,No Development Reported,2014-09-24 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,TVAX Biomedical LLC,1049288,US,US,"autologous therapeutic vaccine, TVAX Biomedical",64503,Biological,Phase 2 Clinical,Discovery,DR,C2,Mycobacterium tuberculosis infection,221,true,2014-12-03 00:00:00,TVAX Biomedical LLC,1049288,Discovery,2012-12-06 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,iThemba Pharmaceuticals Pty Ltd,1049788,South Africa,ZA,"nitroimidazole derivatives (tuberculosis), iThemba Pharmaceuticals",67090,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2010-05-06 00:00:00,iThemba Pharmaceuticals Pty Ltd,1049788,Discovery,2010-05-06 00:00:00,DR,6,Respiratory disease,711
Protein subunit vaccine,12372,LOCAL_AND_MAJOR,Adjuvantix Ltd,1002784,UK,GB,ADX40-TB,64522,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-10-21 00:00:00,Adjuvantix Ltd,1002784,No Development Reported,2014-10-21 00:00:00,NDR,2,Respiratory disease,711
Protein subunit vaccine,12372,OTHER,Novartis Vaccines and Diagnostics Ltd,17976,UK,GB,"protein subunit vaccine (Mycobacterium tuberculosis, intranasal), Novartis Vaccines & Diagnostics/Statens Serum Institut",66563,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2011-11-30 00:00:00,Novartis AG,23137,No Development Reported,2011-11-30 00:00:00,NDR,2,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Novartis Vaccines and Diagnostics Ltd,17976,UK,GB,"protein subunit vaccine (Mycobacterium tuberculosis, intranasal), Novartis Vaccines & Diagnostics/Statens Serum Institut",66563,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2011-11-30 00:00:00,Novartis AG,23137,Phase 1 Clinical,2007-02-26 00:00:00,C1,8,Respiratory disease,711
Antibacterial,1594,OTHER,RecipharmCobra Biologics,20370,UK,GB,"tuberculosis DNA vaccine (ORT), RecipharmCobra Biologics",69165,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-03-13 00:00:00,Recipharm AB,1058217,No Development Reported,2013-03-13 00:00:00,NDR,2,Respiratory disease,711
DNA vaccine,1879,OTHER,RecipharmCobra Biologics,20370,UK,GB,"tuberculosis DNA vaccine (ORT), RecipharmCobra Biologics",69165,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-03-13 00:00:00,Recipharm AB,1058217,Discovery,2010-02-04 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,TB Drug Boost,1054643,France,FR,"EthR inhibitors (Mycobacterium tuberculosis), TB Drug Boost",67295,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-06-20 00:00:00,TB Drug Boost,1054643,No Development Reported,2012-06-20 00:00:00,NDR,2,Respiratory disease,711
Live attenuated bacterial vaccine,12363,LOCAL_AND_MAJOR,VIB,25058,Belgium,BE,"tuberculosis vaccine, VIB/Ghent University",70144,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-10-07 00:00:00,University of Antwerp,22741,No Development Reported,2014-10-07 00:00:00,NDR,2,Respiratory disease,711
Live attenuated bacterial vaccine,12363,LOCAL_AND_MAJOR,VIB,25058,Belgium,BE,"tuberculosis vaccine, VIB/Ghent University",70144,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-10-07 00:00:00,University of Antwerp,22741,Discovery,2011-01-26 00:00:00,DR,6,Respiratory disease,711
Recombinant bacterial vector vaccine,12369,LOCAL_AND_MAJOR,Tianjin CanSino Biotechnology Inc,1069870,China,CN,Ad5Ag85A,71323,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2012-05-07 00:00:00,Tianjin CanSino Biotechnology Inc,1069870,Discovery,2012-05-07 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,TB Drug Boost,1054643,France,FR,"EthR inhibitors (Mycobacterium tuberculosis), TB Drug Boost",67295,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-06-20 00:00:00,TB Drug Boost,1054643,Discovery,2010-05-06 00:00:00,DR,6,Respiratory disease,711
Protein kinase G inhibitor,3958,LOCAL_AND_MAJOR,Vichem Chemie Ltd,1031147,Hungary,HU,"PknG inhibitors (Mycobacterium tuberculosis infection), Vichem Chemie",68370,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2015-04-24 00:00:00,Vichem Chemie Ltd,1031147,No Development Reported,2015-04-24 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Qurient Therapeutics,1062405,South Korea,KR,"Q-201, Qurient",71430,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-04-17 00:00:00,Qurient Therapeutics,1062405,Discovery,2010-10-31 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Medisyn Technologies Inc,1005984,US,US,"Gram positive antibacterials (tuberculosis infection), Medisyn Technologies",65284,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2009-12-17 00:00:00,Medisyn Technologies Inc,1005984,Discovery,2009-12-17 00:00:00,DR,6,Respiratory disease,711
Protein tyrosine phosphatase inhibitor,1651,LOCAL_AND_MAJOR,Aarden Pharmaceuticals Inc,1058608,US,US,"protein tyrosine phosphatase inhibitor (tuberculosis infection, cancer, autoimmune diseases), Aarden Pharmacueticals",69351,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2015-01-05 00:00:00,Aarden Pharmaceuticals Inc,1058608,Discovery,2009-11-10 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Medicine in Need,1054651,US,US,"capreomycin (inhalant/powder, tuberculosis), Medicines in Need",70827,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-09-24 00:00:00,Medicine in Need,1054651,Discovery,2008-10-16 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,"BCG Vaccine (oral lipid matrix, Liporale), Immune Solutions/Aeras Global TB foundation",66314,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2010-05-04 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Discovery,2010-05-04 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Statens Serum Institut,21502,Denmark,DK,H-56,69824,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-08-22 00:00:00,Statens Serum Institut,21502,Discovery,2011-12-01 00:00:00,DR,6,Respiratory disease,711
Folate synthesis inhibitor,553,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"folate biosynthesis inhibitors (tuberculosis), AZ/TB Alliance",71614,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-11-30 00:00:00,The Global Alliance for TB Drug Development,29411,No Development Reported,2012-11-30 00:00:00,NDR,2,Respiratory disease,711
Folate synthesis inhibitor,553,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"folate biosynthesis inhibitors (tuberculosis), AZ/TB Alliance",71614,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-11-30 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2011-02-04 00:00:00,DR,6,Respiratory disease,711
Folate synthesis inhibitor,553,LOCAL_AND_MAJOR,AstraZeneca plc,14190,UK,GB,"folate biosynthesis inhibitors (tuberculosis), AZ/TB Alliance",71614,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-11-30 00:00:00,AstraZeneca plc,14190,Discovery,2011-02-04 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Wayne State University,20702,US,US,"tubercuslosis program, B&C Biopharm/Reyon Pharma/Wayne State University",67413,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2010-07-21 00:00:00,Wayne State University,20702,Discovery,2010-07-21 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Colorado State University,20562,US,US,"menaquinone synthase inhibitors (tuberculosis infection), Colorado State University/TB Alliance",71664,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2009-05-27 00:00:00,Colorado State University,20562,Discovery,2009-05-27 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"malate synthase (tuberculosis infection), GSK/TB Alliance/Texas A&M University",71667,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2007-12-31 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2007-12-31 00:00:00,DR,6,Respiratory disease,711
Bacterial cell wall synthesis inhibitor,104,LOCAL_AND_MAJOR,Shaheed Beheshti Medical University,1034641,Iran,IR,KBF-611,65935,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-06-19 00:00:00,Shaheed Beheshti Medical University,1034641,No Development Reported,2012-06-19 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Johns Hopkins University,20596,US,US,TBA-354,71742,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-01-30 00:00:00,Johns Hopkins University,20596,Discovery,2014-01-30 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,The Institute of Microbiology Chinese Academy of Sciences,1015456,China,CN,"protease inhibitors (tuberculosis infection, TB Alliance/Institute of Microbiology Chinese Academy of Sciences",71743,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-18 00:00:00,Chinese Academy of Sciences,23863,No Development Reported,2013-01-18 00:00:00,NDR,2,Respiratory disease,711
Protease inhibitor,331,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"protease inhibitors (tuberculosis infection, TB Alliance/Institute of Microbiology Chinese Academy of Sciences",71743,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-18 00:00:00,The Global Alliance for TB Drug Development,29411,No Development Reported,2013-01-18 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"protease inhibitors (tuberculosis infection, TB Alliance/Institute of Microbiology Chinese Academy of Sciences",71743,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-18 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2009-05-27 00:00:00,DR,6,Respiratory disease,711
Inactivated bacterial vaccine,12366,OTHER,Immodulon Therapeutics Limited,1051823,Argentina,AR,"heat-killed Mycobacterium vaccae (tablet formulation, tuberculosis), Immunitor",70934,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-26 00:00:00,Immodulon Therapeutics Limited,1051823,Clinical,2010-03-31 00:00:00,CU,7,Respiratory disease,711
Therapeutic vaccine,12379,OTHER,Immodulon Therapeutics Limited,1051823,Argentina,AR,"heat-killed Mycobacterium vaccae (tablet formulation, tuberculosis), Immunitor",70934,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-26 00:00:00,Immodulon Therapeutics Limited,1051823,No Development Reported,2014-03-26 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,OTHER,Immodulon Therapeutics Limited,1051823,Argentina,AR,"heat-killed Mycobacterium vaccae (tablet formulation, tuberculosis), Immunitor",70934,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-03-26 00:00:00,Immodulon Therapeutics Limited,1051823,No Development Reported,2014-03-26 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Chiron PathoGenesis,18741,US,US,PA-647,11233,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,1996-10-01 00:00:00,Novartis AG,23137,Discovery,1995-11-02 15:31:09,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,LeukoMed Inc,30043,US,US,LMP-420,41819,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2009-03-16 00:00:00,LeukoMed Inc,30043,No Development Reported,2009-03-16 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Otsuka Pharmaceutical Co Ltd,18717,Japan,JP,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Discovery,2005-03-16 00:00:00,DR,6,Respiratory disease,711
Angiogenesis inhibitor,61,LOCAL_AND_MAJOR,Otsuka Pharmaceutical Co Ltd,18717,Japan,JP,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Discovery,2005-03-16 00:00:00,DR,6,Respiratory disease,711
Anticancer,1545,OTHER,Otsuka Pharmaceutical Co Ltd,18717,EU,EU,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Pre-registration,2011-11-30 00:00:00,PR,11,Respiratory disease,711
Anti-inflammatory,2953,OTHER,Otsuka Pharmaceutical Co Ltd,18717,EU,EU,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Pre-registration,2011-11-30 00:00:00,PR,11,Respiratory disease,711
Anti-inflammatory,2953,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Estonia,EE,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 2 Clinical,2008-04-30 00:00:00,C2,9,Respiratory disease,711
Angiogenesis inhibitor,61,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Estonia,EE,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 2 Clinical,2008-04-30 00:00:00,C2,9,Respiratory disease,711
Antibacterial,1594,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Latvia,LV,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 3 Clinical,2011-09-19 00:00:00,C3,10,Respiratory disease,711
Anticancer,1545,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Estonia,EE,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 3 Clinical,2011-09-19 00:00:00,C3,10,Respiratory disease,711
Angiogenesis inhibitor,61,OTHER,Otsuka Pharmaceutical Co Ltd,18717,EU,EU,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Registered,2014-04-28 00:00:00,R,12,Respiratory disease,711
Mycolic acid synthase inhibitor,6542,OTHER,Otsuka Pharmaceutical Co Ltd,18717,South Korea,KR,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Registered,2014-10-29 00:00:00,R,12,Respiratory disease,711
Mycolic acid synthase inhibitor,6542,OTHER,Otsuka Pharmaceutical Co Ltd,18717,Peru,PE,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Phase 3 Clinical,2013-07-26 00:00:00,C3,10,Respiratory disease,711
Anticancer,1545,OTHER,Otsuka Pharmaceutical Co Ltd,18717,UK,GB,delamanid,16545,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2014-11-13 00:00:00,Otsuka Holdings Co Ltd,1040632,Launched,2014-05-31 00:00:00,L,13,Respiratory disease,711
Bacterial protein synthesis inhibitor,1538,LOCAL_AND_MAJOR,AstraZeneca plc,14190,US,US,posizolid,26493,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2012-12-27 00:00:00,AstraZeneca plc,14190,Phase 2 Clinical,2012-12-27 00:00:00,C2,9,Respiratory disease,711
Live attenuated bacterial vaccine,12363,LOCAL_AND_MAJOR,Vakzine Projekt Management GmbH,1020740,Germany,DE,VPM-1002,55569,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-03-27 00:00:00,Vakzine Projekt Management GmbH,1020740,No Development Reported,2013-03-27 00:00:00,NDR,2,Respiratory disease,711
Anticancer,1545,LOCAL_AND_MAJOR,Vakzine Projekt Management GmbH,1020740,Germany,DE,VPM-1002,55569,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-03-27 00:00:00,Vakzine Projekt Management GmbH,1020740,Discovery,2004-03-24 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,PolyMedix Inc,1011746,US,US,"SMAMPs (malaria), Fox Chase Chemical Diversity Center",62968,Chemical,Discovery,No Development Reported,NDR,DR,Mycobacterium tuberculosis infection,221,false,2013-09-09 00:00:00,PolyMedix Inc,1011746,No Development Reported,2011-02-09 00:00:00,NDR,2,Respiratory disease,711
Anti-inflammatory,2953,LOCAL_AND_MAJOR,InterMune Inc,26430,US,US,Actimmune,3365,Biological,Launched,No Development Reported,NDR,L,Mycobacterium tuberculosis infection,221,false,2014-09-19 00:00:00,Roche Holding AG,19446,No Development Reported,2007-03-31 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,PolyMedix Inc,1011746,US,US,PMX-10072,63306,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2013-09-09 00:00:00,PolyMedix Inc,1011746,Discovery,2008-12-31 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"pleuromutilin derivatives (tuberculosis), GlaxoSmithKline/The Global Alliance for TB Drug Development",56410,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-06-18 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2005-03-21 00:00:00,DR,6,Respiratory disease,711
STAT3 gene inhibitor,19075,LOCAL_AND_MAJOR,SciClone Pharmaceuticals Inc,19829,US,US,"golotimod (oral), SciClone/Verta",55521,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2011-10-10 00:00:00,SciClone Pharmaceuticals Inc,19829,Phase 1 Clinical,2006-05-25 00:00:00,C1,8,Respiratory disease,711
Live attenuated bacterial vaccine,12363,OTHER,Biofabri SL,1077737,South Africa,ZA,MTBVAC,89744,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-11-15 00:00:00,Biofabri SL,1077737,Discovery,2013-11-15 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Biofabri SL,1077737,South Africa,ZA,MTBVAC,89744,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-11-15 00:00:00,Biofabri SL,1077737,Discovery,2013-11-15 00:00:00,DR,6,Respiratory disease,711
Live attenuated bacterial vaccine,12363,LOCAL_AND_MAJOR,Biofabri SL,1077737,Spain,ES,MTBVAC,89744,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-11-15 00:00:00,Biofabri SL,1077737,Discovery,2011-05-25 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Biofabri SL,1077737,Spain,ES,MTBVAC,89744,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-11-15 00:00:00,Biofabri SL,1077737,Discovery,2011-05-25 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,National Institute of Biomedical Innovation,1031352,Japan,JP,"mucosal vaccines (rhPIV2 vector/nasal, tuberculosis), NIBIO/Aeras/Create Vaccine",89879,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-12-26 00:00:00,National Institute of Biomedical Innovation,1031352,Discovery,2013-12-26 00:00:00,DR,6,Respiratory disease,711
Recombinant viral vector vaccine,12370,LOCAL_AND_MAJOR,Create Vaccine Co,1089867,Japan,JP,"mucosal vaccines (rhPIV2 vector/nasal, tuberculosis), NIBIO/Aeras/Create Vaccine",89879,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-12-26 00:00:00,Create Vaccine Co,1089867,Discovery,2013-12-26 00:00:00,DR,6,Respiratory disease,711
STAT3 gene inhibitor,19075,LOCAL_AND_MAJOR,Verta Ltd,1004196,Russian Federation,RU,"golotimod (oral), SciClone/Verta",55521,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2011-10-10 00:00:00,Verta Ltd,1004196,Discovery,1999-08-26 00:00:00,DR,6,Respiratory disease,711
Immunomodulator,1596,LOCAL_AND_MAJOR,Agenus Inc,23221,US,US,"tuberculosis vaccine (CD1), Antigenics",22778,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2002-10-15 00:00:00,Agenus Inc,23221,Discontinued,2002-10-15 00:00:00,DX,3,Respiratory disease,711
Bacterial cell wall synthesis inhibitor,104,LOCAL_AND_MAJOR,L2 Diagnostics Llc,1007281,US,US,"alanine racemase inhibitors (Mycobacterium tuberculosis infection), L2 Diagnostics",72479,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2015-01-02 00:00:00,L2 Diagnostics Llc,1007281,Discovery,2011-05-26 00:00:00,DR,6,Respiratory disease,711
Phospho MurNAc pentapeptide transferase inhibitor,64334,LOCAL_AND_MAJOR,Sequella Inc,28087,US,US,"TL1 inhibitors (tuberculosis infection), Sequella",71741,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2009-11-13 00:00:00,Sequella Inc,28087,Discovery,2009-11-13 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,The Global Alliance for TB Drug Development,29411,World,WO,"indazole derivatives (Mycobacterium tuberculosis infection), GlaxoSmithKline/The Global Alliance for TB Drug Development",86639,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-07-31 00:00:00,The Global Alliance for TB Drug Development,29411,Discovery,2013-07-31 00:00:00,DR,6,Respiratory disease,711
Glycosyltransferase inhibitor,1025,LOCAL_AND_MAJOR,Medical Research Council (MRC),18438,UK,GB,"GlgE inhibitors (tuberculosis), MCRT",78428,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-06-25 00:00:00,Medical Research Council (MRC),18438,Discovery,2012-05-31 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Vaxil BioTherapeutics Ltd,1036156,Israel,IL,MTbuVax,66172,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2009-02-25 00:00:00,Sheldonco Ltd,1095293,Discovery,2009-02-25 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Finlay Institute,15912,Cuba,CU,"polyclonal antibodies (Mycobacterium tuberculosis infection), Finlay Institute",73038,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-08-09 00:00:00,Finlay Institute,15912,Discovery,2011-08-09 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Yonsei University,25184,South Korea,KR,"therapeutic DNA vaccine (tuberculosis), Pohang/Yonsei Universities",53019,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2009-12-24 00:00:00,Yonsei University,25184,No Development Reported,2009-12-24 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,OTHER,PharMida AG,1043700,Switzerland,CH,"targeted gold nanoparticle (Mycobacterium tuberculosis infection), Midatech",66235,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-02-06 00:00:00,Midatech Ltd,1011432,Discovery,2009-10-14 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,OTHER,PharMida AG,1043700,Switzerland,CH,"targeted gold nanoparticle (Mycobacterium tuberculosis infection), Midatech",66235,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-02-06 00:00:00,Midatech Ltd,1011432,Discovery,2009-10-14 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,PharMida AG,1043700,Switzerland,CH,"targeted gold nanoparticle (Mycobacterium tuberculosis infection), Midatech",66235,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-02-06 00:00:00,Midatech Ltd,1011432,No Development Reported,2013-02-06 00:00:00,NDR,2,Respiratory disease,711
Macrolide antibiotic,1540,LOCAL_AND_MAJOR,Ascenion GmbH,1050467,Germany,DE,"thuggacines (tuberculosis), Helmholtz",82363,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-11-14 00:00:00,Ascenion GmbH,1050467,Discovery,2012-11-14 00:00:00,DR,6,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,Lanzhou Institute of Biological Products,1061250,China,CN,T-Biovax,67683,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-10-17 00:00:00,Sinopharm,1055632,Discovery,2011-10-17 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Lanzhou Institute of Biological Products,1061250,China,CN,T-Biovax,67683,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-10-17 00:00:00,Sinopharm,1055632,Discovery,2011-10-17 00:00:00,DR,6,Respiratory disease,711
Topoisomerase I inhibitor,141,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"topoisomerase I inhibitors (tuberculosis infection), TB Alliance/NYMC/AZ",71897,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-06-27 00:00:00,The Global Alliance for TB Drug Development,29411,No Development Reported,2013-06-27 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"topoisomerase I inhibitors (tuberculosis infection), TB Alliance/NYMC/AZ",71897,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-06-27 00:00:00,The Global Alliance for TB Drug Development,29411,No Development Reported,2013-06-27 00:00:00,NDR,2,Respiratory disease,711
Heat shock protein modulator,7992,LOCAL_AND_MAJOR,Medical Research Council (MRC),18438,UK,GB,"vaccine (tuberculosis), MRC",12867,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2009-03-16 00:00:00,Medical Research Council (MRC),18438,No Development Reported,2009-03-16 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Shenzhen Neptunus Interlong Bio-Technique Co Ltd,1015704,China,CN,"recombinant human interleukin-2 (cancer/AIDS/autoimmune disorders/infections), Shenzhen Neptunus",80864,Biological,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2012-09-10 00:00:00,Shenzhen Neptunus Bioengineering Co Ltd,1031729,Launched,2012-09-10 00:00:00,L,13,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Colorado State University,20562,US,US,GI-19000,86853,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-08-22 00:00:00,Colorado State University,20562,Discovery,2013-08-22 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,Beech Tree Labs Inc,1052204,UK,GB,ML-05,69033,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-09-13 00:00:00,Beech Tree Labs Inc,1052204,Discovery,2011-09-13 00:00:00,DR,6,Respiratory disease,711
Keratinocyte modulator,18803,OTHER,Beech Tree Labs Inc,1052204,UK,GB,ML-05,69033,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2011-09-13 00:00:00,Beech Tree Labs Inc,1052204,Discovery,2011-09-13 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,University of Maryland,20611,US,US,"tuberculosis vaccine, University of Maryland",76032,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-02-10 00:00:00,University of Maryland,20611,Discovery,2012-02-10 00:00:00,DR,6,Respiratory disease,711
Protein kinase C modulator,1457,LOCAL_AND_MAJOR,Cadila Pharmaceuticals Ltd,30025,India,IN,"rifampicin + isoniazid + piperine (fixed dose combination, tuberculosis), Cadila Pharmaceuticals",69440,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2009-10-31 00:00:00,Cadila Pharmaceuticals Ltd,30025,Launched,2009-10-31 00:00:00,L,13,Respiratory disease,711
Live attenuated bacterial vaccine,12363,LOCAL_AND_MAJOR,Sanofi Pasteur,22127,France,FR,"rBCG30, UCLA",9831,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,false,2014-07-07 00:00:00,Sanofi,1009547,No Development Reported,2003-06-14 00:00:00,NDR,2,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,Abera Bioscience AB,1091260,Sweden,SE,"multivalent vaccine (Bera-V, Mycobacterium tuberculosis infection), Abera Bioscience/Statens Serum/Institut Pasteur",89342,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2013-12-20 00:00:00,Abera Bioscience AB,1091260,Discovery,2013-12-20 00:00:00,DR,6,Respiratory disease,711
Alpha crystallin inhibitor,59382,LOCAL_AND_MAJOR,Finlay Institute,15912,Cuba,CU,"alpha crystallin inhibiting IgA mAbs (tuberculosis infection), Finlay Institute",72912,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-09-25 00:00:00,Finlay Institute,15912,Discovery,2003-09-24 00:00:00,DR,6,Respiratory disease,711
Non-nucleoside reverse transcriptase inhibitor,1833,LOCAL_AND_MAJOR,Sarawak MediChem Pharmaceuticals Inc,24735,US,US,(+)-calanolide A,9539,Chemical,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2010-09-20 00:00:00,Sarawak State Government,29393,Discovery,2002-06-20 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Sarawak MediChem Pharmaceuticals Inc,24735,US,US,(+)-calanolide A,9539,Chemical,Discontinued,No Development Reported,NDR,DX,Mycobacterium tuberculosis infection,221,false,2010-09-20 00:00:00,Sarawak State Government,29393,No Development Reported,2010-09-20 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Beijing Tuberculosis & Thoracic Tumor Research Institute,1060211,China,CN,TBI-166,57790,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2014-12-22 00:00:00,Beijing Tuberculosis & Thoracic Tumor Research Institute,1060211,Discontinued,2013-06-30 00:00:00,DX,3,Respiratory disease,711
Bacterial cell wall synthesis inhibitor,104,LOCAL_AND_MAJOR,INSERM,17229,France,FR,"L,D-transpeptidase inhibitors (Mycobacterium tuberculosis infection), INSERM",78290,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-05-24 00:00:00,INSERM,17229,Discovery,2008-04-11 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,INSERM,17229,France,FR,"L,D-transpeptidase inhibitors (Mycobacterium tuberculosis infection), INSERM",78290,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-05-24 00:00:00,INSERM,17229,Discovery,2008-04-11 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,University of Illinois,20592,US,US,"actinomycetes metabolites (multi-drug resistant tuberculosis infection), Univeristy of Illinois/Institute for Tuberculosis Research/Univeristy of Illinois at Urbana-Champaign",71899,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-01-24 00:00:00,University of Illinois,20592,Discovery,2009-11-30 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,SmithKline Beecham plc,19962,US,US,"MTB72F vaccine (tuberculosis), GSK/Aeras",9490,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2014-08-26 00:00:00,GlaxoSmithKline plc,28355,Discovery,1995-10-01 00:00:00,DR,6,Respiratory disease,711
Transcriptional regulator protein EthR inhibitor,74415,LOCAL_AND_MAJOR,GlaxoSmithKline plc,28355,UK,GB,"EthR inhibitors (mycobacterium tuberculosis), BioVersys/ University of Lille/ GSK",92193,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-05-27 00:00:00,GlaxoSmithKline plc,28355,Discovery,2014-05-27 00:00:00,DR,6,Respiratory disease,711
Transcriptional regulator protein EthR inhibitor,74415,LOCAL_AND_MAJOR,BioVersys AG,1052531,Switzerland,CH,"EthR inhibitors (mycobacterium tuberculosis), BioVersys/ University of Lille/ GSK",92193,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2014-05-27 00:00:00,BioVersys AG,1052531,Discovery,2014-05-27 00:00:00,DR,6,Respiratory disease,711
Recombinant viral vector vaccine,12370,OTHER,Crucell NV,17254,Netherlands,NL,AERAS-402,53975,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2010-09-22 00:00:00,Johnson & Johnson,17332,Discovery,2004-03-24 00:00:00,DR,6,Respiratory disease,711
Recombinant viral vector vaccine,12370,OTHER,Crucell NV,17254,Kenya,KE,AERAS-402,53975,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2010-09-22 00:00:00,Johnson & Johnson,17332,Phase 1 Clinical,2008-10-17 00:00:00,C1,8,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Crucell NV,17254,South Africa,ZA,AERAS-402,53975,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2010-09-22 00:00:00,Johnson & Johnson,17332,Phase 2 Clinical,2008-10-17 00:00:00,C2,9,Respiratory disease,711
Recombinant bacterial vector vaccine,12369,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,AERAS-405,59144,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-09-18 00:00:00,Aeras Global TB Vaccine Foundation,1007376,No Development Reported,2012-09-18 00:00:00,NDR,2,Respiratory disease,711
esaT6 gene modulator,25530,LOCAL_AND_MAJOR,Polymun Scientific Immunobiologische Forschung GmbH,21851,Austria,AT,"tuberculosis vaccine (nasal, influenza virus carrier), Polymun",54201,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2013-06-10 00:00:00,Polymun Scientific Immunobiologische Forschung GmbH,21851,Discovery,2005-09-15 00:00:00,DR,6,Respiratory disease,711
Immunostimulant,393,LOCAL_AND_MAJOR,EyeGene Inc,1006553,South Korea,KR,"anti-tuberculosis vaccine, EyeGene",93723,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2012-06-30 00:00:00,EyeGene Inc,1006553,Discovery,2012-06-30 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,SciClone Pharmaceuticals Inc,19829,US,US,golotimod,25023,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,false,2013-11-12 00:00:00,SciClone Pharmaceuticals Inc,19829,Discovery,1999-08-27 00:00:00,DR,6,Respiratory disease,711
Immunostimulant,393,LOCAL_AND_MAJOR,SciClone Pharmaceuticals Inc,19829,US,US,golotimod,25023,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,false,2013-11-12 00:00:00,SciClone Pharmaceuticals Inc,19829,Discovery,1999-08-27 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,THERAMetrics Holding AG,29586,Switzerland,CH,"valorphin-containing peptides (tuberculosis), THERAMetrics Holding",95367,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2015-02-16 00:00:00,THERAMetrics Holding AG,29586,Discovery,2015-02-16 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,THERAMetrics Holding AG,29586,Switzerland,CH,"valorphin-containing peptides (tuberculosis), THERAMetrics Holding",95367,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2015-02-16 00:00:00,THERAMetrics Holding AG,29586,Discovery,2015-02-16 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,University of Georgia,20579,US,US,"small molecule therapeutics (tuberculosis/HIV), University of Georgia",95507,Biological,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,true,2015-01-28 00:00:00,University of Georgia,20579,Discovery,2015-01-28 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Myongji University (MJU),1004393,South Korea,KR,"actinomycetes metabolites (multi-drug resistant tuberculosis infection), Univeristy of Illinois/Institute for Tuberculosis Research/Univeristy of Illinois at Urbana-Champaign",71899,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2014-01-24 00:00:00,Myongji University (MJU),1004393,Discovery,2009-11-30 00:00:00,DR,6,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Myongji University (MJU),1004393,South Korea,KR,"actinomycetes metabolites (multi-drug resistant tuberculosis infection), Univeristy of Illinois/Institute for Tuberculosis Research/Univeristy of Illinois at Urbana-Champaign",71899,Chemical,Discovery,Discovery,DR,DR,Mycobacterium tuberculosis infection,221,false,2014-01-24 00:00:00,Myongji University (MJU),1004393,Discovery,2009-11-30 00:00:00,DR,6,Respiratory disease,711
Bacterial nucleic acid synthesis inhibitor,3984,LOCAL_AND_MAJOR,Dong Wha Pharmaceutical Co Ltd,15745,South Korea,KR,DW-286,35974,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-04-27 00:00:00,Dong Wha Pharmaceutical Co Ltd,15745,Discovery,2001-09-13 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,OTHER,Pfizer Inc,18767,South Africa,ZA,sutezolid,11088,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2013-07-17 00:00:00,Pfizer Inc,18767,Phase 2 Clinical,2011-08-11 00:00:00,C2,9,Respiratory disease,711
Ribosome binding agent,463,LOCAL_AND_MAJOR,Pfizer Inc,18767,US,US,sutezolid,11088,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2013-07-17 00:00:00,Pfizer Inc,18767,Phase 1 Clinical,2009-05-19 00:00:00,C1,8,Respiratory disease,711
Ribosome binding agent,463,OTHER,Pfizer Inc,18767,Europe,X5,sutezolid,11088,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,false,2013-07-17 00:00:00,Pfizer Inc,18767,Discontinued,2013-07-17 00:00:00,DX,3,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,University of Illinois,20592,US,US,"replicating and nonreplicating Mycobacterium tuberculosis inhibitors (tuberculosis), SRI International/University of Illinois",82340,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-07-25 00:00:00,University of Illinois,20592,No Development Reported,2013-07-25 00:00:00,NDR,2,Respiratory disease,711
DNA gyrase inhibitor,431,LOCAL_AND_MAJOR,The Global Alliance for TB Drug Development,29411,US,US,"quinolone analogs (Mycobacterium tuberculosis), KRICT/TB Alliance",57730,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-11-30 00:00:00,The Global Alliance for TB Drug Development,29411,No Development Reported,2012-11-30 00:00:00,NDR,2,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Ohio State University,20649,US,US,"tuberculosis therapy, Ohio State University",17342,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2009-12-24 00:00:00,Ohio State University,20649,Discovery,1998-03-03 00:00:00,DR,6,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,AERAS-407 rBCG,62397,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-11-27 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Discovery,2008-03-31 00:00:00,DR,6,Respiratory disease,711
Apoptosis stimulator,1589,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,AERAS-407 rBCG,62397,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-11-27 00:00:00,Aeras Global TB Vaccine Foundation,1007376,No Development Reported,2014-11-27 00:00:00,NDR,2,Respiratory disease,711
Immunostimulant,393,LOCAL_AND_MAJOR,Aeras Global TB Vaccine Foundation,1007376,US,US,AERAS-407 rBCG,62397,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-11-27 00:00:00,Aeras Global TB Vaccine Foundation,1007376,No Development Reported,2014-11-27 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Institute of Materia Medica Chinese Academy of Medical Sciences & Peking Union Medical College,19595,China,CN,TBI-166,57790,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2014-12-22 00:00:00,Chinese Academy of Medical Sciences & Peking Union Medical College,1066199,No Development Reported,2014-12-22 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Sequella Inc,28087,US,US,SQ-109,31010,Chemical,Phase 3 Clinical,Phase 3 Clinical,C3,C3,Mycobacterium tuberculosis infection,221,true,2012-12-19 00:00:00,Sequella Inc,28087,Discovery,2000-10-09 00:00:00,DR,6,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Infectex,1068619,Russian Federation,RU,SQ-109,31010,Chemical,Phase 3 Clinical,Phase 3 Clinical,C3,C3,Mycobacterium tuberculosis infection,221,true,2012-12-19 00:00:00,Maxwell Biotech Group,1061894,Phase 3 Clinical,2012-12-19 00:00:00,C3,10,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,GlaxoSmithKline plc,28355,UK,GB,"pleuromutilin derivatives (tuberculosis), GlaxoSmithKline/The Global Alliance for TB Drug Development",56410,Chemical,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2012-06-18 00:00:00,GlaxoSmithKline plc,28355,No Development Reported,2012-06-18 00:00:00,NDR,2,Respiratory disease,711
CDw137 modulator,5449,LOCAL_AND_MAJOR,ApoVax Inc,29552,US,US,ApoVax104-TB,68211,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2015-01-05 00:00:00,ApoVax Inc,29552,Discovery,2008-08-31 00:00:00,DR,6,Respiratory disease,711
Subunit vaccine,12371,LOCAL_AND_MAJOR,ApoVax Inc,29552,US,US,ApoVax104-TB,68211,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2015-01-05 00:00:00,ApoVax Inc,29552,No Development Reported,2015-01-05 00:00:00,NDR,2,Respiratory disease,711
DNA vaccine,1879,LOCAL_AND_MAJOR,Merck & Co Inc,18077,US,US,"vaccine (naked DNA, TB), Merck & Co",17424,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2008-03-03 00:00:00,Merck & Co Inc,18077,Discovery,1995-03-10 00:00:00,DR,6,Respiratory disease,711
Unspecified vaccine,12380,LOCAL_AND_MAJOR,Medicine in Need,1054651,US,US,"auxotroph vaccine (tuberculosis), Medicine in Need",70953,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2014-09-24 00:00:00,Medicine in Need,1054651,Discovery,2011-04-05 00:00:00,DR,6,Respiratory disease,711
Bacterial protein synthesis inhibitor,1538,OTHER,Sequella Inc,28087,South Africa,ZA,sutezolid,11088,Chemical,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2013-07-17 00:00:00,Sequella Inc,28087,Phase 2 Clinical,2013-07-17 00:00:00,C2,9,Respiratory disease,711
Therapeutic vaccine,12379,LOCAL_AND_MAJOR,Pohang University of Science & Technology,25083,South Korea,KR,"therapeutic DNA vaccine (tuberculosis), Pohang/Yonsei Universities",53019,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2009-12-24 00:00:00,Pohang University of Science & Technology,25083,No Development Reported,2009-12-24 00:00:00,NDR,2,Respiratory disease,711
Unspecified drug target,59620,LOCAL_AND_MAJOR,Aquila Biopharmaceuticals Inc,24317,US,US,"tuberculosis vaccine (CD1), Antigenics",22778,Chemical,Discontinued,Discontinued,DX,DX,Mycobacterium tuberculosis infection,221,false,2002-10-15 00:00:00,Agenus Inc,23221,Discovery,1999-03-30 00:00:00,DR,6,Respiratory disease,711
Mycobacterium early secretory antigen modulator,25527,LOCAL_AND_MAJOR,Shanghai H&G Biotechnology Co,1066720,China,CN,HG856-SeV,75156,Biological,No Development Reported,No Development Reported,NDR,NDR,Mycobacterium tuberculosis infection,221,false,2013-01-17 00:00:00,Shanghai H&G Biotechnology Co,1066720,No Development Reported,2013-01-17 00:00:00,NDR,2,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,GlaxoSmithKline plc,28355,Belgium,BE,"MTB72F vaccine (tuberculosis), GSK/Aeras",9490,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-08-26 00:00:00,GlaxoSmithKline plc,28355,Discovery,2004-06-15 00:00:00,DR,6,Respiratory disease,711
Subunit vaccine,12371,LOCAL_AND_MAJOR,GlaxoSmithKline plc,28355,US,US,"MTB72F vaccine (tuberculosis), GSK/Aeras",9490,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-08-26 00:00:00,GlaxoSmithKline plc,28355,Phase 1 Clinical,2004-03-08 00:00:00,C1,8,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,GlaxoSmithKline plc,28355,South Africa,ZA,"MTB72F vaccine (tuberculosis), GSK/Aeras",9490,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-08-26 00:00:00,GlaxoSmithKline plc,28355,Phase 2 Clinical,2014-08-26 00:00:00,C2,9,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,GlaxoSmithKline plc,28355,Belgium,BE,"MTB72F vaccine (tuberculosis), GSK/Aeras",9490,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-08-26 00:00:00,GlaxoSmithKline plc,28355,Phase 2 Clinical,2012-08-31 00:00:00,C2,9,Respiratory disease,711
Prophylactic vaccine,12378,OTHER,Aeras Global TB Vaccine Foundation,1007376,South Africa,ZA,"MTB72F vaccine (tuberculosis), GSK/Aeras",9490,Biological,Phase 2 Clinical,Phase 2 Clinical,C2,C2,Mycobacterium tuberculosis infection,221,true,2014-08-26 00:00:00,Aeras Global TB Vaccine Foundation,1007376,Phase 2 Clinical,2014-08-26 00:00:00,C2,9,Respiratory disease,711
Live attenuated bacterial vaccine,12363,LOCAL_AND_MAJOR,University of California Los Angeles,25623,US,US,"rBCG30, UCLA",9831,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2014-07-07 00:00:00,University of California,20547,Phase 1 Clinical,2004-02-17 00:00:00,C1,8,Respiratory disease,711
Prophylactic vaccine,12378,LOCAL_AND_MAJOR,University of California Los Angeles,25623,US,US,"rBCG30, UCLA",9831,Biological,Phase 1 Clinical,Phase 1 Clinical,C1,C1,Mycobacterium tuberculosis infection,221,true,2014-07-07 00:00:00,University of California,20547,Phase 1 Clinical,2004-02-17 00:00:00,C1,8,Respiratory disease,711
Antibacterial,1594,LOCAL_AND_MAJOR,Verta Ltd,1004196,Russian Federation,RU,golotimod,25023,Chemical,Launched,Launched,L,L,Mycobacterium tuberculosis infection,221,true,2013-11-12 00:00:00,Verta Ltd,1004196,Launched,2008-08-15 00:00:00,L,13,Respiratory disease,711